Synthetic polymers for interaction with vascular endothelial growth factor. by Gilmore, Louisa Jean
The 
University 
Of 
Sheffield. 
Synthetic Polymers for Interaction 
with Vascular Endothelial Growth 
Factor 
Louisa Jean Gilmore 
Submitted for the degree of Doctor of Philosophy 
Department of Chemistry, University of Sheffield 
June 2009 
Declaration 
This thesis is submitted to the University of Sheffield for the degree of Doctor of 
Philosophy, having not been submitted to any other University for any degree. I declare 
that all work contained herein is my own work, except where referenced and 
acknowledged accordingly . 
.... ~ .... -;-.................... . 
Louisa Gilmore 
June 2009 
Acknowledgements 
I would like to thank my supervisors, Dr Stephen Rimmer and Professor Sheila 
MacNeil, for their guidance and support throughout this PhD. 
The BBSRC is gratefully acknowledged for providing the financial support for this 
project. 
I am very grateful to Dr Tracie Whittle, Dr Sally McArthur, Mr Christopher Hill, Dr 
Heath Bagshaw, Mr Neil Bramall and Dr David Apperley for help with analysis of my 
materials. I would also like to thank Mrs Melanie Hannah for much appreciated 
technical assistance. Special thanks must also go to Dr Lynne Perlin and Dr Arthur Moir 
for advice on peptide synthesis, Dr Steven Carter for advice on polymer synthesis and 
Dr Louise Smith and Dr Emilia Krajewska for considerable help and support with cell 
culture. 
I wish to thank the members of both the Polymer and Biomaterials Laboratory in the 
Chemistry Department and the Tissue Engineering group at the Kroto Research Institute 
and the related technical staff for help and support, as well as for providing an enjoyable 
environment in which to carry out my research. 
Finally I would like to thank my family and Dan for their support and encouragement 
throughout. 
Abstract 
Angiogenesis, the fonnation of new blood vessels from previously established blood 
vessels, is a vital process within wound healing and is regulated by a number of 
stimulators and inhibitors. A critical pro-angiogenic factor is Vascular Endothelial 
Growth Factor (VEGF), which stimulates cell growth, survival and proliferation upon 
binding with and activating two specific receptors on the endothelial cell membrane. 
This binding is influenced by interactions with heparin-like glycosaminoglycans. 
The aim of this project was to synthesise a biomaterial dressing which would be able to 
bind and release the patient's own bioactive VEGF within a wound area, thereby 
stimulating angiogenesis through treatment with VEGF without the need to deliver 
external growth factors. Two systems were developed to meet this aim. 
Core-shell molecularly-imprinted particles (CS-MIPs) with phosphate functionality 
were developed via the epitope approach to produce VEGF-binding particles. CS-MIPs 
were synthesised in the presence of a pentapeptide template (DKPRR) and were able to 
bind and release both this pentapeptide and VEGF 165, although a molecular imprinting 
effect was only observable upon peptide binding and release. Phosphate-functionalised 
core-shell particles were shown to bind and release VEGF 165, maintaining its biological 
activity for up to 48 hours. 
Crosslinked hydrogels of N-vinyl-2-pyrrolidone and acrylic acid were functionalised 
with synthetic trilysine and triarginine peptides to produce materials capable of 
interacting with VEGF via heparin. These basic peptide sequences were able to interact 
with the highly sulphated heparin which in turn was able to interact with the heparin-
binding domain of VEGFI6S• These hydrogels were able to bind and release bioactive 
VEGF 165 and cytocompatibility was confinned in vitro with primary human dennal 
fibroblasts and human dennal microvascular endothelial cells (HDMECs). VEGF- and 
heparin-bound triarginine-functionalised hydrogels stimulated HDMEC proliferation 
and had a significant directional effect on HDMECs, which fonned tubules directed 
towards these materials in an in vitro angiogenesis assay. 
11 
Contents Page 
Acknowledgements ........................................................................................................... i 
Abstract ............................................................................................................................ ii 
Abbreviations .................................................................................................................. 1 
1 Introduction .................................................................................................................. 3 
1.1 The Skin ............................................................................................................. 3 
1.2 Wound Healing .................................................................................................. 5 
1.3 Angiogenesis: The Formation of New Vasculature ........................................... 7 
1.4 Vascular Endothelial Growth Factor (VEGF) ................................................... 9 
1.5 Therapeutic Applications ofVEGF ................................................................. 13 
1.5.1 Requirements for Delivery System ................................................... 14 
1.5.2 Current Approaches .......................................................................... 14 
1.6 Project Aim ...................................................................................................... 22 
1.7 Strategy 1: Core-Shell Molecularly-Imprinted Particles ................................. 23 
1.7.1 Molecular Imprinting ........................................................................ 23 
1.7.2 Peptide and Protein Imprinting ......................................................... 26 
1.7.3 Current Approaches to Protein Imprinting ....................................... 30 
1.8 Strategy 2: Peptide-Functionalised Hydrogels ................................................ 43 
1.8.1 Hydrogels ................................................................ ~ ......................... 43 
1.8.2 Hydrogels for Biological Applications ............................................. 43 
1.8.3 Hydrogels as Wound Dressings ........................................................ 45 
1.8.4 Hydrogels for Drug Delivery ............................................................ 46 
1.8.5 Current Approaches for Hydrogel-Based Protein Delivery 
Systems ............................................................................................. 48 
1.8.6 Hydrogel Summary ........................................................................... 51 
1.9 Summary .......................................................................................................... 51 
1.10 Project Overview ........................................................................................... 52 
2 Strateg)" 1: Core-Shell Particles ................................................................................ 53 
2.1 Consideration of VEGF as a Target for Molecular Imprinting ....................... 53 
2.2 Methodology .................................................................................................... 55 
2.3 Optimisation of Synthesis ................................................................................ 57 
2.4 Redox Initiation Study ..................................................................................... 58 
2.4.1 Results of Redox Initiation Trials ..................................................... 59 
... 
m 
2.5 Investigation into Alternative Initiator Systems .............................................. 61 
2.5.1 Summary of Initiator Study .............................................................. 67 
2.6 Optimisation of Thermal Potassiwn Persulphate Initiation ............................. 68 
2.7 Final Summary ................................................................................................. 69 
3 Core-Shell Molecularly-Imprinted Particles ........................................................... 70 
3.1 Determination of Peptide Sequence ................................................................. 70 
3.2 Synthesis and Characterisation ........................................................................ 75 
3.3 Peptide Binding Studies ................................................................................... 78 
3.3.1 Colorimetric Peptide Binding Study ................................................. 78 
3.3.2 Zeta Potential Peptide Binding Study ............................................... 90 
3.3.3 Conclusion of Peptide Binding Studies ............................................ 92 
3.4 VEGF Binding and Release Study .................................................................. 94 
3.5 Discussion of Results ....................................................................................... 97 
3.5.1 Effect of Molecular Imprinting ......................................................... 97 
3.5.2 Comparison of Alternative Approaches to Protein Imprinting ......... 99 
3.5.3 Summary of Core-Shell Molecularly-Imprinted Particles .............. 105 
4 Strategy 2: Peptide-Functionalised Hydrogels ...................................................... 107 
4.1 Determination of Methodology ..................................................................... 108 
4.1.1 Determination of Polymer Composition ......................................... 108 
4.1.2 Determination of Peptide Sequences .............................................. 109 
4.l.3 Determination of Peptide Coupling Procedure ............................... 111 
4.2 Results of Polymer Synthesis ........................................................................ 113 
4.2.1 Thermally-Cured Poly(NVP-co-DEGBAC-co-AA) Hydrogels ..... 113 
4.2.2 UV-Cured Poly(NVP-co-DEGBAC-co-AA) Hydrogels ................ I13 
4.2.3 Effect of Crosslinker and Acrylic Acid Incorporation .................... 115 
4.3 Results of Peptide Functionalisation ............................................................. 117 
4.3.1 Analysis of Coupling Efficiency ..................................................... 117 
4.3.2 Coupling Trials with Lysine Hydrochloride ................................... 119 
4.3.3 Coupling Trial with Lysine Peptides - Effect of Peptide 
Sequence Length ............................................................................ 122 
4.3.4 Peptide Coupling to UV-Cured Hydrogels ..................................... 124 
4.3.5 XPS and ToF-SIMS Assessment of Peptide Binding ..................... 127 
4.4 Summary of Results for Peptide-Functionalised Hydrogels ......................... 133 
5 Ileparin and VEGF Binding Analysis .................................................................... 134 
IV 
5.1 Heparin Binding Studies ................................................................................ 134 
5.1.1 Quantitative Fluorescent Heparin Study ......................................... 134 
5.1.2 Qualitative XPS Heparin Study ...................................................... 137 
5.1.3 Conclusion of Heparin Binding Studies ......................................... 142 
5.2 VEGF Binding and Release Study ................................................................ 143 
5.3 Discussion of Heparin and VEGF Binding Studies ....................................... 146 
6 Cell Compatibility of Peptide-Functionalised Hydrogels •••••••••.....•••.••••••••••••..•.... 152 
6.1 Effect of Poly(NVP-co-DEGBAC) Hydrogels with Acid and Peptide 
Functionalisation on Primary Human Dermal Fibroblast Cells ................... 154 
6.1.1 Fibroblasts Cultured in 10% FCS-Containing Medium ................. 156 
6.1.2 Fibroblasts Cultured in Serum-Free Medium ................................. 161 
6.2 Effect of Poly(NVP-co-DEGBAC) Hydrogels with Acid and Peptide 
Functionalisation on Human Dermal Microvascular Endothelial Cells ....... 165 
6.3 Conclusion of Cell Compatibility Study ........................................................ 168 
7 Assessment of VEGF- and Heparin-Bound Peptide-Functionalised 
Hydrogels as a Pro-Angiogenic Treatment .......................................................... 171 
7.1 Effect ofVEGF and Heparin on HDMEC Proliferation ............................... 172 
7.1.1 Vascular Endothelial Growth Factor Dosing .................................. 173 
7.1.2 Heparin Dosing ............................................................................... 174 
7.1.3 Combined VEG F and Heparin Dosing ........................................... 175 
7.2 Effect of VEGF- and Heparin-Bound Peptide-Functionalised Hydrogels 
on HDMEC Proliferation ............................................................................. 177 
7.2.1 Effect of VEGF- and Heparin-Bound Hydrogels (5% Serum 
Medium) ......................................................................................... 179 
7.2.2 Effect of VEGF- and Heparin-Bound Hydrogels (Serum-
Starved Medium) ............................................................................ 187 
7.3 Discussion of Proliferation Data .................................................................... 191 
7A.Effect of VEGF- and Heparin-Bound Hydrogels on Angiogenesis -
Tubule Formation Assay .............................................................................. 196 
704.1 Effect of Soluble Heparin and VEGF on Tube Formation ............. 197 
704.2 Effect of VEGF- and Heparin-Bound RRR Hydrogel on Tube 
Formation ....................................................................................... 200 
7.5 Discussion of Angiogenesis Assay Results ................................................... 205 
8 Conclusion ................................................................................................................. 207 
v 
9 Future Work ............................................................................................................. 212 
10 Materials and Methods .......................................................................................... 213 
10.1 Peptide Synthesis ......................................................................................... 213 
10.1.1 Materials ....................................................................................... 213 
10.1.2 Equipment ..................................................................................... 213 
10.1.3 Solid Phase Peptide Synthesis (SPPS) Protocol ........................... 214 
10.1.4 Peptide Cleavage ........................................................................... 214 
10.1.5 Peptide Analysis ........................................................................... 216 
10.2 Monomer Synthesis ..................................................................................... 221 
10.2.1 Materials ....................................................................................... 221 
10.2.2 Instrumentation ............................................................................. 221 
10.2.3 Synthesis of Oleyl Phenyl Hydrogen Phosphate .......................... 221 
10.3 Core-Shell Particle Synthesis and Characterisation .................................... 223 
10.3.1 Materials ....................................................................................... 223 
10.3.2 Instrumentation ............................................................................. 223 
10.3.3 Optimisation of Synthetic Procedure for Core Particles ............... 224 
10.3.4 Synthesis of Poly(OPHP-co-EGDMA) Outer Shell (Core-
Shell Particle) ................................................................................. 225 
10.3.5 Study of Initiator Systems for Core and Core-Shell Particle 
Synthesis ......................................................................................... 226 
10.3.6 Synthesis of Core-Shell Particles by Starve-Fed Monomer 
Addition .......................................................................................... 227 
10.3.7 Final Synthetic Procedure for Core and Core-Shell Particles ....... 227 
10.3.8 Synthesis of Molecularly-Imprinted Core-Shell Particles ............ 228 
10.3.9 Analysis ........................................................................................ 229 
10.3.10 Colorimetric Peptide Binding Study ........................................... 231 
10.3.11 Zeta Potential Peptide Binding Study ......................................... 232 
10.3.12 Enzyme-Linked ImmunoSorbent Assay (ELISA) of VEGF 
Binding (MIP) ................................................................................ 233 
10.4 Hydrogel Synthesis, Functionalisation and Characterisation ...................... 234 
10.4.1 Materials ....................................................................................... 234 
10.4.2 Instrumentation ............................................................................. 234 
10.4.3 Synthesis of Diethylene Glycol Bis Allyl Carbonate 
(DEGBAC)-Crosslinked Poly(NVP-co-AA) Hydrogels ................ 235 
vi 
10.4.4 Hydrogel Analysis ........................................................................ 237 
10.4.5 Synthesis of Peptide-Hydrogel Conjugates .................................. 238 
10.4.6 Analysis of Coupling Efficiency ................................................... 240 
10.4.7 Fluorescent Heparin Binding Study .............................................. 242 
10.4.8 XPS Heparin Binding Study ......................................................... 243 
10.4.9 Enzyme-Linked ImmunoSorbent Assay of VEGF Binding 
(Hydrogels) ..................................................................................... 244 
10.5 Cell Culture .................................................................................................. 245 
10.5.1 Materials ....................................................................................... 245 
10.5.2 Equipment ..................................................................................... 245 
10.5.3 Standard Solutions ........................................................................ 246 
10.5.4 Cell Counts and Viability Assessment. ......................................... 247 
10.5.5 Cell Culture ................................................................................... 248 
10.5.6 Fibroblast Experiments ................................................................. 249 
10.5.7 Endothelial Cell Experiments ....................................................... 250 
11 References ............................................................................................................... 253 
vu 
Abbreviations 
AA 
ADH 
AIBN 
ANOVA 
BSA 
CAM 
COOH 
CS-MIP 
Cyt-C 
DCC 
DEGBAC 
DIPEA 
DKPRR 
DMEM 
DMF 
DMSO 
DVB 
ECM 
EDC 
EDS 
EGDMA 
ELISA 
EtOH 
EWC 
FACS 
FCS 
FGF 
GAA 
GAG 
GC 
HAEC 
HBTU 
HCI 
HDMEC 
HOBt 
HPLC 
HS-GAG 
HUVEC 
ICP-AES 
IL-8 
IPA 
KGF 
KKK 
KKKKKK 
MES 
MIP 
MTT 
Acrylic acid 
Alcohol dehydrogenase 
a,a' -azobisisobutyronitrile 
Analysis of variance (statistical test) 
Bovine serwn albumin 
Chick chorioallantoic membrane 
Carboxylic acid 
Core-shell molecularly-imprinted particle 
Cytochrome C 
Dicyclohexylcarbodiimide 
Diethyleneglycol bisallylcarbonate 
Diisopropylethylamine 
Aspartic acid-Iysine-proline-arginine-arginine peptide 
Dulbecco's modified eagles medium 
Dimethylformamide 
Dimethyl sulphoxide 
Divinylbenzene 
Extracellular matrix 
l-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
Energy dispersive spectroscopy 
Ethylene glycol dimethacrylate 
Enzyme-linked immunosorbent assay 
Ethanol 
Equilibrium water content 
Fluorescence-activated cell sorting 
Foetal calf serum 
Fibroblast growth factor 
Glycine-alanine-alanine peptide 
Glycosaminoglycan 
Gas chromatography 
Human aortic endothelial cell 
2-(1 H-Benzotriazole-l-yl)-l, 1 ,3,3-tetramethyluronium 
hexafluorophosphate 
Hydrochloric acid 
Human dermal microvascular endothelial cell 
N-Hydroxybenzotriazole 
High performance liquid chromatography 
Heparin/heparan sulphate glycosaminoglycan 
Human umbilical vein endothelial cell 
Ion-coupled plasma atomic emission spectroscopy 
Interleukin-8 
Isopropyl alcohol (Propan-2-ol) 
Keratinocyte growth factor 
Trilysine peptide 
Hexalysine peptide 
2-Morpholinoethanesulfonic acid 
Molecularly-imprinted polymer 
3-( 4,5-Dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide 
1 
MW 
NHS 
NMR 
NVP 
OPHP 
PBS 
PDGF 
PIGF 
PLG 
PND 
PNDA 
PNDKKK 
PNDRRR 
PVP 
PRKRD 
ROD 
RRR 
SDS 
SEM 
SIMS 
SSSSSSSS 
TCP 
TEMED 
TGF 
THF 
TNBS 
TNF 
ToF-SIMS 
UV 
VEGF 
VPF 
Wt% 
XPS 
Molecular weight 
N-hydroxysuccinimide 
Nuclear magnetic resonance 
N-vinyl-2-pyrrolidone 
Oleyl phenyl hydrogen phosphate 
Phosphate buffered saline 
Platelet-derived growth factor 
Placenta growth factor 
Poly(lactide-co-glycolide) 
Poly(NVP-co-DEGBAC) hydrogel 
Poly(NVP-co-DEGBAC-co-AA) hydrogel 
Poly(NVP-co-DEGBAC-co-AA) hydrogel functionalised with 
KKKpeptide 
Poly(NVP-co-DEGBAC-co-AA) hydrogel functionalised with 
RRRpeptide 
Poly(N-vinyl pyrrolidone) 
Proline-arginine-Iysine-arginine-aspartic acid peptide 
Arginine-glycine-aspartic acid (cell adhesion peptide) 
Triarginine peptide 
Sodium dodecyl sulphate 
Standard error of mean 
Secondary ion mass spectrometry 
Octaserine peptide 
Tissue culture polystyrene 
N,N,N',N'-Tetramethylethylenediamine 
Transforming growth factor 
Tetrahydrofuran 
Trinitrobenzenesulphonic acid 
Tumour necrosis factor 
Time-of-flight secondary ion mass spectrometry 
Ultra-violet 
Vascular endothelial growth factor 
Vascular permeability factor 
Weight percent 
X-ray photoelectron spectroscopy 
2 
1 Introduction 
1.1 The Skin 
The skin is the largest organ of the human body and plays a crucial role through the 
regulation of water and electrolyte balance, thermoregulation, and by acting as a barrier 
to external agentsl. The skin consists of two principal layers, the epidermis and the 
dermis (Figure 1.1). 
Dermis 
~-:----:-i~-Sweat 
gland 
pore 
,~~::::-~'L~,-Capi 11 ary 
Dermal 
papilla 
Figure 1.1: The structure of human skin t 
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The epidermis is the outer layer of skin, comprising four layers, primarily consisting of 
stratified squamous epithelium. The basal cell layer is the deepest layer of the epidermis 
and is the location of keratinocyte mitosis, the process of cell division, supplied with 
nutrients from blood vessels in the adjacent dermis. As mitosis occurs, cells migrate 
upwards to replenish outer layers of cells. At any given time, up to 30% of the 
keratinocytes in this layer are preparing to divide2• Above the basal cell layer are the 
spinous layer, the granular cell layer and the stratum corneum. These layers reflect the 
visible changes along the continuous process ofkeratinocyte maturation from basal 
t Adaptation of Figure 6.2 reprinted from Hole 's Human Anatomy & Physiology, 81h Edition, Shier, 
David; Butler, Jackie; Lewis, Ricki , Copyrightl999 McGraw-Hill. Permission requested 15/05/09 
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layer to stratum corneum (reviewed by Powell et at2). In the spinous layer the cells are 
connected by spine-like cohesive desmosomes. In the granular cell layer the cells flatten 
and contain granules, lysozymes which cause cell death by destroying the cell's 
organelles, including the nucleus. Finally, in the stratum corneum, the keratinocytes are 
flat, dead cells. The cells overlap and have thick cell membranes which adhere to each 
other to provide the barrier functionality of skin. Gradually these cells are removed and 
are replaced with cells from the underlying layers of epidermis. 
Below the epidermis is the basement membrane, a layer which adheres the two layers, 
supports the basal cells and allows nutrients and cells to move to the epidermis from the 
dermis2• Below the basement membrane is the dermis which contains a number of cell 
types including fibroblasts, macrophages, mast cells and white blood cells3• This layer 
consists of dense, fibrous connective tissue, predominantly collagen and elastin. The 
texture of the collagen fibres gives rise to two layers within the dermis, the papillary 
layer and the reticular layer3. The papillary layer at the top of the dermis makes up 
approximately 20% of the dermis thickness and consists of loosely woven collagen and 
elastin fibres and numerous blood vessels. The reticular layer consists of larger, coarser 
connective tissue with a network of blood vessels present between the dermis and the 
subcutaneous layer. The dermis has numerous functions including mechanical strength, 
a substrate for diffusion of nutrients and waste and immune system functions2• Finally, 
the innermost layer of the skin is the subcutaneous layer4. It contains fat cells which 
vary in number depending on the area of the body. This layer loosely binds skin to the 
underlying organs. 
The skin can be disrupted due to a number of different problems, including ulcers, bums 
and trauma, resulting in the loss of barrier function of this crucial organ. A major loss of 
barrier function can result in bacterial entry, sepsis and death in, for example, severe 
burns injuries. It is clear therefore that it is of great importance to restore skin integrity 
as soon as possible. 
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1.2 Wound Healing 
A wound is "a defect or break in the skin which occurs as a result of physical or thermal 
damage, or an underlying medical or physiological condition"s. Severe wounds can be 
classified by the repair process and are described as acute or chronic. Acute wounds 
(generally tissue damage caused by external forces) will usually heal completely over a 
reasonable time-frame unless extensive skin loss occurs, whereas chronic wounds are 
those which fail to heal in the normal manner, or become fixed in any stage of the 
healing process for six weeks or more6• Chronic wounds are predominantly venous, 
pressure or neuropathic ulcers 7• 
Wound healing is a complex, dynamic process involving the coordinated actions of both 
resident and migratory cell populations which repair injured tissue and restore skin 
functions. The process of wound healing is often described as having three to five main 
stages (depending on how the events are linked by the author) which overlap in time. In 
this thesis a brief overview of wound healing is provided as detailed discussions of 
wound healing can be found in a number of review articles8•11 • The process occurs with 
the four main events of haemostasis, inflammation, proliferation and maturation. 
1. Haemostasis 
Upon injury, blood vessels are ruptured, activating haemostasis, the stoppage of 
bleeding by platelet aggregation, clot formation and vasoconstriction7• Cytokines and 
growth factors are released during this phase, promoting clotting and enlisting critical 
cellular elements for wound healing. 
2. Inflammation 
Inflammation occurs almost simultaneously with haemostasis. This stage often occurs 
from a few minutes to 24 hours after the initial injury and lasts for around 3 dayss. This 
stage is triggered by the mediators released in the haemostasis process as well as by 
injured tissue and capillaries. Vasodilation allows infiltration by immune cells and 
phagocytosis occurs, with neutrophils present to contain any microorganisms and 
macrophages present to ingest necrotic tissue 12. Macrophages also release further 
cytokines which regulate the wound healing process 10. After this stage the wound 
should be clean, bleeding should have been halted and the proliferation stage can begin. 
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3. Proliferation 
The proliferation stage consists of a nwnber of events9• Fibroblasts migrate from 
surrounding tissue and deposit granular tissue, consisting of nwnerous substances 
including fibronectin, hyaluronan and other extracellular matrix (ECM) compounds. 
This process is known as granulation, which replaces the fibrin clot and provides the 
skin with strength and form. The flow of blood to the tissue is restored through the 
process of angiogenesis, the formation of new blood vessels via the migration of 
endothelial cells into the site of injury. Re-epithelialisation then occurs as keratinocytes 
completely cover the wound. This involves keratinocyte proliferation and migration 
from the edges of the wound bed. Migration stops once the cells from opposite sides of 
the wound bed meet. The reepithelialisation which occurs re-establishes the skin barrier. 
4. Maturation 
Finally, maturation, or remodelling, of the granular tissue occurs to produce mature 
connective tissue, and the density of cells is reduced by apoptosis9• This process is 
important as the rate, quantity and total amount of matrix deposition determines the 
strength of the scar tissuell . 
6 
1.3 Angiogenesis: The Formation of New Vasculature 
The growth of new blood vessels through angiogenesis is a fundamental requirement for 
a developing embryo but is less common in adults I3 , occurring primarily in the female 
reproductive cycle and in wound healing. It has been related to pathological conditions 
including diabetic retinopathy, rheumatoid arthritis and tumour development l4 . 
control 60 hou~ IIft ll. woundlllll LJ 
100 "m 
Figure 1.2: New capillary formation in response to wounding. Scanning electron micrographs of 
casts of the system of blood vessels surrounding the margin of the cornea. Sixty hours after 
wounding new capillaries sprout toward the site of injury, just above the picture, showing the 
response of the endothelial cells to an angiogenic factor released at the wound t • 
Healing in wounds occurs as a sequential cascade of overlapping processes that requires 
the coordinated completion of a variety of cellular activities. As previously discussed, 
wound angiogenesis occurs during the proliferative stage of wound healing and such 
healing, other than the most superficial, could not occur without this process. Damaged 
vasculature must be repaired in the wound site to allow epithelialisation and the cellular 
activity required by wound healing would not be possible without the nutrient supply 
from the restored bloodstream 15. Therefore angiogenesis is a critical early stage 
component of wound healing. 
Angiogenesis involves a number of sequential events, closely regulated by a number of 
angiogenic stimulators and inhibitors. Stimulators include vascular endothelial growth 
factor (VEGF), fibroblast growth factor-l (FGF-l), fibroblast growth factor-2 (FGF-2), 
transforming growth factor-a (TGF-a), transforming growth factor-p (TGF-P), platelet-
derived growth factor (pDGF), tumor necrosis factor-a (TNF-a), pleiotropin, 
t Reproduction of figure 22-27 reprinted from Molecular Biology oJ the Cell. Alberts, Bruce; Johnson, 
Alexander; Lewis, Julian; RafT, Martin; Roberts, Keith; Waiter, Peter, 4th Edition, Garland Science, New 
York, USA, Copyright 2002. Permission requested 15105109 
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anglOgenm, and interleukin-8 (IL-8). Inhibitors include thrombospondin, cartilage-
derived inhibitor, angiostatin, platelet factor 4, and interferon-a and interferon-~ 13. 
Angiogenesis is controlled by the balance between stimulators and inhibitors, and in 
health there is an exact and coordinated balance between the two. 
The process of angiogenesis involves a number of coordinated events l6 (Figure 1.3). 
Firstly angiogenic growth factors are released by injured tissue, diffuse into nearby 
tissue and bind to specific endothelial cell receptors on pre-existing blood vessels, 
initiating a cascade of events. Vasodilation occurs, increasing vascular permeability in 
response to vascular endothelial growth factor (VEGF). This allows release of plasma 
proteins which produce a provisional scaffold for endothelial cell migrationl 7, 18. 
Vasodilation is followed by proteolytic degradation of the basement membrane and 
extracellular matrix 19. The endothelial cells then proliferate and migrate towards the 
injured tissue, regulated by chemotactic, haptotactic and mechanotactic stimuli , with 
further ECM degradation to accommodate the sprouting vessel2o. The sprouting blood 
vessels, initially present as a solid cord, subsequently form a lumen and are able to 
increase vessel diameter and length by thinning of the endothelial cells, intercalation or 
by fusion with other blood vessels21 • Finally maturation of the blood vessel occurs, 
including the introduction of mural cells (pericytes or smooth muscle cells), production 
of basement membrane, specialisation for a specific function or vascular regression22 . 
[C 
prOlI~,etIon 
• • " .... f 'Xc. 
lion 
~a 
C> 2000 The Ang iogenesIS Foundallon. Ine. All rlghtJ. re~erved . 
Figure 1.3: Schematic representation of the events occurring during angiogenesist 
'l' Reproduction of an image from the Angiogenesis Foundation. Permi ssion requested 16/04/09. 
Image from http://www.angio.org/understanding/understandingarchive.html on 18/05 /09. 
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1.4 Vascular Endothelial Growth Factor (VEGF) 
VEGF (also known as VEGF-A) was identified in media conditioned by bovine 
pituitary follicular cells by Ferrara et al23 in ] 989. This protein was shown to be the 
same as Vascular Permeability Factor (VPF) which was identified in 1983 by Senger et 
a1 24. Ferrara et al23 showed that the growth factor is heparin-binding, cationic and heat 
stable, with a molecular weight of approximately 45,000 Da under non-reducing 
conditions. Under reducing conditions, a molecular weight of ~23,000 Da was 
determined, suggesting that VEGF is a dimer, comprised of two units with identical 
molecular weight. It was found to have a unique N-terminal amino acid sequence of 
Ala-Pro-Met-Ala-Gly and to be a potent mitogen to vascular endothelial cells only. 
Since the identification of VEGF there have been numerous publications in this area, 
detailing its structure as well as its influence in physiological and pathological 
angiogenesis, and there are many review papers available l3, 21, 25-27 . It is beyond the 
scope of this thesis to discuss in detail the exact role ofVEGF within physiological 
h 
Figure 1.4: Ribbon representation of a) the receptor-binding domain of VEGF and b) a VEGF 
dimer. The two disulfide bonds are shown as black lines. Helix a I consists of residues 16 to 24, 
and the central four-stranded b-sheet is formed by bl (residues 27- 34), b3 (51-58), b5 (73-83), 
and b6 (89-99), with the characteristic cysteine knot motif at one end Istrands b4 (67-69) and b7 
(103-105)1, and a short three-stranded b-sheet Istrands b2 (46-49), b5, and b61 at the other end. 
Reproduced from Hoeben et alt 
t Reproduction of figure I reprinted from Pharmacological Reviews, Vo!. 56 no. 4, Hoeben, Ann, 
Landuyt, Bart, Highley, Martin S., Wildiers, Hans, Van Oosterom, Allan T., De Bruijn, Emst A., 
"Vascular Endothelial Growth Factor and Angiogenesis", 549-580, Copyright 2004, with permission 
from The American Society for Pharmacology and Experimental Therapeutics. 
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angiogenesis but VEGF is known to play a pivotal role in this process, inducing 
endothelial cell proliferation and migration, as well as stimulating vascular permeability 
and hexose transport and playing a role in endothelial cell survivat28. VEGF is also a 
regulator of pathological angiogenesis. This was confirmed by Kim et a129, who 
demonstrated that monoclonal antibodies for VEGF inhibited the growth of tumours in 
nude mice. 
This protein belongs to a family of VEGF proteins, also including the physiological 
subtypes; VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PIGF), and the 
exogenous subtypes; VEGF-E (viral VEGF) and VEGF-F (derived from snake 
venomio. VEGF was shown to belong to the cysteine knot growth factor superfamilyl. 
This family consists of dimeric growth factors which are characterised by a cysteine 
knot motif at one end of a conserved four-stranded ~-sheet within each unit32. The 3D 
structure ofVEGF is represented in Figure 1.4. 
The human gene for VEGF is present on chromosome 6p21.333.1t exists as a number of 
different molecular species28, including proteins with 121, 145, 165, 183, 189 or 206 
amino acid residues, the molecular heterogeneity being caused by alternative splicing 
from a single human VEGF gene containing 8 exons. VEGF is produced by many 
different cell types, including macrophages and T -cells, smooth muscle cells, kidney 
cells, keratinocytes, mesangial cells, astrocytes, osteoblasts and tumour cells (discussed 
by Klagsbrun et al1\ which preferentially express VEGFl21, VEGF165 and VEGFI89. 
VEGF 183 is also widely distributed throughout the body but VEGF 145 and VEGF206 are 
more rare and seem to be restricted to placental cells28. 
Muller et ae4 reported that VEGF comprises two identical polypeptide chains which are 
joined together covalently by a pair of disulphide bonds between Cys-51 and Cys_6034. 
They report that the main feature of the protein is a cystine knot motif consisting of an 
eight residue ring formed by disulphide bridges between Cys-57 -Cys-I 02 and Cys-61-
Cys-I04 with a third disulphide bond between Cys-26-Cys-68 passing through it. 
Fairbrother et atl5,36 reported that various isoforms all share a common amino-terminal 
receptor-binding domain of 115 residues, with crystal structure of the VEGF species 
varying in the length of the carboxy-terminal end. 
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The mitogenic activity of VEGF to vascular endothelial cells involves the growth factor 
binding with two receptors on the surface of endothelial cells which make up the blood 
vessels (reviewed by Ferrara et aI26). These receptors are VEGFR-I (FIt-t), a fms-like 
tyrosine kinase37 and VEGFR-2 (KDRlFlk-I), the kinase domain region38. These 
receptors have a high affinity for VEGF and are also receptors for other similar growth 
factors. 
It was reported by Ferrara et al23 in 1989 that VEGF is a heparin-binding growth factor. 
Heparin and heparan sulphate are members of the glycosaminoglycan (GAG) family, a 
family of linear polysaccharides present on most animal cell surfaces, basement 
membranes and In the extracellular matrix39. Heparin/heparan sulphate 
glycosaminoglycans (HS-GAGs) comprise a linear chain of 10-200 disaccharide units 
of N-acetyl-D-glycosamine linked to D-glucuronic acid. Modifications of this 
disaccharide unit occur, including N- and 0- sulphation, and epimerisation of ~-D­
glucuronic acid to a-L-iduronic acid, resulting in high heterogeneity of the HS-GAG 
family4o. Heparin is a highly sulphated polysaccharide, with an average of 2.7 sulfo 
groups per disaccharide unit, and the highest negative charge density of any known 
biological macromolecule, whereas heparan sulphate has less sulphation with a highly 
varied sequence, often found in the ECM and attached to the cell surface41 . This family 
is known to play an important role in the regulation of a number of physiological 
processes, including cell growth and differentiation, blood coagulation and cell-cell and 
cell-matrix interactions, and is subsequently widely studied (reviewed by Capila et al41). 
It has been shown that the more basic VEGF189 and VEGF206 bind heparin with high 
affinity and are found in the extracellular matrix, whereas VEGF 121 is an acidic 
polypeptide, is not heparin binding and is therefore freely diffusible. VEGF 165 displays 
intermediate properties, it is heparin-binding and is found in the extracellular matrix, 
attached to the cell surface and is also secreted42, 43. Of particular relevance to this 
research, all of the heparin-binding forms of VEGF share a 50 amino acid heparin-
binding region at the carboxy-terminus35. 
The binding of VEGF with VEGFR-I and VEGFR-2 has been shown by a number of 
groups to be significantly influenced by heparin-like GAGs, associated with the cell 
surface, as well as exogenous heparin and heparan sulphate, and thus the interaction of 
VEGF with HS-GAGs is vital in the process of angiogenesis44-47. Research by Keyt et 
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al48 has detennined that the binding ofVEGFI65 to heparin is localised to 55 amino acid 
residues present at the carboxy tenninal. Plasmin cleavage of VEGF 165 was carried out 
and produced a homodimer which is composed of 2 disulphide-linked amino tenninal 
regions (1-110) (VEGFllO) and two identical carboxy-tenninal fragments (111-165). 
With the heparin binding domain (111-165) missing, VEGF llO lacked the ability to 
significantly bind to heparin but maintained the ability to bind with the VEGF receptors. 
However, the carboxy-tenninal fragment (111-165) was able to bind with heparin with 
the same affinity as intact VEGF 165, demonstrating that the carboxy-tenninal is the 
heparin-binding domain. Further tests on VEGF 110 showed that removal of the carboxy-
tenninal fragment substantially decreases the mitogenic potency of VEGF towards the 
endothelial cell. This suggests that the heparin binding domains influence VEGF-
receptor interactions, which are vital for effective signal transduction and stimulation of 
endothelial cell proliferation. 
The extracellular matrix, including glycosaminoglycans as well as collagens, laminin 
and fibronectin49, is therefore thought to play an important role in the regulation of 
heparin-binding growth factors. Associations occur between heparin-binding growth 
factors and heparan sulphate proteoglycans in the ECM, followed by release of the 
growth factors, including VEGF, as the ECM is degraded by proteases in a highly 
localised manner at the cell surface. This association is able to prevent diffusion of the 
growth factors from the localised area, control the release of the growth factor and 
modulate the stability and bioactivity of many important angiogenic growth factors, 
including VEGF50. 51. 
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1.5 Therapeutic Applications of VEGF 
The process of angiogenesis is vital and therefore therapeutic strategies to control 
angiogenesis by administering angiogenic regulators have become an important 
research area52• A number of growth factors are capable of inducing blood vessel 
fonnation and, although research is available detailing administration of synthetic 
molecules which are reported to induce angiogenesis53, most strategies employed to 
achieve this involve the administration of known biological angiogenesis stimulators, 
primarily VEGF or acidic and basic fibroblast growth factors. The previous discussion 
of angiogenesis shows the complex biological processes involved, and it is suggested 
that the therapeutic administration of a combination of angiogenic regulators may lead 
to the most successful results. Despite this, research has shown that the simplified 
approach of administering single growth factors, including by bolus injection or 
polymeric implants, has been trialled for various conditions, and some successes in 
stimulating angiogenesis in animal and small-scale clinical studies have been reported54-
61 
The simplistic approaches of intravenous or intra-arterial bolus delivery or delivery of 
VEGF directly into the localised area could lead to a number of potential problems, 
especially at high doses. Potential hazards (extensively reviewed by Epstein et a162) 
include the development of new blood vessels in non-target tissue, an increase of 
vascular penneability in non-target tissue and the growth of tumours. This knowledge 
leads to the widely accepted opinion that low and localised doses of angiogenic growth 
factors give better results than one-off large doses. Therefore considerable research 
efforts are currently directed towards synthetic and natural biomaterials which are able 
to act as protein carriers and provide local and controlled delivery of proteins. This 
approach is expected to have numerous advantages over bolus injections of the growth 
factor. Such localised delivery could minimise unwanted side effects and provide a 
sustained release of growth factor to the target area, thus optimising the therapeutic 
potential. Release of VEGF from a biomaterial should also be able maintain the 
bioactivity of the protein in comparison to bolus delivery where the half-life is reported 
to be less than one hour63-66. This approach is expected to lead to safer, more successful 
treatment, as well as enabling the use of low quantities of growth factor which would be 
economically advantageous as the VEGF protein is expensive to make or buy. 
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1.5.1 Requirements for Delivery System 
In order to produce successful delivery vessels for growth factors it is prudent to mimic 
the extracellular matrix which is known to regulate the localised release of growth 
factors in biology. It is also thought to retain growth factors in the local environment, 
stabilise the active conformation of the growth factors and protect them from 
inactivationso, SI. Thus, numerous biomaterial delivery methods aim to mimic the ECM 
to deliver bioactive growth factors to specific locations. 
When producing a material for a biological application, the material must be non-
immunogenic, it must not produce toxic byproducts, it must be suitable for sterilisation 
and be free of pathogens. For a biodegradable application it must also degrade into non-
toxic products which can be removed from the body. For delivery of a growth factor, 
the material and synthesis route must also protect the growth factor to ensure it remains 
biologically active. Finally, for clinical applications, the material should be relatively 
easy to produce and handle, it should also be of reasonable cost and should be a socially 
accepted approachSl. 
1.5.2 Current Approaches 
A variety of approaches to deliver growth factors are currently under investigation, 
including diffusion-controlled systems and environmentally-responsive materials. There 
are already a number of detailed reviews in this areaS 0, 51, 67, 68, providing many 
examples of biomaterials for angiogenic growth factor delivery. In this thesis, an 
overview of the different material approaches will be provided to give an insight into 
current developments in this area. 
Natural Materials 
Natural materials have been used extensively in this area of research, in many cases due 
to their similarities to the ECM and their biocompatibility. A variety of materials have 
been investigated including agarose69 and chitosan7o, but the majority of delivery 
vessels are based around fibrin, collagen and gelatin, alginate and hyaluronic acid. 
The natural presence of fibrin within a wound means that it is a common material for 
angiogenic growth factor delivery57, 71, 72. In a case study reported by Kipshidze et al57 
14 
of a patient with an ischemic limb, new blood vessels were formed after treatment with 
VEGF in a fibrin matrix. The fibrin matrix slowed the release of the growth factor and 
thereby sustained angiogenesis. Wong et al72 also utilised fibrin in their approach, and 
showed the binding and release of bFGF, VEGFI65 and VEGFI2I from fibrin sealant 
clots. Delivery of the growth factors alone in a chick chorioallantoic membrane assay 
led to an angiogenic response, but the blood vessels produced were leaky and immature, 
whereas more mature vessels were observed as a combination of the growth factors 
were applied. Ehrbar et at11 recently covalently bound VEGF to fibrinogen implants 
utilising a variant of VEGF which crosslinks to fibrinogen by the transglutaminating 
activity of factor XIII during polymerisation. The protein can then be released by 
proteolysis rather than diffusion. Histology of an in vivo assay at a three week timepoint 
revealed that VEGF released by proteolysis promoted blood vessel growth significantly 
more than diffusion-based release. In this method VEGF should only be released when 
required, thus having a more pronounced effect. 
Collagen and gelatin, a natural polymer derived from collagen, are also commonly used 
biomaterials which have been employed in angiogenic growth factor delivery73-78. 
Collagen hydrogels were produced by Tabata et al7s with varying amounts of 
crosslinker to study the release of VEGF and the effect on angiogenesis in vivo. They 
concluded that bioactive VEGF was released upon hydrogel degradation and that the 
rate of release was determined by the amount of crosslinking. A prolonged angiogenic 
effect was observed upon VEGF release when subcutaneously implanted in mice. 
Gelatin microparticles were employed by Patel et at16 to release VEGF in vitro and in 
vivo. Again, release kinetics were shown to be dependent on crosslinking. The 
microspheres were able to maintain the bioactivity of the VEGF over 14 days, 
determined by an in vitro cell based assay; this was a significant improvement over the 
bioactivity of VEGF in bolus injections. 
Alginate, an anionic polysaccharide derived from algae, forms a hydrocolloid gel when 
mixed with divalent cations (eg. Ca2179. Simple aqueous gelation which can entrap 
molecules makes this material popular as a delivery system6S, 80-82. Elcin et a182 reported 
the effect of VEGF release from calcium alginate microspheres on neovascularisation at 
the subcutaneous site of the rat model, and showed that this system promoted vigorous 
angiogenesis. More recently Jay et a165 were able to tune VEGF release by varying the 
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divalent cation employed and found that VEGF bioactivity could be retained for at least 
15 days. 
Hyaluronic acid, a non-sulphated GAG, has also been employed in growth factor 
delivery systems. A considerable amount of the research in this area has been carried 
out by the groups of Peattie and Prestwich64• 83-86, who have recently been investigating 
copolymers of hyaluronic acid and other polysaccharides, which will be discussed 
further in a later section of this introduction. In 2004 Peattie et al85 released VEGF and 
bFGF from hyaluronic acid hydrogels. Release of the growth factors individually in vivo 
resulted in an increase in blood vessel growth in comparison to the hydrogel alone. 
Interestingly, a synergistic interaction was observed between the GAG and VEGF and 
as a result, a significantly larger effect was observed for the VEGF-releasing GAG than 
the other treatment groups. In 2006 Peattie et al86 analysed the release of VEGF and 
keratinocyte growth factor (KGF). In this case in vivo studies showed the hydrogel 
containing both KGF and VEGF produced the greatest angiogenic response out of all 
the treatment groups. 
Synthetic Materials 
There are a number of potential advantages to using synthetic delivery devices over the 
natural alternatives. Using synthetic materials may reduce the risk of infection and 
immunogenicity issues in comparison to natural substances and also allows the 
synthesis of reproducible materials with controllable properties5o. A variety of different 
synthetic biomaterials are available today which allow for numerous different 
approaches to be undertaken. 
A number of research groups have investigated the use of poly(lactide-co-glycolide), a 
well-known biomaterial due to favourable degradation into non-toxic byproducts87-91 . 
Release of the encapsulated growth factor should be related to this degradation, offering 
control of release kinetics by modification of the chemical composition of the 
material92. An interesting study by Richardson et al89 details the release ofVEGF165 and 
PDGF-BB from a porous poly(lactide-co-glycolide) (PLG), synthesised through a high 
pressure C02 fabrication process. The growth factors were released with individual 
release kinetics, made possible by different incorporation methods for each growth 
factor. The results of the in vivo study in the subcutaneous tissue of Lewis rats (a strain 
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of rat frequently used as an anjmal model) revealed that PDGF alone led to blood vessel 
maturation but no increase in blood vessel density, and VEGF alone led to an increase 
in the number of blood vessels, but the vessels were small and immature, whereas the 
combined release of the two growth factors led to the formation of mature blood 
vessels. Kanczler et al90 produced poly (D,L-lactic acid) scaffolds using supercritical 
C02 to release VEGF. The resultant VEGF release led to increased tubule formation in 
an in vitro Matrigel study. Poly(lactide-co-glycolide) microspheres with acid end groups 
were synthesised by Cleland et al91 to release VEOF. The growth factor release was 
sustained over a 21 day period, probably due to association of the acid end groups and 
the heparin-binding domain of VEGF, and generated a dose-dependent angiogenic 
response in a corneal implant assay. 
The use of hydrogels as delivery devices is also popular due to their favourable 
properties (further discussed in section 1.8). Release of bFGF was sustajned for up to 28 
days from degradable dextran hydrogels, synthesised by Hiemstra et al93 from dextran 
vinyl sulfone conjugates and tetrafunctional mercapto-poly(ethylene glycol) (Figure 
] .5). 
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Figure 1.5: In situ hydrogel formation carried out by Hiemstra et al by Michael addition of dextran 
vinyl sulfone conjugates (dex-Et-VS or dex-Pr-VS) with tetrafunctional mercapto PEG (PEG-4-
SH). Reproduced from Hiemstra et al t 
t Reproduction of scheme I reprinted from Journal of Controlled Release, Vol. 122 no. I, Hiemstra, 
Christine; Zhong, Zhiyuan; Van Steenbergen, Mies J. ; Hennink, Wim E.; Feijen, Jan, " Release of model 
proteins and basic fibroblast growth factor from in situ forming degradable dextran hydroge ls", 71-78, 
Copyright 2007, with permission from Elsevier. 
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Norton et al94 reported hydrogels containing 2-hydroxyethyl methacrylate, N-vinyl-2-
pyrrolidone and poly( ethylene glycol), which also contained microspheres. This dual 
material approach allowed controlled release of VEGF as well as an anti-inflammatory 
drug with individual release kinetics. Poly(ethylene glycol)-based hydrogels were also 
produced by Zisch et al95. These innovative hydrogels allowed cell adhesion by the 
incorporation of pendant RGD-based peptides, as well as the incorporation of 
crosslinking matrix metalloproteinase substrate peptides to allow cell-mediated 
remodelling of the matrix. VEGFI21 and VEGFI65 were covalently incorporated and in a 
chick charioallontoic membrane assay new blood vessel formation was observed in the 
presence of the hydrogels. An in vivo investigation in rats saw these biomaterials 
remodelled into native, vascularised tissue. An alternative monomer, N-
isopropylacrylamide (NIP AM), was employed by Kavanagh et al96 to produce 
thermosensitive copolymer films for delivery of VEGF to human aortic endothelial cells 
(HAECs). Films loaded with VEGF were shown to release 30 ng ofVEGF over 7 days 
in vitro, increasing HAEC proliferation by 18.2% over the control. 
An elegant approach to growth factor delivery was recently reported by Ehrbar et a197• A 
genetically engineered bacterial gyrase subunit B (Gyr B) was coupled to 
polyacrylamide (Figure 1.6). Gyr B could then be dimerised by the addition of 
coumermycin, an antibiotic, resulting in gelation of the hydrogel. VEGF 121 with a 
hexahistidine motif at the N-terminus was incorporated into the hydrogel to determine 
release characteristics. Release of the protein occurred only as increasing concentrations 
of novobicin were added, resulting in dissociation of the hydrogel. Novobicin 
concentrations were able to control the release of VEGF 121 and the VEGF 121 released in 
this way was shown to increase proliferation of human umbilical vein endothelial cells 
(HUVECs). This approach shows the considerable potential of pharmacologically 
controlled hydrogels for drug delivery. 
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Figure 1.6: Schematic of drug-sensitive hydrogel adapted from Ehrbar et al t. GyrB coupled to an 
acrylamide polymer is dimerised by coumermycin, resulting in gelation of the hydrogel. In the 
presence of novobiocin, GyrB is dissociated, resulting in dissolution of the hydrogel. 
Heparin Incorporation 
As mentioned previously, heparin and heparan sulphate GAGs play a significant role in 
regulating angiogenesis. A number of natural and synthetic routes to a heparin-mimic 
have been detailed which are able to release bioactive growth factors but they are 
generally unable to truly offer the spatial localisation, stability and controlled release 
offered by heparin in the ECM. Considerable research efforts have therefore turned to 
the incorporation of heparin into many of the materials discussed previously, including 
heparin in alginate systems58, 98, heparin in poly(ethylene glycol) gels49, 99 and in fibrin 
matrices 100, thus combining the advantages of heparin regulation with support offered 
by the materials. 
The effectiveness of heparin incorporation was nicely demonstrated by the group of 
Peartie64 who produced chemically modified hyaluronan and gelatin hydrogels 
containing very low quantities of heparin of 3% w/w and below. Their heparin-
containing hydrogels were able to regulate the release ofVEGF and bFGF for up to 42 
t Adapted by permission from Macmillan Publishers Ltd: Nature Materials, Vol. 7, Ehrbar, Martin ; 
Schoenmakers, Ronald; Christen, Erik H.; Fussenegger, Martin; Weber, Wilfred, "Drug-Sensing 
Hydrogels for the Inducible Release of Biopharmaceuticals", 800-804, Copyright 2008. 
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days and in vivo studies in mice showed that the presence of heparin allowed sustained 
vascularisation over 28 days. Most recently this group utilised their hydro gels to release 
VEGF, angiopoietin-l (Ang-l), KGF and PDGF in an in vivo study in the Balhle mouse 
ear pinnas3• Dual growth factor delivery was found to produce the best results, resulting 
in more mature vasculature. They also recorded more mature vessel formation for the 
heparin-containing hydrogels than for those without heparin. Dual growth factor 
delivery from a heparin-based biomaterial was also shown to give the most successful 
results in a study by Nillesen et allOI. In this case, VEGF and FGF were released from 
collagen-heparin scaffolds and, when subcutaneously implanted in rats, a combination 
of the two growth factors resulted in the highest density of blood vessels and the most 
mature blood vessels of all the treatment groups. 
The release of single growth factors has also elicited positive results in heparin 
containing materials. Biodegradable Pluronic/heparin hydrogels to deliver bFGF were 
produced by Yoon et al102 and resulted in release over one month which enabled 
neovascularisation in vivo. Steffens et al103 utilised heparin to modulate the angiogenic 
potential of their collagen matrices. Heparin was covalently incorporated into the 
matrices using l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) and an increase in endothelial cell proliferation was 
observed in the presence of heparin in comparison to the collagen matrices alone. A 
further increase in proliferation was observed as VEGF was loaded in to the matrices. 
A two-component delivery system was reported by Jeon et al104• Heparin was 
incorporated covalently into poly(L-lactide-co-glycolide) nanospheres in the presence of 
EDC to enable long-term zero-order delivery of bFGF. No burst release was observed 
with this delivery method and the bFGF was released over three weeks. When these 
nanospheres were further incorporated into fibrin gels the release period was extended 
to four weeks, with release dependent on fibrinogen concentration in the fibrin gel. The 
bFGF was shown to be bioactive in vitro and led to microvessel formation in vivo in a 
mouse ischemic limb. 
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Summary o(Current Growth-Factor Delivery Approaches 
The synthesis of ECM-mimics by a variety of routes has been described, employing 
both natural products and synthetic materials, as well as a combination of the two. 
These results demonstrate that stimulation of angiogenesis is significantly more 
successful with growth factors delivered via a biomaterial than when growth factors are 
delivered by bolus injection. This is expected to be due to stability of the growth factor 
within the biomaterial and its sustained release over a longer time period. A number of 
approaches showed improvements when more than one growth factor was released, but 
stimulation of angiogenesis was also observed when only one growth factor was 
delivered. Finally, results of studies incorporating heparin into the biomaterial suggest 
that the presence of heparin is advantageous and is able to further improve the ability of 
growth factor delivery vessels to stimulate angiogenesis. 
Despite a number of impressive reports detailing significant improvements in 
angiogenesis upon localised growth factor delivery, no single material is currently able 
to fulfil all roles of the ECM whilst meeting the requirements for a biomaterial, 
particularly regarding a simple, reproducible and cost-effective synthesis. 
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1.6 Project Aim 
The aim of this research is to synthesise a cost-effective, simple and reproducible 
biomaterial which could mimic the ECM and bind and release VEGF to stimulate 
angiogenesis for wound-healing applications. The biomaterial should be biocompatible 
and be able to be stored, as well as being stable and able to release bioactive VEGF. It 
should also be easy to remove after use without disruption of the healed tissue. 
In contrast to the previous examples of growth factor delivery systems, we plan to 
stimulate angiogenesis using the VEGF produced within the wound bed. In this study a 
biomaterial is designed which could act as a "VEGF reservoir" within a wound bed; 
binding, storing and releasing the patient's own VEGF to aid angiogenesis. Utilising a 
patient's own VEGF would have a number of advantages over the application of 
exogenous growth factor including: 
• Prevention of protein inactivation during the synthetic procedure 
• Avoidance of the high cost of growth factors 
• Avoidance of clinical issues related to the delivery of exogenous growth factor 
• Avoidance of complex regulatory issues related to the delivery of exogenous 
growth factor 
The intention is to produce biomaterials for future use as an external wound healing 
material, designed to be removed after use. For this reason the materials are not 
designed to be biodegradable. Instead, the required properties for an external wound 
healing dressing include a robust, flexible and easy to handle biocompatible material 
which is neither light nor temperature sensitive, and which is compatible with standard 
sterilisation procedures and easy to remove. 
Two approaches are investigated to meet these requirements; a VEGF-specific 
molecularly-imprinted polymer system and a heparin-binding peptide-functionalised 
hydrogel. An initial introduction to the background of the two techniques is provided in 
this section. Detailed information regarding the methodologies and the specific 
chemical compositions for each approach employed is provided in the following 
chapters. 
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1.7 Strategy 1: Core-Shell Molecularly-Imprinted Particles 
In this approach, core-shell particles were designed utilising molecular imprinting to 
interact directly with vascular endothelial growth factor (VEGF). 
1.7.1 Molecular Imprinting 
The concept of molecular imprinting is based on the principle of molecular recognition, 
described as the preferential binding of a chemical to its "receptor". This binding is 
highly selective and occurs favourably in comparison to the binding of structural 
analogues of the chemical. It is well known that molecular recognition occurs within 
nature and an example of this is the highly specific recognition between antibody and 
antigen. Proteins are complex macromolecules which are able to achieve highly specific 
molecular recognition with target molecules as a result of attractive forces between 
complementary functionality on the protein and the target molecule. 
Such recognition observed in nature has led chemists to attempt to produce synthetic 
receptors, crosslinked polymers containing functionalised cavities, which can mimic the 
molecular recognition and operate with the same degree of selectivity. The production 
of such molecularly-imprinted polymers is a challenging goal, but it would also be 
extremely rewarding as these materials would be able to complement the current 
biological recognition tools, such as antibodies, and would also be able to provide 
significant advantages, as they could be more robust and more cost-effective. 
Since the introduction of molecularly-imprinted polymers (MIPs) by Wulff'°5 this 
technology has grown rapidly in popularity. Only a brief literature search is required to 
reveal the versatility of this approach. Potential applications for highly selective 
molecularly-imprinted polymers are widespread and could include drug delivery, 
immunoassays, drug screening, enantioseparation, solid phase extraction, capillary 
electrophoresis, chromatographic and membrane separation and catalysisI06-1l5, and 
there are already a number of excellent reviews in this areall6-I22. 
Basic Principles 
The principle behind molecular imprinting is to allow a template molecule to interact 
with a functional monomer, producing a template-monomer complex. The monomer 
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present is then polymerised with a suitable cross-linker to produce a rigid polymer. The 
template is removed to leave cavities with a memory for the template in terms of size, 
shape and functionality. Upon the reintroduction of the template molecule to the 
polymer, it should rebind to these cavities with high selectivity over any other 
compounds present. This method is illustrated schematically in Figure 1.7. 
- -
Figure 1.7: A schematic representation of molecular imprinting 
The synthesis of molecular recognition units in this manner could have many possible 
advantages over the use of antibodies. Synthetic recognition materials may be cheaper 
to produce and more robust than an antibody, with increased stabil ity to temperature, 
pH and organic solvents. Natural antibodies are generally incompatible with organic 
solvents and so cannot be used successfully within such media. 
Preparation ofMolecularly-lmprinted Polymers 
The association between the template molecule and the binding monomer can be 
covalent or non-covalent, including, for example, hydrogen bonding, hydrophobic 
interactions and Van der Waal interactions. The type of interaction will affect the ease 
of synthesis and the selectivity of the produced polymeric species. 
The covalent approach, initially reported by Wulff et al 105 in 1972, is thought to be able 
to produce MIPs with high selectivity. There are a number of drawbacks to this 
method 123; often the synthesis is difficult and time consuming, it is only appropriate for 
certain templates, the recognition speed is slower and the removal of the template 
requires harsh conditions as it involves the cleavage of a covalent bond. The alternative 
approach of non-covalent imprinting, first realised by Mosbach et a1 124, 125, would be 
expected to result in less selective polymers due to the weaker non-covalent interactions 
employed but may also have a number of advantages 123. The synthesis of non-covalent 
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polymers is more straightforward and this method is compatible with a large range of 
templates. The template can be removed under mild conditions, which is vital for a drug 
delivery application, and template rebinding may be faster than in the covalent 
approach. 
The advantages and disadvantages of these approaches mean that it is important to 
consider which type of molecular imprinting is suitable for the aim of the project. 
Considerations necessary include the class of template molecule, the required 
selectivity, the timescale and costl23• Hybrid techniques may also be employed, such as 
the combination of the covalent and non-covalent approach 126, 127 or the use of a 
template immobilised on a solid support128. 
Format Considerations 
Molecularly-imprinted polymers are traditionally produced as a macroporous polymer 
in one step. This procedure is relatively straightforward and involves bulk 
polymerisation in non-polar solvents followed by grinding and sieving of the solid MIP 
to produce the required particle size. The majority of literature on molecular imprinting 
describes such an approach, but the synthesis of a macroporous monolith often leads to 
difficulty in the removal of the template molecule, as cavities can be formed throughout 
the entire polymer. There are numerous alternative preparations for various physical 
configurations that have been discussed to date 120, including uniform beads, 
microspheres, membranes, rods and polymer monolayers. It is important to select the 
monomer and polymerisation procedure not only with regard to the template molecule, 
but also with consideration to the required format for the desired application. 
Solvent Considerations 
The solvent is an important considerationl23• It must simultaneously dissolve the 
reagents, act as a porogen to allow the synthesis of accessible cavities, disperse the heat 
of reaction and allow the formation of the template-monomer complex. The solvent 
must also be compatible with the application of the imprinted polymer. In most cases, 
the solvent utilised in the imprinting step is the same solvent used when rebinding the 
template, which is an important consideration for MIPs with specific applications. 
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The majority of the research in this area has been performed entirely in organic solvents 
as this is traditionally the solvent choice for molecular imprinting, especially for non-
covalent imprinting techniques. This is primarily due to the non-covalent interactions 
which are possible within an organic medium. The most appropriate interaction for 
precise molecular recognition between template and monomer is hydrogen bonding. 
This interaction is thought to be the most effective for the synthesis of selective MIPs as 
it is dependent on distance and direction of the monomer and template123• Hydrogen 
bonding can occur with minimal interference within organic solvents, such as toluene 
and dichloromethane, and so the use of organic solvents is popular to optimise the 
selectivity through such interactions129• In order to truly produce versatile receptors for 
use within both academia and industry, MIPs are required which are able to function 
within water. 
1.7.2 Peptide and Protein Imprinting 
Protein imprinting has become more popular recently as successful polymers would be 
extremely rewarding. A number of reviews are now available for protein-imprinted 
polymers120• 130-137. Current protein binding relies upon antibodies for various 
applications such as assays, extraction and biosensors132 but these are very expensive 
and fragile. These drawbacks provide a niche for more inexpensive, robust and reusable 
materials. It is thought that such polymers could have applications within protein 
purification, diagnostics, biosensors and drug deliveryl3l· 136. 
Difflculties in Protein Imprinting 
The nature of large, flexible peptides and proteins leads to a number of synthetic 
difficulties when producing an imprinted polymer for this type of template molecule, 
which renders the standard procedure of bulk imprinting in non-polar solvents and the 
subsequent grinding and sieving ineffective. One of the synthetic challenges 
encountered within this type of situation is diffusion. In a nice overview of molecular 
imprinting, Flam 138 highlighted the fact that a bulky protein will not be able to move in 
and out of a polymer network with the same ease as a low molecular weight compound. 
This can lead to permanent entrapment of the protein in the polymer material131 • 
Although porogens can be added to improve the situation by increasing the surface area, 
for the usual bulk polymerisation method grinding would most likely still be necessary 
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to free the template and make the binding sites accessible. Grinding this material could 
damage any binding sites produced. 
Another synthetic consideration is the flexibility of polypeptides and proteins, which is 
not experienced for the traditional low molecular weight templates used in molecular 
imprinting. The conditions for polymerisation must be considered as some conditions 
could denature the protein which would render it inactive. The use of such flexible 
templates can yield less well-defined recognition sites as a protein could alter 
conformation to fit into an imprint formed for a different template, or it may no longer 
fit into its imprinted cavity in different conditionsl32• Thermodynamic considerations for 
the design of a MIP, including consideration of more flexible templates, have been 
discussed in detail by Nicholls 139. 
Finally, and probably the most significant challenge of protein imprinting, is the poor 
stability and solubility of proteins in organic solvents and the necessity for a polymer 
which is capable of operating in an aqueous environment for biological applications l3l • 
Imprinting in an aqueous environment is discussed in more detail in the following 
section because of the extra considerations required. 
In recent years there have been a number of different approaches suggested for the 
binding of macromolecules to overcome these difficulties. A number of groups have 
attempted to utilise conventional bulk polymerisation procedures with water-soluble 
monomers. However, as will become apparent, the majority of imprinting techniques 
discussed for biomacromolecules utilise surface imprinting techniques to avoid the 
aforementioned diffusion difficulties. The challenges of imprinting these templates 
within an aqueous environment are also met by a number of different interactions 
including the use of functional groups capable of strong interactions such as metal-
chelating, as well as hydrophobic and electrostatic interactions and also reliance on 
shape specificity, combined with multiple weak interactions including hydrophobic and 
hydrogen-bonding interactions in water. 
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Imprinting in an Aqueous Environment 
The techniques available for imprinting in aqueous media are limited in comparison to 
those available for organic solvents. There are difficulties associated with the use of 
water as a solvent, primarily the incompatibility with hydrogen bonding, an interaction 
of vital importance for the organisation of template and functional monomer within the 
majority of non-covalently imprinted polymers produced in organic medial4o. Water, 
due to its hydrogen donor and hydrogen acceptor abilities, prevents the hydrogen 
bonding between template and functional monomer occurring, instead forming such 
bonds itself with both the template and monomer speciesl41 . As the solvent in an 
imprinted polymerisation is generally present in large quantities in comparison to the 
other components, the solvent-template and solvent-monomer interactions render 
conventional hydrogen bonding useless in aqueous media and so it is generally accepted 
that imprinted polymers relying on such hydrogen bond interactions alone are 
incompatible in aqueous systems. This means that other non-covalent interactions 
become more important within aqueous imprinting, including hydrophobic interactions 
and electrostatic interactions. The most successful aqueous imprinting systems would be 
expected to utilise a combination of non-covalent interactions. 
A large number of different approaches have been trialled to achieve molecular 
imprinting in an aqueous environment. These include the use of a combination of 
organic and aqueous solventsI42-145, although work by Nicholls et al141 suggests that in 
order to achieve specific interactions in aqueous media it is advantageous to carry out 
the imprinting process within the media required for recognition. 
A number of innovative approaches to an entirely aqueous MIP have been recorded 
including covering a pre-formed MIP with a thin film of mineral Oil146, the use of 
cyclodextrin as a novel monomer147 and imprinting at the air-water interfacel48. The sol-
gel technique has also been used extensively, and is discussed in a review by Diaz-
Garcia et a1 149. 
A popular approach to aqueous imprinting is the synthesis of molecularly-imprinted 
particles by emulsion polymerisation and mini-emulsion polymerisation. Mini-emulsion 
polymerisation for molecular imprinting has been employed extensively by G. Tovar et 
aI150-153 and has been shown to enable the production of selective MIPs. Core-shell 
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molecularly-imprinted particles (CS-MIPs), in which the functional monomer is present 
in the outer-shell of the particle, have also been reported by a number of research 
groups. A considerable amount of work in this area was carried out by Perez-Moral et 
aI154-156. Research published by Perez et al154 produced cholesterol-binding particles via 
a two-stage aqueous emulsion polymerisation of a poly(styrene-co-divinylbenzene) core 
and an outer shell consisting of a specially designed template-surfactant, pyridinium 12-
(cholesteryloxycarbonloxy)dodecane-sulfate, which allowed the template to be 
positioned at a predefined distance from the surface of the polymer, and a polymerisable 
surfactant, pyridinium 12-( 4-vinylbenzyloxycarbonyl)dodecanesulfate. Results 
illustrated that the hydrophobic cavities were able to rebind cholesterol from a 0.5 mM 
solution in 60:40 2-propanol:water. No rebinding of cholesterol was observed when the 
rebinding experiments were carried out in isohexane, a nonpolar solvent. This 
demonstrates that the interactions involved are hydrophobic in nature as cholesterol is 
reasonably soluble in isohexane and will therefore tend to remain in solution rather than 
rebind to the hydrophobic cavities. Perez-Moral et al155 also employed the core-shell 
methodology to bind propranolol through non-covalent interactions in the presence of 
an organic solvent porogen. Results suggested that the presence of a porogen during 
shell synthesis increased the level of uptake of propranolol in both aqueous and organic 
media. As expected, it was also demonstrated that particles imprinted with a larger 
amount of template showed a higher rebinding capacity in both aqueous and organic 
environments. More recently, the same group have also imprinted propranolol, 
morphine and naproxen into core-shell nanoparticles using non-aqueous surface-
initiated living-radical polymerisation156. 
Carter and Rimmer157 reported the synthesis of core-shell molecularly-imprinted 
particles (CS-MIPs) by emulsion polymerisation in aqueous media, which were shown 
by selective extraction and saturation binding experiments to be able to differentiate 
between the template, caffeine, and theophylline, a structurally similar analogue. The 
particles utilised both hydrophobic interactions as well as a phosphate binding system, 
previously employed by Takagi et a1158, leading to electrostatic interactions between the 
phosphate binding monomer and the template molecule. Core particles of poly(styrene-
co-divinylbenzene) were coated by an outer layer of a long chain alkyl phosphate and 
ethylene glycol dimethacrylate (EGDMA) in the presence of the template. The presence 
of phosphate within the shell was confirmed by ion-coupled plasma mass spectrometry 
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(ICP-MS) of acid digests of the latexes produced. Competitive binding studies 
demonstrated the selectivity of the caffeine-imprinted particles, although imprinting 
with theophylline did not lead to a product which was able to selectively extract 
theophylline. The competitive binding studies were carried out in both water and a 
buffer solution, and results revealed that particles produced in this way performed better 
in water. Radiotracing experiments were carried out to prove that, in such surface-
imprinted particles, all of the caffeine template could be successfully removed in the 
extraction process. Further research showed that this technique was also able to produce 
MIPs which could differentiate between close structural analogues (S)-propranolol and 
(S)-atenoloI159, as well as a system which could selectively bind the Gly-Gly sequence 
in the tripeptides Tyr-Gly-Gly and Gly-Gly-His whilst excluding the sequence Met-Leu-
Phe160• 
From these examples it is obvious that molecular imprinting in aqueous environments is 
possible and that a variety of approaches can be utilised depending on the required 
application. Consideration of each individual template will allow for determination of 
the most suitable technique to achieve the most successful results. 
1.7.3 Current Approaches to Protein Imprinting 
Recently this area has become popular and so an ever increasing number of publications 
are available. The imprinting of the standard low molecular weight template molecules 
has previously relied upon a small number of strong interactions between template and 
functional monomer. The nature of proteins and polypeptides and their large quantities 
of functional groups over large surface areas suggests that the imprinting of these 
biological materials would likely result in large numbers of less specific interactions 
which could possibly produce less specific polymers. The type of interactions required 
and therefore the polymerisation method, the monomers and the format of the produced 
polymer, are all highly dependent on the desired template and application of the MIP. 
For this reason a number of techniques are discussed, with examples of two different 
approaches to protein imprinting; whole protein imprinting and the epitope approach. 
30 
Whole Protein Imprinting 
A number of different approaches have been reported for the imprinting of whole 
proteins, all of which attempt to overcome the specific difficulties observed for large, 
multifunctional templates. The majority of the approaches fall within the following 
three categories. 
3D Polymer Gels 
Firstly research continues to focus on 3D matrices, as bulk systems are able to contain 
numerous binding sites and therefore have a high potential binding capacity. Hjerten et 
al161 have polymerised acrylamide and N,N'-methylene bisacrylamide in the presence of 
various proteins including ribonuclease and myoglobin from horse to produce a gel. The 
imprinted polymers were packed into chromatography columns and were able to 
specifically absorb all of the proteins tested, and showed that the absorptive properties 
were highly dependent on ionic strength and gel concentration. An interesting point 
discussed was that gels could be produced which were capable of recognising several 
proteins simultaneously and were able to discriminate between two proteins differing by 
only twenty amino acid residues. Hjerten et al have since employed this type of polymer 
to recognise viruses and bacterial cellsI62-164. Polyacrylamide gels were also produced 
by Du et al165 with methacrylic acid and 2-(dimethylamino)ethyl methacrylate to 
imprint lysozyme. The imprinted polymer was able to absorb 85% more lysozyme than 
the non-imprinted polymer although a number of problems were encountered. The 
polymer was shown to be not specific for the template and more than a quarter of the 
template could not be extracted from the polymer. This may be due, in part, to the use of 
a gentle elution method. It was suggested that a higher crosslinking density leads to a 
more selective and compact gel from which diffusion of the protein is more 
problematic. This is expected to be similar for many of the gels produced by bulk 
polymerisation for protein recognition. The ease of template removal and subsequent 
accessibility with a lightly crosslinked material must be balanced against the superior 
imprinting efficiency of a highly crosslinked material. 
Pang et al l66 produced protein-imprinted beads from acrylamide and N,N' -methylene 
bisacrylamide by inverse-phase suspension polymerisation. The beads were imprinted 
with BSA and it was observed that the MIP had a much higher capacity than the non-
imprinted polymer. The MIP was also shown to be selective for BSA over ovalbumin. 
31 
Binding was attributed to complementary cavities for BSA with multiple electrostatic 
interactions and an enhanced imprinting effect was observed when the surface zeta 
potential for the template and beads were equal. 
The use of molecularly-imprinted hydro gels has also become popular (reviewed by 
Bergman et al l3l and Byrne et alI67). Several advantages, including compatibility with 
an aqueous environment and swelling capabilities, which minimise diffusion 
difficulties, make hydrogels promising materials for protein delivery. The hydrogel 
approach for binding biologically relevant materials has been utilised by a number of 
groups, but the majority of work has been aimed towards the imprinting of small 
molecules including nitrophenyl esters168 and norephedrinel69• Uysal et al170 have 
produced a molecularly-imprinted hydrogel for haemoglobin from N-t-butylacrylamide, 
acrylamide and itaconic acid. They found that preparation pH was critical for materials 
with an isoelectric point. The resultant hydro gels were selective for haemoglobin over 
fibrinogen and myoglobin and the imprinted polymer absorbed 1.5-2.2 times more 
haemoglobin than the non-imprinted equivalent. 
Stimuli responsive molecularly-imprinted hydrogels were produced by Hua et al l7l to 
bind bovine serum albumin (BSA). The use of "smart" hydrogel materials could lead to 
drug delivery applications, as altering environmental conditions could allow release of 
the template. The hydrogel relied upon interaction of the acidic BSA with a basic 
monomer N-[3-(dimethylamino)propyl]-methacrylamide (DMAPMA) and the stimuli-
responsive properties of N-isopropylacrylamide (NIP AM). It was possible to remove the 
template in mild conditions with sodium chloride by disruption of electrostatic 
interactions. The use of sodium chloride also inhibited the significant non-specific 
absorption experienced. The selectivity observed when removing the template from a 
protein mixture, and the control offered by external stimuli such as temperature and 
ionic strength suggest that there is some potential for this technique. 
An interesting approach was also described by Miyata et al l72 who produced a MIP 
consisting of a functionalised lectin and polyclonal anti-AFP antibody crosslinked with 
N,N' -methylene bisacrylamide in the presence of AFP, a tumor-specific marker 
glycoprotein. The hydrogel was shown to shrink as AFP was rebound and caused 
reversible crosslinking, whereas the non-imprinted hydrogel was found to swell slightly 
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upon addition of AFP. No change in the MIP was observed for the addition for 
ovalbumin, a control protein. The use of an antibody would be expected to make this 
approach less robust than a synthetic alternative but it does have potential as a sensing 
device. 
The use of 3D gels to imprint whole proteins has the advantages of a high binding 
capacity together with the flexibility and high porosity required for a macromolecular 
template. The negative aspect of this approach is an inherent lack of stability and 
mechanical strength compared to standard bulk imprinting methods132, as well as 
diffusion difficulties. The high crosslinking required to improve stability would make 
the diffusion of proteins more difficult and so a balance must be met. Improving the 
issue of mechanical strength could make the use of 3D gels attractive for protein 
binding. One method to improve mechanical strength was shown by Guo et al t 73 by 
incorporating a matrix of macroporous chitosan beads to polyacrylamide gels. The 
imprinted polyacrylamide gel was formed in the pores of the chitosan beads to provide 
mechanical strength. Haemoglobin-MIPs were shown to absorb considerably more 
haemoglobin than a non-imprinted equivalent and were selective for haemoglobin over 
BSA, which is a protein with a different shape. It was reported that the MIP could be 
reused but that acetic acid and sodium dodecyl sulphate were required to remove the 
bound protein. This suggests that this approach is more suitable for a sensor application 
than a protein delivery system. 
Surface Imprinting 
An alternative approach to overcome diffusion difficulties is the use of a surface-
imprinting approach, generally achieved by producing a thin film or polymerising on a 
supporting surface. The first reported MIP for proteins was produced by Glad et al t74 
who utilised organic silanes polymerised on the surface of porous silica particles in 
aqueous solution. A boronate silane functional monomer was incorporated to produce a 
polymer capable of recognising the glycoprotein transferrin. When compared to MIPs 
produced from the same monomers but via bulk polymerisation the beads were shown 
to offer superior recognition, demonstrating the advantages of surface imprinting for 
proteins. 
33 
The use of sol-gel chemistry has been discussed together with surface-imprinting by 
Zhang et all75 to produce a human serum albumin (HSA) MIP film on the surface of a 
piezoelectric quartz crystal gold-electrode. At the most effective binding temperature of 
20-35°C, the film was selective for the template against guest compounds, haemoglobin 
horseradish peroxidise, egg yolk, egg white and trypsin, and was relatively stable to pH. 
The binding capacity of the films produced was shown to be highly dependent on the 
salts and solvents employed. Wang et al176 have also employed surface-imprinting to 
produce a sensor for myoglobin and haemoglobin. In this synthesis a gold-coated silicon 
chip was coated with a protein-containing self assembled monolayer of alkanethiol, able 
to attach to the gold surface via sulphur-metal bonds and to the protein via the hydroxyl 
group. Again, the use of a surface imprinting technique allowed the synthesis of a MIP 
sensor capable of selectively detecting a target protein. 
Metal interactions used to bind proteins have been described by Shnek et al l77 and 
involves the attachment of the protein to an artificial lipid membrane using metal ion 
coordination. In this system, Cu2+, a divalent transition metal ion, is immobilised onto a 
solid support through chelating agents. The desired target compound is used as a 
template to position the metal. The chelating agents bind the metal tightly yet leave a 
coordination site available for the formation of a complex with the protein. Imidazole 
moieties in histidyl residues, present on the surface of proteins, coordinate to the Cu2+, 
immobilising it to the surface. This method is obviously only suitable for proteins 
containing an exposed histidine residue at its surface. 
Surface-imprinting techniques have also been employed by Bossi et al17S to coat 
polystyrene microplate wells with MIPs specific for various proteins including 
microperoxidase, horseradish peroxidase, lactoperoxidase and haemoglobin. They 
discuss that the imprinted polymer consists of 3-aminophenylboronic acid which 
attaches to the polystyrene surface through "aromatic ring electron-pairing interactions", 
presumably 1t-1t interactions. A strong imprinting effect was observed for all proteins 
reported with little cross-reactivity. It was shown that utilising the grafted MIP 
considerably improved the affinity to the template in comparison to the equivalent free-
standing MIP, probably due to the formation of highly accessible binding sites and a 
stabilised polymer. 
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Polypyrrole based MIPs were produced by Ramanaviciene et al179 for label-free 
detection of bovine leukaemia virus glycoproteins. The polymer was produced by 
electrochemical deposition onto the surface of a platinum black electrode in the 
presence of the template. The template was finally extracted with sulphuric acid. Pulsed 
amperometric detection was then used to detect the protein and showed that the protein 
could be bound, removed and rebound over several cycles, but that the polymer became 
less effective with each repeat cycle. 
Work has also been carried out for protein binding to a lipid monolayer on a solid 
support or at the airlliquid interface 1 80. Binding of the acidic protein ferritin was 
expected to interact with cationic/non-ionic lipids and induce charge patterns in the fluid 
monolayer. Interestingly, mono layers on a solid support saw ferritin adsorption reduce 
as the charge in the monolayer reduced, whereas at the air/water interface binding was 
increased as the amount of non-ionic lipid increased and the amount of charged lipid 
decreased. These results demonstrate the influence of lipid mobility at the air/water 
interface. The practicality and stability for this approach for use in a specific application 
needs to be further investigated. 
The surface-imprinting approach avoids difficulties associated with diffusion and offers 
obvious mechanical advantages. Utilising a surface-imprinting technique means the 
shape-selectivity offered by a 3D cavity may not be provided and so these materials 
may exhibit less selectivity. A surface technique could also require less protein but will 
therefore also have a lower binding capacity. 
Surface-Imprinting via Template-Immobilisation 
A number of groups are also carrying out surface-imprinting using a template-
immobilisation approach where the template is attached to a solid support and the 
polymer is formed around it before removal of the template on the support. This 
approach has the advantages of being compatible with insoluble templates, minimising 
protein aggregation and allowing the formation of homogeneous binding sites 130. It may 
also be a cost effective approach as it could minimise the amount of protein required in 
the imprinting step. 
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Tn a report from Chou et al 181 thin imprinted polymer films were formed on glass 
supports (Figure 1.8). In this study, a monolayer of protein was formed on a glass 
support, on to which a polymer was formed by UV initiation. The glass support and 
template were removed to leave a polymer with surface recognition cavities for a 
protein, in this case C-reactive protein, a marker of inflammatory response. This so-
called "micro-contact" imprinting meant that the template could be easily removed, 
avoided diffusion problems of the macromolecule through a bulk polymer and also 
meant that only a small quantity of expensive template was required. In this procedure, 
a phosphorylcholine (PC) derivative was used as a functional monomer as PC is a 
natural ligand for the pentaprotein. The 10 J.1m film MIP produced was shown to be 
selective to the template over HSA and lysozyme. Recently this group have used the 
"micro-contact" approach to produce MIPs for lysozyme, ribonuclease A and 
myoglobin182, creatine kinase l83 and ovalbumin l84. 
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Figure 1.8: A schematic of the "micro-contact" approach utilised by Chou et al t (a) the protein is 
adsorbed onto a cover glass together with the functional mono mer; (b) the cover glass is combined 
with the support containing the crosslinker and initiator and placed in a UV reactor; (c) the cover 
glass is removed; (d) the template is extracted; (e) rebinding of the template occurs. 
t Reproduction of figure I reprinted from Ana/yUca Chimica Acta, Vol. 542, Chou, Pei-Chen; Rick, John; 
Chou, Tse-Chuan, "C-reactive protein thin-film molecularly imprinted polymers formed using a micro-
contact approach", 20-25, Copyright 2005, with permission from Elsevier. 
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Radio-frequency glow-discharge plasma depositions were used by Shi et al 185 to 
produce thin film MIPs around proteins which had been coated with disaccharide 
molecules (Figure 1.9). The protein was deposited onto a mica surface and then coated 
with disaccharide, allowing formation of multiple hydrogen bonds. Polymerisation of 
C3F6 was carried out, reacting with the disaccharide molecules to produce 
polysaccharide-like cavities for recognition of various templates including albumin, and 
streptavidin. The polymer film produced was mounted onto a solid support and the mica 
and protein were removed. It is reported that non-specific protein binding should be 
minimal due to the highly directional nature of a hydrogen bond. Protein recognition for 
these particles was evident in competitive adsorption studies, suggesting that the 
required selectivity could be possible with this approach. It is thought that firstl y 
proteins are adsorbed non-specifically. In this case the template protein would be 
retained more successfully on the surface whereas an adsorbed protein with low affinity 
for the cavity would be exchanged with a dissolved protein in solution. Although the 
results suggest that non-specific protein adsorption occurs, the ability to preferentially 
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Figure 1.9: Schematic of the imprinting approach employed by Shi et al t. The protein was 
deposited onto a mica surface and then coated with disaccharide. Plasma polymerisation of C3F6 
·was carried out around the disaccharides. The polymer film produced was mounted onto a solid-
support and the mica and protein were removed to produce disaccharide-based recognition 
cavities. 
t Adapted by permission from Macmillan Publishers Ltd: Nature, Vo\. 398, Shi, Huaiqiu; Tsai, Wei-Bor; 
Garrison, Michael D. ; Ferrari, Sandro; Ratner, Buddy D., "Template-imprinted nanostructured surfaces 
for protein recognition", 593-597, Copyright 1999. 
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retain the template protein is key, and this could lead to selective polymers through 
dynamic adsorption-exchange. 
An immobilised template was also utilised by Shiomi et al186 to form molecularly-
imprinted silica surfaces. Haemoglobin was immobilised covalently via imine bonds 
between the protein and aldehyde groups on the silica. Organic silane monomers, 3-
aminopropyltrimethoxysilane and propyltrimethoxysilane, were then polymerised onto 
the haemoglobin-silica surface. The template was removed by treatment with oxalic 
acid to produce polymers with cavities selective for haemoglobin over myoglobin, 
transferrin and chymotripsinogen. The results showed that polymers produced with 
immobilised templates were more successful than those produced with the protein in 
solution and also demonstrated that the selective absorption of haemoglobin onto the 
MIP was dependent on the isoelectric point and the molecular weight of the protein as 
well as the shape and hydrophobicity of the cavities. 
Li et a1 18? have developed polymer nanowires with surface recognition sites for possible 
applications such as affinity chromatography. The target molecule was immobilised on 
the pore walls of nanoporous alumina, a technique analogous to the immobilised 
templates on porous beads previously discussed by Mosbach128• The nanopores were 
then filled with acrylamide and N,N' -methylenebisacrylamide and polymerisation 
occurred to produce selective polymer nanowires which were able to recognise protein 
molecules including albumin, haemoglobin and cytochrome c in pH 7.0 PBS solution. 
Matsunaga et al188 discussed an interesting approach using crystallised lysozyme. 
Crystallised proteins are regularly oriented with no mobility, thus reducing difficulties 
related to conformational changes of macromolecules in the imprinting process. 
Crystallised lysozyme on a cellulose membrane was coated with a pre-polymerisation 
mixture of acrylic acid (functional monomer), 2-(methacryloyloxy) 
ethylphosphony1choline (co-monomer), N,N' -methylene bisacrylamide (crosslinker) 
and poly(ethylene glycol). A sensor chip was placed on top of the mixture and 
polymerisation was then carried out. Removal of the cellulose membrane and template 
left a lysozyme-imprinted polymer-coated sensor chip. The crystallised lysozyme-MIP 
showed a higher selectivity than the free-lysozyme MIP and the non-imprinted polymer 
and suggests that such an approach may lead to successful MIPs for protein recognition. 
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Core-shell particles were employed by Tan et al189 to recognise bovine serum albumin. 
The particles were formed by a two-stage mini emulsion polymerisation. Firstly core 
particles were produced and the template was then immobilised to the core particle via a 
spacer chain containing an imine bond. The shell of methyl methacrylate and EGDMA 
was then polymerised around the core, producing core-shell particles with surface 
cavities after removing the BSA template by hydrolysis of the imine group. In 
agreement with other studies, the immobilised BSA MIP had a higher binding capacity 
than the free BSA MIP and a non-imprinted version. Selectivity studies showed that 
only the immobilised BSA MIP was able to selectively bind BSA. 
Epitope Approach 
The nature of proteins and the large quantities of functional groups over a large surface 
area suggests that the imprinting of such materials would likely result in large cavities 
with large numbers of less specific interactions which could produce less specific 
polymers. The true selectivity of these MIPs is of interest as a number of proteins of 
similar size and with similar functionality would generally be present within a 
biological sample. Without highly selective functionality it is unclear as to whether such 
a cavity could provide the selectivity observed for a more size-selective binding site. 
A very interesting approach towards protein imprinting and a much cited report was 
published by Rachkov190 detailing an "epitope approach" to the imprinting of peptides 
(Figure 1.10). This name refers to the biological interaction of an antibody with an 
antigen, as when an antibody binds with an antigen it interacts only with a small section 
of it, known as the epitope (the anti genic site of the protein). This approach utilises a 
short peptide chain as the template. which is an amino acid sequence present on the 
target protein or polypeptide. The cavity formed should then be specific for that amino 
acid sequence and should therefore be able to bind both the short peptide as well as the 
larger protein. Rachkov et al190 showed this approach to be successful in the imprinting 
of a tetrapeptide, producing MIPs capable of selectively recognising both the 
tetrapeptide and oxytoxin, a nonapeptide containing the tetrapeptide sequence. Bulk 
radical copolymerisation of methacrylic acid (MAA) and ethylene glycol dimethacrylate 
(EGDMA) produced macroporous MIPs, which were then ground and sieved to give the 
desired peptide-imprinted MIPs. Some selectivity was demonstrated with this system 
but the polymers performed best in a mixed-aqueous mobile phase. 
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Figure t.t 0: Schematic of the epitope approach, reproduced from Rachkov et ai' 
The possible advantages of this approach, including cost and reduction of problems 
associated with a flexible protein template, have meant that the epitope approach has 
been investigated by a number of researchers. 
The epitope approach was combined with a solid support in a study by Titrici et a1191 • A 
crude peptide was synthesised on a silica support and then used as the template. The 
pores of the silica support were then filled with MAA and EGDMA and polymerisation 
was initiated. The silica mould was dissolved by NH.HF2 to give organic imprinted 
polymer beads. In chromatographic binding experiments a heptadecapeptide nociceptin 
H-FGGFTGARKSARKLANQ-OH was retained twice as strongly on a particle 
imprinted with P(H-Phe-Gly-Si) (the correct sequence for this peptide) than P(H-Gly-
Si), again demonstrating that the epitope approach described can produce highly 
selective MIPs for polypeptides. From the Sellergren group, Emgenbroich et al192 also 
report the use of the epitope approach to recognise short peptide sequences, this time via 
the phosphate group on phosphorylated tyrosine. With their system it was possible to 
produce MIPs containing a diaryl urea monomer which were selective for peptides 
t Reproduction of figure 1 reprinted from Biochimica et Biophysica Acta, Vol. 1544, Rachkov, 
Alexandre; Minoura, Norihiko, "Towards molecularly imprinted polymers selective to peptides and 
proteins. The epitope approach", 255-266, Copyright 2001, with permission from E1sevier. 
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containing phosphorylated tyrosine, with significantly higher binding observed for the 
target peptide on the MIP than for the non-imprinted equivalent. These systems 
demonstrate success with the epitope approach but do not truly show whether this 
methodology can be applied to larger proteins. 
Nishino et al193 successfully combined template immobilisation with the epitope 
approach to produce MIPs selective for cytochrome c, alcohol dehydrogenase and 
bovine serum albumin. Nonapeptide sequences reproduced from the respective proteins 
were tethered to a functionalised silane surface, followed by polymerisation of a 
mixture of acrylamide, N,N-ethylenebisacrylamide and poly(ethylene glycol) 200 
diacrylate around the peptide template. Surface-imprinted cavities were formed which 
were highly selective for the target proteins. The success of this study was attributed to 
collective hydrogen bonding within the cavities which could only offer very low 
binding strength to non-target proteins. 
Tai et al194 have also employed the epitope approach to produce a MIP film able to 
detect the dengue virus protein. This system was produced as a sensor with a quartz 
crystal microbalance chip. A I5-mer peptide from the protein was selected as a template 
and was present as the monomers, acrylic acid, acrylamide and N-benzylacrylamide, 
were copolymerised onto the chip by UV initiation. The use of the epitope approach 
meant that the proteins had to orientate in a specific way to bind to the chip. Although 
no information regarding selectivity of the MIP was provided, this approach was able to 
provide quantitative detection of the dengue virus protein. 
Very recently an interesting report was published by Xue et al l9S, who imprinted 
staphylococcus aureus protein A (SpA) to produce MIPs which could then recognise the 
bacteria staphylococcus aureus. The imprinted polyacrylamide gel beads were able to 
selectively bind SpA in the presence of four competitor proteins (ovalbumin, ~­
lactoglobulin, lysozyme and bovine serum albumin) and staphylococcus aureus over 
two competitor bacteria (E. coli and S. thermophilus). 
Summary of Current Protein Imprinting Techniques 
Protein imprinting is currently an area of considerable research interest but there are a 
number of difficulties associated with this technique, including compatibility with 
aqueous media, flexibility of the target molecule and diffusion difficulties. There have 
been a variety of approaches suggested to overcome these difficulties, including 
utilising 3D gels, surface imprinting techniques and the epitope approach. All of the 
techniques discussed are able demonstrate protein binding, often with impressive 
selectivity, but differences between the approaches, templates and potential applications 
makes it very difficult to truly compare the results. As shown in this section, excellent 
progress in this area has been made in the last few years, and there are now many 
innovative approaches to producing a MIP for a protein target. It is expected that 
research in this area will continue, combining current approaches as well as finding new 
solutions to this challenge. 
From consideration of the literature it is clear that in order to produce a protein-
imprinted polymer for a specific application, it is necessary to consider the target 
protein, the material requirements and the potential application before determining the 
most effective imprinting approach. 
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1.8 Strategy 2: Peptide-Functionalised Hydrogels 
An alternative approach to producing a VEGF-binding polymer is to utilise the VEGF-
binding ability of heparin itself. Hydrogels were designed to bind heparin which could 
then bind VEGF, thus mimicking the extracellular matrix. 
1.8.1 Hydrogels 
Wichterle and Liml96 first proposed poly(2-hydroxyethyl methacrylate) (P(HEMA)) 
hydrogels for use in contact lenses in 1960. This class of material was defined in 1986 
by Peppas and Mikosl97 as "water-swollen networks (cross linked structures) of 
hydrophilic homopolymers and copolymers". Hydrogels are 3D materials with 
crosslinks that may be chemical; ionic, covalent or non-covalent (e.g. hydrogen bonding 
or Van der Waal forces), or physical due to entanglement or crystallitesl98. The 
crosslinker then provides the network structure and physical integrity of the resultant 
hydrogel. Hydrogels are able to achieve very high water contents, absorbing amounts of 
water from 10-20% (an arbitrary lower limit) of their dry weight up to thousands of 
times their dry weightl99, in comparison to the much more limited water absorption of 
hydrophobic polymer networks such as poly(lactic acid) and poly(lactide-co-glycolide) 
of less than 5-10 wt%200. Design of an appropriate synthetic approach as well as 
consideration of the chemical composition of a hydrogel (including choice of 
monomers, crosslinking method and crosslinker density) allows control of vital 
properties such as equilibrium water content, mechanical strength and degradation, as 
well as response to external stimuli. 
1.8.2 Hydrogels for Biological Applications 
Duncan201 describes biomaterials as "any material, natural or synthetic, that comprises 
the whole, or a part, of a living structure or biomedical device and performs, augments, 
or replaces a natural function". The most important feature of a biomaterial is that it is 
biocompatible to allow the material to be used successfully for the specific application. 
The desired biological response to a biomaterial may vary depending on its function. 
For some applications it may be desirable to have a material which does not interact 
with the biological system and so would be inert. Alternatively, it may be necessary to 
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produce a material which interacts with the cells close to the material. Marchant202 
suggests that biocompatibility can be considered as a "dynamic two-way process that 
involves the time-dependent effects of the host on the material and the material on the 
host". 
Hydrogels are now important materials for pharmaceutical and medical applications. 
The extremely high water contents achievable with hydrogels leads to unique 
physiochemical properties as the water content of these materials, and their resulting 
soft and rubbery consistency, enable hydrogels to resemble natural living tissue more 
closely than other synthetic biomaterials203• These properties are advantageous in many 
biological applications including drug delivery, tissue engineering, diagnostics and cell 
attachment, and a number of reviews of this area are available \98, \99,204-209. 
It is possible to produce hydrogels from both natural and synthetic polymers and both 
types of materials have advantages and disadvantages (Table 1.1). Natural polymers 
have advantages of inherent biocompatibility, biodegradability and may also contain 
moieties which are able to support cellular activities2OO• The possible disadvantages of 
insufficient mechanical properties and the chance that they may evoke an immune or 
inflammatory response must be weighed up against the advantages. Similarly, synthetic 
hydrogels may have the advantages of being well-defined structures and therefore have 
controllable degradation and functionality, but have no inherent bioactive properties. 
The properties required for a particular application must be considered when selecting 
the basic hydrogel formulation. 
Natural Materials 
Alginate 
Chitosan 
Collagen 
Dextran 
Fibrin 
Gelatin 
Hyaluronic acid 
Synthetic Materials 
Acrylic acid (AA) 
2-Hydroxyethyl methacrylate (HEMA) 
N-(2-hydroxypropyl) methacrylate (HPMA) 
Methacrylic acid (MAA) 
N-isopropyl acrylamide (NIPAM) 
N-vinyl-2-pyrroJidone (NVP) 
Poly(etbylene glycol) acrylate/methacrylate (PEGAlPEGMA) 
Poly(ethylene glycol) diacrylate/dimethacrylate (PEGDAlPEGDMA) 
Vin I acetate (VAc) 
Table 1.1 Monomers commonly employed in hydrogel synthesis (adapted from Lin et al 
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!&J. Hydrogels as Wound Dressings 
Dressings for wound healing have been used throughout history, with traditional 
dressings including natural or synthetic bandages, lint, gauzes and cotton woolS. These 
traditional approaches aimed to keep the wound dry and free from bacteria. It is now 
known that wounds heal faster and more effectively in a moist environment. A review 
by Menaker et ae10 discusses that a moist environment can prevent tissue loss, promote 
enzymatic activity to clear residual debris in the early stages of wound healing and 
facilitate keratinocyte migration. All of these factors mean that a wound able to heal in a 
moist environment can develop greater breaking strength and is cosmetically 
superio.-2 lO• There are a number of requirements for a successful wound dressing. These 
include being able to maintain a moist environment, allowing gaseous exchange whilst 
being impermeable to exogenous micro-organisms, being able to remove excess 
exudates, maintaining a suitable temperature and pH, having appropriate mechanical 
strength and allowing easy removal without traumas, 10, 211. Many different types of 
dressings are available to meet these criteria for different applications211 (Table 1.2). 
Dressing categories 
Non-adherent fabrics 
Absorptive fabrics 
Occlusive dressings: 
Non-biologic 
Biologic 
Sub-categories 
Foam, gauze 
Alginates, Films, Foams, Hydrocolloids and 
Hydrogels 
Amnion, Homograft, Skin substitutes and 
Xenograft 
Creams, ointments and solutions Antibacterial, En matic and others 
Table 1.2: Types of dressings (adapted from Lionelli et al with additions from Menaker et al 
Occlusive dressings, those dressings that maintain a moist wound surface when in 
place212, can be defined in two categories, biologic and non-biologic, with the non-
biologic category further divided into five major groups; films, foams, alginates, 
hydrocolloids and hydrogels210-212. 
There are many types of hydrogels currently on the market including Vigil on, Cutinova, 
Gelfolie, Nu-gel, Tegagel, Flexigel, Curagel, Flexderm, Aquaform, Granugel, Hypergel, 
Intrasite gel and Purilon gee lO, 211,213. Suitable hydrogels are made from a variety of 
polymers including poly(ethylene oxide), poly(propylene glycol), 
carboxymethylcellulose,poly(methacrylate) and poly(N_vinyl_2_pyrrolidonei,210,211,213. 
45 
Hydrogels are well suited to application as an occlusive dressing and are available as 
gels, sheets or impregnated gauze211 . Due to the high water contents discussed earlier, 
they are able to maintain a moist environment but are not always able to absorb much 
wound exudate, generally limiting their application to light and moderately exuding 
woundss. The flexibility of hydrogel sheets means that they can be cut to fit a wound 
and will follow the wound contours. They are non-adherent and so are easy to remove 
but therefore also require a secondary cover to secure them. A secondary cover also 
provides a barrier to bacteria as hydrogels themselves are poor bacterial barriers21O. 
Hydrogels are also non-reactive with biological tissue, non-irritant and permeable to air 
and waters. An advantageous property of hydrogel-based dressings is a cooling effect 
that occurs. Hydrogels have a high water content, which has a high specific heat 
capacity and is therefore able to absorb excess heat from the epidermis, thus cooling the 
skin. The application of a hydrogel is able to cool the skin surface by up to 5°C and 
maintain the temperature reduction for up to six hours, thereby helping to reduce pain 
and inflarnmation212. Due to numerous advantageous characteristics, hydrogels are 
thought to be suitable for use at all stages of wound healing except for infected or 
heavily-exuding wounds214. 
1.8.4 Hydrogels for Drug Delivery 
As previously discussed, protein delivery by bolus injection is not optimal due to short 
half-lives of the proteins and proteolytic degradation, leading to short circulation times 
and fast renal clearance2OO. This has led to development of many polymeric protein 
delivery devices (as detailed in section 1.5). Hydrophilic hydrogels have many unique 
properties which make them suitable for drug or biomolecule delivery. The use of 
hydrogels often allows mild synthetic and encapsulation procedures, and these materials 
are flexible and as such they are able to conform to a required shape. Crucially, 
hydrogels are generally biocompatible due to their high water content and resultant 
physiochemical similarity to the ECM203. The fact that hydrogels are hydrophilic in 
nature also provides an advantageous "stealth" characteristic in vivo through avoidance 
the host's immune response, thereby causing a reduction in phagocytosis (reviewed by 
Lin et al200). 
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The highly porous structure of hydrogels can be easily controlled by altering the 
chemical composition of the material which allows loading of the drug or biomolecule 
into the matrix and subsequent release. Many hydrogel formulations also offer a stimuli 
responsive character which is used extensively in drug delivery. It is possible to produce 
hydro gels which exhibit dramatic changes in swelling behaviour, network structure, 
permeability and mechanical strength when presented with an external stimulus, such as 
temperature, electric field, light, pressure, magnetic fields, pH and the presence of 
ions21S. This responsive characteristic is ideal for a delivery system as the reversible 
swelling allows controlled release. 
Modification of the chemical composition of a hydrogel also provides a number of 
attractive properties. Addition of a functional group (e.g. acrylic acid) allows 
bioadhesiveness2oo and control of the concentration of a particular functionality allows 
incorporation of the desired quantity of drug into the hydrogel matrix. It is also possible 
to design hydrogels to be biodegradable via a variety of mechanisms, including 
enzymatic, hydrolytic or environmental degradation due to pH or temperature204. 
Loading and Delivery Mechanisms 
The loading of drugs or biomolecules into a hydrogel matrix is thought to be performed 
by two approaches; post loading and in situ loading20o. In post loading the compound is 
absorbed after the hydrogel has been formed. In this case absorption occurs via 
diffusion and is also influenced by any functionality in the hydrogel which interacts 
with the compound. In situ loading occurs simultaneously with hydrogel matrix 
formation and encapsulates the compound as the hydrogel is formed around it. 
Methods to deliver drugs or biomolecules from hydro gels range from very simple to 
more sophisticated approaches, the major types of which are as follows, as discussed by 
Baldwin et a1216. If hydrogel systems are only physically crosslinked the compound will 
be released upon polymer dissolution. Degradation of chemically crosslinked hydro gels 
can occur by a number of mechanisms and for these systems the release can occur at a 
rate dependent on this degradation. For those hydrogels containing functionality for 
interaction with the compound (e.g. ionisable groups), the release rate may be 
determined by the binding release rate between the polymer and drug or biomolecule. 
Release from hydrogels with covalently incorporated compounds will be dictated by 
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cleavage of the covalent bond. Release rates can also be detennined by the swelling 
characteristics of hydrogels which are chemically crosslinked. These different 
mechanisms lead to a wealth of delivery methods which can be tuned for a specific 
application. Chemical composition including choice of monomer and crosslinking 
density can be modified to provide the desired rates of dissolution and degradation, as 
well as detennining the stimuli responsiveness of a system. 
1.8.5 Current Approaches for Hydrogel-Based Protein Delivery Systems 
There is a wealth of literature available detailing protein drug release from hydrogels, a 
number of which, developed by Tabata et aes, Peattie et al64, 83, 85, 86, Hiemstra et a193, 
Norton et al94, Zisch et a195, Kavanagh et a196, Ehrbar et al97 and Yoon et al102, have 
already been discussed in section 1.5.2 for the delivery of angiogenic growth factors. 
There are number of recent reviews available204,217,218 and the reader is directed to these 
for a detailed insight into this area. Here a few recent examples will be provided to 
demonstrate the variety of hydro gels currently available for protein delivery. 
Various pH sensitive systems have been well researched and there are a number of 
examples available. A pH sensitive system was reported by George et a1219, synthesised 
from alginate and guar gum, a non-ionic polysaccharide, crosslinked by glutaraldehyde, 
for intestinal delivery of BSA. Such materials could minimise release in the acidic 
stomach and then release the drug upon swelling as pH increases in the intestinal tract. 
Alginate, the pH sensitive component, dissolves fast at high pH and so it was combined 
with guar gum and crosslinker to control the release. Guar gum was expected to retard 
release as it swells when hydrated, fonning a viscous layer. The optimum ratio of 3: 1 
alginate to guar gum with 0.5% crosslinker was shown to release the drug at pH 7.4 due 
to hydrogel swelling. At pH 1.2 only 22% of BSA was released, in comparison to 94% 
at pH 7.4. Very recently Xiao et al220 produced a pH sensitive hydrogel from 
carboxymethyl pachyman, a P-D-glucan, crosslinked with epichlorohydrin. This 
hydrogel was found to be biodegradable and the release of two model proteins, BSA 
and lysozyme, in simulated intestinal media was found to be due primarily to diffusion 
but also due to degradation of the matrix. Encouragingly, when released from the 
hydrogel, the stability and enzymatic activity of the protein was retained, presumably 
because the hydrogel is able to shield the proteins from proteolytic attack. 
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Temperature can also be used to control protein release. Wu et al221 employed poly(N-
isopropylacrylamide) (poly(NIPAM» hydrogels to release BSA and insulin in a 
thermosensitive system. Poly(NIP AM) hydrogels have a lower critical solution 
temperature (LCST) at approximately 32°C. Below this LCST, the hydrogel is swollen 
and hydrophilic but above this temperature the hydrogel shrinks into a collapsed 
hydrophobic state. In this case poly(NIP AM) was crosslinked with varying 
concentrations of N,N'-methylene bisacrylamide and release was shown to be 
dependent on the size of the protein as insulin, the smaller protein, was released faster 
than BSA and over 48 hours almost 94% of the insulin loaded was released in 
comparison to only 57% of the BSA. 
A number of hydrogels are designed to be injectable, gelling upon introduction to the 
body. Tae et al222 prepared physically cross linked hydrogels produced by poly(ethylene 
glycol) modified with fluorocarbon end groups. This composition results in an 
injectable liquid which became a hydrogel upon introduction to an aqueous environment 
due to hydrophobic interactions between the end groups. Their results showed that when 
human growth hormone (hGH) is complexed with Zn2+, release is prolonged up to two 
weeks from these hydrogels with no destabilisation, aggregation or burst release. BSA, 
hGH and y-globulin were all found to be released by diffusion, but surface erosion of 
the hydrogel also occurs and it was suggested that larger proteins would only be 
released as the material is degraded. Injectable amphiphilic poly(ethylene glycol) based 
hydrogels were also synthesised by Huyng et a1223 from pentablock copolymer 
containing poly(p-aminoester), poly(ethylene glycol) and poly(e-caprolactone). This 
system is temperature and pH sensitive. At low temperatures and low pH the polymer is 
in solution and interacts with the protein, insulin, ionically. After injection into the 
body, and resultant increase in temperature and pH to 37°C and pH 7.4, a micellar gel is 
formed, containing the insulin by ionic interactions with the aminoester functionality. 
Release of the insulin then occurs by diffusion and also by degradation of the poly(P-
amino ester). Other injectable and biodegradable hydrogels include poly(ethylene 
glycol) hydrogels produced from acrylated poly(lactic acid)-b-poly(ethylene glycol)-b-
poly(lactic acid) macromonomers. These hydro gels were produced by Piantino et ae24 
to control the release of Neurotrophin-3 by degradation via ester hydrolysis of the 
crosslinks. In vitro analysis showed that release could be controlled by chemical 
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composition, with the optimised composition allowing release over 2 weeks. In vivo 
analysis showed that the released Neurotropin-3 was biologically active. 
Natural polymers are also used extensively in systems controlled by diffusion and 
degradation. Carvalho et af25 discuss dextrin hydrogels which are produced by 
derivatising dextrin with vinyl acrylate groups. These hydrogels were shown to release 
BSA over various time frames as release was diffusion-based and was dependent on 
crosslinking density. Two natural, hydrophilic polymers; sodium alginate and 
hydroxypropyl methylcellulose (HPMC), were used to produce hydrogel beads for 
release of BSA by Nochos et a1226. A high BSA loading was exhibited for all hydrogel 
formulations. The incorporation of HPMC into alginate hydrogel beads resulted in an 
increased degree of swelling, due to high hydrophilicity, which in turn resulted in 
improved BSA release in a physiological saline solution. 42% of BSA was released 
from the HPMC-alginate system in 7 hours, in comparison with the 5% released for 
sodium alginate only. 
Enhanced corneal epithelial wound healing was achieved by controlled release of 
epidermal growth factor by Hori et af27. Cationic gelatin hydrogels, crosslinked with 
glutaraldehyde, were used and release of the growth factor was as a result of 
biodegradation of this material. In vitro the release was shown to be biphasic with an 
initial burst followed by slow release. In vivo analysis showed that release of the growth 
factor from these hydrogels led to accelerated wound healing in a rabbit corneal 
epithelial defect model. 
The release of multiple growth factors was discussed in section 1.5 and was shown to be 
beneficial in the examples given. The release of two different proteins was also reported 
by Lee et al228 from hyaluronic acid and tyramine hydrogels. They showed that release 
was related to the mechanical strength of the hydrogel, with weaker hydrogels releasing 
proteins faster than stronger ones. Release was also shown to be dependent on the 
interaction of the protein with the hydrogel. Negatively charged a-amylase was released 
by diffusion from the hydrogel, whereas lysozyme, a positively charged protein, 
interacted with hyaluronic acid and therefore was released only due to degradation of 
the hydrogel, resulting in unique release kinetics for each protein. 
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1.8.6 Hydrogel Summary 
Hydrogels have been used extensively as drug delivery systems due to many 
advantageous properties including biocompatibility, mild synthetic procedures and the 
wide range of formulations possible. A significant property of hydrogels is the release 
control that can be achieved depending on the chemical composition selected. Drug 
release can be controlled by swelling of the materials, often in response to an external 
stimulus, and degradation of the polymer, thus material design can be tailored to 
achieve the release kinetics required. As discussed previously, hydrogels have already 
been investigated to release growth factors and the successes reported suggest that there 
is considerable scope to develop new hydrogel formulations for specific growth factor-
delivery applications. 
1.9 Summary 
The vital role of angiogenesis within the wound healing process has been discussed and 
the important role of angiogenic growth factors has been highlighted. VEGF, a potent 
angiogenic stimulator, was discussed in detail, as well as the influence of heparin-
interaction. The potential of VEGF for therapeutic application was considered and a 
number of current approaches were discussed for delivery of exogenous angiogenic 
growth factors. Whilst impressive results have been presented by a number of groups, 
no material is currently able to fulfil all roles of the ECM whilst remaining simple to 
produce, reproducible and cost-effective. In order to produce a successful ECM-mimic, 
two approaches to protein delivery have been introduced, molecularly-imprinted 
polymers and hydrogel delivery systems. In both cases a number of impressive systems 
have been detailed, showing the potential of these approaches for protein delivery in a 
wide range of applications. 
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1.10 Project Overview 
As discussed in section 1.6, this thesis details the development of a biocompatible 
system that is capable of binding and releasing a patient's own VEGF in a wound 
healing application. An approach utilising a patient's own growth factors is expected to 
be more cost-effective than exogenous protein delivery, as well as easier to develop and 
get regulatory approval for moving to the clinic. It also removes the risk of protein 
denaturation during the synthetic procedure. 
Two approaches are investigated: VEGF-specific molecularly-imprinted particles and a 
heparin-bound peptide-functionalised hydrogel for interaction with heparin-binding 
growth factors. These materials were designed to mimic the ECM, binding growth 
factors non-covalently to allow release within a wound, whilst fulfilling the clinical 
requirements of being relatively simple to produce, easy-to-handle, stable, cost-effective 
and socially-acceptable as they would not require delivery of exogenous growth factor. 
Project Objectives 
Approach J: Molecularlv-Imprinted Polvmers 
1. Design a suitable MIP system for binding and release ofVEGF 
2. Optimise synthetic procedure 
3. Synthesise and characterise MIP and a false-imprinted and non-imprinted 
companson 
4. Analyse the VEGF binding and release characteristics 
Approach 2: Heparin-Bound Peptide-Functionalised Hydrogels 
1. Design a hydrogel system capable of binding and release ofVEGF through 
interaction with bound heparin. 
2. Synthesise and characterise a heparin-binding hydrogel 
3. Analyse VEGF binding and release characteristics 
4. Analyse hydrogel cytocompatibility with relevant skin cells 
5. Analyse hydrogel potential to stimulate angiogenesis with an in vitro 
angiogenesis model 
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l Strategy 1: Core-Shell Particles 
2.1 Consideration of VEGF as a Target for Molecular Imprinting 
The crucial role of VEGF within both physiological and pathological angiogenesis 
makes this protein an intriguing template for molecular imprinting. As discussed in the 
introduction to this report, there are a variety of approaches utilised to imprint such 
biological materials into molecularly-imprinted polymers, each with advantages and 
disadvantages. It is thought that to produce a selective MIP, the synthetic route 
undertaken should consider the application of the material produced, time and cost 
constraints, the type and format of polymeric material and the nature of the template 
itself. 
As discussed in section 1.7, core-shell molecularly-imprinted particles (CS-MIPs) have 
been produced previously in our research group. These particles consist of a 
poly(styrene-co-divinyl benzene) core with a molecularly-imprinted outer shell of oleyl 
phenyl hydrogen phosphate crosslinked with ethylene glycol dimethacrylate. Research 
carried out with these particles by Carter et all 57. 159. 160 prior to this project concentrated 
on hydrophobic, low molecular weight organic compounds. The use of such compounds 
as templates enabled electrostatic interactions and hydrogen bonding with the phosphate 
functional monomer, as well as hydrophobic interactions, to produce successful 
recognition polymers. These materials meet many of the criteria discussed for the 
imprinting of biomacromolecules, such as the location of the cavities in the outer shell 
only and the compatibility with aqueous medium. Prior to this project, such particles 
had been imprinted with tripeptide sequences and the results suggested that recognition 
of short peptide sequences is possible I 60. As mentioned previously, Rachkov et al190 
have reported the "epitope approach" for the imprinting of proteins; a promising 
approach involving the imprinting of peptides consisting of a specific amino acid 
sequence which is also found on the protein of interest (Figure 2.1). The resulting 
polymer would then be able to recognise the protein through the amino acid sequence 
imprinted. This approach is thought to be cost-effective as it allows the use of synthetic 
peptide sequences rather than expensive protein, and could potentially produce 
imprinted polymers with higher selectivity than whole-protein systems due to the use of 
unique peptide sequences, allowing size and shape selectivity, instead of relying on 
multiple hydrogen bonds alone. 
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Figure 2.1: Schematic of the epitope approach to molecular imprinting. An amino acid sequence 
from a protein is selected and this amino acid sequence is used to synthesise a peptide. The peptide 
is then imprinted into the polymer. Following removal of the template, an imprinted cavity is then 
present in the polymer which is able to bind both the peptide as well as the original protein 
(adapted from Rachkov et al
'
9l). 
Heparin and cell surface-bound heparin-like glycosaminoglycans (GAGs) bind with 
VEGF in vivo, influencing the interaction of VEGF with endothelial cell receptors and 
therefore VEGF's ability to induce angiogenesis44, 46. This research initially attempts to 
produce a polymer capable of interacting with the protein as a "heparin-mimic", 
meaning it should interact with the protein via its heparin binding region and through 
similar interactions. Whereas heparin is able to bind electrostatically with basic amino 
acids present on VEGF through its sulphate moieties, the core-shell particles produced 
would be designed to interact electrostatically through the phosphate-based functional 
monomer present in the shell of the particles. Sulphate-based monomers have been 
investigated previously in unpublished work by S. Carter and were shown to produce 
less effective CS-MIPs than the phosphate alternatives. 
The previous success reported for the imprinting of short peptide sequences in these 
core-shell particles, as well as the advantages expected for the epitope approach meant 
that this approach was selected for this project. Core-shell particles with phosphate 
functionality in the outer shell were targeted for interaction with a peptide sequence 
containing basic amino acids from the heparin-binding region ofVEGF. 
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2.2 Methodology 
Core-shell particles molecularly-imprinted with biological materials were produced via 
emulsion polymerisation. An emulsion is defined by IUPAC as being a "fluid colloidal 
system in which liquid droplets and/or liquid crystals are dispersed in a liquid,,229. This 
type of polymerisation requires a dispersing medium (in this case water), a water-
insoluble or only slightly water-soluble mono mer, a water-soluble initiator and a 
surfactant, which is employed above the critical micelle concentration (CMC) to allow 
formation of micelles23o. Polymerisation then occurs within these micelles, generally 
resulting in polymer particles with diameters ranging from 50-500 nm231 . 
The core-shell particles for this application were produced following the general 
procedure described by Carter et all57, 159, 160. The particles were prepared via a two-
stage batch emulsion polymerisation process leading to a core-shell structure (Figure 
2.2). The core particles were synthesised from a styrene/divinylbenzene mono mer feed 
in the presence of surfactant to produce crosslinked poly(styrene-co-divinylbenzene) 
nanoparticles. A second polymerisation phase was then initiated in the presence of a 
template to coat the core particles with an outer shell of crosslinker, EGDMA and 
functional monomer, oleyl phenyl hydrogen phosphate (OPHP). 
The functional monomer employed in this research, oleyl phenyl hydrogen phosphate, 
originally isolated by Takagi et a1158, is a long chain alkyl phosphate, combining 
surface-active functionality with the ability to interact electrostatically with nitrogen 
donor atom-containing templates via the phosphate group. This allows the formation of 
core-shell molecularly-imprinted particles containing easily accessible imprinted 
cavities within the outer shell, offering advantages including ease of template removal, 
accessibility of imprinted cavities and compatibility with water, but it is also 
acknowledged that, as for most techniques, this methodology is not without its 
disadvantages. Consideration of the functional monomer reveals that it has 
disadvantages due to its polymerisability. The location of the double bond, internal to 
the long alkyl chain, renders it relatively unreactive and it is suggested that the 
monomer is not truly copolymerised but is instead incorporated into the EGDMA 
network through transfer of the radical via hydrogen abstraction 157. 
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Figure 2.2: Methodology of core-shell molecularly-imprinted particle synthesis (shown with 
arginine as an example template). (a) Synthesis of crosslinked polystyrene core particles. (b) 
Equilibriation of shell monomers around core particles. (c) Interaction of template molecule with 
functional monomer. (d) Polymerisation of the outer shell in the presence of the template molecule. 
(e) Removal of the template molecule. (f) Reintroduction of the template molecule to the 
molecularly-imprinted core-shell particle. 
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2.3 Optimisation of Synthesis 
In this work, a basic amino acid sequence from the heparin binding region of VEGF was 
selected as the template for imprinting (discussed in Chapter 3). It was thought that 
selecting a basic region should allow optimum selective binding with the phosphate 
groups of the CS-MIP. It was hypothesised that peptides which contain more 
hydrophobic or neutral amino acids, such as those trialled previously by Carter et a1 16o, 
will be imprinted more readily than those containing highly basic and hydrophilic 
moieties, as charged sequences may not be influenced by the hydrophobic effect and 
will therefore rely upon electrostatic interactions with the functional monomer alone to 
incorporate the peptide into the shell of the particles. It was therefore considered 
necessary to attempt to optimise electrostatic binding between the CS-MIP and template 
species in this case, to improve molecular imprinting of a basic peptide. Non-covalent 
interactions, such as the hydrophobic effect and electrostatic binding, are thought to be 
strongest in lower temperature environments and lower temperature synthesis routes 
have been shown to produce MIPs with higher selectivit;32. The initial attempt at 
optimising the process was therefore to consider the possibility of carrying this reaction 
out at a low temperature to optimise the non-covalent interactions. 
o 
11 (CH2)e-O-P-OH 
I 
O~ 
V 
Figure 2.3: Structure of oleyl phenyl hydrogen phosphate 
Another area for consideration was the functional mono mer, oleyl phenyl hydrogen 
phosphate (Figure 2.3). The surfactant-like properties of this mono mer were thought to 
locate imprinted cavities at the surface of the core-shell particles, but as discussed 
previously, the location of the double bond internal to the alkyl chain renders oleyl 
phenyl hydrogen phosphate fairly unreactive in radical polymerisation. The location of 
cavities at the particle surface is vital in epitope imprinting to allow access of the larger 
protein, and so it was decided to continue using this monomer despite its low reactivity 
and attempt to optimise incorporation of this monomer into the core-shell particles. 
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2.4 Redox Initiation Study 
Potassium persulphate and ascorbic acid were selected as a redox initiator system to 
allow polymerisation to occur at a low temperature. Research by Gafurov et af33 
showed that ascorbic acid is a promising component of a redox initiator system, as it 
retains a high reducing power at a wide range of pH, and demonstrated its use at 30°C. 
The decomposition of the potassium persulphate is thought to be accelerated by the 
dienol group of ascorbic acid through the following donor-acceptor interactions which 
allows the reaction to occur at lower temperatures (Figure 2.4). 
° ° OH 0-
+ S2082- --- + SO.-" + H+ + SOl-
OH OH 
HO HO 
° ° 0- 0 
+ S20l---- + SO -" + H+ + SO 2-4 4 
OH 
° 
HO HO 
Figure 2.4: Suggested interaction between potassium persulphate and ascorbic 
acid (from Gafurov et al232) 
A number of experiments were carried out to determine whether this redox system 
could be used to produce core-shell particles at 30°C, as well as the effect of ascorbic 
acid on the stability of the resulting latex. 
58 
2.4.1 Results of Redox Initiation Trials 
Different latex formulations for the synthesis of cross-linked polystyrene core particles 
were trialled both to investigate the effect of this initiator system on the latexes 
produced, and to optimise the polymerisation with this initiator system. 
Styrene DVB SDS Potassium Ascorbic Molar Temp acid Molar Sample (g) (g) Ratio (g) (OC) Persulphate Ratio ~g~ ~2) 
4.64 5.82 1:1 1.00 RT 0.105 0.068 1:1 
2 8.36 1.16 9:1 1.00 RT 0.105 0.068 1: 1 
3 8.36 1.16 9:1 0.50 30 0.105 0.068 1:1 
4 8.36 1.16 9:1 2.00 30 0.105 0.068 1:1 
5 8.36 1.16 9:1 1.00 30 0.105 0.068 1:1 
6 8.36 1.16 9:1 1.00 30 0.209 0.068 2:1 
7 4.50 0.50 t 1: 1 1.00 30 0.209 0.068 2:1 
Table 2.1: Latex formulations for poly(styrene-co-divinylbenzene) core particles (RT = room 
temperature SOS = sodium dodecyl sulphate surfactant) 
All latexes produced followed the method described in section 10.3.3 with varying 
conditions (Table 2.1), with the aim of synthesising a latex with little or no coagulum. 
Solids Particle 
Formulation Content Diameter Comment 
(%) (nm)(·) 
1 5.9 23 Coagulated 
2 12.2 68 Significant coagulation 
3 10.4 33 Significant coagulation 
4 13.4 37 Significant coagulation 
5 12.3 33 Significant coagulation 
6 13.1 42 Slight coagulation 
7 7.2 43 No coagulation 
Table 2.2: Physical properties of poly(styrene-co-divinylbenzene) latexes (a) average particle 
diameter determined by light scattering 
Initially a 1: 1 molar ratio of styrene to divinylbenzene was employed, as in sample 1, 
but this ratio led to a low viscosity emulsion with large amounts of coagulum forming 
within the reaction vessel. Switching from 1: 1 to 9: 1 styrene to divinylbenzene reduced 
the quantity of coagulum produced significantly, although it was only when the solids 
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content within the emulsion was halved, for sample 7, that an emulsion free from 
coagulation was produced. 
The solids contents of the latexes were analysed, which suggested that the overall yield 
of the reaction was largely unaffected by factors such as surfactant quantity, molar ratio 
of potassium persulphate to ascorbic acid or monomer ratio. Formulations from 2 to 6 
were found to have solids contents from 10.4% to 13.4% after coagulation and washing. 
The latex produced in sample 1 was found to have a solids content of only 5.9%, due to 
the extremely high amount of coagulum observed. A 7.2% solids content was observed 
for sample 7, a latex with half of the initial monomer content. It is acknowledged that 
these values are inaccurate as they do not take into account the solids present as 
coagulum, and for this reason no final monomer conversion values are available. 
The particle diameters of these latexes, both for the core particles discussed here and the 
core-shell particles which are discussed later, are very small, in the region of 20-70 nm. 
The particle sizes observed are smaller than would be anticipated from a standard 
emulsion polymerisation technique (generally 50-500 run), and instead bear 
resemblance to particles produced by microemulsion polymerisation (generally 10-100 
nm), which can occur when either the surfactant concentration is very high or the 
.. I 231 234 I h· . . d h th c • monomer concentratIOn IS very ow-' . n t IS case It IS expecte t at e 10rmatlOn 
of such small particles is due to the large quantities of surfactant. This high level of 
surfactant was employed following the general procedure previously described by 
C al157 159 160 Th C • f . 1 . h 11 d· . b arter et ". e 10rmatIon 0 partlC es WIt sma 1ameters IS thought to e 
advantageous as this will lead to an increased surface area of the resultant polymer; 
which is important for surface-imprinting techniques. 
After the alteration of monomer composition from 1: 1 styrene/divinyl benzene to 9: 1 
styrene/divinyl benzene, the particle size increased from 23 nm to 68 nm. This is most 
likely to be due to the coagulation of the larger particles present in sample 1, leading to 
a lower particle size for this sample. Altering the monomer composition in this way 
would not be expected to significantly affect the particle size of the latexes produced. 
No significant effect on particle size was observed as surfactant level was varied in 
samples 3, 4 and 5. At such a high level of surfactant, any further increases in surfactant 
concentration would be expected to have a minimal effect on the particle size observed. 
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In sample 6, the quantity of potassium persulphate was doubled to give a 2: 1 molar ratio 
of potassium persulphate to ascorbic acid as suggested in research by Gafurov et at233• 
This had little effect on the overall solids content of the latex, but led to an increase in 
particle size and a decrease in coagulation. This is likely to be due to minimising the 
quantity of unreacted ascorbic acid present in the latex, thereby increasing the colloidal 
stability of the system. Finally, halving the mono mer content of the reaction in sample 7 
produced the most successful latex with a solids content of 7.2%. No coagulation was 
observed for this system and particles of 43 run diameter were produced. It was this 
system that was chosen as the optimised procedure for further investigations into core-
shell synthesis. 
2.5 Investh!ation into Alternative Initiator Systems 
It was thought that to optimise the imprinting efficiency of this polymer system it would 
be important to achieve the highest incorporation of the functional mono mer, OPHP, as 
possible in the outer shell of the particles. This should lead to improved recognition 
properties as it may enable interaction with more template molecules, or especially 
where templates with more than one functional group are concerned, the template may 
interact with more than one functional monomer, possibly producing a more specific 
recognition cavity. Five formulations were trialled for core-shell synthesis, both redox 
and thermal systems, using the optimised formulation of sample 7, varying only in the 
choice of initiator. The systems trialled were potassium persulphate and ascorbic acid 
(system 1), 4,4'-azobis-(4-cyanovaleric acid) (system 2), hydrogen peroxide and 
ascorbic acid (system 3), ammomum persulphate and N,N,N',N'-
tetramethylethylenediamine (TEMED) (system 4) and potassium persulphate (system 
5). All of these were used successfully to produce latexes of core particles with solids 
contents of7.2%, 7.8%, 6.9%, 6.8% and 7.3% for initiator systems 1 to 5 respectively. 
The effect of outer shell formation around the core particles (Le. core-shell synthesis) 
was then analysed with respect to particle size, zeta potential and incorporation of oleyl 
phenyl hydrogen phosphate as determined by ion coupled plasma atomic emission 
spectroscopy (lCP-AES). ICP-AES was carried out at the Centre for Analytical 
Sciences, University of Sheffield. 
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Initially initiator system 1 was analysed to determine whether it was possible for the 
outer shell polymerisation to occur at a low reaction temperature. ICP-AES was 
employed to investigate the practicality of such a system with a relatively unreactive 
monomer such as oleyl phenyl hydrogen phosphate. Particle size analysis of the core 
and core-shell particles produced by initiation with potassium persulphate and ascorbic 
acid showed a significant increase in particle size as the shell is formed, as would be 
expected. An increase of approximately 7 % in diameter is observed from the core to the 
core-shell particles, from 44 nm to 47 nm. Although these results infer that a shell is 
formed on the surface of the poly(styrene-co-divinylbenzene) core particles, it does not 
provide any information on the incorporation of the functional monomer. ICP-AES 
analysis revealed that 59.3 mg/kg of phosphorous was found within the core-shell 
particles, equating to the incorporation of only 1.9% of the functional monomer 
introduced to the reaction mixture. Absence of phosphorous in the core particles was 
confirmed by ICP-AES analysis, which showed that, as expected, the poly(styrene-co-
divinylbenzene) particles contain less than 4.45 mg/kg phosphorous, which is below the 
threshold of the technique. This confirms that phosphorous in the core-shell particles 
was due to the phosphate monomer. Such a low incorporation of functional OPHP 
monomer into the outer shell of the particles suggests that this initiator system may not 
be suitable in this case. 
In order to determine whether oleyl phenyl hydrogen phosphate could be successfully 
incorporated into the core-shell particles in a low temperature reaction, the other two 
redox initiator systems were trialled; hydrogen peroxide with ascorbic acid at 35·C 
(initiator system 3), and ammoruum persulphate with N,N,N' ,N'-
tetramethylethylenediamine (TEMED) at 30·C (initiator system 4) (Table 2.3). Particle 
size analysis of both systems showed a significant increase in particle size (Figure 2.5) 
upon formation of the outer shell, inferring that a shell had been formed on the particles. 
However, as for the potassium persulphate redox system, these low temperature systems 
afford relatively low functional monomer incorporation of 3.5% and 1.9% for hydrogen 
peroxide system and ammonium persulphate system respectively. When considering the 
functional monomer incorporation, these results suggest that hydrogen peroxide and 
ascorbic acid is the most successful initiator system for a low temperature reaction, but 
the limited incorporation of OPHP for all of the low temperature systems suggests that, 
for this monomer, this approach may not be suitable. 
62 
Initiator Sl:stem 1 2 3 4 5 
Potassium 4,4' -azobis-( 4- Hydrogen Ammonium Potassium 
Initiators persulphate & cyanovaleric peroxide & persulphate & persulphate 
ascorbic acid acid} ascorbic acid TEMED 
Particle Type Core Core- Core Core- Core Core- Core Core- Core Core-
shell shell shell shell shell 
Temp. eC) 30 30 60 60 35 35 30 30 70 70 
Average Particle 
44.0 47.2 42.1 45.5 51.1 53.8 47.4 51.9 28.7 111.7 Diameter (omia) 
Average Zeta 
-46.3 -47.7 -46.8 -47.9 -42.2 -47.5 -39.6 -44.7 -44.2 -52.6 Potential (mV) 
Phosphorous 
content (mg/kg)(b) 59.3 201.3 101.5 56.6 350.2 
Functional 
mooomer 1.9 6.5 3.5 1.9 11.7 
inco!:Eoration (%) 
Table 2.3: Results of initiator trial (a) average particle diameter determined by light scattering (b) 
phosphorous content determined by ICP-AES 
As discussed previously, the internal double bond present within the alkyl chain of oleyl 
phenyl hydrogen phosphate is thought to be fairly unreactive and so this monomer does 
not copolymerise very successfully. The monomer is most likely incorporated into the 
shell of the core-shell particles via transferls7, the reaction between a radical and a non-
radical species in which a hydrogen atom is abstracted from oleyl phenyl hydrogen 
phosphate leaving a radical present on the monomer. The radical can be stabilised 
through resonance with the double bond present, subsequently decreasing the reactivity 
of the radical. A transfer reaction between a radical and a non-radical species may have 
a higher activation energy than a standard propagation reaction which could make this 
reaction strongly temperature-dependent235• It is suggested that at the temperatures 
previously trial led, 30-35°C, the activation energy had not been overcome and therefore 
the incorporation of the functional mono mer into the shell of the particles was minimal. 
Any phosphate monomer present within the shell was unlikely to have been covalently 
bound and was therefore removed during the vigorous washing steps undertaken prior to 
ICP-AES analysis. 
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Although it is thought that the use of low temperature systems could optimise non-
covalent reactions between the template and functional mono mer employed in 
molecular imprinting, it is necessary to incorporate as much of the functional monomer 
as possible to produce molecularly-imprinted polymers capable of recognition. The two 
thermal initiator systems were then tri alled, 4,4'-azobis(4-cyanovaleric ac id) (initiator 
system 2) and potassium persul phate (i ni tiator system 5) (Table 2.3). It was 
hypothesised that a higher temperature would enable the acti vation energy for a transfer 
reaction to be reached, and therefore should lead to an increase in the incorporation of 
OPHP. The ICP-AES results confirmed thi s hypothesis, as incorporations of 6.5% and 
11 .7% for 4,4' -azobis(4-cyanovaleric ac id) and potassium persulphate respecti vely were 
achieved. Although still relati vely low values, they represent a significant improvement 
compared to those at low temperature. As for the low temperature systems, an increase 
in particle diameter for both systems was observed once the shell had been fo rmed, 
from 42 nm to 46 run for 4,4' -azobis( 4-eyanovaleri c aeid) and from 29 nm to I 12 nm 
fo r potassium persulphate (Figure 2.5). 
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Figure 2.5: Particle diameter increase upon outer-shell formation for different initiator systems. 
Va lues shown are mea n ± SEM. 
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Unlike initiator systems 1-4, for which the particle diameter increase upon shell 
formation is as would be expected for these particles, the extremely large increase in 
particle size from core to core-shell for the potassium persulphate injtiator trial (system 
5) is obviously not due to increased shell thickness. In this case, the monomer feed in 
the shell formation reaction could obviously not lead to such a large increase. Instead 
this increase is expected to be as a result of partial tlocculation within the sample, 
leading to a multimodal particle size distribution, which is confirmed by the increased 
viscosity of this sample. Although flocculation is complex it is suggested that this may 
be due to the large amount of potassium persulphate utilised. This could cause the 
polymerisation rate to be too high, as well as affecting the pH of the system and the 
ionic strength, all of which would be expected to have a significant effect on latex 
stability. 
Finally, the zeta potentials of all latexes in the initiator trial were analysed. Zeta 
potential is a physical property exhjbited by particles in suspension. A net charge at a 
particle surface affects the ion distribution in the surrounding interfacial region236. This 
results in an increased counter-ion concentration adjacent to the particle surface. The 
liquid layer surrounding the particle therefore consists of two layers, referred to as an 
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Figure 2.6: Schematic showing the electrical double layer surrounding a charged particle and the 
slipping plane, the boundary at which the zeta potential is measured. 
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electrical double layer. The inner region, known as the Stem layer, is where the ions are 
strongly bound to the particle, and the outer region (the diffuse layer) contains ions 
which are less firmly associated236, 237. There is a notional boundary within the diffuse 
layer, known as the surface of hydrodynamic shear, or the slipping plane238• When the 
particle moves, ions within this boundary move with it and those ions outside of this 
boundary remain with the bulk solution. Zeta potential is the potential which exists at 
this boundary. The magnitude of the zeta potential indicates the stability of the 
colloidal system239. If the particles are highly charged, either positively or negatively, 
they will repel each other and are unlikely to coagulate. 
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Figure 2.7: Change in zeta potential upon formation of outer-shell for different initiator systems. 
Values shown are mean values ± SEM. 
Due to the large amounts of surfactant present in the latexes, as well as the fact that the 
crude latexes were analysed, thereby leading to varying pH and ionic strength values for 
the individual latexes, the zeta potential results are utilised primarily to compare with 
ICP-AES data and consider the change in zeta potential upon shell formation. 
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Results from the latexes produced during the initiator trials show that, as hypothesised, 
the formation of a charged shell around the core particles leads to an increase in the zeta 
potential of the particles (Figure 2.7). The overall zeta potentials for the core particles 
were negative due to the presence of sodium dodecyl sulphate at the surface of the 
particles. The zeta potentials measured for the core particles were all fairly similar, 
ranging from -39.6 mV to -46.8 mY. Although all particles for all five initiator systems 
showed an increase in zeta potential upon shell formation, the increases observed for the 
potassium persulphate and ascorbic acid system and the 4,4'-azobis-(4-cyanovaleric 
acid) system were not statistically significant (two sample student t-test). The other 
systems all demonstrate a statistically significant increase in zeta potential when the 
shell is present on the core particle (two sample student t-test, p < 0.05). Initiation by 
. the hydrogen peroxide and ascorbic acid and the ammonium persulphate and TEMED 
systems led to a zeta potential increase of 13% as the outer shell was formed. As 
expected, initiation by potassium persulphate at 70·C gave the largest zeta potential 
increase from -44 mV to -53 mY, an increase of 18%. This is in agreement with the 
ICP-AES results, which show that this system leads to the highest phosphorous content 
in the polymer. 
2.5.1 Summary of Initiator Study 
Initially it was thought that the optimum polymerisation procedure for peptide-
imprinted core-shell particles would involve a low temperature initiation method, in 
order to optimise the non-covalent interactions between template and functional 
monomer. From the three redox initiator systems trialled it was determined that such an 
approach led to very low incorporation of the functional monomer, which is believed to 
be due to the low reactivity ofOPHP. It was thought that improving incorporation of the 
functional monomer would be vital for the molecular imprinting process, and so thermal 
initiators, potassium persulphate and 4,4' -azobis-( 4-cyanovaleric acid), were also 
trialled. Both thermal systems allowed formation of the core-shell particles and led to 
increase in particle size and zeta potential as the outer shell was formed. Initiation by 
potassium persulphate at 70·C gave the highest incorporation of oleyl phenyl hydrogen 
phosphate of 11.7%, and so this system was used for further investigations involving 
this monomer, despite the weak flocculation observed in this technique. 
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2.6 Optimisation of Thermal Potassium Persulphate Initiation 
Initiation by potassium persulphate at 70°C allowed the highest incorporation of 
functional monomer but also resulted in a partially flocculated system, which is more 
difficult to handle in the next stage of the process and also decreases the latex surface 
area. It was therefore necessary to determine a formulation which minimises 
flocculation before this procedure could be used for molecular imprinting. Two 
approaches were trialled, reduction of initiator content and replacing the batch process 
with a starve-fed emulsion polymerisation. 
Starve-fed emulsion polymerisation refers to a method of monomer addition where the 
monomer is gradually introduced into the reaction vessel at a specific rate in order to 
allow the majority of the monomer to be polymerised before further monomer is added. 
In a batch emulsion polymerisation (as carried out previously), the polymer particles are 
swollen with monomer which makes them "soft", and so upon collision these particles 
are likely to flocculate. It was hypothesised that carrying out the reaction using a starve-
fed approach for the optimised system of initiation by potassium persulphate at 70·C 
would avoid the presence of heavily swollen polymer particles and would thereby 
reduce the amount of flocculation. Reduction of the initiator concentration was also 
expected to reduce aggregation. Although flocculation is a complex process, it is known 
that latex stability is affected by the rate of polymerisation and also the pH and ionic 
strength, all of which could be influenced by a high concentration of potassium 
persulphate. 
Properties Core Core-shell Core-shell Core-shell 
Batch Starve-fed Reduced Initiator 
Avemge Particle Diameter (nmia) 30 112 33 44 
Particle Diameter Increase (%) 273 10 47 
Phosphorous content (mglkg)(b) < 4 350.2 260.3 338.7 
Phosphate monomer inCOrporation (%) 0 11.7 8.7 11.2 
Table 2.4: Physical properties of core and core-shell particles produced in the optimisation of a 
thermal potassium persulphate initiated core-shell synthesis (a) average particle diameter 
determined by dynamic light scattering (b) phosphorous content determined by ICP-AES 
The hypotheses above were confirmed when comparing the same formulation for both 
batch and starve-fed reactions and reaction with reduced initiator concentration (Table 
2.4). The core latexes produced had average particle diameters of approximately 30 nm 
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but a considerable difference was observed when the core-shell particles were formed. 
For the batch reaction, as used in all previous experiments, a particle diameter of 112 
nm was measured for the core-shell particles, whereas under starve-fed conditions and 
with reduced initiator particle diameters of 33 nm and 44 nm were determined. 
Although the use of the starve-fed approach is able to completely eliminate the problem 
of flocculation, ICP-AES analysis of the particles showed that the phosphorous content 
of the sample was reduced. Phosphorous contents of 11.7% and 8.7% were obtained for 
the batch and starve-fed reactions respectively. A possible explanation for this 
observation is that in the batch reaction there is a higher concentration of monomer 
present at all times, which may result in a slightly higher rate of the transfer reaction, 
and thus slightly higher functional monomer incorporation. By halving the initiator 
concentration it was possible to produce core-shell particles with an average diameter of 
44 nm with no significant change in phosphorous content, and therefore this optimised 
formulation was selected for the imprinting experiments. 
2.7 Final Summary 
A core-shell approach to molecular imprinting developed by Carter et a1151, 159, 160 was 
chosen for this project. It was thought that the use of a redox initiation system would 
allow the synthesis to be carried out close to room temperature, thus optimising the non-
covalent interaction between the template and functional monomer that is required in 
molecular imprinting. An initial study with the redox system of potassium persulphate 
and ascorbic acid enabled the formulation to be optimised for this approach. It was 
determined that synthesis of the core-shell particles was possible with redox initiation, 
but that incorporation of the functional monomer was very low. This was also shown to 
be the case for two alternative redox systems, hydrogen peroxide with ascorbic acid and 
ammonium persulphate with TEMED. From these results it was determined that it 
would not be possible to carry out the molecular imprinting technique with redox 
initiation, as it was vital to maximise functional monomer incorporation and thereby 
increase interaction between template and functional monomer. Thermal initiation was 
then considered, with the most successful incorporation of OPHP observed with 
potassium persulphate initiation at 70°C. Finally, optimisation of initiator concentration 
allowed a synthetic procedure to be developed to produce a stable latex, which could 
then be employed in molecular imprinting studies. 
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3 Core-Shell Molecularly-Imprinted Particles 
Following optimisation of the core-shell synthesis procedure, the next step in the 
. . . t' oC \["CGf tenuites the detennination of a suitable peptide sequence to 
epltope lml'nn m<?, l L, '"\ 
be imprinted during the formation of the outer shell. 1n this chaptet the choice of 
template is rationalised and the ability of the resultant core-shell molecularly-imprinted 
particles to bind both peptide sequences and VEGF is discussed. 
3.1 Determination of Peptide Sequence 
A discussion of VEGF was provided previously (section 1.4) and the structure and 
folding of this protein, together with information available relating to the activity of 
different regions of the protein, must be carefully considered in order to determine 
which amino acid sequence is chosen as the peptide template for epitope imprinting. It 
is also necessary to ensure that the sequence chosen is located in an accessible region of 
the protein if recognition of the protein by the polymer is to be achieved. 
VEGF consists of two identical polypeptide chains which are covalently linked by a pair 
of disulfide bonds35. A number of different isoforms exist, but VEGF I65 , the most 
common isoform, will be considered here. It is known that all heparin-binding isoforms 
share the same 50 residue C-terminal, termed the heparin-binding domain (Figure 3.1 & 
Figure 3.2 & Figure 3.3)35. 
- ~o 20 ) 0 40 50 
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Figure 3.1: A schematic representation ofVEGFI65• The darker regions represent the heparin-
binding domain. Disulphide bridges are represented by lines. Reproduced from Fairbrother et alt. 
t Reproduction of figure 1 reprinted from Structure, Vo!. 6 no. 5, Fairbrother, Wayne J., Champe, Mark 
A., Christinger, Hans W., Keyt, Bruce A., Starovasnik, Melissa A., "Solution structure of the heparin-
binding domain of vascular endothelial growth factor" , 637-648, Copyright 1998, with permission from 
Elsevier. 
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The 50 residue heparin-binding region of VEGF 165, after plasmin cleavage, can interact 
with heparin with the same affinity as VEGF 165 but does not interact with cell receptors 
for VEGF48. Conversely, VEGF 165 with this 55 residue fragment removed will bind to 
cell receptors but not heparin. Moreover, upon binding with cell receptors the mitogenic 
potency ofVEGF is significantly reduced in comparison to VEGF I65. 
It is thought that the heparin-binding region of VEGF must be relatively accessible to 
allow interaction with large polysaccharides like heparin and cell surface-bound 
heparin-like GAGs and so it is postulated that this region would also be accessible for 
binding with phosphate groups on the surface of the CS-MIPs produced. 
c 
Figure 3.2: A schematic stereo representation of the structure of the 55-residue heparin-binding 
region of VEGF'6S, highlighting secondary structure, disulfide bridges and hydrophobic packing 
of selected sidechains. Adapted from Fairbrother et al t 
t Adaptation of figure 5 reprinted from Structure, Vol. 6 no. 5, Fairbrother, Wayne J., Champe, Mark A., 
Christinger, Hans W., Keyt, Bruce A., Starovasnik, Melissa A., "Solution structure of the heparin-binding 
domain of vascular endothelial growth factor", 637-648, Copyright 1998, with permission from Elsevier. 
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The high negative charge density of heparin suggests that an excess of positive charge 
would be present on any specific heparin-binding site on VEGF55 • The areas of positive 
charge on the heparin binding region can be seen when considering the solvent-
accessible molecular surface of VEGF55 (Figure 3.3i5• Thus it is expected that the 
heparin binding site on VEGF55 will include Arg13, Arg14, Lysl5, Lys30, Arg35, 
Arg39, Arg46 and probably also Lys52, Arg54 and Arg55. 
Figure 3.3: Solvent-accessible molecular surface of minimised mean structure of 55-residue 
heparin-binding region of VEGFI6S• Colour code: red = acidic residue, white = no charge, blue = 
basic residue. The two views are related by 180· rotation about the vertical axis. Reproduced from 
Fairbrother et al t 
In order to replicate heparin binding it was therefore decided to select an amino acid 
sequence rich in basic residues. Research by Rachkov et al 190 suggests that the most 
suitable template size for epitope imprinting is 3-6 amino acid sequences with a surface 
area in the region of 650-900 A2. For an unfolded polypeptide chain, the total accessible 
surface area, Ab is directly proportional to its molecular weight, Mw 
At = 1.45Mw 
t Reproduction of figure 7 reprinted from Structure, Vol. 6 no. 5, Fairbrother, Wayne J., Champe, Mark 
A., Christinger, Hans W. , Keyt, Bruce A., Starovasnik, Melissa A., "Solution structure of the heparin-
binding domain of vascular endothelial growth factor", 637-648, Copyright 1998, with pennission from 
Elsevier. 
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A 3-6 amino acid residue was therefore required from the heparin-binding region for 
initial investigations. Although a number of highly basic residues of a similar size exist 
within this region it is acknowledged that these regions are likely to be involved in 
folding and hence it may be difficult to replicate the 3D conformation of these residues 
in the protein when imprinting only the short peptide sequence. This could have a 
negative effect on the recognition properties of the polymer produced, as the sequence 
of interest on the protein may not have the correct conformation to fit into the 
previously formed recognition cavity. In order to avoid this complication, a sequence 
from the end of the carboxy terminus was selected as this is unlikely to be affected by 
folding. 
The sequence selected was the pentapeptide Asp-Lys-Pro-Arg-Arg (DKPRR), residues 
51-55 (Figure 3.4). This residue has an approximate total accessible surface area of 973 
A2 and offers a number of advantages. Firstly, it is a highly charged species containing 
three basic amino acids. Secondly, this sequence includes two adjacent arginine 
residues, Arg54 and Arg55, which is also observed in another part of the heparin-
binding sequence, Argl3 and Argl4. This may mean that different areas of the heparin-
binding region of the protein could also interact with the recognition cavity. As 
mentioned previously, this sequence is not involved in protein folding (shown in Figure 
3.2) and also contains a proline residue. The distinctive cyclic structure of proline's side 
chain locks its <p backbone dihedral angle at approximately -600 , giving proline an 
exceptional conformational rigidity compared to other amino acids24o• This introduces 
rigidity into the peptide and therefore is expected to reduce the number of 
conformations possible for this peptide in relation to other less rigid pentapeptide 
sequences. 
Figure 3.4: Structure of DKPRR peptide 
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The high proportion of basic amino acid residues in this sequence is expected to be 
highly beneficial for this application. Interactions between basic amino acid residues, 
including lysine and arginine, and acidic phosphate groups, such as those present on the 
core-shell particles, are known to play an important role in nature. A significant 
example is the formation of ionic bonds between these groups in DNA-binding 
proteins241 • In particular, arginine, characterised by its basic guanidinium group, is 
capable of forming electrostatic and hydrogen bonds of a highly specific nature with 
anions, primarily phosphates, sulphates and carboxylates242• The exceptional ability of 
arginine to form strong non-covalent bonds is based on its guanidine moiety. This 
guanidinium functionality is able to use "Y -delocalisation" for stability, sharing the 
positive charge evenly over the three nitrogen atoms (Figure 3.5), and possesses a 
number of potential hydrogen bond donors242• Arginine is highly water-soluble and has 
a pKa of 12.48243• 
+ 
OH 
\1\1'0 O---H-NH 
'Po#' ~N 
/" / H \1\1'0 O---H-N 
OH 
H 
(b) 
Figure 3.5: (a) Structure of arginine. The guanidine moiety is highlighted and shown in the singly 
protonated form utilising Y-delocalisation (b) Suggested phosphate-arginine interaction 
Research by Fromm et ae44 details the high frequency of arginine residues in heparin-
binding regions of proteins and shows that stronger hydrogen bonding and more 
exothermic electrostatic interactions between the sulphate and carboxylate groups on 
GAGs with arginine side chains, rather than other basic amino acids, contributes 
significantly to the strong protein-GAG interaction. It is therefore thought that the use 
of an anionic phosphate functional monomer and an arginine-based template molecule 
could lead to more specific interactions between the polymer produced and the template 
due to a possible reduction in non-specific hydrophobic binding and an increase in more 
specific electrostatic interactions. 
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3.2 Synthesis and Characterisation 
Four types of particles were produced to determine the ability of core-shell molecularly-
imprinted particles (CS-MIPs) to bind and release VEGF. Firstly, core particles were 
produced as previously discussed in Chapter 2 and these particles were analysed for 
their recognition ability. A second emulsion polymerisation step was then carried out to 
produce three further samples; DKPRR-imprinted CS-MIPs, imprinted with the peptide 
sequence present on VEGF, GAA-imprinted CS-MIPs, imprinted with an unrelated 
peptide sequence for comparison and blank-imprinted CS-MIPs, core-shell particles 
produced without the presence of a peptide. 
The samples were produced by the procedure determined in Chapter 2. After synthesis 
of the core particles, the functional monomer and crosslinker were added to the 
emulsion and allowed to equilibrate around the core particles. The template was then 
added in pH-adjusted buffer, and was left for one hour to interact with the functional 
monomer to form the desired template-monomer complex. The reaction was then 
initiated by potassium persulphate at 70°C and the reaction was carried out for 16 hours. 
After the polymerisation, the template was washed from the particles prior to peptide 
and protein binding and release studies. 
Figure 3.6: TEM images of (a) blank-imprinted CS-MlP (b) GAA-imprinted CS-MIP (c) DKPRR-
imprinted CS-MIP and (d) core particles. Scale bar for core-shell particles = 50 nm. 
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This synthetic procedure allowed the formation of core-shell particles. It was observed 
that coagulum formed during the synthesis of the peptide-imprinted particles, but in all 
cases the stable portion of the latex was analysed. 
By this method, core particles of35 run were produced with a zeta potential of -38 mV. 
Formation of the outer shell led to changes in the physical properties, as would be 
expected (Table 3.1). As the outer shell was formed an increase in particle diameter was 
observed in all cases. The increase in particle size was accompanied by a small increase 
in zeta potential from -38.0 mV to -41.6 mV, -42.9 mV and -42.7 mV for the blank CS-
MIP, DKPRR CS-MIP and the GAA CS-MIP respectively, but this zeta potential 
increase was not shown to be significant. 
Sample Particle Zeta Potential Phosphorous content 
Diameter (nm) (mV) Ibl (mglkg) (c) 
(a) 
Core 34.9± 0.2 -38.0 ± 1.6 <to 
Blank CS-MIP 44.4 ± 0.8 -41.6 ± 0.9 347.4 
DKPRR CS-MIP 48.2 ± 0.1 -42.9± 1.1 390.0 
GAACS-MIP 45.4 ± 0.3 -42.7 ± 1.3 344.6 
Table 3.1: Physical properties of core and core-shell particles. (a) Particle diameter as determined 
by dynamic light scattering. (b) Zeta potential determined after dialysis to remove template from 
the core-shell particles. (c) Phosphorous content determined by ICP-AES after washing procedure. 
The incorporation of the functional monomer is vital for a molecularly-imprinted 
monomer as it is this functional group that would provide the recognition site for 
binding the target molecule. The presence of the functional monomer was analysed by 
ICP-AES, considering total phosphorous content. The location of the phosphate 
monomer at the surface of the particles was then investigated by X-ray Photoelectron 
Spectroscopy (XPS) and Energy-Dispersive Spectroscopy (EDS). Prior to analysis by 
any of these techniques, the samples were vigorously washed, either by coagulation 
with isopropyl alcohol and subsequent washing or by dialysis, to remove any unbound 
monomer and template material. This meant that their phosphorous content is assumed 
to be from monomer bound into the core-shell particles. 
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Figure 3.7: Energy-Dispersive Spectroscopy (EDS) spectra of (a) core and (b) DKPRR-imprinted 
core-shell particles showing the presence of a phosphorous peak (p). The presence of a phosphorous 
peak is seen in all of the core-shell particles. 
Qualitative confirmation of the presence of the monomer in the shell was provided by 
EDS (Figure 3.7) and XPS (Figure 3.8). For both techniques, no phosphorous was 
observed for the core particles and phosphorous peaks were observed for all core-shell 
particles (core-shell images shown are representative of all core-shell images produced). 
Quantitative analysis by ICP-AES showed no phosphorous present on the core particles. 
As the outer shell is formed it is possible to detect phosphorous with 347.4 mg/kg 
present within the blank CS-MIPs. Similar quantities of 390.0 mg/kg and 344.6 mg/kg 
were observed for the DKPRR CS-MIP and the GAA CS-MIP respectively. These 
results are comparable to the results shown in Chapter 2 for core-shell particles 
produced in the same manner and confirm that the functional monomer is present in the 
outer shell of the material. 
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Figure 3.8: X-ray Photoelectron Spectroscopy (XPS) spectra of the phosphorous 2P region of (a) 
core and (b) DKPRR-imprinted core-shell particles. Phosphorous presence was confirmed for all 
core-shell particles. 
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3.3 Peptide Binding Studies 
The molecularly-imprinted particles in this study were produced to recognise, bind and 
subsequently release VEGF. The particles were first tested to determine their ability to 
recognise and rebind the peptide template, DKPRR. Due to the high costs involved 
when working with a synthetic peptide and a biological protein, only small quantities of 
the particles were produced, and therefore binding studies were carried out on a small 
scale. Two approaches to a peptide binding study were used to investigate whether the 
molecular imprinting would influence selectivity: a colorimetric study and a zeta 
potential study. The particles were analysed for their ability to bind DKPRR, the 
template of interest, PRKRD (proline-arginine-Iysine-arginine-aspartic acid), a 
scrambled version of the peptide, and SSSSSSSS (octaserine), an unrelated and 
relatively inert peptide sequence. 
3.3.1 Colorimetric Peptide Binding Study 
Due to the low quantities of CS-MIPs available, it was thought that a colorimetric study 
would allow easy assessment of the binding abilities of the different particles. A number 
of molecularly-imprinted polymers have been previously reported in which the 
recognition process can be optically analysed using a variety of sophisticated 
approaches, including incorporation of fluorescent or chemiluminescent compounds 
within the MIp245.247 and the use of fluorescent templates and labels248-25o. MIPs have 
been produced for which binding can be analysed by UV Nis, infrared and surface 
plasma resonance251 . Fewer reports are available which result in a visual colour change. 
Analysis of binding by colour change has been achieved in a variety of ways. A change 
in yellow colour intensity was reported by Manesiotis et al252 upon binding of Z-
glutamate with a 1-(4-styrl)-3-(3-nitrophenyl)urea functional monomer, and Grafe et 
al250 utilised the azo dye 4-trifluoroacetyl-4'-[N-(methacryloxyethyl)-N-(ethyl)amino] 
azobenzene which exhibits a colour change from red to yellow upon covalent binding 
with amines in organic solvent. 
In order to conduct a colorimetric study, it was decided to produce the peptide 
sequences required for the binding study with a suitable chromophore at the end of the 
sequence. It was thought that this would allow both qualitative analysis of the peptide 
when bound to the particles, as well as provide quantitative data about the binding by 
analysis of the peptide solutions before and after exposure to the polymer samples. A 
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similar approach was previously used by Chow et at249 who analysed homocysteine-
imprinted MIPs using fluorescently-tagged homocysteine. 
Methyl red was selected as the chromophore for this work. Methyl red is a weakly basic 
azo dye with a pKa of 4.8253 which is known to undergo a colour change from yellow to 
red when pH is lowered within an aqueous solution. Methyl red is employed as a pH 
indicator in the range of 4.4 to 6.0254. It is widely documented that the colour change 
observed is due to the azo form, which exists in neutral conditions, being converted into 
a tautomeric equilibrium of the protonated ammonium species and the azonium 
species255, 256. 
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Figure 3.9: Protonation equilibria for methyl red (as discussed by Tawarah et ae~ 
Ueno et a1257. 258 discuss the use of methyl red-modified cyc10dextrin to demonstrate 
guest selective binding. In this wor~ methyl red is attached to the wall of a ~­
cyclodextrin, present in a cavity, and a binding study was carried out in an acid solution. 
Even in acid the modified cyclodextrin remains yellow as the methyl red is inside the 
cavity and therefore protected from protonation. An organic guest compound then 
displaces the methyl red from the cavity and a colour change from yellow to red is then 
observed. It was hypothesised that producing methyl red-modified peptide sequences to 
analyse the effect of molecular imprinting may allow a colorimetric assessment of the 
quantity of peptide binding but also a method to detect the presence of binding regions 
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or cavities. It was suggested that binding regions or cavities in the outer shell of the 
particles may be able to interact with the imprinted peptide through numerous 
electrostatic interactions, thus preventing the structural changes occurring during 
protonation and preventing, or at least minimising, the colour change usually observed 
upon decreasing the pH for a methyl red moiety in solution. The selectivity of the 
binding regions would then be demonstrated, since unrelated peptide sequences, despite 
being bound to the particle, may not be tethered by as many electrostatic interactions 
and would therefore be susceptible to structural change, and therefore also colour 
change, upon lowering the pH of the solution. 
The methyl red-tagged peptides (methyl red-SSSDKPRR (MRSSSDKPRR), methyl 
red-SSSPRKRD (MRSSSPRKRD) and methyl red-SSSSSSSS (MRSSSSSSSS)) 
(Figure 3.10) were synthesised by solid phase peptide synthesis to allow colorimetric 
binding and release analysis of the imprinted polymers. The methyl red moiety 
possesses a carboxylic acid group which enabled incorporation by the formation of an 
amide bond between this and the terminal amine present on the peptide sequence. The 
methyl red molecule could therefore be attached to the peptide at the end of the standard 
peptide synthesis programme. Three serine spacer units were added between the 
DKPRR sequence and the methyl red molecules for two reasons. Firstly, the methyl red 
molecule is relatively hydrophobic and so the water-soluble serine units were added to 
keep the peptide water-soluble. Secondly, the serine units were added as a spacer unit, 
to prevent the methyl red molecule affecting the ability of the DKPRR sequence to bind 
with the CS-MIPs. 
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Figure 3.10: Structures of (a) methyl red; (b) MRSSSDKPRR; (c) MRSSSSSSSS; (d) 
M RSSSPRKRD 
Firstly, the modified peptides were analysed in solution to confirm that the expected 
colour changes occurred as for the methyl red moiety alone. The structural changes 
from the azo species, in alkaline and neutral pH, to the tautomeric equilibrium of the 
protonated ammonium species and the azonium species are also observed with UV Nis 
spectroscopy in aqueous solution for methyl red-modified peptides employed in this 
study. The azo form of the methyl red peptides produces two main absorption maxima 
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at 270 run and 470 run. Following the research published onp-methyl red by Tawarah et 
a1256, the peak at 470 nm is attributed to the 1t-1t* transition of the azo group and the 
maximum at 270 run is due to the n-1t* transition of the amide group. As the pH is 
lowered, and the structure is converted to the protonated ammonium species and the 
azonium species, the maximum at 270 nm is gradually replaced by an absorption 
maximum at 315 nrn and the peak at 470 nm is shifted to 510 nm (Figure 3.11 a). This 
shift is visible by eye as the colour changes from orange to red (Figure 3 .11 b). 
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Figure 3.11: Results of a visible absorption spectroscopy pH study on MRSSSDKPRR. (a) UVlVis 
spectrum of MRSSSDKPRR at different pH values showing the colour change upon protonation. 
(b) Visual colour change image of MSSSDKPRR at different pH values (L-R) I M H3P04, pH 2 and 
pH 6. 
Peptide Binding Study Results 
The ability of the core and core-shell particles to bind peptide sequences was analysed 
by three different methyl red-tagged peptides; MRSSSDKPRR, the peptide sequence of 
interest, MRSSSPRKRD, a scrambled version of the peptide, and MRSSSSSSSS, an 
unrelated peptide sequence with different functionality. Prior to peptide binding all 
polymer samples were coagulated and washed thoroughly to remove any template 
(Section 10.3).0.1 ml of each latex (equating to 4.6 mg, 4.2 mg, 3.6 mg and 2.8 mg of 
core, blank CS-MlP, GAA CS-MIP and DKPRR CS-MlP, respectively) was then 
exposed to solutions of the three different peptides to determine whether there was any 
selectivity observed in non-competitive studies. 
In all cases, the introduction of methyl red-tagged peptide solution to the polymer 
resulted in 100% peptide bound to the polymer. This strong binding was attributed to 
the presence of the methyl red moiety, a hydrophobic group which binds preferentially 
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to the organic polymer rather than remaining in solution. This interaction between the 
methyl red moiety and the core and core-shell particles meant that it was not possible to 
determine a binding constant by this method. Instead it was decided to remove the 
peptide bound only by hydrophobic interactions, and thereby determine the amount of 
peptide interacting with the particles via electrostatic interactions with the polymer. In 
order to remove peptide bound entirely by this hydrophobic interaction, a series of 
washes was employed with increasing concentrations of isopropyl alcohol (IPA) from 
0% to 100% alcohol. It was anticipated that introducing isopropyl alcohol would 
minimise hydrophobic interactions, resulting in peptide bound only through electrostatic 
interactions with the phosphate monomer present in the particle outer shell. 
When considering the MRSSSDKPRR peptide, introduction of IPA led to a significant 
decrease of peptide on the core material (Figure 3.12d). By 80% isopropyl alcohol only 
8% of the initial peptide loading remained bound to this polymer. No further peptide 
was removed from this material despite washes to 100% isopropyl alcohol being carried 
out. Much higher quantities ofMRSSSDKPRR were retained on the core-shell particles, 
thereby demonstrating binding through interaction of the peptide with the phosphate 
functionality of the polymer. 88% of the MRSSSDKPRR exposed to the GAA-
imprinted polymer remained on the polymer, even in a 100% isopropyl alcohol solution 
(Figure 3.12a). A similar result was observed for the DKPRR-imprinted polymer 
(Figure 3.12b), with 83% of MRSSSDKPRR remaining on the polymer after the 
washing steps. The blank CS-MIP (Figure 3.12c), produced in the absence of the 
template, bound 92% of the peptide binding to the polymer even in 100% isopropyl 
alcohol. It is hypothesised that the high binding observed for the blank-imprinted 
particles may be due to the random distribution of functional monomer in the outer shell 
of the particles. This could lead to a high number of less selective binding sites, or 
binding sites with a 1: 1 functional monomer to peptide interaction, in comparison to 
imprinted core-shell particles which may contain fewer binding sites but with a higher 
affinity for the peptide due to higher functional monomer concentration in the imprinted 
cavities. 
The selectivity of binding was tested by comparing MRSSSDKPRR with 
MRSSSPRKRD, a scrambled sequence, and MRSSSSSSSS, an unrelated peptide 
sequence. The binding study with MRSSSPRKRD resulted in a similar binding pattern 
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to that obtained with MRSSSDKPRR (Figure 3. 12). By an 80% isopropyl alcohol 
solution only 10% of the peptide remained on the core particles, compared to a fi nal 
value of 94% for GAA-imprinted particles, 95% on the blank-imprinted particles and 
84% on the DKPRR-imprinted polymer. 
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Figure 3.12: Results of peptide binding studies showing peptide release with increasing isopropyl 
alcohol percentage for the four different polymer sa mples; (a) GAA CS-MIP (b) DKPRR CS-MIP 
(c) Blank CS-MIP (d) Core particles. 
It is hypothesised that any binding occurring between peptide and core-shell particles 
would be due to electrostatic interaction of the anionic phosphate functionality in the 
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polymer with the cationic amine or guanidinium functionality on the peptide sequences. 
Using this hypothesis, it was anticipated that the methyl red-tagged serine peptide 
(MRSSSSSSSS) would show minimum interaction with the polymer, other than 
hydrophobic interactions due to methyl red. Experimental results agreed with this 
hypothesis, with only I % of the total MRSSSSSSSS peptide exposed to the polymer 
remaining on the core particles after isopropyl alcohol washes (Figure 3.l2d). Low 
quantities of peptide after washing were also observed for the core-shell particles. 4% 
of total peptide was found remaining after washes for the DKPRR CS-MIP, the blank 
CS-MIP and the GAA CS-MIP (Figure 3.12a-c). In all cases with this peptide, any 
peptide that was removed had been recovered by 50% isopropyl alcohol, suggesting that 
hydrophobic interactions were indeed responsible for the initial binding observed. 
Amount of peptide remaining on polymer after IPA Selectivity (S) 
washes (pg/mg polymer) 
MRSSSDKPRR MRSSSPRKRD MRSSSSSSSS UIIU2 UIIU3 
(UQ (U2~ ~U3~ 
Core particles 0.26 0.30 0.02 0.85 11.80 
Blank CS-MIP 3.19 3.18 0.15 1.00 21.25 
GAACS-MIP 3.53 3.67 0.18 0.96 20.16 
DKPRR CS-MIP 4.29 4.23 0.24 1.02 17.59 
Table 3.2: Selectivity oC methyl red-tagged peptide binding experiments. U = amount oC peptide 
remaining per milligram of polymer after all washes where 1 = MRSSSDKPRR, 2 = 
MRSSSPRKRD and 3 = MRSSSSSSSS. 
Consideration of the final quantity of each of the peptides on the polymers after all 
isopropyl washes reveals binding selectivities (Table 3.2). The selectivity value, S, for 
each binding experiment could be determined (S = amount of target molecule 
bound/amount of competitor peptide bound). A value of 1 shows no selectivity to either 
compound, a value higher than 1 denotes selectivity towards MRSSSDKPRR, the target 
molecule, and a value lower than I shows selectivity towards the competitor compound. 
When comparing MRSSSDKPRR to MRSSSPRKRD the blank particles show no 
selectivity to either peptide, as would be expected, with a value of 1.00. A value of 1.02 
for the DKPRR CS-MIP shows very weak selectivity towards the target peptide, 
whereas a value of 0.96 for the GAA CS-MIP shows that particles imprinted for GAA 
are slightly selective towards the scrambled competitor, MRSSSPRKRD. It is not too 
surprising that the selectivity values in this experiment are insignificant since the two 
compounds are identical in terms of their charge and functionality, varying only in the 
sequence of five of the amino acids. From these results, it was confirmed that both basic 
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peptides could bind to the core-shell particles, with no significant differences between 
the two. 
When comparing the results from MRSSSDKPRR with MRSSSSSSSS, strong 
selectivity was observed in all cases. Selectivities of 11.80,21.25,20.16 and 17.59 were 
determined for the core particles, GAA CS-MIP, blank CS-MIP and DKPRR CS-MIP 
respectively. 
Peptide Release Studies 
The best way to determine the effects of molecular imprinting may not be just to 
consider binding, but to also consider the release of the target molecule, especially for 
drug delivery applications. The molar ratio of monomer to target molecule was 1: 1 in 
the synthesis, but it is likely that more than one monomer could interact with one 
peptide moiety due to the high functionality of the peptide sequence employed. If this 
is the case, it may be that high selectivity would not be immediately observed on 
binding, as all polymers with phosphate functionality in the shell would be expected to 
bind with basic peptides to some degree. It is suggested that, upon binding into a 
molecularly-imprinted cavity, the target molecule is bound by numerous simultaneous 
electrostatic interactions, resulting in stronger binding and therefore possibly having a 
significant effect on the release characteristics. 
Colour Change 
The methyl red-modified peptide sequences were bound to the polymer as described in 
the peptide binding study discussion above. After the peptide binding and isopropyl 
washes, an acid release study was carried out, with washes of 50% isopropyl alcohol 
and 50% phosphoric acid of increasing molarity, until the peptide had been removed by 
interrupting the electrostatic interactions between the phosphate groups in the polymer 
and the amine and guanidine groups in the peptides. As the bound methyl red peptides 
were exposed to an increasingly acidic environment, a colour change for the polymer-
peptide material was confirmed by the naked eye. 
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In the MRSSSDKPRR study for the non-specific polymers, core, GAA-imprinted and 
blank-imprinted particles, the bound-peptide changed colour immediately from orange 
to red, whereas the peptide bound to the specific DKPRR-imprinted polymer remained 
orange (Figure 3.13). 
Figure 3.13: Polymer samples with bound MRSSSDKPRR peptide at 0.05 M phosphoric acid 
showing colour change (L-R) DKPRR CS-MIP, Blank CS-MIP, core particles, GAA CS-MIP. 
DKPRR-imprinted CS-MIP remains orange, whereas the other three samples turned red/pink, 
which is associated with the protonated form of methyl red. 
A similar but less dramatic effect was also observed for the MRSSSPRKRD peptide 
study, with obvious colour changes to red/pink for the core, blank CS-MIP and GAA 
CS-MIP. For the MRSSSPRKRD on DKPRR CS-MIP, a colour change was observed 
to a darker orange. The obvious lack of colour change from orange to red for the peptide 
bound to DKPRR CS-MIP in the MRSSSDKPRR and MRSSSPRKRD studies 
demonstrates that, for these samples, protonation of the methyl red moiety was 
prevented. In previous experiments on the methyl red-tagged peptides in solution, it was 
shown that a colour change will occur as the solution becomes more acidic. It is 
suggested that the lack of colour change is due to the presence of the methyl red peptide 
in a specific binding area (cavity) in the DKPRR-imprinted particles, in which the 
peptide is bound to numerous functional monomer groups. This could protect the 
peptide from protonation and thereby prevent the colour change. For the non-specific 
polymers, cavities for this peptide are not present and so it is hypothesised that any 
bound material present is loosely bound on the surface of the particles where it is 
susceptible to protonation. 
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Phosphoric Acid Release Study Results 
The release characteristics for the imprinted core-shell particles bound with 
MRSSSDKPRR and MRSSSPRKRD were assessed using a series of washes with 50% 
isopropyl alcohol (to prevent absorption of the peptide by hydrophobic interactions) and 
50% phosphoric acid solutions at varying molarities. The molarity of phosphoric acid 
was increased at regular intervals from 0.01 M to I M. By I M phosphoric acid, the 
majority of both peptides on all of the polymer samples had been released into the 
supematant. This result demonstrates that the binding observed is due to electrostatic 
interactions between the basic peptides and the phosphate functional monomer. The 
blank and GAA CS-MIP release profiles were very similar for both the MRSSSDKPRR 
and the scrambled MRSSSPRKRD peptides (Figure 3.14). 
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For the blank CS-MIP (Figure 3.14a) the peptide was released from 0.05 M phosphoric 
acid in both cases. Both peptides were then steadily released from the polymer in a very 
similar release pattern until 0.5 M, at which point the quantity of peptide measured in 
the supernatant reduced until 0.7 M was reached and no further peptide was removed 
from the polymer. The final quantity of peptide remaining on the blank CS-MIP after all 
washes was 1.0% for both MRSSSPRKRD and MRSSSDKPRR peptides. 
A similar result was obtained for the GAA CS-MIP, and both peptides showed very 
similar release patterns (Figure 3.14c). In this case the MRSSSPRKRD was released 
from 0.05 M phosphoric acid, and the MRSSSDKPRR was released from 0.04 M. Both 
peptides were then released in very similar release profiles until 0.8 M at which point no 
further peptide was removed. For the GAA-imprinted particles 5.3% and 3.8% of the 
initial peptide loading remained on the polymer after all of the washes for 
MRSSSPRKRD and MRSSSDKPRR respectively. 
The effect of the molecular imprinting process was observed in the results for the 
DKPRR-imprinted particles (Figure 3.14b). For this polymer, different release profiles 
were observed for the methyl red-tagged DKPRR and the scrambled version, PRKRD. 
For MRSSSPRKRD, as for the GAA CS-MIP and the blank CS-MIP, the peptide was 
released from 0.05 M phosphoric acid and above. The peptide was then released 
steadily until 0.5 M, at which point the amount of peptide released per wash reduced 
until 0.8 M phosphoric acid, beyond which no further peptide was released. When 
considering MRSSSDKPRR, all of the peptide remained on the polymer up to 0.08 M 
phosphoric acid. The peptide was then released reasonably consistently until 0.9 M. 
After the final wash 3.1% of the MRSSSPRKRD peptide and 4.2% of the 
MRSSSDKPRR remained on the DKPRR-imprinted CS-MIP. The obvious differences 
in these release profiles, and more specifically the delay in release of the 
MRSSSDKPRR peptide from the DKPRR-imprinted polymer until 0.08 M phosphoric 
acid, suggests that the imprinting of DKPRR in the synthesis of the outer shell of the 
particles has led to the creation of binding regions which are selective towards DKPRR. 
For both of the other polymers, GAA CS-MIP and blank CS-MIP, no significant 
difference was observed for the two peptide sequences. The delay in the release of 
MRSSSDKPRR can be explained by the peptide being bound by a number of phosphate 
groups simultaneously, in the correct spatial arrangement for the DKPRR sequence. The 
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scrambled peptide sequence may also bind to the phosphate groups in these regions but 
may not be of the correct 3D structure to interact with all of the phosphate groups 
available, thus resulting in a weaker binding interaction and release of the peptide at a 
lower acid molarity than observed for the imprinted DKPRR sequence. The differences 
in release of MRSSSDKPRR and MRSSSPRKRD from the DKPRR CS-MIP IS 
indicative of a molecular imprinting effect. 
3.3.2 Zeta Potential Peptide Binding Study 
The zeta potentials of the four particle types; core particles, blank CS-MIP, DKPRR 
CS-MIP and GAA CS-MIP, were analysed as it was hypothesised that the binding of 
the peptide to phosphate groups present in the outer shell of the polymer particles may 
lead to a reduction in the zeta potential of the particles, resulting in destabilisation of the 
latex and possibly coagulation. Two peptides were investigated, DKPRR, the basic 
peptide sequence from VEGF, and SSSSSSSS, an unrelated peptide sequence with no 
basic functionality. In order to investigate this hypothesis, the latexes were first dialysed 
against phosphoric acid (with sodium dodecyl sulphate (SDS)) and then deionised water 
(with SDS) to remove the template peptide sequences as well as any other species that 
may interfere with the measurement. The dialysis was carried out in the presence of 
SDS to ensure that the latex did not coagulate during the process. Aliquots of peptide 
were then added to the latexes and the zeta potential was analysed after each addition to 
determine the effect of peptide binding on the zeta potential. 
The first three additions of DKPRR did not have a significant effect on the zeta 
potential of the particles. but the fourth addition led to a dramatic reduction in zeta 
potential for the blank-, DKPRR- and GAA-imprinted core-shell particles to -6.45 mY, 
-7.98 mV and -19.20 mV respectively (Figure 3.l5b). The zeta potential of the core 
particles remained largely unaffected by the peptide additions, even up to 6 additions of 
DKPRR (30 ~g DKPRR peptide). Due to dialysis with equal quantities of surfactant it 
is thought that the particles will be stabilised with comparable amounts of surfactant, 
and so if the observed reduction in zeta potential was due entirely to the interaction of 
DKPRR peptide with surfactant it is expected that a similar result would be obtained for 
the core particles. As this is not the case, the lack of binding of the peptide with the core 
particles suggests that the decrease in zeta potential observed for the core-shell particles 
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is a direct result of interaction of the peptide with the phosphate functionality of the 
outer shell. 
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binding study. 
A second zeta potential investigation was also carried out with an unrelated peptide, 
SSSSSSSS. The same experiment was carried out as for DKPRR peptide but in this case 
no reduction in zeta potential was observed for any of the particles (Figure 3.ISa). In 
fact, the zeta potentials did not alter significantly for the entire duration of the 
experiment. This suggests that the binding observed through the decrease in zeta 
potential for core-shell particles with DKPRR was due to the functionality of the amino 
acids present on the DKPRR sequences, and furthermore it is anticipated that the 
arginine and lysine functionalities play the major role. 
In polyacrylamide gel beads produced by Pang et al 166 to bind BSA, the importance of 
surface charge was demonstrated by zeta potential studies, as the most successful MIP 
formulation was shown to have a zeta potential which was of equal value but opposite 
charge to the BSA target molecule. In their paper, no study was shown for the zeta 
potential when the MIP was bound to the BSA but it does agree with the zeta potential 
findings in this thesis. In this thesis, the zeta potential was shown to approach zero as 
the basic peptide sequence, DKPRR, became bound to the core-shell particles, showing 
that surface charge is reduced upon binding with the positively charged peptide. 
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3.3.3 Conclusion of Peptide Binding Studies 
Peptide binding to the core-shell molecularly-imprinted particles was analysed 
colorimetrically and by monitoring zeta potentials. Zeta potential results showed that 
interaction occurred between the DKPRR peptide and the functional phosphate 
monomer present in the outer shell of the core-shell particles, as a sharp reduction in 
zeta potential was observed as the peptide concentration increased for the blank-, 
DKPRR- and GAA-imprinted CS-MIPs. No reduction in zeta potential was observed 
with the core particles, confirming that the peptide interacts only with the mono mer 
present in the outer shell. The aqueous electrophoresis studies with the peptide 
SSSSSSSS saw no reduction in zeta potential for any particle type. This result 
confirmed that the interaction between the DKPRR peptide and functional monomer is 
due to the basic amino acid functionality interacting with the phosphate group of the 
mono mer. No selectivity was observed in the zeta potential study. 
In the colorimetric study, binding was observed by the core-shell particles for the 
MRSSSDKPRR and the MRSSSPRKRD peptide types, with significantly less 
MRSSSSSSSSS binding to the particles. Again, this confirms the interaction between 
the phosphate monomer and the basic amino acid functionality. No binding selectivity 
was observed between the MRSSSDKPRR and MRSSSPRKRD peptides for the three 
types of core-shell particles. More significant differences between the core-shell 
particles were observed in the peptide release study, and indicated a molecular 
imprinting effect. Firstly, the initial addition of phosphoric acid led to a colour change 
of the peptide bound to the polymer from orange to red. This colour change occurred for 
all samples apart from MRSSSPRKRD bound to DKPRR-imprinted particles, and most 
significantly, MRSSSDKPRR bound to DKPRR-imprinted particles. It is suggested that 
this effect was due to these peptides being bound through multiple phosphate groups in 
imprinted cavities on the DKPRR-imprinted CS-MIP, which prevented protonation of 
the methyl red moiety. This result implies that a molecular imprinting effect has 
occurred, positioning the functional monomers in such a way as to provide specific 
binding sites. 
This effect is further confirmed in the acid release study. For both the blank CS-MIP 
and the GAA CS-MIP, the MRSSSPRKRD and the MRSSSDKPRR peptides are 
released in a very similar pattern, suggesting no difference in binding between the two. 
92 
Conversely, for the DKPRR-imprinted CS-MIP, the MRSSSPRKRD and 
MRSSSDKPRR have different release profiles, with the scrambled MRSSSPRKRD 
peptide being released at lower acid concentrations than the MRSSSDKPRR peptide. 
This result also suggests that a molecular imprinting effect is occurring, as the 
MRSSSDKPRR peptide appears to be more strongly bound to the polymer. It is 
hypothesised that both MRSSSDKPRR and the MRSSSPRKRD were able to bind to 
the imprinted cavities present on the DKPRR polymer, but the MRSSSDKPRR polymer 
may be more strongly bound as the spatial arrangement of phosphate groups may lead 
to this peptide being bound through numerous binding regions. 
No significant molecular imprinting was observed in the amount of peptide bound, but 
an effect was observed in the release of the peptide, as the MRSSSDKPRR peptide was 
more strongly bound to the DKPRR-imprinted polymer than the scrambled version. 
This is as might be expected when considering the similarity of the two peptides. The 
ability of the core-shell particles to interact with the basic peptide sequences meant that 
it was decided to carry out a protein binding study. 
93 
3.4 VEGF Binding and Release Study 
The aim of the CS-MIPs was to synthesise a polymer which had been imprinted with an 
amino acid sequence present in VEGF and subsequently produce a material which is 
able to selectively bind this protein. It was also hypothesised that such an imprinted 
polymer would be able to bind VEGF more effectively than either blank-imprinted 
particles or particles imprinted with an unrelated peptide sequence (in this case GAA). 
The selectivity of the CS-MIPs for VEGF over different proteins has not yet been 
analysed, but the ability of the DKPRR-imprinted particles to bind and release VEGF in 
comparison to other core-shell molecularly-imprinted particles has been investigated. 
Consideration of the peptide binding study results meant that it was expected that all of 
the core-shell particles would be able to bind VEGF, and that any difference in binding 
was more likely to be observed on release of the protein. 
The ability of the core-shell molecularly-imprinted particles to bind and subsequently 
release VEGF was determined using an Enzyme-Linked ImmunoSorbent Assay 
(ELISA). The following conditions employed were selected for an initial study and it is 
acknowledged that future studies with varying time scales, temperatures and doses 
could provide further relevant information. Future studies carried out within cell culture 
medium could also provide a more realistic biological environment. 
To prepare the particles for analysis, 0.1 ml of emulsion (equating to 4.6 mg, 4.2 mg, 
3.6 mg and 2.8 mg of core, blank CS-MIP, GAA CS-MIP and DKPRR CS-MIP 
respectively) was coagulated using isopropyl alcohol. The particles were then washed 
following the standard washing procedure previously used in the peptide binding and 
release study (Section 3.3). Before introduction of the VEGF, SDS removal was 
confirmed by conductivity analysis of the wash solutions. This was important to prevent 
denaturation of the protein when it came into contact with the particles. The particles 
were washed until no change in conductivity of the wash solution was observed. The 
particles were then used for the protein binding study as a damp slurry in a 
polypropylene eppendorf sample tube. 
A solution of PBS containing 150 ng of VEGF was then added to the eppendorf tube 
and the particles were allowed to bind the VEGF over a 24 hour period at 4°C. After the 
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binding period, the supernatant solution was removed. For the release study, aliquots of 
PBS containing 1 % bovine serum albumin (a protein stabilizer) were added to the 
particles, agitated and incubated at 37°C until the time point for sample collection. At 
each time point the sample was centrifuged and the supernatant was removed and stored 
at -20°C until analysis by ELISA to determine VEGF content. A fresh aliquot of 1% 
BSA PBS was then added to the polymer for the next time point. Time points up to 48 
hours were analysed and the data was used to consider cumulative as well as 
instantaneous VEGF release from the CS-MIPs. 
A significant result of this study is that all core-shell particles were shown to release 
biologically active VEGF for up to 48 hours at 37°C, as determined by ELISA. The 
VEGF half-life in vivo is reported to be less than one hour63..{j6 . These results suggest 
that being bound electrostatically to the phosphate groups present in the core-shell 
particles stabilises the protein. This is in agreement with results reported by Huang et 
a1 259, who reported that polyelectrolyte complexes were able to stabilise VEGF. 
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Figure 3.16: Cumulative VEGF release per milligram of polymer over 48 hours as determined 
by an ELlSA for human VEGF. Results shown are mean ± 95% confidence (n = 2) 
When considering the cumulative data (Figure 3.16) it is obvious that there is no 
significant imprinting effect on the release of VEGF over this time period. Over the 48 
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hour period, an average of 22.4 ng, 21.3 ng and 20.9 ng of VEGF was released per 
milligram of DKPRR-imprinted, GAA-imprinted and blank-imprinted CS-MIPs, 
respectively. The high error between the repeats in this experiment, particularly for the 
blank-imprinted particles at the first 2 time points, means that it is not possible to 
confirm whether there are any real differences between the polymers. This may be in 
part due to the limited number of repeats (n = 2) but also due to experimental error. It 
would be necessary to repeat this experiment with a higher number of repeats in order to 
determine whether there is any imprinting effect on the cumulative VEGF release. 
The instantaneous data (Figure 3.17) reveals slightly different release patterns for the 3 
polymer types. No significant difference is observed for the first 3 time points (1 hour, 
6 hours and 12 hours) although the 12 hour time point is the only point at which less 
VEGF is released by the DKPRR-imprinted CS-MIP than both the GAA-imprinted CS-
MIP and the blank-imprinted CS-MIP. Significant differences (p < 0.05, one-way 
ANOVA with post-hoc Tukey analysis) were observed at the 24 hour and 48 hour time 
points, at which a significantly higher quantity of VEGF was released by the DKPRR-
imprinted CS-MIP than the other polymers. This suggests that sustained release of 
VEGF might occur for the DKPRR-imprinted CS-MIP. 
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3.5 Discussion of Results 
3.5.1 Effect of Molecular Imprinting 
The molecularly-imprinted core-shell particles were tested for their ability to bind and 
release both short peptide sequences and a biological protein. All core-shell particles 
were able to bind the two basic peptide sequences, MRSSSDKPRR and 
MRSSSPRKRD. It was previously discussed that the similarity in binding for the three 
types of core-shell particles may be due to the location of all functional monomer on the 
surface, thus allowing for binding of the peptide to the blank CS-MIP and the GAA CS-
MIP despite the lack of selective cavities. For both the blank-imprinted CS-MIP and the 
GAA-imprinted CS-MIP the release profiles for both peptides were very similar. A 
molecular imprinting effect was observed for the DKPRR-imprinted CS-MIP, with a 
considerably slower release profile for the MRSSSDKPRR peptide than the scrambled 
MRSSSPRKRD version. This is thought to be due to the higher affinity binding of the 
imprinted sequence to the selective cavities in the DKPRR-imprinted CS-MIP. This was 
confinned as the basic peptides, MRSSSPRKRD and particularly MRSSSDKPRR, were 
protected from protonation when bound to the DKPRR-imprinted CS-MIP, possibly 
because in this polymer the peptides were bound in an imprinted cavity to multiple 
phosphate groups, which prevented the structural changes which occur during 
protonation. It is hypothesised that protonation was possible in the blank CS-MIP and 
the GAA CS-MIP as in these cases the peptides are more loosely associated with the 
polymers and thus susceptible to protonation. 
In the protein study no significant difference between the three particle types was 
observed in the cumulative VEGF release profile, with approximately 20 ng of VEGF 
per milligram of all CS-MIPs released over 48 hours. When considering the 
instantaneous release, a significantly higher amount of VEGF was released from the 
DKPRR-imprinted CS-MIP at the last two time points, 24 and 48 hours. This sustained 
release result may be due to an imprinting effect as the protein may remain bound to the 
DKPRR-imprinted polymer longer as it is bound by multiple phosphate groups. A more 
significant imprinting effect may be seen at later time points as no further time points 
were analysed in this study. This would need to be investigated in an extended study. 
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An interesting release study was carried out by Alvarez-Lorenzo et af60, considering the 
release of norfloxacin (NRF), a low molecular weight (MW) drug, from poly(2-
hydroxyethyl methacrylate) (PHEMA) hydrogels functionalised with acrylic acid. They 
found that at low concentrations of the drug, the imprinted hydrogels were able to take 
up significantly higher amounts of NRF than non-imprinted ones, but this difference 
was not observable at higher concentrations of NRF. They concluded that this was due 
to the amount of functional monomer present in the hydro gels. Imprinting at the perfect 
molar ratio of template to monomer should lead to high affinity binding sites, whereas 
with excess monomer, or in the case of the non-imprinted polymer when no template is 
present, the monomer can randomly distribute within the network, forming low affinity 
binding sites. At low NRF concentration, with only a few NRF molecules in solution, 
they bind exclusively to the high affinity regions but at high concentration the NRF will 
also bind to the low affinity binding regions, present on the non-imprinted polymer and 
also present on the MIP, if excess functional monomer was present during synthesis. In 
their case, the acrylic acid monomer was able to interact strongly with the NRF, 
allowing only a 1: 1 template to monomer interaction to bind the NRF to the polymer. 
This means that at high concentration, the non-imprinted polymer may even bind more 
template than the MIP as it potentially contains more binding sites, albeit with less 
affinity for the drug. In the release study, again the most noticeable results were 
obtained when the drug had been bound at low concentrations. The hydro gels produced 
at 1:3 or 1:4 template to monomer ratio (expected to be the optimum when considering 
the structure ofNRF) sustained release of the drug for 2-5 days, which is expected to be 
due to the presence of the drug in high affinity cavities. 
This idea of heterogeneous binding sites due to various factors such as template to 
mono mer stoichiometry, variability of cavity shape and flexibility of matrix, was also 
discussed by Umpleby et a1261 • They suggested that the heterogeneous binding sites 
makes the binding properties of MIPs highly concentration dependent, with low 
selectivity observed at high loading and high selectivity observed at low loading. 
These findings are in agreement with our own conclusions in Section 3.3, that the 
location of the monomer on the surface of the core-shell particles due to its surfactant 
quality, despite the imprinting effect, means that a high amount of low affinity binding 
sites may be produced when the monomer is not consumed in template binding, 
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particularly in the case of the blank-imprinted CS-MIPs and the GAA-imprinted CS-
MIPs. This is a significant observation as the functional monomer employed has a high 
affinity for the amine and guanidine functionality of the MRSSSDKPRR and 
MRSSSPRKRD peptides and therefore a 1: 1 interaction can lead to binding, resulting in 
the lack of selectivity in the binding study. It also follows therefore, that a significant 
difference in release was observed for both the peptide and protein, because in this 
instance, the low affinity binding sites release the molecule readily, and so sustained 
release only occurs in the case of the imprinted polymer, where the peptide or protein is 
released from multiple binding points within the high affinity imprinted cavity. 
3.5.2 Comparison of Alternative Approaches to Protein Imprinting 
It is difficult to directly compare this work to reports of molecularly-imprinted proteins 
in the literature. In this work, the aim was to produce CS-MIPs which could bind and 
release bioactive VEGF over an extended period. Currently only the interaction of these 
particles with VEGF has been investigated. Also, in the case of most molecular 
imprinting literature, the work focuses primarily on the binding of the protein, whereas 
the work presented in this thesis has focused on the release profile of VEGF from the 
particles. A wealth of literature is currently available on molecular imprinting for 
protein binding, and it would not be possible to discuss all of the approaches utilised. 
Instead, the most relevant comparison to make is with similar approaches to those used 
in this thesis. 
Epitope Approach 
The epitope approach to molecular imprinting has been employed by a number of 
groups since the work for this thesis was begun in 2005, and has met with varying 
degrees of success. The majority of successful work in this area is still for the 
recognition ofpolypeptides rather than proteins, including work by Rachkov et al190 and 
Titirici et al l9l • Work by Emgenbroich et al192 has utilised the epitope approach to 
recognise short peptide sequences. This work aimed to recognise tyrosine 
phosphorylated peptides through the interaction of a phosphate group on the target 
molecule with a diaryl urea monomer. This relies on similar electrostatic interactions as 
the phosphate monomer and basic amino acids in the work discussed in this thesis. 
Their results show that the strong binding observed led, unsurprisingly, to MIPs with 
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clear selectivity for phosphorylated tyrosine over amino acids without a phosphate 
group, as well as being able to bind short peptide sequences containing phosphorylated 
tyrosine. In contrast to the results reported in this thesis, they showed that no binding is 
observed for the non-imprinted polymers, despite the urea monomer and phosphate 
target being present. It is surprising that no interaction would occur in this case. We 
suggest that this is due to the imprinting technique employed. Imprinting is carried out 
in a bulk polymerisation in the work by Emgenbroich et al192 and so the monomer 
would be expected to be randomly distributed throughout the material. This may mean 
that in the non-imprinted polymer the urea moieties may not be accessible to the target 
molecule, and therefore no binding is observed, whereas the MIP would have accessible 
cavities after template removal. In this thesis, no significant binding difference was 
observed between the DKPRR CS-MIP and blank CS-MIP, possibly because the 
phosphate is always present on the surface in low affinity binding sites and so is always 
available for binding whether imprinted cavities are present or not. 
A few reports have been published on the epitope approach for the binding of large 
proteins. Probably the most successful epitope imprinting work to date for the 
recognition of a protein was reported by Nishino et a1 193• Unique nonapeptide sequences 
of the carboxy-termini of 3 proteins; cytochrome C (Cyt C), alcohol dehydrogenase 
(ADH) and bovine serum albumin (BSA) were imprinted into thin MIP films by 
tethering the peptide to a functionalised silane surface before UV polymerising around 
the peptide with acrylamide, N,N-ethylenebisacrylamide and poly(ethylene glycol) 200 
diacrylate. This method allowed for surface-imprinted cavities to be formed as the film 
was removed from the peptide substrate. Selective binding showed that each peptide 
imprint selectively bound only its relevant protein within detection limits, with no 
binding observed for the non-imprinted polymer. Also, when the BSA peptide template 
was altered, differing only by one amino acid, the resulting MIP bound displayed 
diminished affinity for BSA. 
Very recently Xue et al195 utilised a variation on the epitope approach to bind 
staphylococcus aureus by imprinting the staphylococcus aureus protein A (SpA), which 
is a protein found only on the surface of staphylococcus aureus. In this approach, 
polyacrylamide gel beads were used which were formed with a low crosslinker content 
to provide a macroporous structure for template diffusion. The results showed that the 
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MIP was able to bind SpA over four other proteins, whereas no absorption was 
observed for the non-imprinted polymer. The MIP was then shown to bind 
staphylococcus aureus selectively over two other types of bacteria. This is a good 
example of the successful application of the epitope technique, although this approach 
would not be compatible with the desired drug delivery application of this thesis, as 
there was a low elution efficiency from the beads when removing the bound target 
molecule, and bacterial removal required the use of acetic acid and SDS surfactant. 
Brown et al262 have imprinted lysozyme, comparing the imprinting of the whole 
lysozyme protein to the epitope imprinting of a 16 residue lysozyme C peptide. Only the 
binding process was considered, and lysozyme binding was compared with the binding 
of RNase A. In a non-competitive environment the MIPs behaved similarly with both 
materials binding approximately the same amount of lysozyme, and in both cases over 
five times more lysozyme bound to the MIPs than RNase A. In a competitive situation 
the whole protein-imprinted MIP bound four times more lysozyme than RNase A, 
whereas no significant difference between the two proteins was observed for the 
peptide-imprinted MIP. Reasons given for the lower selectivity of the peptide MIP 
include the fact that the smaller peptide molecules may become embedded in the 
polymer and therefore not be surface-accessible. Also, the use of a small peptide 
fragment restricts the orientation in which the protein can bind. Success for the epitope 
approach was reported initially by Rachkov et al190 but the peptide imprinted in that 
case was 44% of the desired polypeptide. In the report by Brown et at262 the peptide was 
only 12 % of the protein, which is a similar situation to the DKPRR-imprinted CS-MIP 
employed in this thesis. This suggests that successful epitope imprinting may require 
templates of a certain percentage of the overall protein. 
The literature available on the epitope approach of imprinting proteins is varied, with 
the most success seen for the rebinding of shorter polypeptides. Some achievement has 
been reported with larger proteins for different formulations which offer better 
selectivity, but the inherent difficulties of this technique, such as the importance of 
orientation of the template to allow binding of the protein, may need to be overcome 
using techniques such as immobilised templates before this approach is truly successful 
for proteins. It is acknowledged that approaches by Nishino et al l93 and Xue et al l95 
report favourable results for the epitope imprinting of proteins, but it seems that there 
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are still a lot of improvements required, and investigation into the release of bioactive 
protein would be necessary before this technique would produce polymers which could 
be used for the desired wound healing application. 
Molecularlv-Imprinted Particles 
The diffusion difficulties associated with macromolecular templates mean that the 
majority of protein imprinting is carried out with surface imprinting techniques or 
mesoporous bulk polymers. Recently, the use of molecularly-imprinted particles have 
been popular for protein imprinting. Pang et al166 have produced polyacrylamide gel 
beads via inverse-phase suspension polymerisation, with methacrylic acid as the 
functional monomer and bovine serum albumin as the target molecule. It was reported 
that the BSA-imprinted polymer was selective for BSA over a comparison protein, 
ovalbumin, and showed a much higher adsorption capacity than the non-imprinted 
beads. They report that the considerably lower absorption capacity for the non-
imprinted material is due to the lack of a cavity containing multiple binding points. The 
functional monomer is thought to be randomly distributed throughout the gel, leading to 
very weak interaction and reduced BSA adsorption. In the blank-imprinted CS-MIP 
particles discussed in this thesis, it is also expected that the functional mono mer is 
randomly distributed in the shell, but in this case always at the surface due to its 
surfactant properties. The functional monomer is a phosphate in our case, which is 
known to interact strongly with the basic amino acids on either peptide or protein target 
molecules. The lack of difference in binding observed in this project between the 
DKPRR-imprinted CS-MIP and the blank-imprinted CS-MIP is attributed to these 
points. Even in the blank-imprinted CS-MIP, the functional monomer is still accessible 
on the surface of the particles, and the electrostatic interaction it provides is still strong 
enough to tether the target molecule. Thus binding still occurs even though imprinted 
cavities are not present. It is therefore unsurprising that for this system the differences 
between the imprinted and blank-imprinted polymers are observed in the release of the 
compound as this will be affected by how many functional monomers are interacting 
with the target compound simultaneously. 
Bovine serum albumin was used as a target by Tan et al189 for core-shell particles 
produced by mini emulsion polymerisation. In this case the template was immobilised to 
the core particle via a spacer chain containing an imine bond. Formation of the shell was 
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then formed by polymerising around the core, producing core-shell particles with 
surface cavities after removing the BSA template by hydrolysis of the imine group. In 
batch binding studies, the MIP produced with the immobilised template bound 
significantly more than the non-imprinted polymer, and also bound considerably more 
than a MIP produced with free BSA template. In a competitive binding study of BSA 
and lysozyme, the free-BSA MIP and the free-BSA non-imprinted polymer showed 
similar non-preferential uptake of the proteins. Conversely, the immobilised BSA MIP 
absorbed BSA selectively, whereas the non-imprinted polymer predominantly bound 
lysozyme. The impressive results from these core-shell particles are attributed by the 
authors to the immobilisation approach, although the results also demonstrate the 
success of the whole protein approach to imprinting. Whether or not this method could 
be utilised for the desired biological application of this project would depend on 
whether the process is compatible for a bioactive protein. The BSA-immobilised core 
particle is exposed to a surfactant and prolonged synthesis at 40°C. It is not discussed 
by the authors whether the BSA binding sites formed bind BSA in an active 
conformation. To determine whether this could be an effective approach for a biological 
protein delivery application, it would be prudent to study the activity of the released 
protein. 
Core-shell particles were produced by Qin et al263 to recognise lysozyme using surface-
initiated living radical polymerisation. A shell of lysozyme-imprinted copolymer of 
acrylamide and N,N' -methylenebisacrylamide was formed on a mesoporous 
chloromethylated polystyrene bead support. The imprinted beads were selective for 
lysozyme over four other proteins in aqueous non-competitive and competitive HPLC 
studies, an effect not seen for the non-imprinted bead. The retention time of lysozyme 
was increased on the MIP but the protein was released. This may mean that this 
approach could be used for a delivery application, but again no mention was made of 
the bioactivity of the protein after release by the MIP. 
Surface-imprinted nanoparticles were produced by Tan et a1264 via miniemulsion 
polymerisation of methyl methacrylate and EGDMA. Varied results were reported, with 
a good imprinting effect for a ribonuclease A (RNase A) template, a modest effect when 
the template was lysozyme, and no imprinting effect was observed at all when bovine 
serum albumin (BSA) was imprinted. These differences were attributed to the 
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interaction of the protein template with surfactant used in the particle synthesis. The 
authors hypothesise that interaction was required between the template protein and the 
surfactant to partition the template at the surface of the particle, but it is important that 
the interaction is not enough to denature the protein. In this paper the correct balance 
was only achieved for the RNase A system. It was also discussed that for the successful 
RNase A system, only 38% of the RNase A could be removed from the particles in an 
entirely aqueous system. This report shows some success, but demonstrates the 
difficulties of imprinting proteins due to the denaturing risk during polymerisation, as 
well as the importance of tailoring the approach to the protein in question. 
The most comparable study details core-shell particles, produced by Okutucu et at265 to 
remove albumin from plasma. Albumin was the target molecule and the core-shell 
particles consisted of epichlorhydrin crosslinked chitosan beads and a shell of 
acrylamide and N,N'-methylene-bisacrylamide. Selective absorption of albumin over 
haemoglobin was observed in non-competitive studies, which could be repeated over a 
number of binding and release cycles. The selective binding observed was attributed to 
considerable differences in the shape of the two proteins as well as differences in 
charges that minimise the binding of haemoglobin. Although no comparison was made 
between the MIP and the non-imprinted polymer or between two similar proteins, this 
report shows a system which can bind bioactive polymers and release them, without 
them being destroyed or changing the structure, just by changing the pH. 
Again, the core-shell particles produced in this thesis possess only a very modest 
imprinting effect in comparison to the other particulate systems discussed, but a final 
comparison is not possible until further selectivity studies with alternative proteins have 
been carried out. A number of selective particles have been discussed, but in most cases 
there is limited compatibility of the technique with a bioactive protein, as the release of 
the protein is either poor or not reported, or the technique may only be suitable for 
certain proteins. 
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3.5.3 Summary of Core-Shell Molecularly-Imprinted Particles 
Evaluation of the core-shell particles produced in this report is difficult as currently only 
the target protein has been analysed for binding, but the imprinting effect observed is 
limited, noticeable only in release experiments. All core-shell particles were able to 
rebind the DKPRR sequence and also the VEGF protein, but a molecular imprinting 
effect was observed only for the DKPRR-imprinted CS-MIP, with delayed release of 
the MRSSSDKPRR peptide in comparison to the MRSSSPRKRD peptide, as well as 
sustained release of the VEGF protein. In order to truly determine the molecular 
imprinting effect it would be necessary to carry out further experiments, including 
binding studies with unrelated proteins, binding studies at varying concentrations of 
both peptide and protein, and extending the protein release study to observe the effect of 
sustained release over a longer time period. 
Comparison of this method with other approaches to the molecular imprinting of 
proteins shows that the imprinting effect in this case is very modest when considering 
protein binding. The selective binding exhibited by other groups is not evident in this 
case from the experiments carried out, and the only effect of imprinting is observed 
upon release of the peptide and also the protein. It is evident from the literature, 
particularly that of Tan et at264, that a molecular imprinting technique needs to be 
tailored specifically for the protein in question, the desired application and the level of 
specificity required. A number of approaches have been discussed by other researchers 
which fulfil the requirements for which they were produced, and are analysed with 
primary consideration for the properties required by that application. The aim of this 
project was primarily the binding and release of bioactive proteins from within a wound 
bed, which requires certain criteria either not possible with other approaches or not 
discussed within the reports published. For this application it was necessary to have 
material which could release a large proportion of the protein bound over a reasonable 
time frame and would allow the protein to remain biologically active. Although there 
are reported investigations of molecular imprinting which consider protein binding, 
release time and efficiency, or bioactivity of the template, to our knowledge there are 
very few reports currently available which consider all of these requirements. 
With regard to the molecular imprinting technique, from the results of both the peptide 
and protein study, a slight imprinting effect was observed for the DKPRR-imprinted 
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CS-MIP upon release of the target molecule, but the improved properties in peptide and 
protein binding due to molecular imprinting are currently not considerable. Further 
investigations, including an extended VEGF release study and competitive and non-
competitive protein binding studies with relevant proteins, would now be required. Such 
studies would determine whether the imprinting effect allows VEGF to be bound 
preferentially over other proteins, and also whether the imprinting effect allows the 
VEGF release to be sustained over a longer time period. 
Despite the fact that no significant molecular imprinting effect was observed, there were 
a number of positive outcomes to this study. Core-shell particles have been produced 
containing surface phosphate functionality, which are capable of binding and releasing 
basic peptides and VEGF protein. The protein release study demonstrated that core-
shell particles are able to bind and release bioactive VEGF over a 48 hour period, and 
possibly longer. This is a significant result as the half-life of VEGF in bolus delivery is 
reported to be less than one hour63-66. In conclusion, these core-shell particles achieve 
the aim of binding and releasing biologically active VEGF in a reasonable time frame. 
Although the imprinting effect may not be sufficient to make the time and cost of 
imprinting worthwhile, the use of core-shell particles containing a phosphate monomer, 
if found to be biocompatible, may be a suitable way to achieve protein delivery within a 
wound healing application. 
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4 Strategy 2: Peptide-Functionalised Hydrogels 
The alternative methodology investigated utilised the VEGF-binding ability of heparin 
itself in order to mimic the extracellular matrix. Hydrogels were produced and then 
functionalised with basic peptide sequences. It was hypothesised that such basic peptide 
sequences would bind heparin which could in turn bind to VEGF. This approach should 
bind VEGF via the protein ' s heparin-binding region, thereby allowing VEGF to be 
tethered in a biologically active form (Figure 4.1 ). 
a) b) 
'--------------------------~ 
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Figure 4.1: A schematic representation ofthe hydrogel concept. a) A hydrogel is functionalised with 
basic peptide sequences, b) Heparin is bound to the hydrogel via electrostatic interactions between 
the peptide and sulphate moieties on the heparin, c) VEGF is bound to the hydrogel via interaction 
with heparin. 
For this approach it was necessary to first produce biocompatible polymers with a 
mechanical strength and flexibility suitable for a biological application. It was then 
necessary to include functionality which would allow peptide incorporation without 
negatively affecting the hydrogel, and an investigation into a suitable peptide and 
method of peptide incorporation was carried out to allow the optimum quantity of 
peptide to be attached to the hydrogels. 
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4.1 Determination of Methodology 
4.1.1 Determination of Polymer Composition 
Poly(N-vinylpyrrolidone) (PVP) is the water soluble homopolymer of N-vinyl-2-
pyrrolidone (NVP). Initially developed by I. G. Farben during the 1930s, this material 
has been used extensively for a range of biomedical applications. An early use of PVP 
was as a blood plasma extender during World War 11266. A large number of 
advantageous properties, including being water-soluble, resistant to thermal degradation 
and biocompatible due to its lack of toxicity, immunogenicity and antigenicity, mean 
that PVP has had considerable commercial success as well as prompting academic 
interesr67. PVP is employed in a large number of industries including pharmaceutical, 
food, beverage, cosmetic, toiletry and photographic industries266. Major uses of PVP 
include contact lenses, tablet binders and as an iodine complex, commonly found under 
the trademark Betadine™, which is used as a topical antiseptic. PVP is also widely used 
in academic research as a biomaterial, including possible applications as a 
macromolecular drug carrie~67.269, a vitreous humour substitute270-272 and a surface 
coating for biomedical applications273. 
In our research group, PVP has been investigated as a biomaterial for a number of uses 
including drug-conjugated PVP for pharmaceutical application274-27\ as amphiphilic 
diblock copolymers with poly(D,L-lactide) for micelle formation277 and as crosslinked 
hydro gels for improving cell viabilitl78. In a study by Smith et al278, ethylene glycol 
dimethacrylate- (EGDMA) and diethylene glycol bisallylcarbonate- (DEGBAC) 
crosslinked NVP hydrogels were analysed to determine their ability to affect cell 
viability in direct and indirect contact with a range of cells. Both materials were shown 
to have high equilibrium water contents (EWC) and for 1 % crosslinker formulations the 
poly(NVP-co-DEGBAC) was shown to be a considerably stronger material, making it 
more suitable for cell culture. Cell culture studies revealed that, whilst neither material 
was able to support cells cultured directly on top of the hydrogels, the polymers were 
biocompatible and slightly stimulatory to fibroblasts. In indirect contact the poly(NVP-
co-DEGBAC) stimulated fibroblast viability more reliably than poly(NVP-co-
EGDMA). Due to its superior mechanical properties and positive effect on cell culture, 
poly(NVP-co-DEGBAC) was chosen as the base hydrogel in this investigation. 
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4.1.2 Determination of Peptide Sequences 
An important consideration for this approach was the peptide sequence to be attached to 
the hydrogel. It was necessary to determine a cost-effective sequence capable of 
interacting with heparin, which would interact adequately with the hydrogel to produce 
the peptide-hydrogel conjugate and which would not affect the hydrophilicity of the 
material. As the aim of this project is to produce a biomaterial which could be applied 
within the clinic, the material was designed to be as simple and as easy to produce as 
possible, whilst still providing the desired effect. 
In order to produce a peptide-functionalised hydrogel capable of binding heparin it was 
thought prudent to study the interaction of heparin with proteins in nature in order to 
replicate the binding strategies. It is extensively reported that glycosaminoglycans bind 
and regulate the activities of many proteins, and a number of reviews including those by 
Powell et at279 and Mulloi80 discussed the ability of heparin and heparan sulphate 
sequences to bind with varying affinities to particular proteins. Mulloi80 considered the 
ability of sulphated polysaccharides to bind with proteins at a number of different 
specificities. Firstly, non-specific binding occurs through interaction of the acidic 
polysaccharide with basic areas on the surface of the protein. Secondly, particular 
proteins are able to bind with specific substructures to the sulphated polysaccharides 
(for example the highly specific interaction between heparin and antithrombin, giving 
heparin a high specific activity as an anticoagulant through its ability to potentiate the 
plasma serine protease inhibitor antithrombin28o). Finally, an intermediate reaction can 
occur between certain cytokines, growth factors (for example fibroblast growth factors), 
and morphogens with specific sulphation patterns on cell surface GAG heparan 
sulphate. 
Research into the requirements of GAG-protein interactions has been carried out since 
the late 1980s. Cardin et a1281 used molecular modelling to study heparin binding in 4 
proteins (human apo B, apo E, vitronectin and platelet factor 4), and found similarities 
between the amino acid sequences in the heparin binding domains. The basic amino 
acids (arginine, lysine and histidine) were present in two consensus sites with sequences 
XBBXBX and XBBBXXBX where B is a basic residue and X is a non-basic residue. A 
further sequence of XBBBXXBBBXXBBX was determined a few years later by Sobel 
et a1282• 
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Research reviewed by Hileman et aeS3 shows that specific amino acid residues, as well 
as the spacing in between the residues, affect the strength of the interaction. Assessment 
of a library of 7-mer peptides by Caldwell et a1284 showed that arginine- and lysine-
enriched peptides, but not histidine-enriched peptides, bound heparin and heparan 
sulphate with greatest affinity. Polar amino acids were also often found to be present in 
peptides with high heparin affinity. Asparagines and glutamine were found in heparin 
binding sites, presumably to provide hydrogen bonding. Fromm et at244 used synthetic 
peptides to investigate the differences in binding between arginine and lysine, and found 
that arginine synthetic peptides bound heparin more strongly than lysine. Blocked 
peptides were used to prove that the differences were due only to the side chains, and 
the results showed that arginine was able to bind 2.5 times more strongly than lysine. 
Two explanations were offered for this result. Firstly stronger hydrogen bonding may 
occur between the guanidine and sulphate groups than the amine found on the lysine 
side chain. Secondly, the more diffuse (and therefore softer) guanidinium cation may 
interact better with the soft sulphate anion of the GAG. 
From the information available on heparin-protein interactions it was decided that two 
basic amino acids would be expected to produce the most effective heparin binding 
groups, lysine and arginine. Consideration of the results of Cardin et at2S1 suggests that 
clusters of either di- or tripeptides of basic amino acids can lead to binding with 
heparin. For this work tripeptides, trilysine and triarginine, were selected as it was 
thought that the extra length of the tripeptide over the dipeptide could act as a spacer, 
possibly improving the accessibility of the basic functionality for the heparin chains. A 
hexalysine sequence was also employed to determine whether increasing the sequence 
length would affect the coupling reaction. 
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4.1.3 Determination of Peptide Coupling Procedure 
In order to modify a polymer with a peptide, the polymer requires a functional group to 
which the peptide can be attached285. The functional groups could either be an integral 
part of the material or could be incorporated through modification of the polymer or 
through addition of a comonomer. A number of functional groups can be employed, 
including carboxylic acids, amines, thiols and alcohols. Coupling reactions are carried 
out and generally involve the activation of the functional group, followed by bond 
formation between the material and the peptide. Various methods are reported for this 
procedure involving one or two step reactions depending on the peptide and the 
coupling reagents employed. The concentration of the peptide immobilised on the 
polymer is generally controlled by the amount of functional group incorporated into the 
polymer or by the amount of peptide introduced to the polymer. 
For this study it was decided that acrylic acid, another water-soluble monomer, would 
be incorporated into the poly(NVP-co-DEGBAC) hydrogel to introduce carboxylic acid 
functionality. It has been shown previously by Smith286 that poly(NVP-co-DEGBAC-
co-AA) hydro gels are cytocompatible and offer the required material properties for cell 
culture. 
The coupling procedure used in this work involves the formation of an amide bond 
through the reaction of an activated carboxylic acid on the polymer and a primary amine 
on the peptide. A standard coupling reagent for this reaction is 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCi87. EDC coupling can be carried out in 
aqueous solutions, generally buffer solutions of MES288 and PBS289, but one drawback 
with EDC coupling in aqueous media is the competition of the desired reaction with 
hydrolysis, which will deactivate the ester to a carboxylic acid. Alternatively, depending 
on the polymer composition, DMF can be used as a solvent to avoid the competing 
hydrolysis reaction. In this case dicyclohexylcarbodiimide (DCC) can be substituted for 
EDC290. An alternative method to minimise hydrolysis whilst still allowing the reaction 
to take place within aqueous medium is to add N-hydroxysuccinimide (NHS)287, 
forming an active ester intermediate which does not succumb so easily to hydrolysis. 
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Figure 4.2: Schematic of hydrogel synthesis and peptide functionalisation. (I) UV polymerisation of 
NVP, AA and DEGBAC crosslinker (11) N-hydroxysuccinimide active ester formation (Ill) Peptide 
coupling between active ester and amine from peptide to produce an amide bond (P = peptide). 
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4.2 Results of Polymer Synthesis 
4.2.1 Thermally-Cured Poly(NVP-co-DEGBAC-co-AA) Hydrogels 
Poly(NVP-co-DEGBAC-co-AA) hydrogels of 1 mm dry thickness were synthesised. 
The formulation utilised produced hydrogels with high equilibrium water contents. The 
hydrogels were produced in preformed moulds and were cured thermally with AIBN at 
60°C for 24 hours. 1 wt % crosslinker was employed for a 5 wt % acrylic acid hydrogel. 
When 2 wt % acrylic acid hydrogels were produced with 1 % crosslinker the gels were 
very weak and disintegrated upon swelling in ethanol. The improved strength of the 
hydrogel with 5% acrylic acid may be due to intramolecular hydrogen bonding between 
the acrylic acid and NVP moieties. 2 wt% diethylene glycol bisallyl carbonate 
(DEGBAC) was required in order to produce a 2 wt % acrylic acid hydrogel with the 
required strength. Equilibrium water contents of the 2wt% DEGBAC polymers were 
determined to be 89% and 84% for the 5 wt% and 2 wt% acrylic acid formulations, 
respectively. Residual monomer content was determined by gas chromatography (GC) 
analysis of a methanol wash solution in which the hydrogel had been submerged for 24 
hours. It was shown that after the wash procedure no detectable monomer remained in 
either of the hydrogels produced. I H and I3C NMR spectra of the degraded polymers 
again demonstrated that no unreacted mono mer remained by the absence of any vinyl 
peaks. 
4.2.2 UV-Cured Poly<NVP-co-DEGBAC-co-AA) Hydrogels 
UV polymerisation, an alternative to thermal curing for hydrogel synthesis, was also 
triaIled. For this system a UV initiator was required, and 2-hydroxy-2-
methylpropiophenone was selected for use in this study. Poly(NVP-co-DEGBAC-co-
AA) hydrogels were produced, as for the thermally-cured hydrogels, in preformed 
moulds of quartz plates and with a thinner spacer (500 Ilm) to allow optimum 
penetration of UV light. Utilising UV polymerisation allows a significantly shorter 
reaction time of 6 minutes, during which the moulds had to be turned over every minute 
to allow even polymerisation on both sides of the hydrogel. 
After polymerisation, the hydrogel must be removed from the mould and placed into 
ethanol to allow it to swell and thereby facilitate the removal of any residual mono mer 
or other impurity. The dry hydro gels were found to be glassy and brittle materials. This 
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led to difficulty in removing the hydrogel from the mould. For the thicker, thermally-
cured gels it was possible to synthesise gels with no solvent present, which could be 
relatively easily removed from the moulds. This was not the case for the UV-cured 
hydrogels, and in order to remove these gels without breaking the large sheets it was 
necessary to carry out the synthesis with 1/3 (v/v) ethanol and 213 (v/v) monomer 
mixture. The ethanol lubricated the hydrogel-mould interface and thereby allowed 
easier removal of the polymer. 
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Figure 4.4: Solid state 13c NMR spectrum of poly(NVP-co-DEGBAC-co-AA) with 5% acrylic acid 
content, synthesised by UV polymerisation. Solid state NMR spectra were obtained by the Durham 
University Solid-State NMR Research Service using a Varian VNMRS instrument operating at 
100.56 MHz for 13c. Spectral referencing is with respect to tetramethylsilane. The weak line at 108 
ppm is a spinning sideband relating to the 175 ppm signal. • peak is expected to be due to residual 
ethanol present in the hydrogel due to the storage protocol. 
The solid state NMR spectrum shown in figure 4.4 was obtained for the UV 
polymerised hydrogel poly(NVP-co-DEGBAC-co-AA) with 5% acrylic acid content. 
This spectrum is representative of all spectra produced for the UV -polymerised 
hydrogels. The peaks at 176 ppm (t); 43 ppm (b, c); 32 ppm (a, e) and 19 ppm (d) are 
attributed to the NVP portion of the hydrogel291, 292, which would be expected for a 
hydrogel with such a high NVP content. No peaks were observed in the vinyl region, 
suggesting that the washing steps successfully removed any unreacted monomer 
remaining after polymerisation. In all cases, no signals are observed for the DEGBAC, 
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although this may be expected at such low concentrations of crosslinker. It is also not 
possible to assign any individual peaks for the acrylic acid moiety. It is suggested that 
one signal from the acrylic acid group may overlap with the NVP residue peaks around 
30-40 ppm292. The acid group would be expected to appear at a slightly higher chemical 
shift than the NVP amide peak (t) (at 176 ppm), but these peaks may have overlapped 
due to the linewidths of the peaks. 
All of the hydrogels produced in this manner were also analysed for residual monomer 
by GC analysis as for the thermal hydrogels. No monomer was visible in the GC traces 
showing that for these hydrogels no monomer would leach from the hydrogels into the 
surrounding solution, a significant result when considering cytoxicity of the hydrogels. 
4.2.3 Effect of Crosslinker and Acrylic Acid Incorporation 
Hydrogels were produced with varying NVP, AA and DEGBAC concentrations to 
determine the effect of both the AA content and crosslinker content on the equilibrium 
water content (EWC) (Figure 4.5) as well as the mechanical integrity of the hydrogels in 
terms of ease of handling for a possible medical application. 
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Figure 4.5: Effect of varying the crosslinker and acrylic acid concentrations on percentage 
equilibrium water content (EWC) of hydrogels. 
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Results for hydrogels produced by thennal polymerisation, with 2% and 5% acrylic acid 
at 2% DEGBAC concentration, show that increasing the amount of acrylic acid leads to 
an increase in equilibrium water content. For the thennal polymerisation, 5% acrylic 
acid incorporation and 2% acrylic acid incorporation produced hydrogels with 88.7% 
and 83.9% water content after equilibrium swelling. The same trend was observed for 
the UV -polymerised hydrogels. In this case, the equilibrium water content increased 
from 86.5% to 90.1 % to 92.9% as the acrylic acid concentration increased from 0% to 
2% and finally to 5%. This result would be expected from the thennodynamics of 
hydrogel swelling. The Flory Rehner analysis293 considers hydrogels as neutral, 
crosslinked networks with a Gaussian distribution of polymer chains. According to this 
description the equilibrium water content occurs when the swelling force, due to the 
thennodynamic compatibility of the polymer and solvent, equals the retractive force 
which occurs as the network is stretched294• Incorporation of the highly hydrophilic 
acrylic acid monomer will introduce anionic charge into the hydrogels which would be 
expected to lead to an increase in the equilibrium water content. 
It was not possible to analyse thennally-polymerised hydro gels at either 1 % or 5% 
crosslinker as in both cases the hydrogels disintegrated upon swelling in ethanol. For 
the 0% and 2% acrylic acid UV hydrogels, only a crosslinker concentration of 2% 
enabled the polymer to remain as a sheet, as crosslinking with 1% and 5% DEGBAC 
produced hydrogels which disintegrated upon swelling. With 5% acrylic acid content it 
was possible to produce hydrogels with 1 %, 2% and 5% DEGBAC. This suggests that 
increasing the acrylic acid content increases the strength of the hydrogel, an effect that 
is thought to be due to hydrogen bonding occurring between the acrylic acid and NVP 
moieties present on different polymer chains. Increasing the crosslinker density reduced 
the EWC from 93.6% for 1 % DEGBAC to 92.9% for 2% DEGBAC and 82.8% for 5% 
DEGBAC. This is as expected, as more crosslinking would reduce the polymer chain 
mobility, thereby decreasing the swelling potential. 
All of the hydrogels which remained intact upon swelling were brittle when dry but 
were reasonably flexible and easy to handle when swollen. It was thought that the 
mechanical properties of the hydrogels produced were suitable for a biomaterial and 
could be used for cell culture. 
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4.3 Results of Peptide Functionalisation 
Once the hydro gels had been successfully synthesised and analysed, a number of 
experiments were carried out in order to determine the optimum method for coupling 
peptides to the polymers, trialling both EDC and DCC for the activation step and 
various aqueous buffers for the peptide coupling step. At this stage of the project, only 
the thicker, thermally-cured hydrogels had been synthesised. For this reason all of the 
optimisation investigations and the subsequent results for coupling peptides to 
hydro gels were carried out on these hydrogels. The optimised procedure determined for 
the thermally-cured hydrogels was then adopted for the UV -cured hydrogels without 
further experimentation. 
4.3.1 Analysis of Coupling Efficiency 
Due to the crosslinked nature of the hydrogels, a procedure for coupling analysis was 
required other than the standard NMR approach. The coupling efficiency was indirectly 
analysed for the majority of the polymer-peptide conjugates through the colorimetric 
analysis of the coupling solution post-reaction with trinitrobenzenesulphonic acid 
(TNBS). This assay quantifies the concentration of primary amines in solution29s• Only 
primary amines are analysed in this procedure, as the reaction of secondary amines with 
TNBS is considerably slower and is not thought to occur within the time frame of the 
analysis. The TNBS molecule reacts in a 1:1 ratio with amine functionality (Figure 4.6). 
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Figure 4.6: Nucleophilic aromatic substitution reaction occurring between 2,4,6 - Trinitrobenzene-
sulfonic acid and a primary amine group. 
The coupling efficiency was indirectly analysed by the TNBS assay by measuring the 
amount of amino acid or peptide remaining in an aliquot of the coupling solution and in 
subsequent washes (section 10.4.6). The final coupling value was then calculated by 
subtracting this from the initial concentration of the coupling solution. In order to 
confirm the accuracy of this technique, a direct measurement was carried out on a 
hydrogel-lysine conjugate produced. In this case the base hydrogel and the lysine-
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coupled hydrogel were dissolved in 0.5 M NaOH solution, after coupling and washing 
for 7 days in deionjsed water. It is suggested that this procedure breaks down the 
carbonate groups in the crosslinker, producing linear polymer chains. This is confinned 
by I H and I3C NMR analysis which showed that the NMR spectra of the dissolved 
polymer hydrogels are comparable to NMR spectra produced for linear poly(NVP-co-
AA). The polymer solutions produced were neutralised by the addition of 0.5 M HCl 
and then freeze-dried. The freeze-dried polymers were then dissolved in 0.1 M sodium 
tetraborate at pH 9.3, and analysed with TNBS. As expected, the hydrogel before 
coupling showed no response to the TNBS assay and the hydrogel after coupling gave a 
positive response to the presence of lysine. A comparison of the two results, obtained 
directly and indirectly after coupling with lysine, showed that the results were very 
similar. Indirectly, through analysis of the coupling solution and wash solutions, a 
coupling efficiency of 72.2% was detennined for fonnulation 5. Directly, through 
analysis of the dissolved peptide, a coupling efficiency of 73.6% was detennined. From 
these results it was decided that the indirect analysis of the coupling solutions was 
suitable for detennining coupling efficiency, as well as being simpler to carry out and 
avoiding complications discussed in section 4.3.4, and so all subsequent results shown 
were detennined by this method. 
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Figure 4.7: Absorption spectra ofTNBS-lysine complex 
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4.3.2 Coupling Trials with Lysine Hydrochloride 
In order to determine a successful coupling procedure for the hydrogel-peptide 
conjugates, experiments were first carried out with 5 wt% acrylic acid thermally-cured 
hydrogels and lysine hydrochloride. Lysine was substituted for the peptide sequences 
required, which allowed multiple experiments to be carried out which would not have 
been possible with synthetic peptides due to cost and time restraints. It was thought that 
the activity of lysine in the coupling reaction would be comparable to that of the lysine 
peptides. An optimised procedure for the coupling was determined from the lysine 
hydrochloride experiment before the synthesis of the peptide-functionalised hydrogels. 
Step Parameter Formulation 
1 2 J 4 5 
Reagent 1 Name EDC EDC EDC EDC DCC 
§ c Equivalen~ 5 5 5 5 5 
.- Cl Reagent 2 Name NHS NHS NHS NHS NHS 
-.-~- Equivalen~ 5 5 5 5 5 ~ !.J 
.- ~ 
- QJ Solvent Water Water Water Water DMF !.J~
< Temperature eC) 0 0 0 0 RT 
Time 24 hours 24 hours 24 hours 24 hours 24 hours 
Peptide Equivalen~ 2 2 2 2 2 
eIlc Buffer Sodium Sodium PBS PBS PBS c Cl 
acetate acetate -- --
- -CI.!.J pH 5.5 5.5 8.5 8.5 8.5 = ~ Cl QJ 
U~ Temperature 0 0 0 0 0 
Time 24 hours 72 hours 24 hours 72 hours 72 hours 
'" 
- Coupling Efficiency (% of :; 0 6.4 0.1 33.4 72.2 
'" theoretical coupling) QJ 
= 
Table 4.1: Parameters employed and results obtalDed for coupling experiments of thermally cured 
hydrogels (5% acrylic acid) with lysine hydrochloride. • Equivalent determined by theoretical 
acrylic acid content employed during hydrogel synthesis. 
Coupling experiments were carried out with 5 wt% acrylic acid hydrogels and lysine 
hydrochloride. In all cases a 2: 1 molar ratio of lysine hydrochloride to acrylic acid 
groups was used to determine a suitable coupling procedure. Activation in both aqueous 
and DMF media was considered as well as coupling in different buffer systems (sodium 
acetate buffer at pH 5.5 and phosphate buffered saline (PBS) at pH 8.5). The effect of 
the length of time allowed for coupling was investigated as well as temperature effects. 
The different approaches trialled are detailed in Table 4.1. 
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For each reaction, the hydrogels produced were washed for one week in water which 
was changed twice daily to remove any unreacted lysine or remaining activation 
reagents. The coupling efficiency was analysed by TNBS assay and the water used for 
the washing stages was also analysed by TNBS assay to determine whether any lysine 
was present. 
The initial approach for the modification of poly(NVP-co-DEGBAC-co-AA) hydrogels 
with lysine was to carry out both the activation and coupling steps in aqueous media. In 
aqueous environments the hydrogel is fully swollen, and it is thought that a fully 
swollen hydrogel would enable maximum accessibility of the activation reagents and 
peptide to the acrylic acid moieties present within the hydrogel. Formulations 1-4 
(Table 4.1) utilised activation by EDC with NHS in water at O·C for 24 hours. This 
reaction was carried out at o·e to minimise the effect of the competing hydrolysis 
reaction. The activated hydrogels were then coupled to lysine under different 
conditions. A buffer solution of sodium acetate at pH 5.5 was investigated first in 
formulations 1 and 2 at O·C for 24 hours, and 72 hours respectively. Coupling 
efficiencies of 0 % and 6.4 %, analysed by moles of lysine, were observed for 
fom1Ulations 1 and 2 respectively (Figure 4.8) and it is expected that the extremely low 
efficiency of this reaction is due to hydrolysis of the activated esters before reaction 
with lysine. 
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Figure 4.8: Results of coupling experiment with lysine hydrochloride 
120 
An alternative buffer system of 0.01 M PBS at pH 8.5 was also investigated. Activation 
was again carried out by EDC and NHS in water at O·C, followed by coupling in the 
PBS buffer at O·C for 24 and 72 hours for formulations 3 and 4 respectively. The use of 
PBS buffer at pH 8.5 led to an improvement in the coupling efficiency; 0.13% and 
33.4% of the theoretical coupling possible was observed for formulations 3 and 4 
respectively (Figure 4.8). From these results it is obvious that this coupling approach is 
more successful that the sodium acetate buffer at pH 5.5 and it was therefore used in 
subsequent trials. Coupling of lysine to the hydrogel in either buffer showed that after 
24 hours a very low efficiency of the coupling was achieved but after 72 hours an 
increase in the coupling was observed. It is thought that this is, in part, due to 
temperature of the reaction mixture over the reaction period. In order to agitate the 
samples during the reaction the coupling reactions were carried out in dewars of ice on 
an orbital shaker. For those reactions taking place over 24 hours the solutions were 
maintained at O·C for the entire reaction whereas for the 72 hour reactions the solutions 
remained at O·C for the first 24 hours and then warmed up very gradually over the next 
48 hours, reaching room temperature by 72 hours. It is suggested that the observed 
increase in coupling may occur because the optimum temperature for the reaction of 
lysine with the hydrogel with minimal hydrolysis competition is between O·C and room 
temperature. 
The maximum coupling achieved through activation with EDC and NHS was 33.4 % 
for formulation 4. This relatively low coupling is expected to be due to hydrolysis of the 
activated ester. It was therefore decided that the PBS coupling reaction would be 
combined with activation by DCC and NHS in DMF in order to reduce the hydrolysis 
reaction. The results of this trial, formulation 5, showed a greatly increased coupling 
efficiency at 72.2 % (Figure 4.8). This result suggests that hydrolysis limited the 
efficiency of this reaction in previous formulations. As formulation 5 provided 
significantly improved results it was decided that these conditions would be employed 
for subsequent reactions between the hydrogels and lysine peptides KKK and 
KKKKKK. 
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4.3.3 Coupling Trial with Lysine Pep tides - Effect of Peptide Sequence Length 
Hydrogels were modified with either trilysine or hexalysine peptide sequences using the 
optimised procedure determined in section 4.3.2. It was thought that this study could 
provide information about the effect of the length of the peptide sequence attached on 
the coupling reaction. 
The 5 wt% and 2 wt% acrylic acid hydrogels were modified with KKK and KKKKKK 
peptide sequences. The peptide sequences were coupled to the polymer sheets in their 
crude form. Coupling efficiency was analysed indirectly by TNBS assay of the 
remaining peptide in the coupling solution after coupling and the washing solutions. For 
each different peptide, the results were determined from a calibration curve produced 
for that specific peptide. 
The polymer-peptide conjugates were produced usmg the optimised procedure 
determined in the lysine hydrochloride trial: activation of the hydrogel with DCC and 
NHS in DMF followed by coupling of the peptide sequences in 0.01 M PBS buffer at 
pH 8.5 at O°C for 72 hours. The results obtained are provided in table 4.2. 
Formulation I 2 3 4 
NVP (%) 93 96 93 96 
Acrylic acid (%) 5 2 5 2 
DEGBAC (%) 2 2 2 2 
Peptide KKK KKK KKKKKK KKKKKK 
Peptide incorporation 135.5 36.5 134.0 66.9 (mglg polymer) 
Coupling Efficiency 48.5 32.6 25.1 30.6 (%) 
Table 4.2: Coupling conditions and results for tri- and hexa-Iysine 
The results show that coupling of peptide to the hydrogels was observed in all four 
reactions but with varying efficiency. The highest coupling efficiencies, analysed by 
theoretical molar quantities of peptide reacting with acrylic acid moieties, were obtained 
for the polymers coupled to KKK, being 48.5% and 32.6% for 5 wt% AA polymer and 
2 wt% AA polymer respectively. Lower coupling efficiencies of25.1% and 30.6% were 
observed for the 5 wt% polymer and 2 wt% polymer coupled to KKKKKK. Analysis of 
subsequent washing steps after coupling showed that no peptide was present so it can be 
assumed that all peptide removed from the coupling solutions has been covaJently 
bound to the hydrogels. 
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Coupling efficiencies for the KKK and KKKKKK peptides (Figure 4.9) are 
significantly lower than the 72.2% efficiency achieved under the same conditions for 
lysine (Figure 4.8). It is hypothesised that this is due to a steric effect as the single 
amino acid is bound with higher efficiency than the tripeptide, which is also bound 
more efficiently than the hexapeptide. 
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Figure 4.9: Results of coupling trial with tri- and hexa-Iysine 
Although it was not investigated further within this project, due to time and cost 
constraints, it is expected that a larger excess of peptide would increase coupling 
efficiency. Another possible improvement of this technique would be to carry out the 
coupling procedure in DMF as well as the activation step. Changing the activation step 
from water to DMF gave a significant increase in coupling efficiency and it is expected 
that this would also be observed in the coupling step as this would minimise the 
possibility of a hydrolysis side reaction. 
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4.3.4 Peptide Coupling to DV-Cured Hydrogels 
Coupling of peptides to thinner UV -cured hydrogels for biological application was 
expected to have a number of advantages over the thicker thennally-cured hydrogels. 
Firstly, the thinner DV-cured gels have better mechanical properties and are easier to 
handle and so would be expected to be preferable for cell culture. Secondly, producing 
thinner functionalised hydrogels would require less monomer, peptide and reagent. This 
is a significant cost reduction given that it is necessary to use excess peptide. Finally, in 
order for coupling to occur, the peptide must diffuse through the hydrogel. For the 
thinner hydrogel it would be expected that the peptide could diffuse to the centre of the 
hydrogel more easily and so coupling may be improved. 
Results from peptide coupling to thennally-cured hydro gels showed that the optimum 
coupling procedure involved activation of the hydrogel with DCC and NHS in DMF 
followed by coupling of the peptide sequences in 0.01 M PBS buffer at pH 8.5 at O·C 
for 72 hours. It was also detennined that trilysine coupled with a higher efficiency than 
hexalysine and that a higher percentage yield of coupled peptide was achieved with 5% 
acrylic acid hydrogel than 2% hydrogel. It was therefore decided that 5% acrylic acid 
UV -cured hydrogels would be coupled with two tripeptides, trilysine (KKK) and 
triarginine (RRR). It is the peptide-hydrogel conjugates resulting from this study that 
were taken forward for heparin and VEGF binding and cell culture experimentation and 
any further discussion of peptide-hydrogel conjugates refers to the DV -cured hydro gels 
produced in this manner. 
The coupling efficiency and final peptide loading was detennined quantitatively through 
indirect analysis with TNBS as described previously. Obviously, trilysine, a peptide 
with four amine groups which interact with TNBS, produced a significant colour 
change, from yellow to orange. This is observed for the peptide in solution as well as 
when coupled to the hydrogel, as even when bound to the hydrogel three amine groups 
are still available to react with TNBS. This strong colour change also allowed 
qualitative confinnation of the presence of lysine peptide on the polymer as shown in 
figure 4.1 O. Here it is possible to see the yellow colour of the TNBS solution in the 
swollen unfunctionalised polymer and the orange colour observed for the lysine-
functionalised hydrogel after reaction with TNBS. The indirect approach to quantify 
peptide loading was also possible for the triarginine peptide as it is able to react with 
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TNBS via the amine-terminus of the triarginine III solution. It was not possible to 
qualitatively observe arginine coupling within the solid hydrogel with TNBS as this 
coupling uses the amine-terminus of the RRR peptide and therefore no significant 
colour change is observed. 
(a) (b) (c) 
I t 
Figure 4.10: Qualitative assessment of lysine content of hydrogels by TNBS analysis. (a) acid-
functionalised hydrogel (PNOA) (b) RRR-functionalised hydrogel (PNDRRR) (c) KKK-
functionalised hydrogel (PNOKKK). Orange colour indicates the presence of primary amine 
functionality of lysine. 
In order to visualise the coupling of triarginine to the polymer an alternative 
colorimetric assay was undertaken. In this case the Weber modification296 of the 
Sakaguchi reaction297 for the quantitative determination of arginine was employed. 
Using this method, a colour change from a beige/yellow to dark red (Figure 4.1]) is 
generated by reaction of guanidine derivatives with a-naphthol and sodium hypobromite 
and is stabilized with urea. Weber's modification of the Sakaguchi reaction produces a 
coloured complex upon interaction with arginine which undergoes initial rapid decay 
and therefore requires measurement exactly 20 minutes after the addition of the 
hypobromite reagent to ensure reproducible results298. Due to the importance of time in 
this method, it is used only qualitatively in this study as a means of confirming the 
presence of arginine in the hydrogel. It was decided to continue using TNBS as the 
quantitative assay for both peptide sequences by the indirect measurements as this 
method is considerably less sensitive to time. 
(a) (b) 
Figure 4.11: Qualitative assessment of arginine content of hydrogels. (a) 
acid-functionalised hydrogel (PNDA) (b) RRR-functionalised hydrogel 
(PNDRRR). Red colour indicates the presence of arginine. 
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For cell culture experimentation, peptide loading of the hydrogels was carried out using 
batches of 20 or 40 polymer discs. These were synthesised and washed before being 
stored in ethanol prior to use. Peptide content was analysed prior to transfer to the tissue 
engineering laboratory. In total five batches were utilised for cell culture with an 
average peptide loading shown in Table 4.3. Average coupling efficiencies of 49% for 
the trilysine hydrogel and 59% for the triarginine hydrogels were achieved. 
Peptide Sequence 
KKK 
RRR 
Peptide Loading 
(mg/mg hydrogel) (Coupling efficiency (%» 
0.14 ± 0.01 48.83 ± 3.36 
0.20 ± 0.01 59.03 ± 1.64 
Table 4.3: Peptide loadings achieved for KKK- and RRR-functionalised hydrogels. Results shown 
are an average of S results ± SEM (2 d.p.) 
It was discussed previously that the poly(NVP-co-DEGBAC-co-AA) copolymer 
hydrogel could be dissolved by concentrated sodium hydroxide solution due to cleavage 
of the carbonate groups in the crosslinker producing linear polymer chains. It was 
observed after peptide functionalisation that hydrogels functionalised with the trilysine 
sequence were no longer soluble in concentrated sodium hydroxide. This was not 
observed for the triarginine-functionalised material which was still readily dissolved in 
the base. It is thought that this may be due to the lysine sequence forming crosslinks 
between the acid groups on the hydrogel or by reacting with the carbonate-based 
crosslinke~99. The resulting crosslinks would not be expected to be affected by the 
sodium hydroxide and explains why the resulting hydrogels do not dissolve in an alkali 
solution. This may be one explanation for the lower coupling efficiency observed for 
the trilysine hydrogel. This effect of the lysine peptides reacting via two or more amine 
groups could make the direct method of the TNBS assay less accurate, but would not be 
expected to affect the indirect assay, and so the indirect assay was utilised for all peptide 
coupling analysis. It is also suggested that this lysine crosslinking may also affect the 
heparin and VEGF binding. 
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4.3.5 XPS and ToF -SIMS Assessment of Peptide Binding 
X-ray Photoelectron Spectroscopy (XPS) 
X-ray photoelectron spectroscopy (XPS) is a surface analysis technique commonly used 
to characterise biomaterials. It is able to provide information on both the elemental 
composition of the material and the binding environments of the elements3OO, allowing 
understanding of the functional groups present. XPS spectra are produced when the 
atoms in a sample absorb X-rays and subsequently eject core and valence 
photoelectrons. The photoelectrons emitted have energies which are specific to each 
element, and furthermore, the energy of the photoelectrons emitted can also provide 
information about the chemical state of the elemeneol. The ability of XPS to analyse 
both elemental composition and functionality makes this technique well suited for this 
project and it was therefore employed to investigate changes in the surface composition 
of the hydrogeIs upon peptide functionalisation and heparin binding. It is important to 
remember that XPS is an ultrahigh vacuum (UHV) technique and so requires the sample 
to be dry, which may affect the properties of the hydrogel. XPS is also a surface 
analysis technique and is therefore only able to sample material to a depth of 10 nm or 
less302• It is assumed that peptide functionalisation would occur throughout the hydrogel 
(this is in agreement with visual examination of colorimetrically-analysed hydrogels) 
and so the information provided by this surface technique for peptide functionalisation 
is considered qualitative. 
The Cls profile (Figure 4.12) was utilised to analyse the effects of peptide incorporation 
through consideration of the overall peak shape and the different carbon environments 
that result in a number of overlapping peaks. Figure 4.l2(a) shows the curve fit of the 
acid-functionalised hydrogel (PNDA). From this curve fit we can see that there are four 
types of binding environments distinguishable, the C-C (-285 eV), C-O/C-N (-286 eV), 
C=O/CNO (-288 eV) and COOH (-289 eV). In the acid-functionalised hydrogel, these 
peaks appear in a proportion of 50% for C-C bonds, 36% for C-O or C-N bonds, 12% 
for the CNO amide functionality and 2% for the acidic COOH group. The relative ratios 
of these peaks in the acid hydrogel, and the changes observed in these ratios upon 
reaction with peptide sequences, can be utilised to quantify the extent of peptide 
incorporation into the hydrogel. 
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Figure 4.12: C I I spectra of acrylic acid- and peptide-functionalised hydrogels. A) Ch spectrum of 
acrylic acid-functionalised hydrogel with assignment of peak areas (see colour definitions). B) 
Overlaid Ch spectra of acrylic acid- (PNDA) (- ), KKK- (PNDKKK) (--) and RRR- (PNDRRR) (--) 
functionalised hydrogels. 
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Incorporation of both trilysine (KKK) and triarginine (RRR) peptide sequences results 
in a reduction in the percentage of aliphatic carbon signal, from 50% to 46% and 38% 
for KKK and RRR respectively. The most significant change for the trilysine hydrogel 
(PNDKKK) is an increase from 36% to 39% in C-O or C-N bonds, which is expected to 
be due to C-N bonds present in the amine side chain of lysine. For the triarginine 
hydrogel (PNDRRR) the number of C-O/C-N bonds, again expected to be C-N bonds, 
increases from 36% to 45%. Such a large increase would be expected when considering 
the three nitrogen atoms per guanidinium group in arginine. In the triarginine hydrogel 
it is also possible to observe a 2% increase in amide functionality, as would be expected 
for the incorporation of a tripeptide. 
Hydrogel C-C functionality 
Acid 50.0 
KKK 46.5 
RRR 38.2 
C-O/C-N 
35.9 
38.9 
44.9 
CNO 
11.8 
11.2 
14.0 
COOH 
2.3 
3.4 
2.9 
Table 4.4: Percentage of carbon environments observed for acid- and peptide-functionalised 
bydrogels in XPS study 
Time of Flight Secondary Ion Mass Spec/rome/ry (ToF-SIMS) 
Time of Flight Secondary Ion Mass Spectroscopy (ToF-SIMS) was utilised as a 
complementary analytical technique to identify the presence of both triarginine and 
trilysine on the surface of the hydrogels. ToF-SIMS is a mass spectrometry technique, 
able to analyse both the elemental and chemical compositions of the solid surface. This 
technique is highly sensitive, with a lateral resolution of approximately 50 nm, and a 
sampling depth of 1 o_2oA303. In principle, it has the ability to detect all elements and 
isotopes in the periodic table. 
SIMS consists of a sputtering process304 which involves bombarding the surface of a 
material with ions, which causes motion of the atoms in the sample, leading to bond 
cleavage. These fragments then have sufficient energy to overcome the surface binding 
energy and are then able to leave the material surface as neutral atoms and molecules, 
electrons and ions. A fraction of these sputtered fragments are ionised to produce 
secondary ions, the mass to charge ratio (mlz) of which can then be analysed to produce 
either positive or negative SIMS spectra. 
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The capability of SIMS to analyse the chemical composition of a material makes this 
technique ideal for observing surface modification (in this case with tripeptides). 
Consideration of the C=N- peak in the negative ToF-SIMS spectra of the acid-, lysine-
and arginine-functionalised hydrogels shows an increase in intensity of this species as 
the poly(NVP-co-DEGBAC-co-AA) material is functionalised with lysine and arginine. 
The intensity of this peak is highest in the arginine-containing hydrogel, as would be 
expected when considering the high nitrogen content of this amino acid. 
Research by Samuel at ae05 has provided a comprehensive collection of poly(amino 
acid) spectra acquired with a ToP-SIMS instrument using a Cs+ primary ion source. 
Considering these spectra and comparing to a table of features for the amino acids of 
interest (Table 4.5), it is possible to interpret the positive SIMS spectra produced in this 
study of the hydrogels, before and after peptide functionalisation, to confirm the 
presence of specific amino acids. 
Amino acid Fragment Mass 
Lysine CH4N 30.03 
C2H6N 44.05 
C3~N 56.05 
CsH IoN 84.08 
Arginine CN3HS 59.05 
C.HsN 70.07 
C4HION3 100.08 
CsH"N4 127.10 
Table 4.5: Summary of features of peptide fragments in ToF-SIMS as reported by Samuel et alSOs 
An important consideration when analysing the SIMS spectra for these samples is the 
similarity in elemental content between all polymers, especially the trilysine- and 
triarginine-functionalised materials. In all cases, the bulk of the material is identical, and 
the hydrogels differ only in their functionality. For both arginine and lysine the 
expected fragments used to identify these peptides are based around combinations of 
carbon, hydrogen, nitrogen and oxygen. As the polymer also consists of carbon, 
hydrogen, nitrogen and oxygen, it is possible that these fragments also exist within the 
bulk polymer and could be produced upon sputtering or could be formed by 
combination of different fragments. In these cases it is not possible to distinguish the 
presence of a peptide from the presence of a characteristic peak, as the peak may also be 
present in the unfunctionalised material. Therefore, it is necessary to confirm the 
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presence of the peptide by the increase in intensity of the relevant fragment peaks from 
the acid-functionalised hydrogel relative to the peptide functionalised hydrogel. 
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Figure 4.13: ToF-SIMS spectra of acid-functionalised (Acid), KKK-functionalised (KKK) and 
RRR-functionalised (RRR) hydrogels showing mass fragments that are expected to be present in a 
lysine-containing material. The fragment peaks of interest are labelled in red. 
Although there are no unique peaks for lysine, fragment peaks at 30.03, 44.05, 56.05 
and 84.08, for CH4W, C2H6W, C3H6~ and C5HIO~, respectively, are fonned 
preferentially under the conditions of the SIMS experiment when lysine is present305. 
When considering these fragments it is observed there are increases in intensity for all 
four fragment peaks for the Iysine-functionalised hydrogel in comparison to the acid-
functionalised hydrogel (Figure 4.13). This is as expected and confinns the presence of 
lysine on the material. These peaks are also seen in the spectra of the triarginine-
functionalised hydrogel, and are again at a higher intensity than those observed in the 
acid-functionalised material , despite no lysine being present. This is as would be 
expected due to the similarities between lysine and arginine and the high nitrogen 
content of the guanidine group. 
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Figure 4.14: ToF-SIMS spectra of acid-functionaliscd (Acid), KKK-functionalised (KKK) and 
RRR-functionaliscd (RRR) hydrogels showing mass fragments characteristic for arginine. The 
characteristic fragment peaks are labelled in red. 
The high nitrogen content of the arginine side chain allows for a more conclusive result 
for the presence of arginine. This is because a number of the characteristic fragments 
have a higher number of nitrogen atoms, and so are likely to be fragments that are only 
found in significant quantities in arginine-containing species. When considering the 
spectra for the acid-, trilysine- and triarginine hydrogels (Figure 4.14), the strongest 
signals were obtained for the arginine-containing hydrogel. This is especially noticeable 
for the peaks at mass 59.05 and 70.07, due to CHsN3+ and C4HgW, respectively. The 
significant increase in intensity in these two fragments for the triarginine polymer, 
compared to the acid- and trilysine-functionalised hydrogel spectra, confirms the 
presence of arginine on the hydrogel. The spectra at masses 100.08 and 127.1 , due to 
C4HION3 + and C5HJJN4 +, respectively, also show differences in the size, shape and 
number of peaks in the area of interest, thereby confirming that the hydrogels have been 
successfully functionalised. 
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4.4 Summary of Results for Peptide-Functionalised Hydrogels 
Poly(NVP-co-DEGBAC) and poly(NVP-co-DEGBAC-co-AA) hydro gels were 
synthesised by both thermal and UV polymerisation and analysed for residual monomer 
concentration, equilibrium water content and by NMR. The thinner hydro gels produced 
by UV polymerisation were selected for further investigation as they required less 
peptide for functionalisation and were easier to handle for cell culture studies. 
An optimised peptide coupling procedure of activation by DCC and NHS in DMF at 
room temperature for 24 hours, followed by peptide coupling in PBS (PH 8.5) at O°C for 
72 hours, resulted in the synthesis oftrilysine- and triarginine-functionalised poly(NVP-
co-DEGBAC-co-AA) hydrogels. Peptide loadings of 0.14 gig hydrogel and 0.20 gig 
hydrogel for lysine and arginine respectively were determined by TNBS analysis. The 
presence of peptides was confirmed qualitatively by colorimetric analysis, XPS and 
ToF-SIMS. 
The peptide-functionalised hydrogels were shown to contain no residual mono mer and 
to have suitable mechanical properties and so were analysed further for heparin and 
VEGF binding as well as cell culture experiments. 
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5 Heparin and VEGF Binding Analysis 
5.1 Heparin Binding Studies 
Once hydrogels had been produced and coupled with peptides, the next stage of the 
process was to analyse the ability of the resulting material to bind heparin. The heparin 
chosen for this study was the sodium salt from porcine intestinal mucosa. This is a 
natural unfractionated heparin and supplier information (Sigma) states that the majority 
of the heparin chains lie in the range of 17,000 to 19,000 Da, although some chains may 
range from 6,000 to 30,000 Da. The heparin-binding ability of the hydrogels was 
analysed both quantitatively using fluorescently-tagged heparin and qualitatively by X-
ray photoelectron spectroscopy (XPS). For both analytical techniques, the binding and 
subsequent washing steps to remove unbound heparin were carried out in PBS in an 
attempt to reproduce an environment similar to that which would be experienced in 
vivo. It was hypothesised that functionalising the hydrogels with peptide would increase 
the amount of heparin bound by the hydrogels. As discussed in section 4.1.2, Fromm et 
at244 found that arginine synthetic peptides bind heparin 2.5 times more strongly than 
lysine, so it was expected that the RRR hydrogel would be the most successful for 
heparin binding. 
5.1.1 Quantitative Fluorescent Heparin Study 
The binding of heparin to the functionalised hydrogels was analysed quantitatively 
through a fluorescent binding studio Heparin was tagged with fluorescein-S-
thiosemicarbazide in a two step reaction. Firstly, oxidation of the uronic acid moieties 
of heparin were oxidised to produce an aldehyde306, which subsequently reacted in a 
condensation reaction with the carbazide functionality of fluorescein-5-
thiosemicarbazide to form a covalent hydrazone linkage307 (Figure 5.1). 
t This work was carried out together with a MSc student and parts of this heparin-binding data was 
submitted in the taught MSc report of D. Sun in 2008. However some errors in the data analysis became 
apparent after the submission and the data presented have been corrected for submission in this thesis. 
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Figure 5.1: Reaction scheme for fluorescein tagging of heparin a) oxidation of alcohol to aldehlude 
and b) subsequent condensation reaction between aldehyde and fluorescein-5-thiosemicarbazide 07 
A fluorescence study was then carried out with the fluorescein-tagged heparin to 
quantitatively determine the heparin-binding ability of the acid-functionalised and 
peptide-functionalised hydrogels. 
Each hydrogel was exposed to a solution of fluorescent heparin in 0.1 M sodium 
phosphate buffered saline at pH 7.5 and was allowed to react over 24 hours in the dark 
with agitation at room temperature. Each hydrogel was analysed in triplicate and all 
solutions for analysis were stored at 4°C in the dark until use. A number of washes were 
carried out to remove unbound heparin by replacing the PBS solution with fresh PBS 
and agitating the sample in the dark at room temperature for a set time period. The 
binding solutions and wash solutions were then analysed at room temperature. The 
binding ability of the hydrogels was then determined from these results using a 
calibration of fluorescein-tagged heparin at various concentrations within the required 
range. 
Analysis of the washing solutions showed that, in all cases, no further fluorescein-
tagged heparin was removed after the seventh wash. This information was then utilised 
when determining the heparin-binding procedure employed within the cell culture study 
of these materials. 
The results obtained (Figure 5.2) agreed with the hypothesis that heparin would bind to 
basic peptide sequences and would bind most effectively with the guanidine side chain 
of arginine. The acid-functionalised hydrogel bound 5.2% of the heparin that it was 
initially exposed to, but this binding result was not very consistent, leading to a high 
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standard error of 3.5%. The peptide-functionalised hydrogels were shown to bind 
considerably more heparin, with 13.5% and 20.7% of the heparin remaining bound to 
the hydrogels after the wash steps for the trilysine and triarginine hydrogel respectively. 
These values equate to 0.030 mg, 0.077 mg and 0.117 mg of heparin binding per 
milligram of dry hydrogel for the acid-, KKK- and RRR-functionalised hydrogels 
respectively. 
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Figure 5.2: Quantitative fluorescence study of heparin binding for acrylic acid-functionalised 
hydrogel, KKK-functionalised hydrogel and RRR-functionalised hydrogel. Binding data is 
presented as a percentage of initial heparin in solution bound to hydrogel after washing steps. Data 
shown is average of three results ± SEM. 
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5.1.2 Qualitative XPS Heparin Study 
X-ray photoelectron spectroscopy was employed to qualitatively confirm heparin 
binding to the acid- and peptide-functionalised hydrogels. In 1995, West et at3°8 
analysed the binding of heparin to a range of polymers to determine a method to 
monitor the modification of biomaterial surfaces. They showed that the presence of 
heparin can be confirmed by considering the oxygen, nitrogen and sulphur 
concentrations, as well as a change in high resolution carbon scans and the different 
binding states observed. Changes in Ols and S2p signals were also utilised by Steffen et 
ae09 to show the presence of heparin on diamond-like carbon films. More recently, 
Nakayama et al310 utilised XPS spectra to analyse the N1s and 01s and the N/C and SIC 
elemental ratios to show heparin binding to a cationic thermoresponsive polymer. The 
presence of heparin was also shown through an increase in oxygen and sulphur signals 
as well as changes in the C1s peak by Meng et a1311 for polypyrrole/poly(L,L-lactide) 
composites, and also by Aksoy et al312 for polyurethanes. 
Three approaches have been utilised within this study. Firstly, analysis of the S2p 
spectrum, which is possible due to the sulphate content of heparin. Secondly, analysis of 
nitrogen content before and after heparin binding, and finally, consideration of the effect 
of the binding of heparin on the CIs spectra. Hydrogels were analysed before and after 
heparin binding, with both types of material undergoing washes in both PBS and water. 
XPS analysis was judged as only a qualitative approach to assessing the heparin binding 
for a number of reasons, including the surface-sensitive nature of the technique and the 
heterogeneity of heparin. The difficulty in determining whether heparin is absorbed 
evenly throughout the hydrogel and the effect that drying the hydrogel, which is 
necessary before XPS analysis, would have on the uniformity of heparin distribution 
throughout the material also meant that the results from this analysis can only be 
qualitative. 
It was expected that the presence of heparin in the hydro gels would lead to the presence 
of sulphur in the XPS spectra. XPS analysis of a thick film of heparin by Robinson313 
showed heparin to contain 4.5% sulphur. Surprisingly, consideration of the spectra of 
acid-, lysine- and arginine-functionalised hydrogels prior to heparin binding shows that 
these materials contain a very low amount of sulphur. This may be due to 
contamination, but may also be due to background noise at such low levels and the very 
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large pass energy employed in this study. The presence of sulphur due to heparin was 
analysed by considering sulphur levels before and after heparin binding. It is obvious 
from the S2p spectra (Figure 5.3 and Table 5.1) that heparin binding with the acid-
functionalised hydrogel leads to no significant change in SUlphur content, suggesting 
that little heparin remains on this material after the washing process. A slight increase in 
the sulphur signal is observed for the trilysine hydrogel, showing that some heparin has 
been bound to this material and has remained attached throughout the washing process. 
A larger increase in the intensity of the S2p spectrum is detected after heparin binding on 
the triarginine hydrogel, confirming that more heparin is absorbed by the hydrogel 
functionalised with triarginine. 
Hydrogel Average Sulphur Content (%) Average Nitrogen Content (%) 
Before heparin After heparin Before heparin After heparin 
Acid-functionalised 0.07 0.04 7.20 7.08 
KKK-functionalised 0.03 0.08 5.90 4.88 
RRR-functionalised 0.05 0.12 9.15 4.70 
Table 5.1: Average sulphur and nitrogen content of the hydrogels before and after heparin 
exposure as determined by XPS 
A change in the nitrogen content of the hydrogels was also observed upon heparin 
binding. Only a slight decrease in nitrogen was observed upon heparin-binding for the 
acid-functionalised hydrogel from 7.20% to 7.08%. A more substantial reduction in 
nitrogen from 5.90% to 4.88% was observed for trilysine-functionalised hydrogel and 
an even larger decrease from 9.15% to 4.70% was observed for the triarginine-
functionalised hydrogel. This is as might be expected when considering the nitrogen 
content of the hydrogels and heparin. Although nitrogen is present within heparin 
(found to be 2% by Robinson313), the nitrogen content is lower within this 
polysaccharide than for the hydrogels, particularly the triarginine-functionalised 
hydrogel due to the high nitrogen content of the guanidine moiety. The decrease in 
nitrogen content for the trilysine- and triarginine-functionalised hydrogels therefore 
suggests the binding of heparin. As expected, this decrease is most significant in the 
triarginine-functionalised hydrogel, and is in agreement with the results of the 
quantitative fluorescent study and the S2p spectra. 
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Figure 5.3: XPS S2P spectra before (black) and after (red) heparin binding (a) RRR-
hydrogel (b) KKK-hydrogel (c) acid-hydrogel 
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In order to investigate this further, the C)s profiles from each of the surfaces were also 
analysed. The overlaid C)s spectra for the blank (acid-functionalised hydrogel) before 
and after exposure to heparin (Figure 5.5(a)) shows no significant change in ratio of 
carbon environments, suggesting that little or no heparin is bound in this case. 
Conversely, consideration of the peptide-functionalised hydrogels before and after 
heparin exposure (Figure 5.5(b) and Figure 5.5(c)) shows significant changes in the CIs 
spectra. In both cases, a significant decrease in the contribution from C-O/C-N bonds 
(-286 eV) and amide bonds (CNO, -288 eV) is observed. This is possibly due to the 
surface nature of XPS. Once heparin has bound to the hydrogels this will result in the 
presence of heparin on the surface of the hydrogel, which is then analysed by XPS. This 
means that the bonds previously observed for the hydrogel may now be partially 
masked by the presence of heparin. The signal from the polymer bonds may therefore 
be reduced and signals from the heparin bonds will be seen. In the spectra produced for 
the hydrogels with bound heparin, the signal observed is expected to be due to heparin 
as well as hydrogel beneath the heparin or on the surface due to uneven coverage. After 
the addition of heparin to the peptide-functionalised hydrogels, all binding 
environments are still visible but the predominant bonds observed are now the single 
carbon bond as well as a significant increase in the peak shift associated with the acid 
(COOH, -289 eV) bonds, as might be expected when considering the structure of a 
polysaccharide such as heparin (Figure 5.4). It was expected that incorporation of a 
polysaccharide would not result in a reduction in c-o bonds present but this was 
observed. It is suggested that this may occur because the C-O bonds and C-N bonds are 
observed at the same energy (-286 eV) and a significant reduction in C-N bonds would 
be expected from the high number of C-N bonds in a peptide-functionalised poly(NVP-
co-DEGBAC-co-AA) hydrogel, in agreement with the decrease in nitrogen content 
observed upon heparin binding. 
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Figure 5.4: Major repeating unit of heparin283 
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Figure 5.5: XPS Ch spectra of a) acrylic acid-, b) KKK- and c) RRR-functionalised hydrogels 
before (--) and after (--) exposure to heparin 
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5.1.3 Conclusion of Heparin Binding Studies 
Heparin binding was analysed by a fluorescence study and XPS. Both analytical 
approaches were in agreement that functionalising poly(NVP-co-DEGBAC-co-AA) 
hydrogels with basic peptide sequences leads to an increase in heparin binding. 
XPS analysis showed no change in Cls upon heparin binding for the acid hydrogel, and 
therefore no change in hydrogel composition. For both the KKK- and RRR-
functionalised hydrogels a significant difference in carbon environment was observed, 
in particular a reduction in C-O/C-N and amide bonds and an increase in acid groups. 
These changes were attributed to the introduction of heparin to the hydrogel. Analysis 
of the S2p spectra showed very little heparin absorption for the acid hydrogel, slightly 
higher heparin absorption for the KKK hydrogel and a considerably higher heparin 
content for the RRR hydrogel. This is in agreement with both the XPS analysis of 
nitrogen content, as well as the study of fluorescently-tagged heparin which showed 
binding capacities of 0.030 mg, 0.077 mg and 0.117 mg of heparin per milligram of dry 
hydrogel for the acid, KKK and RRR hydrogels, respectively. These results agree with 
the hypothesis that the RRR hydrogel should bind more heparin than the KKK 
hydrogel. In this case the KKK hydrogel bound 66% of the heparin bound to RRR 
hydrogel. It is thought that the difference between the KKK and RRR hydrogels is due 
to the different affinities for heparin but also might be affected by the lysine-bridging 
observed in the KKK hydrogels (as discussed in Section 4.3.4). 
These studies confirmed that the peptide-functionalised hydrogels are able to bind 
heparin and so were further analysed for VEGF binding and release. 
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5.2 VEGF Binding and Release Study 
Analysis of the binding and release capacity of the hydrogel discs for VEGF was carried 
out using an Enzyme-Linked ImmunoSorbent Assay (ELISA). It was hypothesised that, 
due to the considerably higher heparin loading observed for the RRR-functionalised 
hydrogel, this hydrogel would bind the highest quantity ofVEGF. 
In this experiment, four types of polymer, poly(NVP-co-DEGBAC) (PND), poly(NVP-
co-DEGBAC-co-AA) (PNDA), KKK-functionaIised poly(NVP-co-DEGBAC-co-AA) 
(PNDKKK) and RRR-functionalised poly(NVP-co-DEGBAC-co-AA) (PNDRRR), 
were analysed in duplicate to determine how much VEGF could be bound to the 
material and then released over a 72 hour time period. Heparin was first bound to the 
hydrogel discs by soaking them in a 1 mg/ml heparin solution for 24 hours at room 
temperature before washing off any unbound material. VEGF binding was then carried 
out by placing each disc into a solution containing 100 ng VEGF in PBS in a sample 
vial which had been preblocked with BSA. The heparin-bound hydrogel and VEGF 
were allowed to bind with gentle agitation for 24 hours at 4°C. The VEGF solution was 
then removed from the hydrogel and stored at -20°C until analysis. Three washes were 
carried out at 4°C to remove unbound protein by the addition of an aliquot of PBS, 
which was removed each time after 30 minutes of gentle agitation. A release study at 
37°C was then carried out by the addition of PBS aliquots containing 1 % BSA as a 
protein stabiliser, mimicking the environment experienced within cell culture. The PBS 
aliquots containing 1 % BSA were removed and replaced with fresh PBS containing 1 % 
BSA at defined time intervals. The time intervals studied after the three washes were 
then 30 minutes, 1 hour, 6 hours, 12 hours, 24 hours, 48 hours and 72 hours. All 
aliquots were stored at -20°C until the end of the study and were then analysed by a 
Quantikine® Human VEGF ELISA kit. 
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Figure 5.6: Amount of VEGF initia lly adsorbed by the hydrogels and the amount of VEGF 
remaining attached to the hyd rogel after each of the three wash steps at 4°C. Measurements 
expressed as mean ± 95% confidence level. (n = 2). Sign ificance was assessed using one-way 
ANOVA with post-hoe Tukey analysis in comparison to non-functionalised PND hydrogel (*p < 
0.05, **p < 0.01, ***p < 0.001) 
Analysis of VEGF remaining in the coupling solution, after initial exposure to the 
hydrogel discs, and the wash solutions (Figure 5.6) showed that, as expected, the 
peptide-functionalised hydrogels, particularly the triarginine-functionalised hydrogel , 
were able to absorb a higher quantity of the VEGF. The PND and PNDA polymers were 
found to absorb 24.6 ng and 27.5 ng per hydrogel disc respectively, in comparison to 
28.9 ng and 31.5 ng for the PNDKKK. and PNDRRR materials. These values equate to 
binding capacities of 21.5 ng, 24.0 ng, 25.2 ng and 27.5 ng of VEGF per milligram of 
dry hydrogel for PND, PNDA, PNDKKK. and PNDRRR respectively. After three 
washes at 4°C to remove unbound material it was determined that the unfunctionalised 
PND had retained 21.7 ng (19.0 nglmg dry hydrogel) of the VEGF to which it was 
exposed, which was slightly less than the 23.5 ng (20.5 nglmg dry hydrogel) retained by 
the PNDA polymer. 
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It is hypothesised that the acrylic acid moieties may be able to interact with the basic 
amino acid groups present on the protein. 25.4 ng (22.2 nglmg dry hydrogel) of VEGF 
remained on the PNDKKK hydrogel. This increase is expected due to the higher 
heparin content in comparison to the PNDA hydrogel. Finally, for all three washes the 
amount of VEGF released by the PNDRRR hydrogel was significantly less than for the 
other material, as determined by ANOVA analysis with post-hoc Tukey, with 30.8 ng 
(26.9 nglmg dry hydrogel) of VEGF remaining attached to the PNDRRR hydrogel after 
the wash procedure. 
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Figure 5.7: Amount of VEGF released by the hydrogel after the wash procedure over a 72 hour 
time period at 37°C. Measurements expressed as mean ± 95% confidence level. (n = 2). 
Significance was assessed using one-way ANOVA with post-hoc Tukey analysis in comparison to 
non-functionalised PND hydrogel (* p < 0.05, **p < 0.01, ***p < 0.001) 
Analysis of the 37°C release data (Figure 5.7) showed that for all polymers, VEGF is 
released over the whole time period of the study (72 hours) after the unbound VEGF 
had been removed in the wash steps. The VEGF release pattern is very similar for the 
PND, PNDA and PNDKKK hydrogels. Over this period, a total of 19.8 ng (17.3 nglmg 
dry hydrogel), 19.4 ng (16.9 nglmg dry hydrogel), and 20.1 ng (17.6 ng/mg dry 
hydrogel) of VEGF was released per hydrogel disc for the three polymer types 
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respectively, a release of 91 %, 83% and 79% of the protein remaining after the wash 
steps for PND, PNDA and PNDKKK. At all time points analysed, the PNDRRR 
hydrogel was found to release more VEGF than the other polymers, with 27.0 ng (23.6 
nglmg dry hydrogel) of VEGF released per hydrogel disc in the 72 hour period, which 
corresponds to 88% of the protein that remained after the wash step. ANOVA with post-
hoc Tukey analysis of the results revealed that this difference in release was significant 
after 6 hours. This result is as expected when considering the higher heparin loading of 
the RRR-functionalised material. 
In all cases a small amount ofVEGF, 1.9 ng, 4.1 ng, 5.3 ng and 3.8 ng, remained on the 
hydrogels after the 72 hour period for the PND, PNDA, PNDKKK and PNDRRR 
hydrogels respectively, equating to 1.7 nglmg, 3.6 ng/mg, 4.6 ng/mg and 3.3 ng/mg dry 
hydrogel. A longer time study would be necessary to determine the time required for all 
VEGF to be released by the materials. It was not determined whether the heparin 
remains bound to the hydrogel upon VEGF release or whether the heparin is also 
released with the VEGF. It may therefore be useful to carry out a binding experiment, 
analysing both the VEGF and heparin content of the release aliquots. 
The results from this study show that all of the hydrogels were able to bind and 
subsequently release VEGF, with the peptide-functionalised hydrogels retaining the 
protein most successfully, leading to an extended release. The results are in agreement 
with the initial hypothesis that the PNDRRR hydrogel would be able to bind and slowly 
release a significantly larger quantity of VEGF, which is expected to be due to the 
higher heparin content of the swollen hydrogel. 
5.3 Discussion of Heparin and VEGF Binding Studies 
Analysis of the PND, PNDA, PNDKKK and PNDRRR hydrogels has confirmed that 
when poly(NVP-co-DEGBAC-co-AA) is functionalised with basic peptide sequences 
an increase in heparin binding (and subsequent VEGF binding and release) is observed, 
in particular for the triarginine hydrogel. In all cases, around 80-90% of the bound 
VEGF was released over the 72 hour analysis period. 
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A number of research groups are also interested in the release of VEGF from 
biomaterials to stimulate angiogenesis, as discussed in Section 1.5. A variety of 
approaches have been utilised with different synthetic polymer formulations and the 
quantities of VEGF released are dependent on the VEGF loading employed in each 
study. Some of the most comparable studies are discussed below to allow comparison 
of these hydro gels with other materials currently being developed elsewhere. 
Poly(DL-lactic acid) scaffolds produced with supercritical carbon dioxide by Kanczler 
et al90 were able to release approximately 3 ng/ml of VEGF over 21 days which was 
able to stimulate angiogenesis. A constant release of VEGF was also achieved by Gu et 
al314 by polymerising acrylated slar-polY(E-caprolactone-co-D,L-lactide) macromer and 
encapsulating VEGF, interferon-gamma (lFN-'Y) and interleukin-2 (IL-2) within the 
elastomer matrix. A constant release was achieved over 5-8 days, but with this 
formulation it was observed that only 57% of the VEGF remained bioactive. A further 
poly (DL-Iactide-co-glycolide) material was assessed by E1cin et at315• A burst release 
of 40% to 50% of the initial loading was observed, followed by slow release over 21 
days with 70% -100% of the VEGF loaded being released depending on initial loading. 
In vivo studies showed that the VEGF-activated sponge was permeated with host blood 
vessels. 
Poly(N-isopropylacrylamide) copolymer films were reported by Kavanagh et al96 to 
release VEGF 165 over 7 days, with 10.75 ± 3.11 ng released after 24 hours and a total of 
31.32 ± 8.5 ng released over the whole 7 day period, although this release required a 
high VEGF 165 solution loading concentration of 3000 ng/ml. The VEGF 165 released in 
this case was shown to be bioactive and increased the proliferation of human aortic 
endothelial cells by 18.2% over the control. Hydrogels of 2-hydroxyethyl methacrylate, 
NVP and poly( ethylene glycol) (400) dimethacrylate were produced and combined with 
poly(lactide-co-glycolide) by Norton et al94 to release a combination of VEGF and 
dexamethasone. The base hydrogels, the most comparable system for this study, were 
shown to release between approximately 60-160 ng/ml VEGF in an initial burst in 0-3 
days followed by a very slow release over 2 weeks. In total only 10% of the original 
VEGF loaded in this formulation was released. The release profile in this case was 
thought to be standard for hydrogel release and to be dependent on diffusion through the 
hydrogel and initial loading. 
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A similar burst release was observed by Patel et af6 with gelatin microparticles, with 
the predominant release occurring within the first 24 hours followed by very slow 
release thereafter. The bioactivity of the VEGF released in this case remained over 90%, 
which is thought to be in part due to the association of released VEGF with gelatin 
fragments. The ability of alginate to stabilise VEGF was utilised by Jay et al65 in the 
release of VEGF from alginate microparticles crosslinked by ionic crosslinkers. In this 
case release was maintained over a ten-day period, but again this release generally 
consisted of a high initial release followed by a slow release of low VEGF amounts over 
the remaining days. 
Most of the above approaches show the majority of release occurring within a period of 
24 hours to one week, often with a burst release in the first three days. Not all of the 
loaded VEGF was released in all cases and it was observed by Gu et ae 14 that a 
decrease in bioactivity of VEGF occurred during the release procedure. 
The incorporation of heparin to maintain the bioactivity of the released VEGF or bFGF 
was employed by various researchers. Heparin has been incorporated covalently into 
hydrogels by a number of groups. Yoon et al102 detailed bFGF release from 
Pluronic/heparin hydrogels over 30 days. Approximately 75% of the 25 ng bFGF loaded 
was released from the Pluronic/heparin hydrogel with a small burst release followed by 
consistent release over the remaining period, in contrast to the 99% released from the 
Pluronic hydrogel alone. It was suggested that, for the Pluronic hydrogel, bFGF was 
likely to be released by diffusion, whereas the Pluronic/heparin hydrogel would 
specifically bind the bFGF and thus the release would also be controlled by the 
thermodynamic equilibrium between free bFGF and bound bFGF. A proliferation study 
with HUVECs showed that a higher cell viability was observed when the hydrogel 
contained heparin than for the Pluronic hydrogel alone, despite the Pluronic hydrogel 
releasing more bFGF. In vivo analysis showed dense capillary formation of the 
Pluronic/heparin hydrogel in comparison to the Pluronic hydrogel alone. 
Heparin hydrogels were produced by Benoit et al49 by modifying the heparin with 
methacrylate groups and copolymerising with dimethacrylated poly( ethylene glycol). 
Unmodified PEG gels released all bFGF bound in eight hours but release over five 
weeks was possible with heparin inclusion, although this release has a very large initial 
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release followed by low amounts of VEGF released over the remaining period. Human 
mesenchymal stem cells (hMSCs) were utilised to analyse these materials. The heparin-
modified gels were able to promote hMSC adhesion and spreading on the hydro gels as 
well as proliferation. The attachment of cells to the hydrogel was dependent on the 
heparin dose. 
Maleimide-functionalised high molecular weight heparin and thio-functionalised PEG 
were utilised by Nie et al99 to produce heparin-containing hydrogels which could release 
up to 30% of the bound bFGF over a 6 day period. Almost no burst release was 
observed in this case. 
Pike et aI64 produced hydrogels of hyaluronan, gelatin and small quantities of heparin. 
VEGF or bFGF were incorporated in the hydrogels before crosslinking. In all cases not 
all of the growth factor was released within the 42 day period, with release of 19% to 
48% of the growth factor reported for different formulations. lleparin incorporation 
slowed the release ofVEGF, allowing the release to last over 42 days with less than 1 % 
heparin. In the presence of heparin, the growth factors remained active and 
vascularisation was sustained over 28 days. 
A few groups have also considered the non-covalent incorporation of heparin. Zhang et 
at316 synthesised hydrogels from a heparin-binding peptide-functionalised star PEG and 
low molecular weight heparin-functionalised star PEG. The release of bFGF was 
studied and release occurred as the hydrogel degraded. The release profile consisted of a 
high initial release of25% of the bFGF in the first day and slow release thereafter up to 
approximately 35% of the bFGF after 10 days. Heparinised chitosan-coated calcium-
induced alginate hydrogel beads were utilised by Lee et al98 and were shown to release 
VEGF over 11 days with a small initial burst period. 
The addition of heparin into the polymer formulations in the above studies often had the 
effect of prolonging growth factor release (up to six weeks) but also resulted in the 
incomplete release of VEGF, leading to the waste of expensive growth factor. It is 
suggested that these observations are likely to be due to the strength of the interaction 
between VEGF and heparin. When the heparin is covalently incorporated into the 
material, or crosslinked to a high degree, the release of VEGF would require the 
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disruption of the VEGF-heparin interaction. In this study the heparin is only lightly 
incorporated, so release could be either by disruption of the heparin-VEGF binding or 
the heparin-hydrogel interactions. 
In those studies which compared materials containing heparin to the same materials 
without heparin, it was noted that all of the materials were able to bind the growth 
factors and it was the release profile that was affected by the presence of the 
polysaccharide. This was also observed in this study. All of the hydrogels were able to 
bind and release VEGF and for all hydro gels almost 90% of the bound VEGF was 
released. The release profile for the PNDRRR hydrogel during the washing procedure 
showed less VEGF was released than for the other hydrogels. A higher amount of 
heparin was bound to the hydrogel in this case and so the lower VEGF release observed 
initially is attributed to the VEGF being strongly bound to the heparin, rather than the 
weaker association to the hydrogel that is expected for the other materials, thereby 
retarding the VEGF release. 
From the examples discussed, a considerable proportion of the literature available in 
this area describes release profiles with an initial burst release, followed by much slower 
release kinetics over the rest of the study. Generally, the majority of the release occurs 
within the first three days. Such results are comparable to those observed with the 
heparin-bound hydrogels in this study. In this case the VEGF was released relatively 
consistently over 72 hours and it is feasible that the small percentage ofVEGF found to 
be remaining within the hydrogels would have also been released slowly in the days 
following the 72 hour period if the experiment had been extended. It would be 
necessary to repeat the release study for a longer period of time to confirm this 
hypothesis. 
Fast release is observed with these hydrogels, with almost 90% of the bound VEGF 
released within three days. It is suggested that this is in part due to the high water 
content of the hydrogel, resulting in fast diffusion kinetics. Another explanation for the 
fast rate of release relates to how the release study was carried out. A large number of 
samples were taken in the 72 hour period, with five samples taken within the initial 
three hours. Also, as the samples for the ELISA kinetics study were taken, all of the 
PBS was removed and replaced with fresh PBS. This could lead to an accelerated 
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release assuming the release from heparin or the hydrogel is governed in part by the 
thermodynamic equilibrium between free VEGF and bound VEGF. Constantly 
replacing the PBS would create a high VEGF gradient, which could in turn cause the 
hydrogels to release the VEGF at a higher rate. In order to analyse this, a repeat of the 
release experiment would be required with only small aliquots ofPBS being removed at 
each time point and with less frequent sampling. The different experimental methods for 
VEGF release studies in the examples discussed makes direct comparison difficult but it 
was observed from the literature available that samples were often taken less frequently 
(daily or less frequently) and often only a small aliquot of the solution was removed and 
replaced, thereby minimising the VEGF gradient. 
Those groups who also studied the effect of released growth factor on bioactivity and 
angiogenesis showed that the released VEGF was able to induce angiogenesis. The 
presence of heparin was thought to maintain bioactivity during storage of the VEGF, as 
well as improve the angiogenic capacity by allowing the VEGF to interact with cells as 
a VEGF-heparin complex in those systems which allowed heparin release. 
All of the hydrogels produced in this study were able to bind and release VEGF, with 
slower release observed for the PNDRRR hydrogel. From the literature, it can been seen 
that VEGF release could be tailored by heparin content and VEGF loading, as well as 
how quickly the surrounding environment is depleted of free VEGF. The PNDRRR 
hydrogel especially compares favourably in comparison to other materials detailed in 
the literature with a steady VEGF release of 27 ng per 5 mm diameter hydrogel over 
three days, and low VEGF retention on the material. In summary, the confirmation of 
the ability of the hydrogels to bind and release VEGF meant that these materials were 
suitable for cell compatibility studies and analysis of their potential as a VEGF-
releasing angiogenic treatment. 
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6 Cell Compatibility of Peptide-Functionalised Hydrogels 
The next stage of this project was to assess, both qualitatively and quantitatively, the 
effect of poly(NVP-co-DEGBAC) hydrogels, poly(NVP-co-DEGBAC-co-AA) 
hydrogels and peptide-functionalised poly(NVP-co-DEGBAC-co-AA) hydrogels on 
cells relevant to the desired wound healing application. The reasonable material 
properties experienced with these gels allowed them to be placed in the wells of the cell 
culture plates with no further support. This ease of handling allowed investigations into 
the effect of direct and indirect contact with the hydrogels to be carried out 
simultaneously. Primary human dermal fibroblast cells were investigated initially as 
they are suitable for generic toxicity testing; they are also a relevant cell type for skin 
applications. Further investigations were carried out with endothelial cells, as 
determining the final effect of these polymers on angiogenesis is vital for this project. 
The following four polymers were analysed: poly(NVP-co-DEGBAC) (PND), 
poly(NVP-co-DEGBAC-co-AA) (PNDA), poly(NVP-co-DEGBAC-co-AA) 
functionalised with trilysine (KKK) (PNDKKK) and poly(NVP-co-DEGBAC-co-AA) 
functionalised with triarginine (RRR) (PNDRRR). The relevant analytical data for each 
polymer is provided in Table 6.1. 
Hydrogel Properties 
PND 
Hydrogel Identification 
PNDA PNDKKK PNDRRR 
% composition(a) 
NVP 98 93 93 93 
AA 0 5 5 5 
DEGBAC 2 2 2 2 
EWC(%ib) 86.5 92.9 92.9 92.9 
Peptide loading (mglmg hydrogeliC) 0.14 ± 0.01 0.20 ± 0.01 
Table 6.1: Summary of properties of hydrogels analysed by cell culture. (a) calculated from original 
monomer composition utilised in synthesis. (b) EWe results average of 6 measurements. (c) Peptide 
loading determined by indirect colorimetric TNBS analysis. Result is an average of all 5 batches 
used in cell culture studies. 
152 
In all cases, quantitative data on the effect of treatment on the cells was determined 
colorimetrically by the MIT assatl7, which is based on the purple colour of formazan 
formed by reduction of 3-( 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), as shown in Figure 6.1. 
mitochondrial reductase 
• 
Figure 6.1: Reduction of MIT by mitochondrial reductase enzymesJI8 
Mitochondrial reductase enzymes cause the reduction of MTT and therefore the 
formazan intensity is directly proportional to the activity of these enzymes. The MTT 
assay can therefore provide information about the number of cells present and their 
ability to function. 
Analysis of cellular distress was visualised through the observation of cell morphology, 
since abnonnal morphology can be an indicator of stress in a particular environment. 
Morphology was observed both by light microscopy and fluorescent microscopy. 
One-way ANOV A with Tukey post hoc analysis was used to detennine significant (p < 
0.05) stimulation or inhibition in cell viability, as assessed colorimetrically by MTT 
assay within a single experiment, and the Mann Whitney U Test was utilised to assess 
significance (p < 0.05) over triplicate repeat experiments. 
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6.1 Effect of Poly(NVP-co-DEGBAC) Hydrogels with Acid and Peptide 
Functionalisation on Primary Human Dermal Fibroblast Cells 
The fibroblasts used within this study were obtained from numerous donors and 
different passage numbers (passage numbers 3-9) and the hydrogel samples were from 
multiple batches. None of these variables were found to affect the range of results 
obtained. 
Experiments were performed as illustrated in Figure 6.2 (all cell culture experiments 
and procedures are described in Chapter 10). A hydrogel disc of 5 mm swollen diameter 
was placed in a 48 well plate (10 mm well diameter), followed by random seeding of 
fibroblasts, thus allowing for cells to be cultured in both direct and indirect contact with 
the hydrogels simultaneously. Cells in indirect contact to the hydrogels were of interest 
to provide information on cytotoxicity of the biomaterials, and to determine whether the 
presence of the various hydrogels would have either a stimulatory or inhibitory effect on 
fibroblast viability. In all cases the control was cells on TCP with no hydrogel present. 
Cells in direct contact with the hydrogels (on top of the materials) can provide 
biocompatibility data, as well as determining the effect of hydrogel functionality on cell 
attachment. 
Cells were cultured in fibroblast medium both with and without foetal calf serum (FCS) 
for 96 hours to determine whether the presence of serum influences the reaction of the 
cells to the presence of the hydrogel. 
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Figure 6.2: Schematic of cytotoxicity experiments. a) hydrogel (5 mm diameter) is added to 48 well plate (10 mm diameter), b) media (with or without serum) is 
added to the hydrogel and incubated for 72 hours and then replaced with a further aliquot of media, c) I x 104 cells seeded randomly into each well in a further 
aliquot of media and the cells were incubated for 96 hours, d) MTT assay carried out e) Hydrogel with cells on the hydrogel surface is moved to a separate well, f) 
Formazan is eluted from cells and cell viability is analysed colorimetrically. 
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6.1.1 Fibroblasts Cultured in 10%. FCS-Containing Medium 
In the experiments carried out, the low number of cells often present on the hydrogels 
and the small surface area of the hydrogel meant that the cell count was often very low, 
leading to low precision in the MTT data, particularly for the PND and PNDA 
hydro gels. It is therefore important to consider the quantitative data together with the 
visual analysis to get a true representation of the results. However, both quantitative and 
qualitative analysis of the fibroblasts present on the hydrogel within serum-containing 
media show considerable effects of the functionalisation of the NVP-based hydrogels. 
In all cases, fibroblasts were present on the tissue culture plastic (TCP) (Figure 6.3, 
Figure 6.5, and Figure 6.4) surrounding the hydrogel and grew to the edge of the 
hydrogel with a nonnal fibroblast morphology. These results suggest that all these 
materials are cell-compatible and have no cytotoxic effects. Observation of MTT-
stained wells after removal of the polymer discs reveals that cells were not attached to 
the tissue culture plastic underneath the hydrogel in all cultures. Therefore, in order to 
calculate the quantitative effect of the hydrogels on cell viability in comparison to a 
control well, the MTT response of the control well was adjusted to give an equal TCP 
surface area to that available in the hydrogel-containing wells. 
On tissue culture plastic a slight increase in cell viability was observed in the presence 
of all hydrogels in comparison to the control well (TCP) in two of the three repeat 
experiments but a significant increase (p < 0.01) was observed only in repeat 2 for the 
PND, PNDA and PNDKKK hydrogels. Overall, from the three repeats, it was 
concluded that there was no significant effect of these materials on fibroblast viability. 
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Figure 6.3: Results of fibroblast experiment with 10% FCS DMEM medium. Results of three 
repeat experiments shown individually. Left column shows results of MTT assay of cells on tissue 
culture plastic (TCP) surrounding the hydrogel and right column shows results of MTT assay of 
cells present on the hydrogel. Results expressed as percentage of cell viability in comparison to 
control well (on TCP results) or unfunctionalised PND (on hydrogel results) ± percentage SEM. 
Significance was assessed using one-way ANOV A with post-hoc Tukey analysis. Significance shown 
is for comparison with control well (TCP) for the results on TCP, or PND (hydrogel) for the results 
on the hydrogels (*p < 0.05, **p < 0.01, ***p < 0.001). 
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Cells on TCP next to hydrogel Cells on hyd rogel 
(~a) 
Figure 6.4: Results of fibroblast cell culture experiment in 10% FCS DMEM medium. Fibroblast 
cells in direct and indirect contact with hydrogels column (a) cells on TCP adjacent to hydrogel 
(image shows hydrogel (on the right) and cells on TCP (labelled in image la», column (b) cells on 
top of hydrogel. Row: (1) PND (2) PNDA (3) PNDKKK (4) PNDRRR. 
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Figure 6.5: Human dermal fibroblasts cultured in direct and indirect contact with hydrogels in 
medium containing 10% FCS for 96 hours. Cells were stained with CellTracker™ Red and imaged 
on a Zeiss LSM 510 confocal microscope (abs. 577 nm and em. 602 nm). Images in column (a): 
Fibroblasts on TCP in wells containing hydrogels, images in column (b): Fibroblasts on top of the 
hydrogels. Images in row (1): PNDA, row (2): PNDKKK, row (3): PNDRRR. 
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Information regarding cell attachment to the hydrogel discs was obtained by considering 
the number of cells present on the surface of the polymer and their morphology. No 
significant quantitative difference in cell viability was observed between the PND and 
PNDA hydrogels. Microscopy (Figure 6.4) showed that a few more cells were 
consistently visible on the PNDA hydrogels than on the PND material, but cell numbers 
were low on both substrates. All cells present on both of these materials were viable, but 
upon visual inspection they were found to have an unusual morphology. The cells were 
often present in clumps and when individual cells were present they were of a rounded 
morphology, suggesting that they were stressed and not well attached to the material. 
Comparison of the PND and PNDA hydrogels with the PNDKKK and PNDRRR 
hydrogels shows an increase in cell attachment upon peptide functionalisation. 
Interestingly, a difference was also observed between the PNDKKK and PNDRRR 
polymers, both quantitatively and qualitatively (Figure 6.3 and Figure 6.4). In all 
experiments a large increase in cell numbers was observed for the PNDKKK hydrogel 
in comparison to either the PND or PNDA hydrogel and an even larger increase in cell 
numbers was consistently observed on the PNDRRR hydrogels in comparison to the 
PNDKKK polymers. Consideration of images taken during MTT staining (Figure 6.4) 
shows an improvement in cell morphology as the PNDA hydrogels are functionalised 
with peptides. Cells present on top of the PNDKKK hydrogel appear to be less rounded 
than on either the PND or PNDA hydrogels, and have a more normal fibroblast 
morphology, suggesting that the cells are able to attach more effectively to this material 
and are therefore less stressed. This effect is even more obvious for the PNDRRR 
hydrogels, on which the cells appear to have a normal fibroblast morphology and appear 
relatively well attached to the hydrogel. 
Images were also taken of fibroblasts stained with CellTracker™ Red (Figure 6.5). 
When this experiment was carried out no PND material was available, and therefore 
only PNDA, PNDKKK and PNDRRR hydrogels were analysed in this way. Again, it is 
possible to see that in all cases cells are visible with a normal morphology on the tissue 
culture plastic. The trend for cells present on the hydro gels is the same as when 
observed with MTT staining but it is obvious that cell numbers are considerably lower 
in all cases. It is postulated that the cells on the hydrogel are more loosely attached on 
the polymer than on the TCP and therefore a number of the cells detach during the 
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washing procedure. It is possible to see that the cells present on the RRR hydrogel have 
conventional fibroblast morphology and appear to remain reasonably well attached. 
The observation that a significant proportion of cells attached to the hydrogels detach 
easily upon washing is a positive observation for the required application as hydro gels 
to which cells adhere only loosely would allow easier removal from a wound after use. 
6.1.2 Fibroblasts Cultured in Serum-Free Medium 
The experiment described previously was also carried out within a serum-free 
environment to determine the effect of the serum on the cell compatibility study. 
As observed in serum-containing medium, no cytotoxicity effect was observed for cells 
present on TCP in PND, PNDA and PNDKKK hydrogel-containing wells, as cells were 
present with a normal morphology adjacent to the polymer (Figure 6.6, Figure 6.7 and 
Figure 6.8). For PND and PNDA hydrogels a slight stimulatory effect was observed in 
two of three repeats, although a significant effect (p < 0.01) was only observed in one of 
the three repeats. No significant effect was observed for the PNDKKK hydrogel. 
Overall, for these three materials, no significant effect (p > 0.05) was observed when 
analysed by the Mann Whitney U test. 
A very different effect was observed for the PNDRRR hydrogel. In this case, cells on 
the TCP were either clumped together or they had a rounded morphology, and a 
considerable proportion of the cells present on the TCP surrounded the hydrogel closely 
(Figure 6.7). This inhibitory effect, observed qualitatively and also quantitatively 
through MTT analysis (Figure 6.6), was seen for all repeats and was significant (p < 
0.001) in two of the three repeats. It is suggested that in the serum-free medium this is 
due to amino acid absorption by the hydrogel (further discussed in Section 6.3). 
Very few cells were observed on the hydrogel discs in all cases. A slight increase in the 
number of cells present on the polymer was observed for the KKK hydrogel, although 
this was not found to be statistically relevant. On all materials the cells were present 
with a rounded, stressed morphology. 
161 
(1) 
(2) 
(3) 
On Tissue Culture Plastic 
140 
** ** 
120 
g 100.;_ ..... _ 
c 
o 
u 
a 80 
~ 60 
:.c 
:5 40 
Qj 
u 20 
140 
120 
~ 
e 100 c 
8 
a 80 
~ 60 
:.c 
:5 40 
Qj () 20 
120 
100 
e g 80 
u 
a 
~ 60 
~ 
:0 40 
cv 
:> 
~ 20 
o 
180 
160 
0' 140 
z 
a.. 120 
a 
~ 100 
~ 80 
:0 
:5 60 
Qi 40 
() 
On Hydrogel 
20 
O~~~~~~~~~ 
140 
120 
0' 100 Z 
a.. 
a 80 
~ 60 
:0 
cv 5 40 
a; 
U 20 
140 
120 
0' 100 z 
a.. 
-o 80 
~ 60 
:0 
cv 5 40 
a; 
U 20 
Figure 6.6: Results of fibroblast experiment with serum-free DMEM medium. Results of three 
repeat experiments shown individually. Left column shows results of MTT assay of cells on tissue 
culture plastic (TCP) surrounding the hydrogel and right column shows results of MTT assay of 
cells present on the hydrogel. Results expressed as percentage of cell viability in comparison to 
control well (on TCP results) or unfunctionalised PND (on hydrogel results) ± percentage SEM. 
Significance was assessed using one-way ANOV A with post-hoc Tukey analysis. Significance shown 
is for comparison with control well (on TCP results) or PND (on hydrogel results) (*p < 0.05, ** p < 
0.01, ***p < 0.001). 
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Cells on TCP next to hydrogel Cells on hydrogel 
(la) @J (lb) 
Figure 6.7: Results of fibroblast cell culture in serum-free DMEM medium. Fibroblast cells in 
direct and indirect contact with hydrogels. Images in column (a) cells on TCP adjacent to hydrogel 
(image shows hydrogel and cells on rcp (labelled in image la», column (b) cells on top of hydrogel. 
Row (1) PND (2) PNDA (3) PNDKKK (4) PNDRRR 
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Cells on hydrogel 
Figure 6.8: Human dermal fibroblasts cultured in direct and indirect contact with hydrogels in 
medium without FCS for 96 hours. Cells were stained with CellTracker™ Red and imaged on a 
Zeiss LSM 510 confocal microscope (abs. 577 nm and em. 602 nm). Images in column (a) cells on 
TCP adjacent to hydrogel, column (b) cells on top of hydrogel. Row (1) PNDA (2) PNDKKK (3) 
PNDRRR. 
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6.2 Effect ofPoly(NVP-co-DEGBAC) Hydrogels with Acid and Peptide 
Functionalisation on Human Dermal Microvascular Endothelial Cells 
In this experiment, normal human dermal microvascular endothelial cells from 
Promocell® were used to determine the effect of the hydrogels on endothelial cells, the 
cells which form the walls of blood vessels. Dermal microvascular endothelial cells 
were selected as this cell type is closely related to the required application. Cells were 
used between passage numbers 4 and 8. F ACS analysis of the endothelial cells used in 
all cell culture studies was kindly carried out by Dr. Emilia Krajewska and showed 
strong expression of CD31, a marker speci fic for this cell type. 
Experiments were performed as described in Figure 6.2 to enable determination of 
cytotoxicity of the hydrogels. This experiment was carried out over 96 hours with 
growth factor-supplemented endothelial cell growth medium with 5% serum, which was 
replaced with fresh medium every 24 hours. This was necessary to ensure that a suitable 
number of cells remained viable until MTT analysis as endothelial cells are very 
sensitive to the protein content of the growth medium. For this cell type, the 96 hour 
experiment was carried out only in serum-containing medium, as it was not possible to 
maintain a suitably high content of viable cells for this time period in a serum-starved 
environment. 
120 
100 
-(5 
L-
e 80 0 
0 
-0 
~ ~ 60 
~ 
:0 40 C1l 
:> 
Qj 
20 () 
0 
Control PND PNDA PNDKKK PNDRRR 
Figure 6.9: Effect of the presence of hydrogels on the viability of HDMEC on tissue culture plastic 
(TCP) when cultured for 96 hours within endothelial cell growth medium with 5% foetal calf 
serum. Results shown are the percentage means ± SEM of 3 experiments (3 replicates per 
experiment) 
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Cells on top of hydrogel 
Figure 6.10: Results of 4 day endothelial cell culture experiment in endothelial cell growth medium 
with 5% FCS. Endothelial cells shown after MTT staining in direct and indirect contact with 
hydrogels. Images in column (a) cells on TCP adjacent to hydrogel (image shows hydrogel and cells 
on TCP (labelled in image la», column (b) cells on top of hydrogel. Row (1) PND (2) PNDA (3) 
PNDKKK (4) PNDRRR 
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None of the four hydrogels, PND, PNDA, PNDKKK and PNDRRR, had any cytotoxic 
effect on HDMECs (one-way ANOVA with post-hoc Tukey analysis) (Figure 6.9). As 
seen in the fibroblast data, cells were not attached to the Tep underneath the hydrogel 
but were present over the rest of the available TCP right up to the edges of the hydrogel. 
The cells had a normal "cobblestone" appearance associated with this cell type in 
growth medium (Figure 6.10). The results show that the cells were not unduly stressed 
in this environment. These indirect contact results agree with those obtained for 
fibroblasts in serum-containing medium, and indicate that these materials are suitable 
biomaterials for the desired application and therefore suitable for further investigations. 
The ability of cells to attach to these materials and proliferate on them was analysed 
qualitatively only for the endothelial cells, as so few cells attached to the polymer and 
the MTT response was too low to provide a quantitative signal. The images in Figure 
6.10 are endothelial cells after MTT staining, as the flat morphology of the HDMECs 
prevented clear images being taken without staining. The images provided are 
representative of the three repeat experiments undertaken. 
The morphology of the cells that did attach to the hydro gels is rounded, and 
occasionally clumps of cells are visible, suggesting that these cells are only loosely 
attached to these materials. Visually, it is easy to see that almost no endothelial cell 
attachment occurs with the PND and PNDA materials. As the material was 
functionalised with KKK peptide (PNDKKK) a few cells remained attached to the 
material after four days. Functionalising the material with RRR (PNDRRR) resulted in a 
few more cells remaining attached to the polymer after the four-day experiment. 
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6.3 Conclusion of Cell Compatibility Study 
Experiments were carried out to determine the cytotoxicity of the PND hydrogel, PNDA 
hydrogel and peptide-functionalised PNDA hydrogels. The results from both the 
fibroblast and endothelial cell studies revealed that the materials are cell compatible and 
the base polymer of poly(NVP-co-DEGBAC) is a suitable biomaterial for this work. 
Previous work on poly(NVP-co-DEGBAC) by Smith et at278 showed this polymer to be 
cytocompatible but a poor substrate for cell attachment. 
In the serum-containing experiments for fibroblast and endothelial cells, no significant 
effect on the cells in indirect contact with the materials was observed upon introduction 
of any of the hydrogels. Overall for the serum-free fibroblast experiment a similar result 
is observed for PND, PNDA and PNDKKK, with no overall influence on cell viability. 
Interestingly a significant decrease in cell viability was observed for the fibroblast cells 
in indirect contact with the PNDRRR hydrogels in serum-free medium. It is 
hypothesised that in this case the superior affinity of the RRR group for certain 
components of the medium, primarily amino acids, has led to adsorption of these 
substances, resulting in a surrounding medium that is deficient in key components and 
therefore cannot sustain the cell viability observed in the control well. It is not thought 
that this would cause difficulties in a biological application as the environment 
experienced in vivo is more likely to resemble the conditions of the serum-containing 
medium in which no inhibition was observed. 
When considering the cells in direct contact with the hydrogels, i.e. those cells present 
on the top of the hydrogel, a substantial effect was observed as the hydrogels were 
functionalised. For the base poly(NVP-co-DEGBAC) hydrogels it was observed that it 
is difficult to grow cells in direct contact with the swollen hydrogel (confirming earlier 
work from this lab278) • The few cells that did attach appeared to be stressed and poorly 
attached. One reason for the lack of cell adhesion to this material could be the 
extremely high water content experienced with this formulation. Analysis of 
amphiphilic networks by Haigh et ae l9 showed that the EWe had a significant effect on 
cell attachment with a decrease in cell coverage observed as the EWC was increased 
beyond 29%. In these non-functionalised hydro gels, a combination of the high EWe 
and lack of protein binding sites would minimise the ability of the hydro gels to absorb 
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proteins. This would be expected to lead to minimal cell attachment, as cells do not 
adhere directly to biomaterial surfaces, but in fact bind through adhesion proteins 
(including fibronectin, laminin and vitronectin) which in turn adsorb onto the 
biomaterial, as demonstrated by Nuttelman et al320 through fibronectin-functionalised 
poly(vinyl alcohol) hydrogels. The requirement for the ECM cell adhesion proteins was 
also shown by Hynd et al321 who observed directed cell growth on hydro gels with 
bound ECM proteins. It is thought that protein adsorption to the poly(NVP-co-
DEGBAC) material is negligible, resulting in the low cell adhesion observed for both 
cell types. 
Following this hypothesis it was expected that incorporation of charge in the form of 
carboxylic acid groups would lead to cell attachment. However, this was not the case, 
and no significant differences were observed between poly(NVP-co-DEGBAC) (PND) 
and poly(NVP-co-DEGBAC-co-AA) (PNDA). This result is in agreement with previous 
work by Sun et ae22, analysing polymethacrylate networks as cell culture substrates, 
who showed that the incorporation of carboxylic acid groups into their materials 
allowed some attachment of human dermal fibroblasts but the cells did not spread well 
and were poorly attached to the hydrogels in serum-containing medium. In contrast to 
this result they also showed that incorporation of charge via amines (basic functionality) 
was able to increase cell coverage of the materials, but that this effect was significantly 
influenced by the length of the carbon chain between the amine groups. A chain of a 
minimum of three carbons between the amine groups was required to produce materials 
which were as effective for cell culture as TCP. Epithelialisation of these materials by 
primary amine functionalisation was shown in a later publication323 when corneal 
epithelial cells were co-cultured with stromal cells. 
Functionalisation with the basic peptide sequences, KKK and RRR, as expected, led to 
an increase in cell adhesion, resulting in both an increase in the number of cells 
attaching to the materials and an improvement in the cell morphology, especially for the 
fibroblast cells in 10% FCS, for which the change in morphology is more easily 
recognised. This result was anticipated as the peptide sequences firstly offered protein 
adhesion points through the basic side chain groups for cell adhesion proteins, and 
secondly the amino acids selected were of the required carbon chain length as discussed 
by Sun et a1322• These results are in agreement with a number of other pieces of work 
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currently in the literature. Recent work by Kim et al324 showed that higher charge 
density on HEMA by copolymerisation with 2-(methacryl)-(oxy)ethyl trimethyl 
ammonium chloride (MAETAC) promoted greater cell attachment, thought to be due to 
either absorption of adhesion proteins or through charge-charge interactions between the 
cell and the hydrogel surface. A study on the same polymers by Haxhinasto et al325 had 
also shown that incorporation of acidic moieties could increase cell attachment but that 
the effect was dependent on the base polymer. It is thought that the increase seen by 
peptide incorporation in this study is predominantly due to the adsorption of cell 
adhesion proteins from serum, as this effect was not observed in the serum-free 
fibroblast experiment. 
Interestingly, the increase observed in both cell number and cell morphology is most 
significant for cells in direct contact with the PNDRRR hydrogel, with a considerable 
difference being observed between the PNDKKK and PNDRRR materials. For the 
fibroblast study (10% FCS), the PNDRRR hydrogel was able to sustain almost a fully 
confluent sheet of cells, and the presence of the cells on the hydrogel in the 
CellTracker™ experiment confirmed that the cells were more strongly attached, 
although a significant number of the attached cells could still be easily removed upon 
washing. The difference between the PNDRRR and PNDKKK hydrogels could be due 
to the slightly higher peptide loading achieved with the PNDRRR peptide, but the 
improvement in morphology suggests that it is more likely to be due to differences in 
affinity for the cell adhesion proteins. As discussed previously, arginine is more basic 
than lysine due to the guanidinium group and so would be expected to bind more 
strongly to the proteins required for cell adhesion, thereby leading to the significant 
increase in cell adhesion observed for RRR-functionalised poly(NVP-co-DEGBAC-co-
AA) (PNDRRR). 
The results obtained show that all of these materials are non-cytotoxic and differ 
markedly in their cell attachment capabilities. The materials were determined to be 
suitable for further cell culture experimentation and possible biological applications. 
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7 Assessment of VEGF- and Heparin-Bound Peptide-
Functionalised Hydrogels as a Pro-Angiogenic Treatment 
As previously discussed, angiogenesis is currently a topic of great interest, 
predominantly due to the role of this process in tumour development. A large number 
of angiogenesis models have therefore been developed in order to study both the 
fundamental biological processes and to enable the development of pro- or anti-
angiogenic treatments. It is acknowledged that analysis of pro- or anti-angiogenic agents 
would be most accurate in vivo as such assays are able to provide realistic extracellular 
environments as well as allowing the effect of non-endothelial cells to be determined. 
There are a large number of different in vivo assays including implantation of sponges 
or Matriget326, the widely used chick chorioallantoic membrane assay27, the corneal 
assa/28, chamber assays329 and the zebrafish assaY30. There are also a number of 
difficulties associated with in vivo studies33 ). 332, primarily due to the high variability of 
possible results but also due to difficulties in quantification, the length of time required 
for experimentation and the complex nature of the experiments. A popular alternative to 
in vivo assays are organ culture assays in which angiogenesis is assessed in either whole 
or partial organ culture. The types of assays available include the rat or mouse aortic 
ring333, the embryoid body assay34 and the mouse metatarsal assay3S, all of which 
enable the number and length of microvessel outgrowths from the primary explants to 
be measured. This approach has the advantage of providing a more realistic 
environment with other cell types as well as being simpler than in vivo assays. 
However, as with in vivo assays, they can be difficult to quantify and can suffer from 
high variability. 
In vitro cell culture approaches to the analysis of angiogenesis also have their pros and 
cons33 ). 332. In vitro studies have the advantages of being fast, relatively easy to carry 
out, readily quantifiable and reproducible. The disadvantages are obvious. The 
experiments are carried out in an artificial environment in which the cells may behave 
differently to how they would behave in vivo336, and it is not possible to account for the 
complex interactions that occur in vivo. There are a number of ways to analyse 
angiogenesis in vitro; consideration of matrix degradation, endothelial cell proliferation, 
migration (which is possible due to the fact that endothelial cells can move towards a 
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gradient of angiogenesis-inducing factors), or the ability of the cells to form tubules in 
response to exogenous agents337• 
The opposing advantages and disadvantages for in vivo and in vitro studies mean that 
ultimately a combination of the two approaches may be necessary to provide a detailed 
insight into the effect of a particular treatment agent on angiogenesis. The logical first 
approach however, due to the advantages previously noted, when studying a new pro- or 
anti-angiogenic treatment is the simpler in vitro analysis. 
In this study, two approaches were used to analyse the effect of the VEGF- and heparin-
bound hydrogels on human dermal microvascular endothelial cells (HDMECs), a 
proliferation assay and a tubular assay. The proliferation assay, in this case performed 
with MTT, has the advantages of being easy to perform and very easy to quantify. This 
assay indicates the viability of the endothelial cells in the presence of the treatment but 
no information is provided regarding the ability of the cells to form tubes. To 
complement this study, a tubular formation assay with growth-factor reduced Matrigel 
was also carried out on HDMECs. 
7.1 Effect ofVEGF and Heparin on HDMEC Proliferation 
Prior to analysis of the effect of VEGF- and heparin-bound hydrogels on endothelial 
cell culture, the effect of free heparin and VEGF on endothelial cell proliferation both 
individually and combined was analysed in two experiments. In the first experiment, 
varying concentrations of VEGF and heparin were individually added to endothelial 
cells, which had been pre-seeded 24 hours before experimentation and starved in 2% 
serum medium overnight, to determine the most effective concentrations of each to 
stimulate endothelial cell proliferation. In the second experiment, the most successful 
VEGF and heparin concentrations determined previously were applied to the cells both 
individually and combined to determine whether there was a cumulative effect of the 
growth factor and polysaccharide combined. 
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7.1.1 Vascular Endothelial Growth Factor Dosing 
It was necessary to detennine the concentration of VEGF which elicits a stimulatory 
effect on endothelial cells. This was detennined by treating nonnal human dennal 
microvascular endothelial cells with varying concentrations of VEGF and analysing the 
results by MTT assay after three days. VEGF 165 was utilised and was present within 
endothelial cell growth medium with 2% FCS and no other growth factor additions. 
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Figure 7.1: Effect of increasing concentration of VEGFI65 on the proliferation of endothelial cells 
over three days in serum-starved endothelial cell growth medium. Data expressed as percentage cell 
viability compared to cells with no VEGF present (TCP control) ± percentage SEM (N = 1 
experiment, three replicates). 
There is an obvious effect of VEGF on the endothelial cells in this experiment although 
a number of repeat experiments would be required to detennine the statistical relevance 
of these results. Consideration of these results (Figure 7.1) shows that a concentration of 
10 ng/ml is the most effective, leading to a 20% increase in cell viability in comparison 
to a TCP control. Slight increases in viability were also observed for concentrations of 5 
ng/ml, 15 ng/ml and 20 ng/ml VEGF in this study. By 50 ng/ml VEGF the cell viability 
had reduced to below that of the TCP control and the viability reduced further to 85% 
with the addition of 100 ng/ml VEGF. From these results it was decided that, for further 
studies, the most successful VEGF concentration of 10 ng/ml would be employed. This 
result is in agreement with the optimum VEGF 165 dose of 10 ng/ml for human umbilical 
vein-derived endothelial cells detennined by Cohen et a145• 
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7.1.2 Heparin Dosing 
In order to determine the effect of heparin on endothelial cell proliferation, a similar 
experiment was carried out as for VEGF (7.1.1) with varying heparin concentrations. 
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Figure 7.2: Effect of increasing concentration of heparin on the proliferation of endothelial cells 
over three days in serum-starved endothelial cell growth medium. Data expressed as percentage cell 
viability compared to cells with no heparin present (TCP control) ± percentage SEM (N = 1 
experiment, three replicates). 
The dose response curve for heparin (Figure 7.2) shows that this polysaccharide does 
have an effect on normal HDMECs cultured in vitro. This study was carried out once 
only and further repeats would be required to determine the significance of this data. It 
is clear that heparin doses between 20 ng/ml and 200 ng/ml have a stimulatory effect on 
endothelial cell proliferation, with a peak between 50 ng/ml and 100 ng/mt. Again, as 
for VEGF, a higher dose of heparin results in an inhibitory effect, in this case doses of 
500 ng/ml and 1000 ng/ml lead to cell viabilities of 82% and 80% of the cell viability 
observed for TCP alone. From this study it was determined that the most effective dose 
of heparin is around 50 ng/ml to 100 ng/ml and so it was these concentrations which 
were studied further. 
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7.1.3 Combined VEGF and Heparin Dosing 
An investigation was carried out to determine whether a combination of VEGF and 
heparin would stimulate cell viability to a greater extent than each individual 
component. The concentrations previously determined in 7.1.1 and 7.1.2 were utilised 
in an experiment as described for the compounds individually. 
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Figure 7.3: Effect of combination of VEGF and heparin on the proliferation of endothelial cells 
over three days in serum-starved endothelial cell growth medium. Data expressed as percentage cell 
viability compared to cells with no VEGF or heparin present (TCP control) ± percentage SEM (N = 
3, three replicates). 
As in the individual experiments, the addition of VEGF and heparin alone to the 
endothelial cell growth medium (2% FCS) led to an increase in cell viability in 
comparison to endothelial cell growth medium alone. No increase was observed when 
VEGF was combined with heparin (Figure 7.3), although a stimulatory effect was still 
observed, demonstrating that the combination of VEGF and heparin did not have a 
negative effect. 
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It was expected that a combination of VEGF and heparin cou\d resu\t in a synergistic 
effect, as both components stimulate endothelial cell proliferation individually. A 
similar study by Yamashita et ae38, employing bFGF instead of VEGF, on pulmonary 
artery endothelial cells showed that cell proliferation was increased by the addition of 
the growth factor (analysed up to 3 nglml) and by the addition of heparin with an 
optimum concentration of 100 ng/ml, followed by an inhibitory effect above 1000 
ng/ml. These results were in agreement with the findings of this study. In contrast to this 
study, they found that a combination of bFGF and heparin lead to a further increase in 
cell viability with an optimum heparin concentration of 100 nglml, followed by a 
significant decrease in viability at 1000 nglml heparin and above. 
A study by Weatherford et al339 analysed the effect ofVEGF and heparin in a fibrin glue 
on human aortic endothelial cell (HAEC) proliferation. It was reported that the 
combined addition of VEGF and heparin to the fibrin glue improved stimulation of the 
HAEC in comparison to VEGF alone at day 1, but no difference was observed by day 3. 
It was suggested by the authors that an early synergistic effect of VEGF and heparin 
occurs that plateaus at a level equal to VEGF alone by day 3. It is possible that this is 
also the case in this study as the cell viability was analysed at day 3 only, so any 
synergistic effect occurring at other time points would not have been seen. It would 
therefore be necessary to repeat this study with analysis at a number of time points to 
either confirm or refute this hypothesis. 
These results confirm VEGF and heparin to be slightly stimulatory to endothelial cell 
viability over three days. Hence whether VEGF is released from the hydrogel alone or 
bound to the heparin one might expect stimulation of cell viability, and so in either 
event the release ofVEGF from a hydrogel may still have the desired effect. 
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7.2 Effect of VEGF- and Heparin-Bound Peptide-Functionalised 
Hydrogels on HDMEC Proliferation 
It has already been discussed in this thesis that VEGF has a significant effect on 
HDMEC proliferation (Figure 7.1) and that the hydrogels produced bind and release 
VEGF, especially the PNDRRR hydrogel. A study was then carried out to determine the 
effect of VEGF released by the hydrogels on HDMECs (Figure 7.4). This study was 
carried out simultaneously in both endothelial cell growth medium containing 5% 
serum, and in "starved" endothelial cell growth medium containing only 2% serum. For 
the experiment carried out in starved medium the endothelial cells were serum-starved 
overnight in 2% serum prior to the experiment. Starved medium containing only 1 % 
serum was initially trialled but a very low cell viability was observed after the required 
experimental time period, and so 2% serum medium was selected. Both serum and 
serum-starved environments were investigated to determine whether the hydrogels may 
have more effect in one of these environments. Investigations into the four hydrogel 
types (PND, PNDA, PNDKKK and PNDRRR), as hydrogel alone, heparin-bound and 
VEGF- and heparin-bound, were carried out in a combined experiment. 
For this investigation the hydrogels were prepared as described previously and were 
washed in sterile PBS before use in cell culture. Firstly, heparin was bound to the 
hydrogels by soaking the hydrogels in a 1 mg/ml heparin solution (PBS) for 24 hours at 
room temperature with gentle agitation. The hydrogels were then washed in sterile PBS 
seven times to remove unbound polysaccharide. To then bind VEGF, the heparin-bound 
hydrogels were soaked in a 200 ng/ml VEGF solution (PBS) at 4°C for 24 hours with 
gentle agitation, followed by three PBS washes to remove any unbound protein. 
The hydrogels, alone, heparin-bound and VEGF - and heparin-bound, were then placed 
in a 48 well plate and allowed to equilibrate in the appropriate medium for 2 hours. The 
cells were then seeded into the well (10,000 cells per well), allowing the cells to attach 
to either the hydrogels or the tissue culture plastic surrounding the hydrogels. The 
medium was replaced on both the serum and serum-starved experiments daily. This was 
necessary for the serum-starved experiment to give a quantifiable cell viability and was 
also carried out in the 5% serum experiment to ensure that the results were comparable. 
An MTT assay was carried out after three days. 
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Figure 7.4: Schematic of experiment to determine effect of VEGF released from hydrogel on 
endothelial cell proliferation. Experiment carried out in both serum medium (5% FCS) and serum-
starved medium (2% FCS). 
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7.2.1 Effect ofVEGF- and Heparin-Bound Hydrogels (5% Serum Medium) 
This experiment was carried out in triplicate in medium with 5% serum and the results 
for the quantitative MTT assay of cells in indirect contact with the hydrogels are shown 
in Figure 7.5. Significance within each experiment was determined by one-way 
ANOVA with Tukey post-hoc analysis (Family error rate = 5). In all cases, the 
morphology of the cells present on the TCP in indirect contact with the hydrogels was 
standard for endothelial cells, i.e. they appeared to resemble cobblestones. 
When considering these results (Figure 7.5), for repeats 1 and 2, no significant effect 
was observed due to the presence of the PND hydrogel, either alone, heparin-bound or 
VEGF- and heparin-bound. A significant effect (p < 0.05) was observed for repeat 3 
between the control and the PND hydrogel. However, overall these three experiments 
show no significant effect when the cells were in the presence of any of the PND 
hydro gels, even though the ELISA results discussed in Section 5.2 show that over the 
three-day period 19.8 ng VEGF would be released into the medium for the VEGF- and 
heparin-bound PND hydrogel. A similar result was found for the PNDA hydrogel. 
Although a significant increase in cell viability from the TCP control was observed in 
one of the repeats for the heparin-bound PNDA hydrogel (p < 0.05) and in one of the 
repeats for the VEGF- and heparin-bound PNDA hydrogel (p < 0.05), no overall effect 
of the PNDA hydrogels was observed. This VEGF- and heparin-bound hydrogel was 
also shown by ELISA to release VEGF over a three-day period. 
In contrast, the presence of the PNDKKK hydrogels led to an increase in cell viability 
in two of the three experiments, but the only result that achieved significance (p < 0.05) 
was observed for the heparin-bound hydrogel in comparison to the TCP control in 
repeat 2. No overall trend was shown for the PNDKKK hydrogels in this study. In all 
cases in the PNDRRR hydrogel study, the heparin-bound hydrogel and the VEGF- and 
heparin-bound hydrogel were shown to lead to a higher viability of cells in indirect 
contact with the polymers than the control and PNDRRR-hydrogel alone. This increase 
was significant (p < 0.01) in two of the three experiments. The increase observed for the 
VEGF- and heparin-bound hydrogel was as expected, as the PNDRRR hydrogel was 
shown to release more VEGF (27 ng) over the 72 hour period than the other hydrogels. 
Interestingly, in all three experiments the heparin-bound PNDRRR hydrogel produced a 
larger increase in proliferation than the VEGF- and heparin-bound PNDRRR hydrogel. 
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Figure 7.5: Effect of YEGF- and heparin-bound hydrogels on endothelial cells in indirect contact, 
cultured in serum-containing medium (5% FCS) for three days. Results of three repeat 
experiments shown individually. Data expressed as mean percentage of TCP control (shown in red) 
± percentage SEM (3 replicates per experiment). Significance assessed using one-way ANOV A with 
post-hoc Tukey analysis (*p < 0.05, **p < 0.01, ***p < 0.001). 
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The Mann Whitney U Test was used to analyse the combined results of the three 
repeats, and showed that only the heparin-bound PNDRRR material gave a significant 
cell viability increase from the control and PNDRRR-hydrogel alone (p < 0.01). The 
heparin-bound PNDRRR hydrogel leading to a significant increase in cell viability over 
the three repeats as opposed to the VEGF- and heparin-bound PNDRRR hydrogel was 
an unexpected result. One hypothesis to explain this is that the heparin-bound PNDRRR 
hydrogel would be able to bind a number of proteins present in the serum in the medium 
as opposed to only containing VEGF. This combination of proteins may have had more 
of a significant effect on the proliferation of the endothelial cells than VEGF alone. In 
this experiment the medium was replaced daily, and so the heparin-bound PNDRRR 
hydrogel may have been able to store the required components of the medium and 
release them over the course of the experiment, thus leading to an increase in cell 
viability. Also any effects of VEGF may have been masked by the presence of a high 
quantity of proteins in the foetal calf serum, thus not leading to any significant increase 
in cell proliferation. This however is speculation and was not investigated further in this 
study. 
This experiment also allowed analysis of the cell attachment capabilities of the 
hydrogels either alone, bound with heparin or bound with VEGF and heparin. As 
discussed in Chapter 6, the number of cells present on the polymer after three days was 
so low that these could be visualised using MTT assay but not quantified. 
The MTT assay images (Figure 7.6), taken after three days in culture, show that there 
was no real difference in the number of cells attached to any of the polymers when 
alone, heparin-bound or VEGF- and heparin-bound. No cells were present on any of the 
PND polymers in all three repeats, and there were very few cells on any of the PNDA 
materials. An increase in cell number occurred as the hydrogels were functionalised 
with the trilysine peptide (PNDKKK), although the cell number was still low and no 
effect was seen when either heparin or VEGF and heparin were bound. As in the four 
day experiment (Figure 6.10), a considerably higher number of cells were present on the 
PNDRRR hydrogel in all three cases in all three repeats. From these results it was 
concluded that no significant effect was observed for the number of cells attaching to 
the polymers when either heparin alone or VEGF and heparin were bound to the 
hydrogels. 
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Figure 7.6: Results of endothelial cell culture experiment in 5% FCS endothelial cell growth factor 
medium with hydrogels alone (column 1), heparin-bound hydrogels (column 2) and VEGF- and 
heparin-bound hydrogels (column 3). Endothelial cells shown are those on top of the hydrogels 
after three days, stained with MTT. Row (1) PND (2) PNDA (3) PNDKKK (4) PNDRRR 
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In all of the MTT images (Figure 7.6) for cells attached to the hydrogels, the cells 
appear rounded, stressed and not well attached to the material. However, visual analysis 
of the cells showed that, for the PNDRRR hydro gels only, this is not how they appear 
prior to the MTT assay, suggesting that in these cases their appearance may be due to 
the MTT staining procedure. 
When the cells on the PNDRRR hydrogels are observed without staining (Figure 7.7), 
the morphology of the cells present on top of the hydrogels vary as heparin, and VEGF 
and heparin combined, are added to hydrogels. For the PNDRRR hydrogel alone, the 
cells present on the surface appear rounded and not well attached. Conversely, a very 
different appearance is observed when the PNDRRR hydrogel has heparin attached to it. 
In this case, a large proportion of the cells have a long, thin and stretched morphology, 
often shown to be emanating out from a small cluster of cells. This effect is even more 
obvious for the VEGF- and heparin-bound hydrogels, where a large number of stretched 
cells are observed, the majority of which originate from a small cluster of cells. In this 
case, with VEGF present, the stretched cells are often shown to be joining two groups of 
cells. These stretched cells are present on both the heparin-bound and VEGF- and 
heparin-bound hydrogels from days 1 to 3 in all three repeats of this study. These cells 
appear to be more strongly attached to the hydrogels in comparison to cells on the 
PNDRRR hydrogel alone. The cells also appear to be less stressed than those present on 
the PNDRRR hydrogel alone, and do not possess the standard "cobblestone" 
morphology usually observed within a proliferation study in endothelial cell growth 
medium on tissue culture plastic. 
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Figure 7.7: Endothelial cells on top of RRR-functionalised hydrogels (PNDRRR) with no staining 
after 24 hours in 5% serum medium. (1) PNDRRR hydrogel alone (2) Heparin-hound PNDRRR 
hydrogel (3) VEGF- and heparin-bound PNDRRR hydrogel. 
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Figure 7.8: Human dermal microvascular endothelial cells cultured on top of hydrogels in media 
containing 5% FCS for 72 hours. Cells were stained with CellTracker™ Red and imaged on a Zeiss 
LSM 510 confocal microscope (abs. 577 nm and em. 602 nm). Images (a) cells on top of the hydrogel 
alone, (b) cells on top of heparin-bound hydrogel (c) cells on top of VEGF- and heparin-bound 
hydrogel. Row (1) PND (2) PNDA (3) PNDKKK (4) PNDRRR. 
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In order to confirm the change in morphology observed upon binding heparin and 
VEGF to the polymers, images were taken of cells stained with CellTracker™ Red 
(Figure 7.8). The cells were stained prior to the experiment to minimise stress to the 
cells attached to the polymer during the experiment. In all cases the cells in indirect 
contact were found to be present on the TCP with standard morphology (Figure 7.9 is 
representative of all wells analysed). It was noted that lower strength signals were 
consistently observed for endothelial cells compared to fibroblasts. 
Figure 7.9: Human dermal microvascular endothelial cells cultured in indirect contact with RRR-
hydrogel (PNDRRR) in S% FCS medium for 72 hours. Cells were stained with CellTracker Red 
and imaged on a Zeiss LSM 510 confocal microscope (abs. 577 nm and em. 602 nm). 
When looking at cell attachment, for the PND hydrogels, the results were the same as 
observed by MTT, with no cells present on the polymers. A very low number of cells 
were also observed for the PNDA hydrogels in all three cases. For the PNDKKK 
hydrogels a number of cells were observed on the surface of all three hydrogels after the 
washing procedure for CellTracker™ Red, showing that these cells were reasonably 
well attached, although a number of less well attached cells were detached during these 
washing steps. Again, no significant difference was observed for the PNDKKK 
hydrogel alone, heparin-bound, or VEGF- and heparin-bound. A number of cells were 
washed off during the CellTracker™ Red procedure on the PNDRRR hydrogels, 
showing these cells are still relatively loosely attached, but cells were present on the 
PNDRRR hydrogel alone, as well as on the heparin-bound and VEGF- and heparin-
bound PNDRRR hydrogels. The cells remaining attached to the PNDRRR hydrogel 
alone appear rounded, whereas the images of the heparin-bound and VEGF- and 
heparin-bound hydrogels show stretched cells joining small clusters of cells together, 
confirming the visual analysis prior to staining. 
186 
7.2.2 Effect ofVEGF- and Heparin-Bound Hydrogels (Serum-Starved Medium) 
In the serum-starved experiment (Figure 7.10), there were no significant differences or 
obvious trends observed for either the PND polymers or the PNDA polymers. 
However, for the trilysine-functionalised materials (PNDKKK), the heparin-bound and 
VEGF- and heparin-bound hydrogels were consistently shown to increase cell viability 
in this study, with the VEGF- and heparin-bound hydrogel giving the largest increase, 
which was found to be significant (p < 0.05) in two repeats. A similar result, an increase 
in cell viability for the heparin-bound hydrogel and the VEGF- and heparin-bound 
hydrogel, was obtained for the PNDRRR polymers, and in all cases the increase 
observed was always larger than that observed for the trilysine material. The VEGF-
and heparin-bound PNDRRR polymer consistently led to a considerably larger increase 
than the heparin-bound PNDRRR material, and the improvement in cell viability for the 
VEGF- and heparin-bound PNDRRR hydrogel in comparison to the TCP control and 
PNDRRR hydrogel alone was shown by a one-way ANOV A with post-hoc Tukey 
analysis to be significant (p < 0.01) in all repeats. 
In contrast to the study in serum-containing medium, this study showed the VEGF- and 
heparin-bound PNDRRR hydrogel to have the most significant effect on endothelial cell 
proliferation rather than the heparin-bound PNDRRR hydrogel as found in 5% serum 
medium. This is as would be expected as the PNDRRR hydrogel was shown to release a 
higher quantity of VEGF over the 72 hour study period than any of the other hydro gels. 
It is expected that this is due to the fact that this study was carried out in a serum-
starved environment, and so unlike the serum-containing experiment, the heparin-bound 
hydrogel was unable to bind as much protein from the medium to release over the 
experiment and thereby affect the proliferation of the endothelial cells. The lack of 
protein in the medium meant that the VEGF released from the VEGF- and heparin-
bound PNDRRR hydrogel could have a more significant effect on the endothelial cells 
than in 5% serum medium. The effect of serum reduction from 5% to 2% on cells on 
TCP can be seen in Figure 7.11. The ELISA study carried out showed that VEGF was 
released over the whole of the 72 hour period and therefore would have been able to 
have a significant effect on the cells, despite the medium being replaced daily. 
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Figure 7.10: Effect of VEGF- and heparin-bound hydrogels on endothelial cells in indirect contact, 
cultured in serum-starved medium (2% FCS) for three days. Results of three repeat experiments 
shown individually. Data expressed as mean percentage ofTCP control (shown in red) ± percentage 
SEM (3 replicates per experiment). Significance assessed using one-way ANOV A with post-hoc 
Tukey analysis (*p < 0.05, **p < 0.01, ***p < 0.001). 
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Figure 7.11: Endothelial cells cultured for three days in 5% serum (left) and 2% serum (right) 
endothelial cell growth medium. Cells shown are cells present on TCP, stained with MTT. 
Quantitative analysis of cell attachment in serum-starved medium (Figure 7.12) shows a 
similar trend to that observed in serum-containing medium, although the overall number 
of cells observed is considerably lower. This suggests that the attachment observed in 
the serum-containing medium is dependent on the proteins present in the foetal calf 
serum. 
No cells are present on any of the PND polymers, and a very low number of cells are 
observed on the PNDA and PNDKKK materials for the hydrogels alone, with heparin 
and with VEGF and heparin. For the PNDRRR hydrogel, a low number of cells 
attached to the polymer alone in all three repeats. The number of cells did increase upon 
heparin binding and VEGF binding, although the number of cells was still low in 
comparison to the serum-containing medium. 
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Figure 7.12: Results of endothelial cell culture experiment in 2% FCS "serum-starved" endothelial 
cell growth factor medium with hydrogels alone (column 1), heparin-bound hydrogels (column 2) 
and VEGF- and heparin-bound hydrogels (column 3). Endothelial cells shown are those on top of 
the hydrogels after three days, stained with MTT. Row (1) PND (2) PNDA (3) PNDKKK (4) 
PNDRRR 
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7.3 Discussion of Proliferation Data 
Cells in Indirect Contact - On rcp 
.In the 5% serum study, only the PNDRRR hydrogels showed a consistent increase in 
endothelial cell proliferation when the hydro gels contained VEGF and heparin, in 
comparison to the TCP control or the hydrogel alone. In this case, the heparin-bound 
PNDRRR hydrogel led to the most significant increase in proliferation. This effect was 
discussed previously and it was suggested that it may be due to the serum proteins being 
bound and released by the heparin-bound PNDRRR hydrogel, or the higher protein 
content masking the effect of VEGF released from the VEGF- and heparin-bound 
PNDRRR hydrogel. 
The results discussed show that proliferation of endothelial cells on TCP in serum-
starved medium was increased significantly (p < 0.01) in all repeats for the PNDRRR 
hydrogel bound with VEGF and heparin. A smaller increase was also observed for the 
PNDKKK hydrogel, which was found to be significant (p < 0.05) in two of three 
repeats. In order to understand this result it is necessary to consider the VEGF release 
data obtained through the VEGF ELISA (Section 5.2). In the ELISA study, all of the 
hydrogels were shown to release VEGF over the 72 hour period. Approximately 20 ng 
of VEGF was released by each of the PND, PNDA and PNDKKK hydrogels, with 27 
ng of VEGF released by the PNDRRR hydrogel. The VEGF release led to an increase 
in cell proliferation for the triarginine (PNDRRR) and trilysine (PNDKKK) 
functionalised materials but no significant increase was observed for the PND and 
PNDA materials, despite the 20 ng ofVEGF released by each polymer. 
It is possible that the significant increase in endothelial cell proliferation observed for 
the VEGF- and heparin-bound PNDRRR hydrogel was simply due to the increased 
VEGF concentration in the medium in comparison to the control and also the other 
hydrogels, but it is hypothesised that there may also be other factors involved. The 
feasibility of the involvement of other factors is also suggested when considering the 
results for the VEGF- and heparin-bound PNDKKK hydrogel. In this case an increase 
in proliferation was observed in comparison to the control, which was found to be 
significant in two of three repeats. This increase was observed for PNDKKK but no 
increase was observed for the PND or PNDA materials, despite equal quantities of 
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VEGF being released by each of these hydrogels, as determined by an ELISA. These 
results therefore suggest that the observed improvement in endothelial cell proliferation 
may be due to both the amount of VEGF released, and also to how VEGF is bound to, 
and released by, the polymer. 
In Chapter 5, a quantitative heparin-binding study was carried out, complemented by an 
XPS study. These experiments showed that 0.117 mg of heparin was bound per 
milligram of PNDRRR polymer, 0.077 mg of heparin was bound per milligram of 
PNDKKK polymer and 0.030 mg of heparin was bound per milligram of PNDA 
polymer, although in this case the measurement error was high. From these results it is 
suggested that the method of VEGF binding would differ for each hydrogel. The high 
quantity of heparin bound by the PNDRRR polymer would suggest that a large amount 
of the VEGF bound to this hydrogel would be bound through the heparin present. It is 
expected that this would be similar for the PNDKKK hydrogel, although the lower 
heparin content may have led to the lower VEGF content. A low amount of heparin was 
found to be present on the PNDA hydrogels, thus suggesting that, in this case, the 
VEGF present may have been bound directly to the polymer, possibly through hydrogen 
bonding with the acid functionality. Although no analysis has been carried out on the 
heparin content for the PND hydrogel, it is expected to have a low heparin content and 
so it is likely that the VEGF in this hydrogel would also be bound directly to the 
hydrogel via non-covalent interactions. 
Through consideration of heparin and VEGF binding studies, as well as cell culture 
results, it is thought that increases in cell proliferation coincide with the likelihood that 
VEGF is bound via heparin to the hydrogel. It is therefore hypothesised that the 
presence of heparin plays an important role in the ability of these hydrogels to stimulate 
endothelial cell proliferation. The exact method for this would need to be investigated 
further, but it is known that in the ECM, heparin and heparan sulphate are thought to 
influence growth factors in a number of different ways. The heparin utilised in this 
study may also be having a similar effect on VEGF in the following ways. 
Protection and Maintenance ofBioactivity 
One significant effect of this method of VEGF delivery may be due to the stability of 
the protein. The half-life of this protein in vivo is very short, with free VEGF being 
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degraded in less than one hour after a bolus injection63-66. Endothelial cell-derived 
heparan sulphate was shown by Saksela et al340 to protect bFGF from proteolytic 
degradation. Soluble bFGF was shown to be readily degraded by plasmin, whereas 
when the growth factor was bound to heparan sulphate it was protected from 
degradation. This protection was not seen after treatment of the heparan sulphate with 
heparinase. The protein may also be degraded by physical factors in vitro and it is 
suggested that this may be reduced if the growth factor is bound to heparin. In a study 
by Gosporarowicz et ae41 , heparin was shown to have a significant protective effect for 
basic and acidic FGF. Heparin was able to prevent a decline in potency upon storage of 
FGF at -80°C as well as in acidic conditions and with short heat exposure. Brandner et 
ae42 reported that heparin binding to VEGF stabilised the protein in a number of tests, 
and thereby concluded that GAG binding in vivo may stabilise the active conformation 
of this growth factor. The role of the polysaccharide is also in agreement with results 
from Huang et al259, who produced VEGF-Ioaded nanoparticles with self-assembled 
polyelectrolyte complexes. It was noted that in this study binding with a polyelectrolyte 
was shown to stabilise VEGF and release bioactive protein in a sustained manner. 
Storage and Release 
The ability of heparin to bind growth factors means that in biology it is expected that 
heparin, in heparan sulphate form or as a heparan sulphate proteoglycan, is able to act as 
a growth factor reservoir. Studies on FGF have shown that basic fibroblast growth 
factor-heparan sulphate complexes can be released from such a reservoir by proteolysis 
of the proteoglycan343, as well as the release of basic FGF by partial degradation of the 
heparan sulphate by heparanase344• Salbach et al345 report from an in vivo study of 
hepatocyte growth factor (HGF) (a heparin-binding growth factor) in humans that the 
administration of heparin resulted in a strong and rapid increase in HGF serum levels. It 
was suggested that HGF is dissociated from the cellular surface and the ECM into 
circulation by the heparin. 
Growth Factor-Heparin Complex 
In 1991, Yayon et al346 showed that the high affinity binding ofbFGF to its receptor 
requires prior low-affinity binding to free heparin or heparan sulphate. Thus heparin 
plays an important role in the interaction of this growth factor with its receptor. It was 
suggested by the authors that this may be due to a conformational change in basic FGF 
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upon heparin binding to enable the FGF to bind with the receptor. Heparin related 
species also play an important role in the binding of VEGF to its receptor. The binding 
of VEGF165 to vascular endothelial cells is strongly modulated by cell surface 
associated heparin-like molecules, and can also be modulated by the addition of 
exogenous heparin44. The most significant effect of heparin was observed for 
unfractionated heparin or heparin fragments longer than 22 sugar units47• The 
therapeutic effect of the VEGF -GAG interaction on VEGF potency has been 
demonstrated by the use of synthetic GAG mimetics. Carboxymethylbenzylamine 
dextrans inhibit VEGF 165 activity by interfering with heparin binding to VEGF 165 and 
VEGFI65-KDR receptor complexes347, whereas a carboxymethyl dextran sulphate was 
shown to potentiate VEGF 165-induced proliferation and migration of HUVEC348• 
Conclusion 
The results in both serum and serum-starved media show that the PNDRRR hydrogel in 
particular is able to bind heparin, which can in turn bind heparin-binding proteins, 
including VEGF. The subsequent release of VEGF and the effect on cell culture was 
most successfully demonstrated in the serum-starved environment, in which the 
presence of the VEGF- and heparin-bound PNDRRR hydrogel led to a statistically 
significant increase in endothelial cell proliferation over three days. 
Cells in Direct Contact - On Hvdrogel Surface 
During both the 5% serum and the serum-starved study, there are more cells present on 
the PNDRRR hydrogel than the other hydrogel types. In the serum-starved experiment, 
a slight increase in cell number on the PNDRRR hydrogel was qualitatively observed as 
VEGF and heparin were present in the hydrogel, although this effect was not observed 
in the 5% serum experiment. In all cases the cells were thought to be relatively weakly 
bound to the hydrogel, as the majority of cells were removed during any washing 
procedure. This is a positive observation for the intended application, as it would be 
desirable to remove the hydrogel after treatment in a wound healing application without 
also removing the healing tissue. 
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In the 5% serum experiment, the cells on the VEGF- and heparin-bound PNDRRR 
materials have a stretched morphology not observed for the PNDRRR hydrogel alone. 
Endothelial cells are anchorage-dependent cells which adhere to extracellular matrix 
proteins or a substrate at focal adhesion points349, which consist of a complex network 
of ECM, membrane and cytoplasmic components 350. These anchorage sites play a 
critical role in maintaining the shape of the cell and differentiation, as well as in 
proliferation and migration351 • When adhering to biomaterials, cell-material binding 
could be either non-receptor-mediated cell adhesion via weak non-covalent bonds 
directly to the material, or receptor-mediated and signal transmitting cell adhesion 
mediated by ECM molecules3s2• In the latter case, anchorage-dependent cells bind 
specific amino acid sequences of those molecules through integrin receptors. It is 
discussed by Oezyuerek et aeS3 that GAGs provide specific cell adhesion ligands, and 
that cell surface receptors, including selectins, bind to sulphated GAG ligands on cell 
surfaces, in the ECM or on artificial materials. 
It is expected that the poor cell adhesion observed for the hydrogel without heparin is 
due to weak interactions directly between the materials and the cells. The heparin-bound 
hydrogels allow specific cell adhesion either directly to the heparin, or to ECM proteins 
which have been tethered to the hydrogel via the sulphated heparin, thus allowing 
adhesion of endothelial cells which appear to be well attached due to the stretched 
morphology. These results are in agreement with those for glycol-block copolymers 
reported very recently by Oezyuerek et al3S3• 
It is observed that a number of the endothelial cells present on the VEGF- and heparin-
bound PNDRRR hydrogels in 5% serum have a stretched morphology, and are 
stretching between groups of cells, resembling the morphology of cells on Matrigel at 
the very beginning of tube formation. It was reported by Kubota et al3S4 that endothelial 
cells are able to rapidly differentiate on a basement membrane-like matrix. Within this 
study it is possible that the presence of heparin on the hydro gels may allow 
accumulation of ECM molecules, either present within the medium or synthesised and 
deposited by the cells themselves, and thereby begin to more closely resemble an ECM-
coated surface. It is feasible that this environment may then be able to begin to stimulate 
morphological differentiation of endothelial cells into tube-like structures. 
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7.4 Effect of VEGF- and Heparin-Bound Hydroe;els on An2io2:enesis -
Tubule Formation.Assay 
As the ability of the hydrogels to stimulate endothelial cell proliferation has been 
demonstrated, it was decided to analyse the most effective hydrogel, the triarginine-
functionalised polymer, for its ability to induce endothelial cell functions specific to 
angiogenesis. Angiogenesis requires a number of endothelial cell functions, including 
matrix degradation, migration and tubule formation, a process also referred to as 
morphogenesis and differentiation. 
In vitro assays stimulating capillary-like tube formation usually involve culturing 
endothelial cells on matrices consisting of fibrin, collagen or Matrigel35S• 356. Although 
there are problems with this procedure, namely whether lumen formation occurs354, and 
that other cell types can also form networks3s7, this tube-forming assay is a very popular 
in vitro assay for analysing pro- and anti-angiogenic treatments. 
In this case Matrigel was employed as the matrix. Matrigel is a mixture of basement 
membrane and extracellular proteins which have been derived from the mouse 
Engelbreth-Holm-Swarm sarcoma. It was shown by Kubota et al354 that human 
umbilical vein endothelial cells seeded at certain densities are able to attach to Matrigel 
and rapidly form tubes which can be maintained for between 12 and 24 hours. Standard 
Matrigel is very rich in angiogenic growth factors and therefore it can be difficult to 
observe the effect of any pro-angiogenic treatment, as network formation occurs readily 
with no extra treatment. An alternative, growth factor (GF)-reduced Matrigel, is now 
available with markedly lower concentrations of the stimulatory growth factors, thereby 
reducing the problem of the treatment effect being masked by the standard Matrigel 
response. In this case a pro-angiogenic treatment is being studied and so GF-reduced 
Matrigel was employed. 
Initially an experiment was carried out to determine the effect of soluble VEGF and 
heparin alone and VEGF and heparin combined on endothelial network formation on 
growth factor-reduced Matrigel. This was followed by an experiment to analyse the 
effect of the most successful polymer, the VEGF- and heparin-bound PNDRRR 
hydrogel, on tube formation. 
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7.4.1 Effect of Soluble Heparin and VEGF on Tube Formation 
Prior to analysis of the effect of VEGF- and heparin-bound PNDRRR hydrogel on tube 
formation, the effect of heparin and VEGF on endothelial cell tube formation was 
determined both individually and combined. For this experiment, a layer of Matrigel 
was laid in a 48 well plate and incubated at 37°C for I hour to allow the Matrigel to set. 
Endothelial cells, which had been previously starved overnight in 1 % serum medium, 
were then seeded in a small volume of serum-starved medium (1 % serum) and allowed 
to attach before the addition of the treatment medium. The 48 well plate was then 
incubated at 37°C for six hours before imaging of the wells by light microscopy. 
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Figure 7.13: Effect of heparin, VEGF and VEGF and heparin combined on cell area within a tubule 
formation assay. Data expressed as mean percentage of Matrigel control ± percentage SEM (three 
experiments with three replicates per experiment). 
The effect of VEGF, heparin and the two combined was measured by two methods, 
firstly by analysis of the cell area, and secondly by analysis of the length of tubes 
formed. Scion image (Frederick, MA) was employed to analyse these experiments. Cell 
area was determined by quantifying the area occupied by cells in each image. Average 
tube length was calculated by manually selecting and measuring ten tubes at random 
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from each image. In each case, a number of Images were analysed for each 
environment. 
When considering the effect on cell area (Figure 7.13), the addition of VEGF, heparin 
or the two combined led to an increase in cell area, although no significant stati stical 
difference was observed overall. 
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Figure 7.14: Effect of heparin, VEGF and VEGF and heparin combined on tubule length within a 
tubule formation assay. Data expressed as mean percentage of Matrigel control ± percentage SEM 
(three experiments with three replicates per experiment). Significance assessed using one-way 
ANOVA with post-hoc Tukey analysis (*p < 0.05, ** p < 0.01, *** p < 0.001). 
Tube length (Figure 7.14 & Figure 7.15) however was found to differ from the control 
upon addition of the growth factor and polysaccharide. The control well containing 
Matrigel only, with no further addition, was found to have an average tube length of 93 
~m. This average tube length decreased slightly to 86 ~m upon the addition of heparin, 
although variation in the results meant that no significant difference between the two 
was observed. Tube length increased to 1 05 ~m upon the addition ofVEGF and I 09 ~m 
for VEGF and heparin combined, which in both cases was a significant increase from 
the Matrigel control. 
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Figure 7.15: Images of endothelial cells on Matrigel taken after six hours in serum-starved medium 
(1 % serum) (a) control well (medium with no supplement) (b) heparin-containing medium (c) 
VEGF-containing medium (d) VEGF- & heparin-containing medium. 
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7.4.2 Effect ofVEGF- and Heparin-Bound RRR Hydrogel on Tube Formation 
The final investigation in this study was to detennine the effect of the VEGF- and 
heparin-bound PNDRRR hydrogel on two other aspects of angiogenesis, migration and 
tube formation. 
Cell migration can be either random or directional. Directional endothelial cell 
migration occurs through three major mechanisms: haptotaxis, the migration towards a 
gradient of immobilised ligands; mechanotaxis, migration due to mechanical forces; and 
chemotaxis, migration towards a gradient of chemoattractive stimulus2o. Analysis of 
endothelial cell migration is generally carried out by a wound healing assay58 or by a 
variation of the method developed by Boyden359, commonly referred to as the Boyden 
chamber. It is well known that soluble VEGF is able to induce endothelial cell 
migration in a concentration-dependent manner, but this process is a balance of many 
growth factors and integrin-stimulated signals, and therefore different cells and different 
conditions may lead to varying results36o. Mastyugin et al361 demonstrated human 
umbilical vein endothelial cell migration due to VEGF, and showed that migration was 
inhibited by the known VEGFR tyrosine kinase inhibitors PTK787 and AAL993. 
Shamloo et atl62 reported that HUVECs chemotax towards VEGF from 18-32 ng/ml 
VEGF and that the steepness of the VEGF gradient was shown to influence directional 
migration, whereas Barkefors et atl63 found that migration of endothelial cells occurred 
at stable gradients of 0-50 ng/ml over a distance of 400 J.lm. 
The effect of chemotaxis on endothelial cells has also been observed for surface-density 
gradients. HUVEC attachment is affected by a RGDS peptide gradient on PEG 
hydrogels364, and bovine aortic endothelial cells (BAECs) migrated on a surface-bound 
fibronectin gradiene65. Liu et al366 showed migration on material with immobilised 
VEGF and fibronectin. Gradients of both proteins stimulated directional migration and 
an increased effect was observed for the two combined in a 24-hour cell culture 
experiment. It has also been reported that endothelial cells guide outgrowing capillaries 
in response to the gradients ofVEGF in retinal angiogenesis367. 
Angiogenic factors spatially affect the direction of tube fonnation during angiogenesis. 
This is well demonstrated by organ culture assays and in vivo assays. Popular methods 
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include the subcutaneous implantation of a polymeric material containing an angiogenic 
factor followed by analysis of the vessel growth into the plug of material32\ and the 
chick chorioallantoic membrane (CAM) assay27, in which angiogenic factors can be 
placed on the CAM through a window in the eggshell. The angiogenic stimulator will 
then typically cause a radial rearrangement of blood vessels towards the implant and an 
increase of vessels around it. VEGF-induced angiogenesis in the CAM assay in vivo, as 
well as inhibition by anti-angiogenic factors, was nicely demonstrated by Benndorf et 
a1368• 
It was hypothesised that VEGF released from the PNDRRR hydrogel would produce a 
VEGF gradient, and therefore may cause cell migration and spatially influence tube 
formation in an angiogenesis assay. A method to analyse both migration and tube 
formation simultaneously, whilst maintaining the simplicity of an in vitro experiment 
and minimising the effect of external factors, was designed to compare the effect of the 
VEGF- and heparin-bound PNDRRR hydrogel and the PNDRRR hydrogel alone 
(Figure 7.16). For this investigation the hydrogels were prepared as described 
previously in Chapter 4, and VEGF and heparin were bound as previously described in 
Section 7.2. After the final PBS wash the hydrogels were placed in 1 ml of serum-
starved medium (l % serum) and allowed to equilibrate. Meanwhile, a layer of Matrigel 
was allowed to set in the wells of a 48 well plate before careful addition of one disc of 
hydrogel to each, avoiding disruption of the Matrigellayer. The cells, starved overnight 
prior to the experiment in 1% serum medium, were then randomly seeded into the well. 
The 48 well plate was then incubated at 37°C for six hours before the cells were imaged 
by light microscopy. 
The addition of a polymer disc covering one quarter of the area of a well meant that it 
was not possible to analyse the tube formation in the standard quantitative method. 
Instead, the effect of the polymer plus heparin and VEGF was compared qualitatively to 
the polymer alone and a control Matrigel well. Within each experiment, three repeats of 
each environment were carried out and the entire experiment was carried out in 
triplicate. 
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Figure 7.16: Schematic of experiment to determine effect of VEGF released from hydrogel on 
endothelial cell differentiation. Studies were carried out in serum-starved medium (I % FCS) on 
growth-factor reduced Matrigel. 
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Figure 7.17: Stitched light microscopy images of PNDRRR hydrogel discs on growth factor-
reduced Matrigel. Top image: VEGF- and heparin-bound PNDRRR hydrogel. Bottom image: 
PNDRRR hydrogel alone (near to well edge). Images show networks of endothelial cells forming 
around the VEGF- and heparin-bound PNDRRR hydrogel where disc has been shifted slightly to 
the left. 
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Previously it was shown that culture of endothelial cells on Matrigel alone leads to the 
formation of an EC network with tubes forming in random directions (Figure 7.15). The 
images in Figure 7.17 show PNDRRR hydrogel alone (bottom image) and VEGF- and 
heparin-bound PNDRRR hydrogel (top image) in wells coated with GF-reduced 
Matrigel. In both cases, the hydrogel itself is visible in the centre of the image (labelled 
to show the edge of the hydrogel) with endothelial cells present on the Matrigel 
surrounding it. Culture of endothelial cells on GF-reduced Matrigel in the presence of 
VEGF- and heparin-loaded PNDRRR hydrogel led to a significant spatial arrangement 
of the EC network, such that the EC network formed radially around the hydrogel 
(Figure 7.17 (top». In this image, the hydrogel has shifted slightly to the left, revealing 
the tube formation that had occurred. For this VEGF- and heparin-bound PNDRRR 
hydrogel, a higher presence of endothelial cells was also observed directly surrounding 
the material than in other areas of the well. This effect was clearly observable after six 
hours of culture for all nine repeats carried out. Such an effect was not observed for the 
control PNDRRR hydrogel with no VEGF and heparin present, with random tube 
formation observed throughout the well in this case (Figure 7.17 (bottom». These 
results suggest that VEGF is released by the VEGF- and heparin-bound PNDRRR 
hydrogel in such a way as to produce a VEGF gradient, thus resulting in EC migration 
towards the source. It is also shown that tube formation is spatially affected by VEGF 
release. Tube formation is observed radially around the VEGF- and heparin-bound 
PNDRRR polymer, but not in direct contact with the hydrogel. This is a positive result 
for a potential wound healing application, as it is hypothesised that the material could be 
removed without seriously damaging the healing tissue or new capillary network. 
A similar spatial effect was previously reported by Tufr0369 for mouse glomerular 
endothelial cell response to avascular metanephric kidneys from rat embryos and 
VEGF-coated agarose beads to confirm that VEGF directs angiogenesis. In this case, 
EC networks were previously formed for 24 hours on collagen I gel before addition of 
either the kidney or the VEGF -loaded beads. Co-culture with the kidney induced spatial 
rearrangement of the EC network, with cells directed towards the explant. The effect 
was observable within 48 hours, at which time a network extending 1373 ± 44.6 Jlm 
radially surrounded each explant. The presence of anti-VEGF neutralising antibodies 
minimised migration. A similar spatial rearrangement was also observed for VEGF-
coated Affi-Gel blue agarose beads in the same study. 
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7.5 Discussion of Angiogenesis Assay Results 
Endothelial cell proliferation studies of VEGF- and heparin-bound hydrogels revealed 
that the most significant stimulatory effect was achieved with the PNDRRR hydrogel. 
This material was therefore selected for further analysis as an angiogenesis stimulator. 
In this final study ofVEGF- and heparin-bound PNDRRR hydrogels, a simple in vitro 
cell culture study on GF-reduced Matrigel was used to determine the effect of the 
VEGF- and heparin-bound hydrogel on migration and tube formation. The PNDRRR 
hydrogel alone had little effect on tube formation. The tubes present were randomly 
distributed and networks present did not extend above a few tubes. On the other hand, 
the VEGF- and heparin-bound PNDRRR hydrogel had a significant spatial effect on 
tube formation, with a relatively well-formed network of tubes present radially around 
the hydrogel in all repeats. Visual comparison of the two wells also shows increased 
tube numbers in the well with the VEGF- and heparin-bound PNDRRR hydrogel. 
Comparison of these results with other growth factor releasing materials is complicated 
due to the different in vitro and in vivo assays employed to analyse angiogenesis. Also, 
although the bioactivity of VEGF and proliferation of endothelial cells was often 
analysed in comparable growth factor delivery systems, only a small number of the 
growth factor delivery systems discussed in Section 5.3 provide information on the 
effect of the delivery system on angiogenesis. The chick chorioallantoic membrane 
assay was utilised by Kanczler et al90 to show that increased numbers of blood vessels 
surrounded their VEGF-encapsulated poly(D,L-lactic acid) scaffolds compared to 
control scaffolds in vivo. Yoon et al102 implanted bFGF-Ioaded Pluronic/heparin 
hydrogels into subcutaneous pockets in the dorsal side of male SD rats and showed that 
the tissue layer formed on the surface of these hydrogels contained more dense 
capillaries than the Pluronic hydrogel control. This observation was confirmed by 
histology of the tissues. Steffens et al103 employed both of these techniques followed by 
capillary counting or analysis of haemoglobin content to confirm that the presence of 
both VEGF and heparin in collagen matrices led to an increased angiogenic potential. 
Interestingly, an increased angiogenic potential was observed for the heparinised matrix 
alone as well as the VEGF-Ioaded heparinised matrix, although a higher increase in 
angiogenesis was observed in the presence of both VEGF and heparin. 
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Pike et al64 produced hyaluronan hydrogels containing gelatin and heparin as well as 
VEGF or bFGF which were implanted into the ear pinnas of Balb/c mice. The results 
showed that the vascularisation observed could be sustained for up to 28 days with the 
presence of heparin. Another report from the Peattie group84 also showed that the 
presence of heparin in hyaluronan-based hydro gels could sustain release of growth 
factors over a period of weeks. In an in vivo mouse model, heparin-containing hydrogels 
loaded with both VEGF and angiopoietin-l led to the development of more mature 
microvessel networks than when the hydro gels lacked heparin or one of the growth 
factors. This result is in agreement with those discussed by Richardson et al89 who 
analysed angiogenic potential by implanting their poly(lactide-co-glycolide) scaffolds 
into the subcutaneous tissue of Lewis rats. No increase in blood vessel density was 
observed for bolus delivery of VEGF and/or PDGF, but delivery of the growth factors 
from the scaffolds had a significant effect. Histology revealed that release of VEGF led 
to increased blood vessel density but the blood vessels remained immature, whereas 
PDGF release led to blood vessel maturation. Combined release of the two growth 
factors led to the formation of mature blood vessels. Despite the variety of assays 
available to analyse angiogenesis, all of the approaches discussed are in agreement with 
the results presented here, namely that the release of VEGF from a biomaterial can 
positively affect the process of angiogenesis. 
In conclusion, the RRR-functionalised hydrogel (PNDRRR) has been shown to be a 
promising biomaterial for VEGF delivery in a wound healing application. This heparin-
binding biocompatible material has been shown to non-covalently bind and release 
biologically active VEGF over a 72 hour period, significantly increasing endothelial cell 
proliferation. The presence of VEGF and heparin bound to the hydrogel also led to 
significant increase in cell attachment. An in vitro study has shown that the VEGF- and 
heparin-bound PNDRRR hydrogel has a positive spatial effect on the formation of tube 
structures on GF-reduced Matrigel. These results suggest that these hydrogels could be 
suitable as wound healing materials by acting as a VEGF reservoir and thereby 
stimulating EC proliferation and tube formation adjacent to the material. Further 
experimentation to examine the angiogenic potential of this hydrogel in vivo would now 
be justified. 
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8 Conclusion 
The aim of this work was to develop a material capable of binding and releasing 
bioactive VEGF (an angiogenic stimulator) for a wound healing application. The 
materials were designed to operate as VEGF-reservoirs, binding endogenous VEGF 
within a wound environment, maintaining VEGF concentrations within a localised area 
and thus aiding the process of angiogenesis and subsequent wound healing. The 
biomaterial was required to act as a "heparin-mimic", interacting non-covalently with 
the basic heparin-binding regions present on the VEGF protein. Two biomaterials were 
investigated to determine their potential for use in this application; core-shell 
molecularly-imprinted particles and heparin-bound peptide-functionalised poly(NVP-
co-DEGBAC-co-AA) hydrogels. 
Core-Shell Molecularlv-Imprinted Particles 
CS-MIPs were developed initially, using the methodology previously employed by 
Carter et al157, 159, 160. The epitope imprinting approachl90 was employed in order to 
overcome difficulties associated with the imprinting of biomacromolecules, and 
DKPRR was selected as the template molecule. A low temperature initiator system of 
potassium persulphate and ascorbic acid was investigated, allowing the synthesis of 
core and core-shell particles but affording only a 1.9% incorporation of the functional 
monomer (OPHP). In order to increase OPHP incorporation a number of alternative 
initiator systems were trialled, with the most successful system found to be initiation by 
potassium persulphate at 70°C, resulting in 11.7% of the OPHP employed being 
incorporated into the outer shells. This system was optimised to produce stable latexes 
of core particles and core-shell particles. 
This system was then employed to produce a series of MIPs; one imprinted with 
DKPRR, a pentapeptide sequence present at the carboxy-terminus of VEGF 165; one 
imprinted with GAA, an unrelated peptide sequence; and a blank version, produced 
without the presence of the template. A colorimetric peptide binding study showed that 
binding occurred between the surface phosphate functionality of the core-shell particles 
and the basic amino acids, confirmed by a zeta potential binding study which showed a 
considerable decrease in surface charge for all core-shell particles as they interacted 
with the DKPRR peptide but not with the SSSSSSSS peptide. A slight influence of 
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molecular imprinting was observed during the colorimetric peptide release study as a 
higher acid concentration was required to remove MRSSSDKPRR from the DKPRR 
CS-MIP than was required for MRSSSPRKRD, a scrambled version of the peptide. For 
the GAA CS-MIP and the blank CS-MIP the release of the two peptides was very 
similar in each case and resembled the release of MRSSSPRKRD from the DKPRR CS-
MIP. The delayed release ofMRSSSDKPRR is attributed to the binding of the DKPRR 
group to molecularly-imprinted cavities, resulting in multiple interactions between the 
polymer and the peptide. A study of VEGF binding and release for the three core-shell 
particle types revealed that over a 48 hour period 22.4 ng, 21.3 ng and 20.9 ng of 
bioactive VEGFI65 was released per milligram of the DKPRR-, GAA- and blank-
imprinted CS-MIPs respectively. 
From the studies carried out to date, no significant effect of molecular imprinting was 
observed in binding or release of the protein, suggesting that the molecular imprinting 
process may not offer any advantages for this application. Nevertheless, synthetic core-
shell particles with surface phosphate functionality have been developed which are 
capable of binding and releasing VEGF 165 over a 48 hour period whilst maintaining the 
bioactivity of this protein, thereby showing the potential of core-shell particles with 
phosphate functionality for heparin-binding protein delivery applications. 
Heparin-Bound Peplide-Funclionalised Hvdrogels 
The second approach investigated involved a heparin-bound peptide-functionaIised 
hydrogel for interaction with VEGF. Poly(NVP-co-DEGBAC) polymers were 
employed as the base hydrogel as this material had already been employed in our 
research group286. Consideration of heparin-protein interactions led to the selection of 
triarginine and trilysine as heparin-binding peptides. Poly(NVP-co-DEGBAC-co-AA) 
hydro gels were designed to couple the peptides via an amide bond between the acrylic 
acid residues and the amine functionality of the peptide. An optimised two-step 
coupling procedure was determined for thermally-initiated hydrogels, involving an 
activation step with DCC and NHS in DMF at room temperature for 24 hours and a 
coupling step with two equivalents of peptide in PBS (PH 8.5) at O°C for 72 hours. The 
highest peptide loadings were achieved using this system with tripeptide sequences and 
5% acrylic acid hydro gels. 
208 
These optimised conditions were employed in the coupling of UV -initiated hydrogels to 
trilysine (0.14 mg/mg hydrogel) and triarginine (0.2 mg/mg hydrogel), which were 
employed in all further investigations, as these hydro gels required less peptide and 
offered superior mechanical properties than the thermally-initiated hydro gels. The 
ability of these materials to bind heparin was confirmed via XPS and a fluorescent 
heparin study; they were shown to bind 0.077 mg and 0.117 mg of heparin per 
milligram of dry hydrogel for the PNDKKK and PNDRRR hydrogels respectively. An 
ELISA study of the heparin-bound hydrogels revealed that these materials were able to 
bind VEGF, resulting in a release of 20.1 ng and 27.0 ng of biologically active VEGF 
per PNDKKK hydrogel and PNDRRR hydrogel disc respectively over a 72 hour period, 
in comparison to 19.8 ng and 19.4 ng for the PND and PNDA hydro gels. The higher 
VEGF release from the PNDRRR hydrogel was attributed to the higher incorporation of 
heparin in the hydrogel. A low retention of VEGF on all hydrogels was observed after 
the study, suggesting this material is suitable for a delivery system. 
Cell compatibility studies on PND, PNDA, PNDKKK and PNDRRR revealed that all 
materials are cytocompatible. When considering fibroblasts and HDMECs in indirect 
contact with the hydrogels, no significant effect was observed due to the presence of the 
hydrogels in FCS-containing medium. In the fibroblast serum-starved experiment, a 
decrease in viability (significant (p < 0.001) in two of three repeats) was observed in the 
presence of PNDRRR, which is attributed to absorption of vital media components by 
this hydrogel. Interestingly, a significant increase in the number of cells in direct contact 
with the hydrogels ( on top) was observed for both cell types as the hydrogels were 
functionalised with peptides, with the most significant effect being observed for the 
PNDRRR hydrogel. 
In a study of HDMEC proliferation in indirect contact with the hydrogels in 5% serum 
medium, an increase in cell proliferation was observed in the presence of both the 
heparin-bound and the VEGF- and heparin-bound PNDRRR hydrogels. Overall, in 5% 
serum medium, only the heparin-bound PNDRRR hydrogel was shown to lead to a 
significant increase in HDMEC proliferation, which is expected to be due to masking of 
the VEGF effect of the VEGF- and heparin-bound PNDRRR hydrogel by the serum in 
the medium. The presence of VEGF- and heparin-bound PNDRRR hydrogels in a 
serum-starved environment led to a significant increase in proliferation in all repeats, 
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and a smaller increase was also observed for the VEGF- and heparin-bound PNDKKK 
hydrogels in two of the three repeats. These results are expected to be due to both the 
VEGF and heparin loadings for these hydrogels, as the presence of heparin is thought to 
increase the effect of VEGF on endothelial cells through a number of mechanisms. The 
PNDRRR hydrogel was shown to bind the most heparin and VEGF and was therefore 
able to have the most significant effect on the endothelial cells. Interestingly, cells 
observed on top of the heparin-bound and VEGF- and heparin-bound PNDRRR 
hydrogels had a stretched morphology not observed for the PNDRRR hydrogel alone. 
This could be due to improved cell adhesion in the presence of heparin, or possibly due 
to the heparin-bound hydrogels more closely resembling the ECM. Thus they should be 
more suitable for differentiation of the endothelial cells into tube-like structures. 
An in vitro experiment was carried out with growth-factor reduced Matrigel in the 
presence of the PNDRRR hydrogel alone and VEGF- and heparin-bound PNDRRR 
hydrogel to determine the effect of these materials on endothelial cell migration and 
tube formation. In the presence of the PNDRRR hydrogel alone tube formation occurred 
randomly throughout the well, as was observed for Matrigel alone. The presence of the 
VEGF- and heparin-bound PNDRRR led to the formation of a radial endothelial cell 
network around the hydrogel, with a higher concentration of cells surrounding the 
polymer than in other areas of the well, suggesting that a VEGF gradient is formed upon 
release of the protein from the hydrogel, causing endothelial cell migration towards the 
source. The radial tube formation surrounding the hydrogel suggests that the orientation 
of the tubes was also affected by directional VEGF release. 
This work clearly shows the potential of these hydrogels, particularly the PNDRRR 
hydrogel, to meet the initial aim of this project. Triarginine- and trilysine-functionalised 
poly(NVP-co-DEGBAC-co-AA) hydrogels were synthesised and were able to bind and 
release biologically-active VEGFl6S over a 72 hour period. These materials were shown 
to be cytocompatible and increased cell attachment was observed in comparison to the 
poly(NVP-co-DEGBAC) and poly(NVP-co-DEGBAC-co-AA) hydrogels. Most 
importantly, the triarginine-functionalised hydrogels were shown to have potential as 
stimulators of angiogenesis, as the VEGF- and heparin-bound PNDRRR hydrogels were 
able to significantly increase HDMEC proliferation, and lead to endothelial cell 
migration and directional tube formation in vitro. 
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Summary 
Both systems investigated resulted in polymers able to bind and release similar 
quantities of VEGF 165, whilst maintaining the biological activity of the protein, with an 
average of 22.4 ng ofVEGF165 released per milligram of the DKPRR CS-MIP (over 48 
hours) and 27.0 ng released per triarginine-functionalised hydrogel disc (over 72 hours). 
It is expected that these materials would similarly be able to bind and release other 
heparin-binding proteins. 
These two materials offer different approaches to achieve the project aim, and as such 
each method has different advantages and disadvantages. The core-shell particles are 
able to bind VEGF in a one-step system as the phosphate functionality required is 
present within the material. This functionality was shown to bind the protein with the 
appropriate strength to be able to release it over a 48 hour period in a biologically-active 
form. It is suggested that this synthetic approach would enable simple control of protein 
binding by varying the phosphate concentration on the particle surface, offering a 
versatile system. It is acknowledged that such particles could not be used directly in a 
wound environment, possibly even being of a size to have implications of phagocytosis, 
and would therefore require coating on, or encapsulating within, a secondary material. 
The triarginine-functionalised poly(NVP-co-DEGBAC-co-AA) hydro gels were also 
able to bind and release bioactive VEGF 165. This cytocompatible material has the 
required mechanical properties without necessitating a secondary material support. This 
system would require a two-step process in order to be utilised in a wound healing 
application as it first needs to interact with heparin before binding VEGF. The use of 
heparin as an intermediate binding system also means that it may be difficult to control 
protein binding amounts and the release kinetics by material design. However, this 
system has the advantage of enabling protein binding in a more natural environment, 
thus possibly allowing growth factor release in response to biological factors. 
To conclude, two systems have been developed that are capable of binding and 
releasing bioactive VEGF. In addition, triarginine-functionalised hydrogels were shown 
to be both cytocompatible and able to increase HDMEC viability and influence 
angiogenesis in vitro. In both cases, the results discussed demonstrate the potential of 
these materials for further development towards the final aim of an angiogenesis-
stimulating material for a wound healing application. 
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2 Future Work 
There are number of areas where further work could be carried out to improve the 
understanding of the results presented and to further develop the materials produced. 
Further peptide and protein binding studies, including a competitive protein binding 
study, would complete the molecular imprinting aspect of the CS-MIP work for 
academic interest, even though the molecular imprinting technique would not be 
suggested for further development of the core-shell particles. It is also suggested that 
more comprehensive VEGF binding and release studies be carried out to detennine the 
release kinetics over a longer time period. Control of the binding capacity of phosphate-
functionalised core-shell particles could also be investigated by varying the 
concentration of phosphate monomer in the synthesis of the outer shell, or by the use of 
alternative phosphate monomers. For further development of the core-shell particles, the 
cytocompatibility of these materials needs to be detennined and, upon a positive 
outcome, the possibility of incorporating the core-shell particles into a secondary 
material to achieve suitable material properties could be investigated. If the core-shell 
particles were found to be cytocompatible and it was possible to incorporate them into 
secondary materials, it would then be necessary to determine the effect of these particles 
on angiogenesis in vitro and in vivo. 
With respect to the heparin-bound hydrogels, it is suggested that future work should 
focus on the development of the most successful material, the triarginine-functionalised 
poly(NVP-co-DEGBAC-co-AA) hydrogel. It would be interesting to investigate 
whether VEGF alone or heparin-bound VEGF is released from the hydrogel in order to 
further understand the effect of this system on angiogenesis. This may be possible by a 
labelled-heparin study or through XPS analysis of the hydrogels after VEGF release. In 
order to detennine the true potential of this material for the application it would also be 
prudent to carry out further angiogenesis studies. The use of the chick chorioallantoic 
membrane angiogenesis assay could be the next logical step. 
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1!! Materials and Methods 
10.1 Peptide Synthesis 
10.1.1 Materials 
All resins for solid phase peptide synthesis were purchased from Novabiochem with the 
first amino acid attached, Fmoc-Arg(Pbf)-Wang resin (100-200 mesh), Fmoc-Lys(Boc)-
Wang resin (100-200 mesh), Fmoc-Asp(OtBu)-Wang resin and Fmoc-Ser(tBu)-Wang 
resin, and were used as supplied. All amino acids were purchased from Novabiochem as 
N-a-Fmoc protected amino acids with side chain protection when appropriate and used 
without further purification. Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-
Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, and Fmoc-Pro-OH were used as supplied. Methyl 
Red (ACS reagent, Sigma Aldrich) was used as supplied. Coupling reagents 2-
mercaptobenzothiazol (2-MBT, 97%, Aldrich), 2-(1 H-benzotriazole-I-yl) -1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU, Novabiochem), 1-
hyroxybenzotriazole hydrate (HOBt, 99.8% dry weight, >20% water, Alfa Aesar), N,N-
diisopropylethylamine (DIPEA, 99%, reagent grade, Aldrich) and cleavage reagents, 
piperidine (99%, Aldrich) trifluoroacetic acid (TF A, 99%, Reagent Plus, Aldrich), 
phenol (~99%, ACS reagent, Aldrich) and triisopropylsilane (TIPS, ~98%, purum, 
Fluka), were also used as supplied. Solvents were used as supplied; acetonitrile (HPLC 
grade, Far UV, Fisher) dichloromethane (DCM, HPLC grade, Fisher), diethyl ether 
(anhydrous, laboratory reagent grade, Fisher), N,N-dimethylformamide (DMF, 
laboratory reagent grade, Fisher) and methanol (HPLC grade, Fisher). Deionised water 
was used throughout. 
10.1.2 Equipment 
Peptide synthesis was carried out on a Chemspeed Technologies PSWI100 automatic 
synthesizer. Analytical HPLC-MS was performed on a Waters 2690 Separations 
Module with Micromass Platform MCZ with a Prosphere HP C18 column (300 A. 5 
J.lm, length = 150 mm, ID = 4.6 mm). Preparative HPLC was carried out on a Polymer 
Laboratories LCl150 module with a Prosphere HP Cl8 column (300 A, 10 J.lm, length 
= 100 mm. ID = 22 mm). NMR spectra were obtained on a DRX 500 MHz spectrometer 
using D20 throughout. 
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10.1.3 Solid Phase Peptide Synthesis (SPPS) Protocol 
The synthesis was carried out in DMF under an argon environment on an automated 
peptide synthesiser which was programmed individually for each synthesis. 
Reagent 
Amino acid 
Coupling reagent (HBTU) 
HOBt 
DIPEA 
Molarity of Solution (M) 
0.5 
0.5 
0.5 in coupling reagent 
Neat 
Required Amount 
(fold excess) 
HBTU 
5 
5 
5 
10 
Table 10.1: Relative reagent quantities employed in solid phase peptide synthesis 
General Synthetic Procedure 
The resin with first amino acid attached (~ 500 mg) was placed into the reaction vials in 
the automatic peptide synthesis robot. The resin was swollen in 5 ml DMF overnight 
under an argon atmosphere and 350 rpm vortex and then washed six times with 5 ml 
DMF. Deprotection of the first a-amino group was carried out by the addition of 5 ml of 
20% piperidine in DMF which was reacted for 5 minutes whilst vortexing at 350 rpm 
before being removed. This was repeated twice in order to achieve optimum coupling. 
The resin was then washed six times with 5 ml DMF. Chain elongation of the peptide 
sequence with subsequent amino acids was carried out using standard HBTU protocols. 
5 equivalents of the amino acid (0.5 M), 5 equivalents of HBTU (0.5 M), 5 equivalents 
of HOBt (0.5 M in HBTU) and 10 equivalents of DIPEA were added to the washed 
resin. The coupling reaction was allowed to continue for 1 hour under argon and vortex 
of 350 rpm before being removed from the reaction vessel. This coupling procedure was 
repeated once. The resin was then washed with 5 ml DMF six times. The above 
procedure of triple deprotection and double coupling was then repeated for the 
remaining amino acids in the required sequence. Once the final amino acid had been 
added the resin was washed six times with 5 ml DMF, six times with 5 ml DCM and 
finally six times with 5 ml methanol before being dried for storage. 
10.1.4 Peptide Cleavage 
The terminal Fmoc protecting group was removed, followed by removal of the resin and 
side-chain protecting group through treatment with trifluoroacetic acid (TFA) in the 
presence of various scavengers. A general procedure for peptide cleavage is described 
and the specific cleavage solutions for each peptide sequence is provided in table 10.2. 
214 
Removal ofFmoc Protection 
The peptide sequence on the resin was swollen in DMF (10 ml per gram of resin) 
overnight and then dried gently under vacuum. The swolfen resin was deprotected in 5 
ml of 20% piperidine in DMF solution for 5 minutes. This was repeated three times. 
The resin was then washed three times each with DMF, DCM and finally with methanol 
to remove all traces of DMF. The peptide sequence on the resin was then placed in a 
vacuum oven for one day to ensure it was completely free of solvents. 
Removal of Side-Chain Protecting Groups and Solid Support 
Peptides were cleaved from the resin using a TF A cleavage cocktail (10 ml per gram of 
resin) for two hours. The resin was washed with 1 x cleavage cocktail and 3 x TF A. The 
TF A was stripped off by rotary evaporation and the peptide was afforded by the 
addition of diethyl ether into the reaction vessel and subsequent trituration. The diethyl 
ether was decanted off and replaced five times, each time being triturated, to remove the 
remaining TFA and scavengers. Finally, the diethyl ether was removed by rotary 
evaporation and a small amount of an acetonitrile/water mixture was added to the flask 
to dissolve the peptide. The peptide was then freeze-dried and stored at _8°C. 
Peptide Cleavage Cocktail 
DKPRR TFA, H20, Phenol, TIPS (88:5:5:2) 
KKK TF A, H20 (95:5) 
KKKKKK TFA, H20 (95:5) 
RRR TFA, H20, Phenol, TIPS (88:5:5:2) 
SSSSSSSS TFA, H20, Phenol, TIPS (88:5:5:2) 
MRSSSDKPRR TFA, H20, Phenol, TIPS (88:5:5:2) 
MRSSSPRKRD TF A, H20, Phenol, TIPS (88:5:5:2) 
MRSSSSSSSS TFA, H20, Phenol, TIPS (88:5:5:2) 
Table 10.2: Cleavage solutions for specific peptide sequences 
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10.1.5 Peptide Analysis 
l3C analysis: On numerous occasions the number of peaks does not equal the number of 
carbon environments. This is attributed to coincident signals due to high similarities 
between a number of the carbon environments. In cases where not enough peptide was 
synthesised to produce NMR spectra, only HPLC-MS data is provided. 
Trilvsine (KKK) 
000 
I 11 H 3 11 H S 11 
H2N-CH-C-N-CH-C-N-CH-C-OH I 2 I 4 I 6 
7 CH2 7 CH2 7 CH2 I I I 
8 CH2 8 CH2 8 CH2 
1 I 1 9 CH2 9 CH2 9 CH2 I I I 
10 CH2 10 CH2 10 CH2 I I I 
NH2 NH2 NH2 
IH NMR (D20, 500 MHz): OH (ppm) = 1.34 (m, 6H, Cfu (8)), 1.54-1.83 (rn, 12H, Cfu 
(7,9)),2.87 (m, 6H, Cfu (10)),3.90 (t, IH, CH (1)),4.15-4.24 (m, 2H, CH (3,5)). l3C 
NMR (JMOD, 250 MHz) Oc (ppm) = 21.16, 21.94, 22.l7 (3C, C (8)),26.32,26.40 (3C, 
C (7)), 29.96, 30.49,30.56 (3C, C (9)), 39.07, 39.24 (3C, C (10)), 52.82, 53.03, 53.83 
(3C, C (1,3,5)), 169.63, 173.41, 175.56 (3C, C (2,4,6)). HPLC-MS ES+: elution time 
11.45 minutes (5% ACN (O.l% TFA): 95% H20 (0.1% TFA) isocratic gradient over 30 
minutes, Alltech Prosphere HP C18 column 150 x 4.6 mm). Mass peaks (ToF MS ES+); 
404 MH+. 100 % purity by integration of peaks generated by detector at 215 nm before 
preparative HPLC so no further purification was undertaken. 
Hexalvsine (KKKKKK) 
00000 0 
t 11 H 3 11 H S 11 H 7 11 H 9 11 H II 11 
H2N-CH-C-N-CH-C-N-CH-C-N-CH-C-N-CH-C-N-CH-C-OH I 2 I 4 I 6 I 8 I 10 I 12 
13 CH2 13 c~ 13 CH2 13 c~ 13 CH2 13 CH2 
I I I I I I 
14 CH2 14 CH2 14 CH2 14 c~ 14 CH2 14 CH2 I I I I I I 
IS CH2 IS CH2 IS C~ IS CH2 IS C~ IS CH2 I I I I I I 
16 CH2 16 C~ 16 CH2 16 CH2 16 CH2 16 CH2 I I I I I I 
NH2 NH2 NH2 NH2 NH2 NH2 
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IH NMR (D20, 500 MHz): OH (ppm) = 1.38-1.45 (m, 12H, Cfu (14)), 1.59-1.88 (m, 
24H, Cfu (13,15)),2.91-2.95 (m, 12H, Cfu (16)),3.94-3.98 (t, IH, CH (1)),4.20-4.28 
(m, 5H, CH (3,5,7,9,11)). I3C NMR OMOn, 125 MHz) Oc (ppm) = 21.27, 21.91, 22.04, 
22.08, 22.12 (6C, C (14)), 26.25, 26.32, 26.35 (6C, C (13), 29.83, 30.45, 30.59, 30.66 
(6C, C (15)),38.96,39.13 (6C, C (16), 52.75, 52.82, 53.42, 53.48, 53.52, 53.63 (6C, C 
(1,3,5,7,9,11),169.66,173.31, 173.44, 173.59, 175.38 (6C, C (2,4,6,8,10,12)). HPLC-
MS ES+: elution time 15.87 minutes (5% ACN (0.1% TFA): 95% H20 (0.1% TFA) 
isocratic gradient over 30 minutes, Alltech Prosphere HP C18 column 150 x 4.6 mm). 
Mass peaks; 788 (MH+). 95.41 % purity by integration of peaks generated by detector at 
215 nm of crude peptide and therefore no further purification was carried out. 
Aspartic Acid-Lysine-Proline-Arginine-Arginine (DKPRR) 
000 
11 H 7 11 H 9 11 
o 0 tJ6C 1:-----rH---C-----N-----rH---C-----OH 
1 11 H 3 11 20 CH2 24 CH2 
H2N-----CH---C-----N-----CH---C-----N ] 8 21 !H 25 !H I 2 I 4 I 2 I 2 
] 1 CH2 13 CH2 17 22 CH 26 CH 
I I 1 2 I 2 
12 c=o 14CH2 NH NH 
1 I I I 
OH 15
1
H2 23
1
=NH 271=NH 
16
1
H2 NH2 NH2 
NH2 
IH NMR (D20, 500 MHz): OH (ppm) = 1.42 (m, 2H, Cfu(l4)), 1.54-2.29 (m, 16H, Cfu 
(13, 15, 18, 19, 20, 21,24,25)),2.86-3.00 (m, 4H, Cfu (11, 16)),3.15 (m, 4H, Cfu (22, 
26)),3.57 & 3.77 (double multiplet, 2H, Cfu (17),4.23 (t, IH) & 4.28-4.37 (m, 3H) & 
4.59 (m, IH) «R)HN-CH(R)-CO(R) (1, 3, 5, 7, 9)). HPLC-MS ES+: elution time 46.80 
minutes (3% ACN (0.1% TFA): 97% IhO (0.1% TFA) isocratic gradient over 50 
minutes, Alltech Prosphere HP C18 column 150 x 4.6 mm) Mass peaks; 671 (MH\ 
411, 336 (2+ ion), 279. 94.81% purity by integration of peaks generated by detector at 
215 nm before preparative HPLC, 98.62% purity after purification. 
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Triarginine (RRR) 
o 0 0 
1 11 H 3 11 H 5 11 
H2N-CH-C-N-CH-C-N-CH-C-OH 
1 2 I 4 I 6 
7 CH2 7 CH2 7 CH2 I I I 
8 CH2 8 CH2 8 CH2 I I I 
9 C~ 9 CH2 9 CH2 I I I 
NH NH NH 
I I I 
10 C=NH 10 C=NH 10 C=NH 
I I I 
N~ N~ N~ 
IH NMR (D20, 500 MHz): ()H (ppm) = 1.53-1.56 (m, 6H, Cfu (8), 1.66-1.93 (m, 6H, 
Cfu (7), 3.07-3.11 (m, 6H, Cfu (9), 3.98 (t, IH, CH (1), 4.20-4.25 (M, 2H, Cfu 
(3,5). l3C NMR (JMOD, 250 MHz) ()c (ppm) = 23.44, 24.34, 24.56, (3C, C (8).27.78, 
28.1 0 (3C, C (7) 40.45, 40.58 (3C, C (9). 52.58, 52.79, 53.84 (3C. C (1,3,5), 156.88 
(3C, C (l0), 169.63, 173.36, 175.37 (3C, C (2,4,6). HPLC-MS ES+: elution time 9.40 
minutes (5% ACN (0.1% TFA): 95% H20 (0.1% TFA) isocratic gradient over 30 
minutes. Alltech Prosphere HP C18 column 150 x 4.6 mm). Mass peaks; 591, 487 
(MW), 313 M (RR fragment). 68% purity by integration of peaks generated by detector 
at 215 nm before preparative HPLC (32% RR). It was not possible to successfully 
separate the tripeptide (RRR) from the dipeptide (RR) with the required yield, so this 
peptide was utilised as a mixture of the tri- and dipeptides. 
Octaserine (SSSSSSSS) 
0000000 0 
I 11 3 11 H S 11 H 7 11 H 9 11 H 11 11 H 13 11 IS 11 H2N-YH-C-~-r-C-N-CH-C-N--cH-c-N--CH-C-N--CH-C-N-CH-C-~-CH-C-~ 
I 2 4 I 6 1 8 I 10 I 12 I 14 I 16 
17 GH, 17 179H. 17 <;:H, 17 ~ 17 CH, 17 CH, 17 CH, L L l l L L L l 
HPLC-MS ES+: elution time 9.55 minutes (25% ACN (0.1% TFA): 75% H20 (0.1% 
TFA) isocratic gradient over 30 minutes, Alltech Prosphere HP C18 column 150 x 4.6 
mm). Mass peaks (ToF MS ES-); 811, 713 (M'). 20.39% purity by integration of peaks 
generated by detector at 215 nm before preparative HPLC, 86.58% purity after 
purification. 
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Methyl Red-Tagged DKPRR (MRSSSDKPRR) 
HPLC-MS ES+: elution time 24.97 minutes (25% ACN (0.1% TFA): 75% H20 (0.1% 
TFA) isocratic gradient over 30 minutes, Alltech Prosphere HP C18 column 150 x 4.6 
mm). Mass peaks (ToF MS ES+); 1183 (MH); 592 (2+ ion); 252 (methyl red fragment, 
CJsHJ4N30). 30.23% purity by integration of peaks generated by detector at 215 nm 
before preparative HPLC, 93.03% purity after purification. 
Methyl Red-Tagged Octaserine Peptide (MRSSSSSSSS) 
Yr~f~~~f~~~f~~~f~~OH 
9
N HO HO HO HO 
~I 
~ 
/N'-.,. 
HPLC-MS ES+: elution time 21.51 minutes (25% ACN (0.1% TFA): 75% H20 (0.1% 
TFA) isocratic gradient over 30 minutes, Alltech Prosphere HP C18 column 150 x 4.6 
mm). Mass peaks (ToF MS ES-); 964 (M-( -If). 30.36% purity by integration of peaks 
generated by detector at 215 nm before preparative HPLC, 94.60% purity after 
purification. 
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Methvl Red-Tagged PRKRD Scrambled Peptide (MRSSSPRKRD) 
HPLC-MS ES+: elution time 26.88 minutes (25% ACN (0.1% TFA): 75% H20 (0.1% 
TFA) isocratic gradient over 30 minutes, Alltech Prosphere HP C18 column 150 x 4.6 
mm). Mass peaks (ToF MS ES+); 1184 (MH+); 592 (2+ ion); 546; 252 (methyl red 
fragment, C1sH14N30). 32.67% purity by integration of peaks generated by detector at 
215 nm before preparative HPLC, 92.53% purity after purification. 
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10.2 Monomer Synthesis 
10.2.1 Materials 
Oleyl alcohol (85%, Aldrich) and phenyl dichlorophosphate (95+%, Aldrich) were used 
as supplied. Deionised water was used throughout, and chlorofonn (HPLC grade, 
Fisher), dichloromethane (DeM, HPLC grade, Fisher) and diethyl ether (anhydrous, 
laboratory reagent grade, Fisher) were used as supplied. Silica Gel 60 (230-400 Mesh, 
Merck) was used for silica chromatography purification. Thin layer chromatography 
(TLC) was carried out using Merck Silica Gel 60 F254 (aluminium sheet) plates 
developed with para-anisaldehyde and potassium pennanganate solutions and viewed 
under UV light. 
10.2.2 Instrumentation 
IH, I3C and 31 p NMR spectra were obtained on a Bruker AC 250 MHz and AMX2-400 
MHz spectrometer using deuterated chlorofonn throughout. 
10.2.3 Synthesis of Oleyl Phenyl Hydrogen Phosphate 
I) RT,90 mins, 60 mins 
2) SOC, overnight 
3) H20, RT, overnight 
Oleyl alcohol (65.5 g, 0.24 mol) was added dropwise to stirring phenyl 
dichlorophosphate (50.0 g, 0.24 mol) over 90 minutes at room temperature and the 
resulting solution was then stirred for a further 60 minutes. The temperature was then 
increased to 50·C and stirring was continued for a further 16 hours. The resultant 
reaction mixture was then added dropwise to 300 ml of rapidly stirring ice-cold water 
and the organics were extracted into diethyl ether (3 x 100 ml) after 60 minutes. 
Anhydrous sodium sulphate was used to dry the combined organic extracts, which were 
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then filtered and rotary evaporated to produce a viscous yellow oil. Purification was 
carried out by flash column chromatography on silica using 100% DCM to 2-10% 
methanoV98-90% DCM to give a straw-coloured oil as the final product of 8.39 g 
(8.24%) (Rf = 0.26 on silica, 37:2:1 CH2ChlMeOHlAcOH). 1H NMR (CDCh, 250 
MHz) oH (ppm): 0.87 (t, 3H, C!:.b), 1.26 (m, br, 22H, -Cfu-), 1.62 (m, br, 2H, -
CfuCHrOP), 2.00 (m, br, 4H, -CfuCH=), 4.05 (dt, 2H, -CfuOP, JPH = 6.71, JHH = 
6.71),5.38 (m, br, 2H, -CH=CH-), 7.10-7.32 (m, 5H, -C6Hs-), 8.88 (s, 1H, OH). 31P 
NMR (CDCl3, 162MHz) oP (ppm): -4.0228. 13C NMR (CDCh. 100MHz) oC (ppm): 
14.55 (-CH3), 23.11-33.04 «R)C-CH2-C(R), 14C), 68.98 (-CH2-0P-), 120.56, 125.42, 
130.02, 130.19, 130.38 (-Clh-CH=CH-CHr and -C6HS-, 7C), 151.00 (O-C (aromatic». 
l3C spectrum provided below (Figure 10.1). Exact l3C peak assignments were not 
possible in all cases as this spectrum was complicated by 31p splitting. Elemental 
analysis: C24~104P Found (calc) (%): C 68.14 (67.90) H 10.43 (9.73). 
-
J J 
I 
160 140 120 100 80 60 40 20 o 
(ppm) 
Figure 10.1: llC NMR spectrum or oleyl phenyl hydrogen phosphate 
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10.3 Core-Shell Particle Synthesis and Characterisation 
10.3.1 Materials 
Styrene (99%, Aldrich), divinylbenzene (OVB, 80%, mixture of isomers, Aldrich) and 
ethylene glycol dimethacrylate (EGDMA, 98%, Aldrich) were purified by washing with 
10% aqueous sodium hydroxide solution three times, then deionised water three times, 
drying over magnesium sulphate and distillation under reduced pressure. Monomers 
were stored in the freezer until use. The surfactant, sodium dodecyl sulphate (SOS, 
BOH), 2-(N-morpholino)ethanesulfonic acid (MES hydrate, Aldrich) and initiators and 
associated oxidising agents, potassium persulphate (99+%, ACS reagent, Aldrich), 
ammonium persulphate (98%, Aldrich), 4,4'-azobis(4-cyanopentanoic acid) (~98%, 
Fluka), N,N,N',N'-tetramethylethylenediamine (;:: 98%, purum, Fluka), L-ascorbic acid 
(99+%, ACS reagent, Aldrich) and hydrogen peroxide (laboratory reagent grade, Fisher) 
were used as supplied. The solvents; acetone (laboratory reagent grade, Fisher), 
methanol (HPLC grade, Fisher) and isopropyl alcohol (HPLC grade, Fisher) were used 
as supplied and deionised water was used throughout. H-Gly-p-Ala-p-Ala peptide 
(GAA, BACHEM) was used as supplied and all other peptides were synthesised as 
described in 10.1. Quantikine® Human VEGF ELISA Kit was supplied by R&O 
Systems and was used as provided. 
10.3.2 Instrumentation 
Centrifugation was carried out using a Fisons MSE Chilspin centrifuge and MSE Micro 
Centaur centrifuge. Centrifugation cartridges (Vivaspin 20, poly(ether sulfone), MWCO 
100,000, 20 ml and Vivaspin 500, poly(ether sulfone), MWCO 30,000, 500 JlI) were 
from Sartorius (Surrey, U.K.». Slide-A-Lyzerilil Dialysis Cassettes (Extra Strength) 
10,000 MWCO, 0.5-3 ml capacity, were obtained from Pierce. Particle size and zeta 
potential analysis were carried out on a Brookhaven Instruments Corporation ZetaPALS 
Zeta Potential Analyser with the 90PlusIBI-MAS Multi Angle Particle Sizing Option. 
UV analysis was carried out on a Oynex Technologies MRXII UV-Vis Plate Reader or 
a HITACHI U-2010 Spectrophotometer. ICP-AES analysis was carried out on a Spectro 
Ciros ICP emission spectrometer (Radial and Axial) by N. Bramall at the University of 
Sheffield Centre for Analytical Sciences. TEM images and EOS analysis were carried 
out by Dr. H. Bagshaw from the University of Sheffield Sorby Centre for Electron 
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Microscopy on a FEI Tecnai G2 Biotwin "Spirit" 120 kV Transmission Electron 
Microscope, running at an accelerating voltage of 80 kV with spot size 3, and EDS 
analysis was carried out on a Link eXL system with "menus" software, running at 120 
k V accelerating voltage. 
10.3.3 Optimisation of Synthetic Procedure for Core Particles 
A general formulation for synthesis of poly(styrene-co-divinylbenzene) core particles 
was determined to allow initiation by the redox system of potassium persulphate and 
ascorbic acid. The monomer composition, reaction temperature and surfactant quantity 
were varied to determine the optimum procedure and details of the various formulations 
are provided in Table 10.3. A table of the varied parameters is provided below and the 
optimised synthetic procedure for this initiator system is described. 
Styrene DVB SDS Potassium Ascorbic 
Sample Molar Temp acid Molar 
(g) (g) Ratio (g) (CC) Persu lphate Ilatio ~g} ~g} 
4.64 5.82 1: 1 1.00 RT 0.105 0.068 1: 1 
2 8.36 1.16 9:1 1.00 RT 0.105 0.068 1:1 
3 8.36 1.16 9:1 0.50 30 0 .105 0.068 1: 1 
4 8.36 1.16 9:1 2.00 30 0 .105 0.068 1:1 
5 8.36 1.16 9:1 1.00 30 0.105 0.068 1:1 
6 8.36 1.16 9: I 1.00 30 0.209 0.068 2: 1 
7 4.50 0.50 11: 1 1.00 30 0 .209 0.068 2: 1 
Table 10.3: Latex formulations for poly(styrene-co-divinylbenzene) 
Oetimised Sl!..nthesis ol Poll!..(stvrene-co-divinl!..lben!t.ene~ Core Particles (pr Redox 
Initiation with Potassium Persulehate and Ascorbic Acid 
+ 
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A 50 mM solution of MES buffer in deionised water was produced by dissolving MES 
buffer (0.533 g, 2.73 mmol) in 45 ml deionised H20. This solution was purged with 
nitrogen for 15 minutes and SDS surfactant (I g, 3.47 mmol) was added and stirred until 
di ssolved. The solution with surfactant was sonicated for 10 minutes and then adjusted 
to pH 6 through dropwise addition of 0.5 M NaOH solution. Polymerisation was 
conducted in a 100 ml jacketed glass flange reaction vessel with a five necked lid 
equipped with paddle stirrer, nitrogen inlet, reflux condenser, temperature probe and 
pressure equalised dropping funnel. The buffer solution was introduced to the reaction 
vessel which was heated and previously purged with nitrogen. The buffer solution was 
stirred at 400 rpm and brought to 30°e. Styrene (4.50 g, 43.21 mmol) and OVB (0.50 g, 
3.84 mmol) were combined, purged with N2 for 5 minutes and added dropwise to the 
solution via an addition funnel over a 30 minute period. Potassium persulphate (0.209 g, 
0.774 mmol) and ascorbic acid (0.068 g, 0.387 mmol) were di ssolved in 5 ml I-hO and 
this initiator solution was then purged with nitrogen for 5 minutes before being added to 
the stirring monomer suspension in a one-shot initiation. Emulsion polymerisation was 
carried out overnight. 
10.3.4 Synthesis of Poly(OPHP-co-EGDMA) Outer Shell (Core-Shell Particle) 
EGDMA (0.226 g, 1.14 mmol) and oleyl phenyl hydrogen phosphate (0.204 g, 0.482 
mmol) were suspended in 13.5 m1 of deionised water and added dropwi se to the stirring 
emulsion of core particles over 15 minutes. The monomer was allowed to equilibrate 
around the core particles for one hour. The initiator solution was produced by dissolving 
potassium persulphate (0.209 g, 0.774 mmol) and ascorbic acid (0.068 g, 0.387 mmol) 
in 5 ml H20 and then the solution was purged for 5 minutes with nitrogen. This solution 
was added to the latex in one shot. The emulsion was reacted at 30·C overnight. 
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10.3.5 Study of Initiator Systems for Core and Core-Shell Particle Synthesis 
The procedures detailed previously for the synthesis of the core and the core-shell 
particles were repeated with various initiator conditions. The procedures described in 
10.3.3 and 10.3.4 were only altered by the reaction temperature and initiation step, the 
conditions and procedures for which are detailed in table 10.4. 
Initiator System 
Potassium persulphate & ascorbic acid 
Hydrogen peroxide & ascorbic acid 
Ammonium persulphate & N,N,N' ,N' tetramethyl-ethylenediamine 
4,4' -azobis( 4-cyanovaleric acid) 
Potassium persulphate 
Table 10.4: Initiator systems trialled for core-shell particle synthesis 
Redox Initiation by Potassium Persulphate and Ascorbic Acid 
Temp Cc) 
30 
35 
30 
60 
70 
The synthetic procedure was carried out in a reactor heated to 30·C. The initiator 
solution was produced by dissolving potassium persulphate (0.209 g, 0.774 mmol) and 
ascorbic acid (0.068 g, 0.387 mmol) in S ml H20 and purging with nitrogen for 5 
minutes before adding to the reactor in a one-shot initiation. 
Redox Initiation by Hydrogen Peroxide and Ascorbic Acid 
The synthetic procedures were carried out in a reactor at room temperature. The initiator 
solution was produced by dissolving ascorbic acid (3.7 mg, 0.021 mmol) in S ml of 
deionised water. 0.122 ml of hydrogen peroxide solution (30% w/v solution) (0.037 g, 
1.09 mmol) was combined with the ascorbic acid solution, the solution was purged with 
N2 for 5 minutes and then added to the reactor in one shot. The reaction mixture was 
heated to 3S·C and reacted overnight. 
Redox Initiation by Ammonium Persulphate and N,N.N',N'-Tetrametl,yl-
ethylenediamine (TEMED) 
The synthetic procedures were carried out in a reactor at 30·C. The initiator solution 
was produced by combining ammonium persulphate (0.269 g, 1.18 mmol) and TEMED 
(0.269 ml, 2.31 mmol) in S ml of deionised water. This solution was purged with N2 for 
5 minutes and added to the reaction mixture in one shot. 
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Thermal Initiation bv 4,4'-A;obis(4-cyanovaleric acid) 
The synthetic procedures were carried out in a reactor at 60·C. Initiation was afforded 
by the addition of 4,4' azobis( 4-cyanovaleric acid) (0.33 g, 1.18 mmol) directly into the 
reaction mixture. 
Thermal Initiation bv Potassium Persulphate 
The synthetic procedures were carried out in a reactor at 70·C. The reaction was 
initiated by the one shot addition of potassium persulphate (0.32 g, 1.18 mmol) in 7.5 
ml de ionised H20, prepurged with N2 for 5 minutes. 
10.3.6 Synthesis of Core-Shell Particles by Starve-Fed Monomer Addition 
The core particles were synthesised as described in section 10.3.3 through thermal 
initiation by potassium persulphate at 70·C (detailed in section 10.3.5). Potassium 
persulphate (0.32 g, 1.18 mmol) in 7.5 ml deionised H20 was added into a stirring 
emulsion of core particles at 70·e. Immediately after initiation the monomers, oleyl 
phenyl hydrogen phosphate (0.204 g, 0.482 mmol) and EGDMA (0.226 g, 1.14 mmol), 
were combined and added dropwise to the emulsion suspended in 30 ml of deionised 
H20 at 0.2 mllmin via a peristaltic pump. The reaction was continued for 24 hrs. 
10.3.7 Final Synthetic Procedure for Core and Core-Shell Particles 
Core Particles 
A 50 mM solution of MES buffer in deionised water was produced by dissolving MES 
buffer (0.533 g, 2.73 mmol) in 45 ml deionised lhO. This solution was purged with 
nitrogen for 15 minutes and SDS surfactant (1 g, 3.47 mmol) was added and stirred until 
dissolved. The solution with surfactant was sonicated for 10 minutes and then adjusted 
to pH 6 through dropwise addition of 0.5 M NaOH solution. Polymerisation was 
conducted in a 100 ml jacketed glass flange reaction vessel with a five necked lid 
equipped with paddle stirrer, nitrogen inlet, reflux condenser, temperature probe and 
pressure equalised dropping funnel. The buffer solution was introduced to the reaction 
vessel. The buffer solution was stirred at 400 rpm and brought to 30°C. Styrene (4.50 g, 
43.21 mmol) and DVB (0.50 g, 3.84 mmol) were combined, purged with N2 for 5 
minutes and added dropwise to the solution via an addition funnel over a 30 minute 
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period. The initiator solution was produced by dissolving potassium persulphate (0.16 g, 
0.59 mmol) in 7.5 ml H20 and then purging the solution for 5 minutes with nitrogen 
before adding to the stirring monomer suspension in a one-shot initiation. Emulsion 
polymerisation was carried out at 70°C overnight. 
Core-Shell Particles 
EGDMA (0.226 g, 1.14 mmol) and oleyl phenyl hydrogen phosphate (0.204 g, 0.482 
mmol) were suspended in 13.5 ml of deionised water and added dropwise to the stirring 
emulsion of core particles at 70°C over 15 minutes. The monomer was allowed to 
equilibrate around the core particles for one hour. The initiator solution was produced 
by dissolving potassium persulphate (0.16 g, 0.59 mmol) in 7.5 ml lhO and then 
purging the solution for 5 minutes with nitrogen. The second stage of polymerisation 
was then initiated by the addition of this solution to the stirring latex in one shot. The 
emulsion was allowed to react at 70·C overnight. 
10.3.8 Synthesis of Molecularly-Imprinted Core-Shell Particles 
Core particles were synthesised as described in section 10.3.7. EGDMA (0.045 g, 0.228 
mmol) and oleyl phenyl hydrogen phosphate (0.041 g, 0.096 mmol) were suspended in 
2.7 ml of deionised water and added dropwise to the stirring emulsion of core particles 
(l0 ml) over 15 minutes. The monomer was allowed to equilibrate around the core 
particles for one hour. The template compound (0.096 mmol, 1 eq.) was added in 2 mt 
of 50 mM MES buffer at pH 6 and stirring was continued for an hour. The initiator 
solution was produced by dissolving potassium persulphate (0.032 g, 0.118 mmol) in 
1.5 ml H20 and then purging the solution for 5 minutes with nitrogen. The second stage 
of polymerisation was initiated via the addition of this solution to the stirring latex in 
one shot. The emulsion was allowed to react at 70·C overnight. Blank-imprinted 
particles were prepared by repeating the procedure in the absence of a template. 
Polymer Template Quantity Equivalent 
(mg) (peptide:functional monomer) 
DKPRR CS-MIP DKPRR 64.7 I: I 
GAACS-MIP GAA 20.9 1:1 
Blank CS-MIP None 0 
Table 10.S: Template quantities employed in molecular imprinting of core-shell emulsion particles 
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10.3.9 Analysis 
Solid Content Analysis 
An aliquot of emulsion of core or core-shell particles and 3 ml of acetone were pipetted 
into a centrifuge tube and agitated to allow precipitation of the whole sample. The 
sample was then centrifuged at 3000 rpm for 5 minutes before removing the 
supernatant. This process was repeated three times. The acetone was again decanted off, 
replaced with deionised water and centrifuged for 5 minutes at 3000 rpm. This was 
repeated twice more with deionised water and finally three times with methanol before 
the solvent was decanted off and the solid was allowed to dry to a constant mass. 
Solid content = W p / mass oflatex 
Where W p = mass of dried polymer 
Particle Size Analvsis 
To prepare the samples, five drops of a particular latex were added to 20 ml of a 1 mmol 
KCI solution. This solution was then sonicated for 20 seconds, filtered through a 0.45 
J.lm aqueous filter and added to a cuvette for measurement at 25°C. Ten analysis runs 
were carried out in triplicate for each sample. 
Zeta Potential Analvsis 
Samples were prepared for zeta potential analysis by the addition of five drops of a 
particular latex into 20 ml of a 1 mmol KCI solution. This solution was pi petted into a 
zeta potential cuvette for analysis, ensuring no air bubbles were present at the electrode 
surface. The zeta potentials were analysed at 25°C in five analysis cycles, each 
consisting of ten repeat runs. 
rEM and EDS Studies 
A 2 ml aliquot of the core or CS-MIP emulsion was injected into a Slide-A-Lyzer@ 
cassette. The emulsions were then dialysed against 1 M phosphoric acid, with the 
addition of 2.5% sodium dodecyl sulphate to prevent coagulation, over three days with 
the solution changed twice daily. Finally, the emulsions were dialysed against 2.5% 
sodium dodecyl sulphate/distilled water for three days, again with twice daily solution 
changes. Materials were prepared for EDS by evaporating the colloidal suspensions 
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onto 600 mesh, 3 mm diameter copper grids coated with a carbon film. Materials were 
prepared for TEM by adsorbing a drop of emulsion onto a carbon-coated grid and 
leaving for 1 minute. The grid was then blotted, washed in a drop of distilled water and 
blotted again. The grid was washed once more in a drop of uranyl formate, blotted and 
then negatively stained by holding the grid in a drop of uranyl formate for 20 seconds 
before blotting. 
Inductivelv Coupled Plasma Atomic Emission Spectroscopv 
Latexes produced during the initiator trial as well as latex produced by starve-fed 
monomer addition and all molecularly-imprinted particles were analysed for total oleyl 
phenyl hydrogen phosphate content by Inductively Coupled Plasma Atomic Emission 
Spectrometry (ICP-AES). 
Preparation of Solid Resins for Inductively Coupled Plasma Atomic Emission 
Spectroscopy (ICP-AES) 
An emulsion sample (2 ml) was added to a 20 ml centrifugation cartridge (MWCO 
100,000) followed by the dropwise addition of isopropyl alcohol (1.1 ml) to induce 
coagulation. The centrifuge cartridge was agitated gently until the solids had 
precipitated out. The sample was allowed to stand for 10 minutes to allow complete 
precipitation and was then centrifuged at 4500 rpm at room temperature using a 
benchtop centrifuge with swing-bucket rotor for 30 minutes. The damp solids remaining 
were washed with 7:3 IP All-hO (5 ml) and the suspension was then agitated and 
centrifuged at 4500 rpm for 30 minutes. This procedure was carried out six times. The 
solids were then washed with deionised water (5 ml) (or 1 M H3P04 for elution of 
template on CS-MIP), gently agitated to produce a suspension and then centrifuged at 
4500 rpm for 5 minutes. This washing step was also repeated six times. The final 
washing step was washing the solids with methanol (5 ml), followed by agitation and 
centrifuging at 4500 rpm for 5 minutes. This step was also repeated six times. The 
polymer was then dried to a constant mass in a vacuum oven at 60·C for 48 hours. The 
polymer was then refluxed in concentrated nitric acid (5 ml) at 160·C for 4 hours 
followed by perchloric acid at 200·C for 30 minutes and the resulting solution was then 
analysed for phosphorous content by ICP-AES. 
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10.3.10 Colorimetric Peptide Binding Study 
Preparation of Po Iv mer 
An aliquot of emulsion (0.1 ml) was pipetted into a 30,000 MWCO Vivaspin centrifugal 
concentrator, followed by isopropyl alcohol (0.5 ml) to coagulate the latex. The sample 
was agitated on an orbital shaker plate at 150 rpm for 10 minutes before being 
centrifuged at 10,000 rpm for 10 minutes. The coagulated polymer was then washed 
with a 7:3 IPAIl-hO solution, agitated for 10 minutes on an orbital shaker plate at 150 
rpm and then removed by centrifugation for 10 minutes at 10,000 rpm. This wash step 
was carried out six times with 7:3 IPAIl-hO, six times with 1 M H3P04 (solvent 
removed by centrifuging for 5 minutes at 5,000 rpm), six times with IhO, six times with 
methanol and finally six times with H20. The polymer slurry was used damp. 
Peptide Binding Study 
0.5 ml of peptide solution (30 J.lglml, MRSSSDKPRR, MRSSSPRKRD or 
MRSSSSSSSS) was added to the polymer slurry and the resulting suspension was 
agitated on an orbital shaker plate at 200 rpm for 30 minutes. The supematant was 
removed after centrifugation for 20 minutes at 10,000 rpm. The peptide was then 
removed from the polymer with solutions of IP AIlhO with IPA percentages of 5, 10, 
20, 30, 35, 40, 45, 50, 60, 70, 80, 90 and 100. In all cases the solution was removed 
after 30 minutes by centrifugation for 20 minutes at 10,000 rpm. All peptide solutions 
were analysed by UV in quartz cuvettes with a 1 mm path length at 470 nm. 
Peptide Release Study 
The remaining methyl red-tagged peptide was removed by sequential washes with 50% 
phosphoric acid solutions and 50% IPA. The acidlIP A solutions were added to the 
polymer slurry, the suspension was agitated and then left on an orbital shaker plate at 
200 rpm for 30 minutes. The liquid was removed by centrifugation for 20 minutes at 
10,000 rpm. The peptide was then washed ofT the polymer with solutions of acid/JP A 
with phosphoric acid molarities of 0.01 M, 0.02 M, 0.03 M, 0.04 M, 0.05 M, 0.06 M, 
0.07 M, 0.08 M, 0.09 M, 0.1 M, 0.15 M, 0.2 M, 0.25 M, 0.3 M, 0.35 M, 0.4 M, 0.45 M, 
0.5 M, 0.6 M, 0.7 M, 0.8 M, 0.9 M and 1 M. In all cases the solution was removed by 
centrifugation for 20 minutes at 10,000 rpm. All peptide solutions were then analysed 
by UV spectrometry in quartz cuvettes with a 1 mm path length at 510 nm. 
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10.3.11 Zeta Potential Peptide Binding Study 
A 2 ml aliquot of the core or CS-MIP emulsion was injected into a Slide-A-Lyzer@ 
cassette. The emulsions were then dialysed against 1 M phosphoric acid, with the 
addition of 2.5% sodium dodecyl sulphate to prevent coagulation, over three days with 
twice daily solvent changes. Finally, the emulsions were dialysed against 2.5% sodium 
dodecyl sulphate/distilled water for three days with solvent changed twice daily. 0.1 ml 
of emulsion was added to 2 ml of 1 mmol KCI and was agitated to produce a 
homogeneous latex. The zeta potentials were analysed at 25°C in five analysis cycles, 
each consisting often repeat runs. 10 JlI ofDKPRR or SSSSSSSS peptide solution (0.5 
mg/ml) was added to each emulsion and agitated before measuring the pH of the 
solution and the zeta potential. In total, six aliquots of each peptide were added and 
analysed for pH and zeta potential. 
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10.3.12 Enzyme-Linked ImmunoSorbent Assay (ELISA) ofVEGF Binding (MIP) 
Three polymer types were analysed in duplicate for this study; DKPRR-imprinted, 
GAA-imprinted and blank-imprinted core-shell particles. The polymers (0.1 ml 
emulsion) were coagulated with 0.5 ml isopropyl alcohol and were then washed as 
described in Section 10.3.10. A conductivity meter was utilised to analyse the final 
wash solutions to confinn SDS removal. VEGF solutions (150 ng in 0.5 ml PBS) were 
then added to the polymer in a polypropylene tube. The solutions were agitated and then 
allowed to interact for 24 hours at 4°C. The suspensions were then centrifuged at 13,000 
rpm for 20 minutes and the supematant was removed and stored at -20°C until an 
ELISA study was carried out. 
0.5 ml of fresh 1 % BSA PBS solution was added to the polymer samples, then agitated 
and placed in an incubator at 37°C for the release study. At defined time points (1 hr, 6 
hrs, 12 hrs, 24 hrs and 48 hrs) the protein solution was removed and replaced with 0.5 
ml fresh 1 % BSA PBS solution. The protein solutions retrieved were stored at -20°C in 
polypropylene tubes until analysis with an ELISA kit. The BSA was utilised to stabilise 
the VEGF during the release study and storage period. Each experimental condition was 
carried out and analysed in duplicate. 
EL1SA Procedure 
The ELISA was carried out as described by the manufacturer. 50 J,ll of assay diluents 
was added to a 96 well plate coated with a mouse monoclonal antibody for VEGF. 200 
J.lI of either the standard, control or sample was added to each well and the plate was 
agitated gently at room temperature for 2 hours. Each well was washed six times with 
wash buffer (400 J,ll) and any remaining wash buffer was removed by blotting on clean 
paper towels. VEGF conjugate (200 J,ll) was added to each well, followed by gentle 
agitation for 2 hours at room temperature. Each well was washed a further six times. 
Substrate solution (200 J,ll), consisting of equal quantities of stabilised hydrogen 
peroxide and stabilised tetramethylbenzidine, was added to each well and was agitated 
gently at room temperature for 20 minutes whilst being protected from the light. 
Sulphuric acid (2 M, 50 J,ll) was added to the wells to stop the reaction and the optical 
density was measured within 30 minutes at 450 nm on a UV -Vis plate reader. 
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10.4 Hydrogel Synthesis, Functionalisation and Characterisation 
10.4.1 Materials 
The monomers N-vinyl-2-pyrrolidone (NVP, ~99%, Aldrich) and acrylic acid (99%, 
Aldrich) were purified by distillation at reduced pressure and were stored at 4°C until 
use. The crosslinker, diethylene glycol-bisallyl carbonate (DEGBAC, 94%, Pfalz & 
Bauer Inc.) and the initiators, 2,2'-azobisisobutyronitrile (AIBN, 97%, BDH) and 2-
hydroxy-2-methylpropiophenone (HMPP, 97%, Aldrich) and were used as supplied. 
The coupling reagents I-ethyl -3-(3-dimethylaminopropyl)-carbodiimide (EDC, 
Aldrich), N,N'-dicyclohexyl-carbodiimide (DCC, 99%, Aldrich), N-hydroxy-
succinimide (98%, Aldrich), sodium acetate (anhydrous, May and Baker), sodium 
dihydrogen phosphate dehydrate (Fluka) and disodium hydrogen phosphate dehydrate 
(Fluka) were used as supplied. The coupling analysis reagents 2,4,6-
trinitrobenzenesulphonic acid solution (5% w/v solution, Sigma), I-napthol (97%, 
Fisons), urea (~ 98%, Sigma) and bromine (Aldrich) were used as supplied. Heparin 
(Sodium salt, Grade I-A, from porcine intestinal mucosa, Sigma), fluorescein-S-
thiosemicarbazide (fluorescence grade, Fluka) and methylene blue (certified by the 
BSC, Sigma Aldrich) were used as supplied. The solvents; ethanol (absolute, laboratory 
reagent grade, Fisher), diethyl ether (anhydrous, laboratory reagent grade, Fisher) N,N-
dimethylformamide (laboratory reagent grade, Fisher) were used as supplied, and 
deionised water was used throughout. A Quantikine® Human VEGF ELISA Kit was 
supplied by R&D Systems and was used as supplied. 
10.4.2 Instrumentation 
I H and l3C spectra were obtained on a Broker AC 250 MHz and AMX2-400 MlIz 
spectrometer using deuterated water throughout. Gas chromatography was carried out 
on a Perkin Elmer Instruments Autosystem XL Gas chromatograph with autosampler 
and FID detector. UV analysis was carried out on a Dynex Technologies MRXII UV-
Vis Plate Reader or a HITACHI U-2010 Spectrophotometer. Fluorescence spectroscopy 
was carried out on a Luminescence Spectrometer LSSOB (Perkin-Elmer Ltd). Slide-A-
Lyzer® Dialysis Cassettes (Extra Strength) 3,500 MWCO, 0.5-3 ml capacity were 
obtained from Pierce. XPS and SIMS analysis was carried out by Dr. T. Whittle at the 
Kroto Institute, University of Sheffield. X-ray photoelectron spectra were acquired on a 
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Kratos Axis Ultra X-ray photoelectron spectrometer (Kratos Ltd, Manchester). All 
samples were run as insulators, requiring use of the electron flood gun. The flood gun 
was operated at a filament current of 1.8 A and charge balance of 3.4 V. The X-ray 
source was a monochromated Al source operated with an X-ray emission current of 10 
mA and an anode high throughput (acceleration voltage) of 15 kV. Survey scans were 
acquired with a pass energy of 160 eV and a step size of 1.0 eV, whilst high resolution 
Cls were collected at a pass energy of 20 eV and a step size of 0.1 eV. Secondary Ion 
Mass Spectrometry data were acquired on an Ion-ToF V mass spectrometer (Ion-ToF, 
Munster, Germany), equipped with a bismuth liquid metal primary ion beam with an 
energy of 25 ke V. Samples were all run as insulators. Positive and negative ion 
spectra were recorded from a fresh 150 J.1Il1 x 150 J.1Il1 analysis area using the Bi/+ 
cluster ion source. The primary ion beam current was adjusted to be less than 0.22 pA 
at 100 JlS cycle time. 
10.4.3 Synthesis of Diethylene Glycol BisaUyl Carbonate (DEGBAC}-Crosslinked 
Poly(NVP-co-AA) Hydroe;els 
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Thermal Polvmerisation: Polv(NVP-co-DEGBAC-co-AA) Hvdrogels 
Into a 100 ml beaker were weighed NVP, DEGBAC, acrylic acid and AIBN (0.1 g,0.6 
mmol). Nitrogen was bubbled through the stirring reaction mixture for 30 minutes to 
degas and homogenise the solution. The solution was injected into a pre-made mould of 
dimensions 7.5 x 7.5 cm2 and thickness of 1 mm, consisting of glass plates and a PTFE 
gasket. The mould was then placed horizontally into an oven at 60·C to react for 24 
hours. The hydrogel produced was removed from the mould and placed in ethanol on an 
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orbital shaker plate at 100 rpm. The ethanol was changed daily for one week before 
final storage in ethanol. 
Polymer NVP DEGBAC Acrylic acid 
Mass (g) 0/. mmol Mass (g) % mmol Mass (g) °/. Mmol 
1 9.3 93 83.7 0.2 2 0.7 0.5 5 6.9 
2 9.6 96 86.4 0.2 2 0.7 0.2 2 2.8 
Table 10.6: Formulations for thermally-cured hydrogels 
UV Polymerisation: PolvrNVP-co-DEGBAC-co-AA) IIvdrogels 
NVP, DEGBAC, acrylic acid and 2-hydroxy-2-methylpropiophenone (0.1 g, 0.6 mmol) 
were weighed into a 100 ml beaker. Ethanol was added to give a 33% ethanol solution 
(v/v). Nitrogen was bubbled through the stirring reaction mixture for 30 minutes in the 
dark to degas and homogenise the solution. The solution was injected into a pre-made 
mould of dimensions 7.5 x 7.5 cm2 and a thickness of 500 J.lm, consisting of two quartz 
plates and a PTFE gasket. The mould was then placed horizontally into a UV oven and 
allowed to react for 6 minutes, 1 minute on each side alternately. The hydrogel 
produced was removed from the mould and placed in ethanol on an orbital shaker plate 
at 100 rpm. The ethanol was changed daily for one week before final storage in ethanol. 
Polymer NVP DEGBAC Acrylic acid 
Mass (g) % Mmol Mass (g) % mmol Mass (g) % Mmol 
1 9.7 97 87.3 0.1 0.4 0.2 2 2.8 
2 9.4 94 84.6 0.1 1 0.4 0.5 5 6.9 
3 9.8 98 88.2 0.2 2 0.7 0 0 0 
4 9.6 96 86.4 0.2 2 0.7 0.2 2 2.8 
5 9.3 93 83.7 0.2 2 0.7 0.5 5 6.9 
6 9.3 93 83.7 0.5 5 1.8 0.2 2 2.8 
7 9.0 90 81.0 0.5 5 1.8 0.5 5 6.9 
Table 10.7: Formulations for UV-cured hydrogels 
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10.4.4 Hydrogel Analysis 
Equilibrium Water Content (EWC) 
The equilibrium water content of the hydrogels was analysed by cutting a circular disc 
from a sheet of hydrogel swollen in water. Any excess water was removed gently by a 
paper towel and the swollen weight of the polymer was recorded. The polymer was then 
placed in a vacuum oven at 50°C over a 48 hour period. The weight of the polymer disc 
was then recorded every two hours until the weight remained constant. 
EWC (%) = «W", -Wd)/WlO,) x 100 
Where W w = wet weight and W d = dry weight 
Residual Monomer Analvsis bv Gas Chromatography 
1 cm2 of hydrogel was weighed and placed in 2 ml of methanol for 24 hours on an 
orbital shaker plate in sealed glass bottles. The solvent was then analysed by GC under 
the conditions described in Table 10.8. The residual monomer content was calculated by 
comparison to calibration curves for the relevant monomers. 
Gas Chromatography Operating Parameters 
GC Instrument 
Column 
Column Dimensions 
Oven Temperature 
Carrier Gas and flow 
Split Flow Rate 
Injection source and mode 
Injection temperature and volume 
Detector 
Sampling rate 
Perkin Elmer Autosystem XL 
Phenomenex, ZB-S (5% Phenyl Polysiloxane) 
L = 30 m x ID = 25 nm x DF = 25 ~ 
Initial = 60'C, increasing 1 O·C/min to 260'C 
Helium, 0.8 mllmin 
50.0ml/min 
Autosampler, Split with a ratio of 61.5/1 
250'C, 0.5 ml 
FID at 250'C 
6.25 pts/s 
Table 10.8: Gas chromatography operating parameters for residual monomer analysis 
237 
10.4.5 Synthesis of Peptide-Hydroe;el Conjugates 
Determination o(Reaction Conditions 
In order to determine a successful procedure for the synthesis of a polymer-peptide 
conjugate a number of coupling reactions were triaIled for the synthesis of a poly(NVP-
co-DEGBAC-co-AA)-lysine conjugate through a two-step reaction involving activation 
of the acid functionality followed by coupling of the activated group and lysine. The 
coupling procedures trialled are detailed in Table 10.9 and a general procedure is 
provided. 
Trial No. 
t 1 3 4 5 
Reagent I 
(compound, EDC (5) EDC (5) EDC (5) EDC (5) DCC (5) 
= 
equivalent) 
Cl Reagent 2 ;: 
= (compound, NHS (5) NHS (5) NHS (5) NHS (5) NHS (5) .~ 
-
equivalent) y 
< Solvent Water Water Water Water DMF 
Temp. (0C) 0 0 0 0 RT 
Time ~rl 24 24 24 24 24 
Peptide Equivalent 2 2 2 2 2 
~ ~ pH 5.5 5.5 8.5 8.5 8.5 ~ .S Buffer Sodium Sodium PBS PBS PBS .- -
- c. c.= acetate acetate (O.OIM) (0.01 M) (O.OIM) ~ Cl 
=-U Temp.COc) 0 0 0 0 0 
Time (hr) 24 72 24 72 72 
Table 10.9: Experimental parameters for coupling trials of lysine to acid-functionalised hydrogels. 
Equivalent values calculated from molar acrylic acid quantities. 
Genera/Procedure 
The poly(NVP-co-DEGBAC-co-AA) hydrogel was removed from the sterile ethanol 
solution and placed in 10 ml of the solvent utilised in the activation reaction step. The 
solvent was replaced after 1 hour and this was repeated three times. The hydrogel was 
placed into the activation solution (10 ml, 5 eq. reagents 1 and 2) and the reaction vessel 
was placed on an orbital shaker at 350 rpm for 24 hours either at room temperature or in 
a dewar with ice at O°C under nitrogen. The hydrogel was removed from the activation 
solution and placed into 10 ml of the solvent utilised in the activation step for one hour 
to remove the remaining activation reagents. The solution was replaced three times and 
the hydrogel was then placed into the coupling solution (10 ml, 2 eq. lysine or lysine 
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peptide). The reaction vessel was placed in a dewar of ice under nitrogen at o·e on an 
orbital shaker for 24 or 72 hours. Once the coupling reaction was complete the polymer-
peptide conjugate hydrogel was placed in 10 ml water to remove any non-covalently 
bound peptide and to hydrolyse any activated acid groups remaining. The water was 
changed twice daily for one week before the hydrogel was finally placed in absolute 
ethanol for storage until use. 
Finalised Coupling Procedure (or Peptide-Conjugated Hvdrogel Svnthe.sis 
20 discs of UV-cured poly(NVP-co-DEGBAC-co-AA) hydrogel (S mm swollen 
diameter, 2 wt% DEGBAC, S wt% acrylic acid) was removed from the sterile ethanol 
solution and placed in anhydrous DMF (4 ml) under nitrogen and allowed to equilibrate 
for 1 hour. The DMF was replaced twice under nitrogen to ensure that the polymer was 
equilibrated within the solvent. The DMF was replaced under nitrogen with activation 
solution (NHS & DCC in 10 ml DMF, S eq.) and the reaction vessel was placed on an 
orbital shaker at 3S0 rpm for 24 hours at room temperature. The activation solution was 
removed under nitrogen and replaced with 5 ml of DMF with agitation for 1 hour to 
remove the remaining activation reagents. The DMF was replaced twice before removal 
of DMF and addition of the coupling solution (10 ml) containing the peptides (KKK or 
RRR, 2 eq.) in 0.01 M PBS (PH 8.S). The reaction vessel was placed in a dewar of ice at 
O·C on an orbital shaker for 72 hours. Once the coupling reaction was complete, the 
peptide-conjugated hydrogels were placed in 10 ml water to remove any non-covalently 
bound peptide and to hydrolyse any activated acid groups remaining. The water was 
changed once a day for one week before the hydrogels were finally placed in absolute 
ethanol for storage until use. 
These peptide-functionalised hydrogels were equilibrated in the relevant medium and 
analysed directly by solid state NMR, XPS and ToF-SIMS. The hydrogels were used 
directly for heparin and VEGF binding and cell culture. 
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10.4.6 Analysis of Coupling Efficiency 
The coupling efficiency was analysed quantitatively by a colorimetric assay for primary 
amines with 2,4,6-trinitrobenzenesulphonic acid (TNBS). The coupling efficiency was 
analysed both indirectly through analysis of peptide concentration remaining in the 
coupling solution after coupling, and directly through the analysis of the concentration 
of the peptide on the hydrogel after the washing steps. Coupling efficiency was 
determined through a calibration curve produced for each individual peptide sequence. 
A fresh calibration was carried out for each analysis. Qualitative coupling analysis for 
arginine presence was carried out by the Weber modification296 of the Sakaguchi 
process297• 
Preparation ofPolyrNVP-co-DEGBAC-co-AA) lIydrogel.f (or Direct Analysis 
A piece of hydrogel was placed in 5 ml of aqueous NaOH (0.5 M) on an orbital shaker 
at 350 rpm for one hour until dissolved. Hydrochloric acid (0.5 M) was added to the 
solution until neutral pH was reached, as measured by a pH meter. The water was then 
removed by freeze-drying before analysis. The freeze-dried polymer obtained was then 
analysed to determine coupling efficiency. 
Colorimetric TNBS Analysis of Coupling Efflcieney 
Analyte solution (coupling solution before and after the coupling reaction, wash 
solution or degraded hydrogel in sodium tetraborate solution) was combined with 
sodium tetraborate (0.10 M, pH 9.3) and 0.1 ml of aqueous TNBS solution (0.03 M) 
(Table 10.10). This solution was agitated to ensure complete mixing and allowed to 
stand for 30 minutes at room temperature. Absorbance was read on a UVNis 
spectrophotometer at 420 nm (Molar extinction coefficient for TNBS-Iysine conjugate, 
E = 9787 ± 590 Lmor1cm-1 at 420 nm). 
Volume ofsodium Volume ofTN8S 
Analyte Amount of analyte 
tetraborate (ml) solution (ml) 
Coupling solution 0.25 ml 1.65 0.1 
Washing solution 1 ml 0.9 0.1 
Dissolved polymer 2mg 1.9 0.1 
Table to.tO: Volumes employed in colorimetric TN8S analysis of peptide coupling efficiency 
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Colorimetric Arginine Determination - Weher Modification of Sakaguchi 
Reaction296 
Reagents: 
(A) 10% KOH aqueous solution 
(B) 0.1 % 1-napthol in 50% ethanol 
(C) 5% urea 
(D) 0.64 ml bromine in 100 ml of 5% KOH (prepared daily) 
One piece of hydrogel was added to 1 ml of A and 1 ml of B and allowed to stand for 3 
minutes. Then 1 ml of C was added with mixing, followed by the addition of 2 ml of D 
with continuous shaking. The solution was allowed to stand for 5 minutes before 
qualitative analysis was undertaken. 
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10.4.7 Fluorescent Heparin Bindine; Study 
Synthesis of Fluorescently-Tagged Heparin 
Heparin (50 mg) was dissolved in 2 ml of a 0.1 M phosphate buffered saline solution 
(0.1 M sodium phosphate, 0.15 M sodium chloride, pH 7.5). 250 mM sodium iodate 
solution (0.2 ml in 0.1 M phosphate buffered saline solution) was added to the heparin 
solution whilst being protected from light and was allowed to react for 2.5 hours. The 
heparin solution was placed into a pre-wetted Slide-a-Lyzerlfil dialysis cassette and 
dialysed against 1500 ml deionised water in the dark for 1 hour. The heparin solution 
was then dialysed against 1500 ml 0.1 M phosphate buffered saline at pH 7.5 for 16 
hours, stirring and in the dark at room temperature. The oxidised heparin solution was 
removed from the cassette, added to fluorescein-5-thiosemicarbazide (FTSC) in DMF 
(0.4 ml, 150 mM) and reacted for 2.5 hours at room temperature in the dark. The 
heparin solution was placed into a pre-wetted Slide-a-Lyzerlfil dialysis cassette and 
dialysed against 1500 ml deionised water in the dark for 1 hour. The heparin solution 
was then dialysed against 1500 ml 0.1 M phosphate buffered saline at pH 7.5 for 16 
hours, stirring and in the dark at room temperature. The dialysis solution was replaced 
until no more dye leeched from the Slide-a-Lyzerlfil cassette. 
Quantification of Heparin Solution Concentration 
A calibration curve for methylene blue with heparin in deionised water was produced by 
the analysis of solutions of constant methylene blue concentration (0.04 mM, 1 ml) and 
increasing heparin concentrations (0 Jlglml -' 100 Jlglml). The absorption of these 
solutions was analysed at 630 nm on a U-2010 spectrophotometer. Triplicate readings 
of polysaccharide-FTSC solution (1 JlI of solution/ml methylene blue solution) were 
taken at 630 nm and the concentration of the heparin-FTSC was derived from the 
calibration curve produced. 
Quantification ofFluorescein-5-Thiosemicarbaz.ide (FTSC) Loading 
A standard calibration curve for FTSC in deionised water was produced at 492 nm on a 
U-201O spectrophotometer. Triplicate readings of the polysaccharide-FTSC solution 
were analysed at 492 nm and the concentration of fluorescein in the solution was 
determined from the calibration curve. 
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Steady-State Binding Study 
Calibration 
A calibration of fluorescent heparin was carried out, from 0 mg/ml to 0.01 mg/ml, in 0.1 
M PBS at pH 7.5 at room temperature on the same day as the experiment. 
Sample Preparation for Steady State Binding Study 
Poly(NVP-co-DEGBAC-co-AA) and KKK- and RRR-functionalised poly(NVP-co-
DEGBAC-co-AA) hydrogels were analysed for heparin binding. A known mass of 
swollen hydrogel was equilibrated in 0.1 M phosphate buffered saline at pH 7.5 at room 
temperature for 1 hour before being placed in a fluorescent heparin solution (0.7 mg/m1, 
0.25 ml) and allowed to react at room temperature in the dark on an orbital shaker plate 
at 150 rpm for 24 hours. The hydrogel was removed from the coupling solution and 
placed into 0.25 ml of 0.1 M phosphate buffered saline at pH 7.5 for 1 hour. The 0.1 M 
PBS solution was replaced hourly for 3 hours and subsequently replaced daily for a 
further three days. 
Analysis 
Analysis was carried out on a Luminescence Spectrometer LS50B (Perkin-Elmer Ltd) 
with excitation at 490 nm, emission at 500-600 nm. The slits were 
2.5-2.5 nm for the excitation and emISSIon source and 10 
accumulation scans were carried out for each spectrum. Analysis of the coupling 
solution was carried out by diluting 20 III of heparin solution in 4 ml of 0.1 M PBS and 
analysing this solution in a quartz cuvette. Analysis of PBS wash solutions was carried 
out by diluting 0.25 ml of wash solution in 2 ml PBS before analysis in a quartz cuvette. 
The amount of fluorescein tagged-heparin washed from the hydrogel was determined 
using the calibration curve produced prior to the experiment. 
10.4.8 XPS Heparin Binding Study 
Preparation of Heparin-Bound Hvdrogels for XPS Analvsis 
Poly(NVP-co-DEGBAC-co-AA) and KKK- and RRR-functionalised poly(NVP-co-
DEGBAC-co-AA) hydrogels were analysed in duplicate by XPS for heparin binding. 
For samples of hydrogel after exposure to heparin, hydrogel discs (5 mm swollen 
diameter) were equilibrated in 0.1 M phosphate buffered saline (PH 7.5) at room 
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temperature for 1 hour before being placed in a 1 mg/ml heparin solution (l ml) and 
allowed to react at room temperature on an orbital shaker plate at 150 rpm for 24 hours. 
The hydrogels were removed from the coupling solution and placed into 1 ml 0.1 M 
phosphate buffered saline (PH 7.5) for 1 hour. The PBS solution was replaced hourly 
for 3 hours and subsequently replaced daily for a further three days. The samples were 
then washed five times in water before being air-dried for 24 hours ready for XPS 
analysis. For samples of hydrogel without exposure to heparin, the above procedure was 
repeated without the presence of heparin. The samples produced were air-dried before 
being submitted for XPS and SIMS analysis by Dr. T. Whittle, University of Sheffield. 
10.4.9 Enzyme-Linked ImmunoSorbent Assay ofVEGF Binding (Hydrogels) 
Sample Preparation 
Four polymer types were analysed in duplicate for this study, PND, PNDA, PNDKKK 
and PNDRRR. For each sample a hydrogel disc (5 mm swollen diameter) was placed 
into a sample tube and was submerged in 1 ml of a 1 mg/ml heparin solution in PBS. 
The hydrogel was then left to bind in this solution for 24 hours at room temperature on 
an orbital shaker at 150 rpm. The hydrogel was washed seven times with fresh PBS. 
Soda glass sample tubes were blocked from protein absorption by the addition of a 3% 
BSA solution in PBS which was agitated at room temperature on an orbital shaker at 
150 rpm for 4 hours. The solution was removed and the tubes were rinsed three times 
with fresh PBS. The heparin-bound hydrogels were transferred to pre-blocked sample 
tubes and 200 ng/ml VEGF in PBS (0.5 ml) was added. The hydrogel was allowed to 
interact with the VEGF for 24 hours at 4°C on an orbital shaker at 150 rpm. The 
hydrogel discs were then washed by being submerged in fresh PBS solution at 4°C for 
30 minutes. This was carried out three times. 
A release study was then carried out by submerging the hydrogel in 0.5 ml of 1 % BSA 
PBS solution and allowing release to occur at 37°C. At defined time points (30 mins, 1 
hr, 6 hrs, 12 hrs, 24 hrs, 48 hrs and 72 hrs) the protein solution was removed and was 
replaced with 0.5 ml fresh 1 % BSA PBS solution. The protein solutions retrieved were 
stored at -20°C in polypropylene tubes until analysis with an ELISA kit as described in 
Section 10.3.12. BSA was utilised to stabilise the VEGF during the release study and 
storage period. Each experimental condition was carried out and analysed in duplicate. 
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10.5 Cell Culture 
10.5.1 Materials 
Hydrogel discs (5 mm swollen diameter) were produced as described in Section 10.4 
and were washed five times in sterile PBS and stored at 4°C before use in cell culture. 
Dulbeccos' Modified Eagles Medium (DMEM) was obtained from Sigma, UK or 
Biowest Biosera. Foetal calf serum was obtained from Biowest Biosera. L-glutamine, 
penicillin-streptomycin, trypsin-ethylenediaminetetraacetic acid (EDT A) (0.05% w/v 
trypsinlO.02% w/v EDTA) and 0.4% w/v Trypan blue were obtained from Sigma, UK. 
Phosphate buffered saline tablets (Dulbeccos' A) were obtained from Oxoid, UK and 
CellTracker™ Red CMTPX (C34552) was obtained from Molecular Probes™. 
Endothelial Cell Growth Medium MV 2 and supplements, and endothelial cell detach 
kit (containing HepesBSS, trypsinlEDTA solution and trypsin neutralising solution) 
were obtained from Promocell GMBH. Trypsin 0.1 % w/v was obtained from Difco, 
UK. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 2-
ethoxyethanol (Cellusolve) were obtained from Sigma, UK. 
Skin for fibroblast cell isolation was obtained from patients undergoing routine breast 
reductions and abdominoplastics at the Northern General Hospital, Sheffield. Full 
informed consent was given by all patients for skin to be used for research through a 
protocol approved by the Ethical Committee of the Northern General Hospital Trust, 
Sheffield, UK. Human Dermal Microvascular Endothelial Cells (HDMECs) were 
obtained as proliferating cells (C-12260) from PromoCell, U.K. 
10.5.2 Equipment 
Cell counts were performed using a modified Neubauer haemocytometer from Weber 
Scientific International, UK. Plasticware for cell culture was purchased from Costar, 
UK. All sterile reagents and cells were handled in class 11 laminar flow hoods. Cell 
culture was performed at 37°C, 5% C02, 95% humidity, in Sanyo CO2 incubators. Light 
microscopy of cell cultures was performed using an Olympus CK40-F200 light and 
phase contrast microscope. Still photographs were taken using a Nikon Coolpix 990 
digital camera. MTT assays were performed at 540 nm using a Dynatech MRSOOO plate 
reader with a reference wavelength of 630 nm. Confocal images were taken using a 
Zeiss LSM 510 Confocal Microscope (abs. 577 nm, em. 602 nm). 
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10.5.3 Standard Solutions 
Trypsin Solution 
"Difco Trypsin" 0.1% w/v was prepared by adding 0.5 g ofDifco Trypsin powder, 0.5 g 
D-glucose and 0.5 ml phenol red to 500 ml PBS. This was adjusted to pH 7.45 using 2 
M NaOH using a pH meter. This was filter sterilised and aliquots stored at -20°C until 
needed. 
Phosphate Buffered Saline (PBS) 
Phosphate buffered saline was prepared by adding 1 PBS tablet per lOO ml of distilled 
water. This solution was autoclaved at 115°C for 15 minutes and left to cool before use. 
Trypan Blue 
Trypan blue solution was made from a 1: 1 mixture of 0.4% trypan blue and PBS. 
Serum-Supplemented Fibroblast Culture Medium 
DMEM high glucose (4500 mg/l glucose) supplemented with 10% v/v foetal calf serum 
(FCS), 2 mM I-glutamine, 0.625 J.1g/mI amphotercin B, 100 IV/ml penicillin and 100 
J.1g/ml streptomycin. The supplements were mixed at room temperature in a class II 
laminar flow hood to a total volume of 500 ml. The resultant medium was stored at 4°C 
for a maximum of six weeks prior to use. Medium was warmed to 37°C before use. 
Serum-Free Fibroblast Culture Medium 
DMEM high glucose (4500 mg/1 glucose) supplemented with 2xlO-3 M I-glutamine, 
0.625 Ilg/ml amphotercin B, 100 IV/ml penicillin and 100 Ilg/ml streptomycin. The 
supplements were mixed at room temperature in a class II laminar flow hood to a total 
volume of 500 ml. The resultant medium was stored at 4°C for a maximum of six weeks 
prior to use. Medium was warmed to 37°C before use. 
Supplemented Endothelial Cell Growth Medium (MV2) 
Endothelial cell growth medium (MV2) (Promocell GMBH), with added supplements 
of 0.05 mUmI foetal calf serum, 5 ng/ml EGF, 0.5 ng/ml VEGF, 10 ng/ml bFGF, 20 
ng/ml IGF-l, 0.2 J.1g/ml hydrocortisone, 1 J.1g/ml ascorbic acid. The supplements were 
added at room temperature in a class II laminar flow hood. The resultant medium was 
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stored at 4°C for a maximum of six weeks prior to use. Medium was warmed to 37°C 
before use. 
Endothelial Cell Growth Medium (MV2) (5% Serum Medium) 
Endothelial cell growth medium (MV2) (Promocell GMBH), with 5% foetal calf serum 
(0.05 mllml). The FCS was added at room temperature in a class II laminar flow hood. 
The resultant medium was stored at 4°C for a maximum of six weeks prior to use. 
Medium was warmed to 37°C before use. 
Serum-Starved Endothelial Cell Growth Medium (MV2) 
Endothelial cell growth medium (MV2) (Promocell GMBH). with added 1 % or 2% 
foetal calf serum (0.01 mllml or 0.02 mllml). The FCS was added at room temperature 
in a class II laminar flow hood. The resultant medium was stored at 4°C for a maximum 
of six weeks prior to use. Medium was warmed to 37°C before use. 
10.5.4 Cell Counts and Viability Assessment 
Cell Viability Determination by Trypan Blue 
Trypan blue was used for cell counts and viability assessments. Cells were suspended in 
a known volume of cell culture medium and 20 J.l.I of this cell suspension was combined 
with 20 J.l.I of trypan blue stock solution. Non-viable cells appear blue. allowing viable 
cells to be counted using a Neubauer haemocytometer and a concentration of viable 
cells to be calculated. 
Cell Viability Assay - MTT 
MTI solution was produced by dissolving MTI in sterile PBS to a final concentration 
of 0.5 mg/ml. The medium was removed from the sample wells and the samples were 
washed gently with PBS. 0.5 ml MTI solution was added to each well. The plates were 
incubated with MTT solution for 40 minutes at 37°C, 5% C02 in a humidified 
atmosphere. The MTI solution was removed from the wells and then polymer was also 
removed from the wells and placed into individual wells. 0.3 ml of Cellusolve was then 
added to each well and was left for a few moments to allow the formazan product to 
elute from the cells. 0.1 ml of the Cellusolve solution was then placed in a 96 well plate 
in duplicate and the optical density was read at 540 nm. 
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10.5.5 Cell Culture 
Fibroblast Sub-Culture 
Cells were cultured in T75 flasks and incubated at 37°C, 5% CO2 in a humidified 
atmosphere. The medium was changed every three to four days until the cells were 
80% confluent. Once the fibroblasts were confluent, the medium was removed and the 
cell layer was washed three times with 10 ml sterile PBS solution. 2 ml trypsinlEDT A 
solution was added to the fibroblasts, which were then incubated at 37°C for 5 minutes. 
Fibroblasts were encouraged to detach by gentle tapping and phase contrast microscopy 
was used to confirm cell detachment. 10 ml of serum-supplemented medium was added 
to the flask to neutralise the trypsin. The resulting cell suspension was centrifuged at 
1000 rpm for 5 minutes to produce a cell pellet. The supematant medium was removed 
from the cell pellet and the cells were resuspended in 1 ml of medium to allow a cell 
count to be performed. The fibroblasts were then used between passages three and nine. 
Endothelial Cell Sub-Culture 
Cells were cultured in T25 flasks and incubated at 37°C, 5% CO2 in a humidified 
atmosphere. The medium was changed every two to three days until the cells were 80% 
confluent. Once the endothelial cells were confluent, the medium was removed and the 
cell layer was washed with 5 ml HepesBSS solution. 2.5 ml trypsinlEDTA solution was 
added to the endothelial cells, which were allowed to detach at room temperature for 5 
minutes. Endothelial cells were encouraged to detach by gentle tapping, and phase 
contrast microscopy was used to confirm cell detachment. 2.5 ml of trypsin neutralising 
solution (TNS) was added to the flask to neutralise the trypsin. The resulting cell 
suspension was centrifuged at 1400 rpm for 5 minutes to produce a cell pellet. The 
supematant medium was removed from the cell pellet and the cells were resuspended in 
1 ml of medium to allow a cell count to be performed. The endothelial cells were then 
used between passages four and eight. 
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10.5.6 Fibroblast Experiments 
Fibroblast Polymer Compatibility Study 
1 sample of each hydrogel (5 mm swollen diameter) was placed into a well in a 48 well 
plate. 0.5 ml of serum-free fibroblast culture medium was added to each well and the 
polymers were incubated for 72 hours. The medium was removed and 0.25 ml of either 
serum-free or serum-supplemented fibroblast culture medium was added to each well. 
Fibroblasts were then seeded at 10,000 cells per well in 0.25 ml of medium. Cells were 
cultured in direct contact with hydrogel samples for four days before an MTT assay was 
carried out and the hydrogels were moved to separate wells to analyse cell viability. 
Each polymer was analysed in triplicate in three repeat experiments. 
Fibroblast CellTrackerM Red Staining 
1 sample of each hydrogel (5 mm swollen diameter) was placed into a well in a 48 well 
plate. 0.5 ml of serum-free fibroblast culture medium was added to each well and the 
polymers were incubated for 72 hours. The medium was removed and 0.25 ml of either 
serum-free or serum-supplemented fibroblast culture medium was added to each well. 
Fibroblasts were then seeded at 10,000 cells per well in 0.25 ml of medium. Cells were 
cultured in direct contact with hydrogel samples for four days. The medium was 
removed and each well was washed twice with PBS. 50 Ilg of CellTracker™ Red was 
dissolved in 20 III DMSO and added to serum-free medium (5 ml). 0.3 ml of this 
solution was added to each well and the cells were then incubated for 40 minutes. The 
medium was removed, the wells were washed three times with PBS and 0.5 ml of serum 
medium was added to each well before incubating again for 30 minutes. Finally, the 
medium was removed, each well was washed three times with PBS and 0.5 ml PBS was 
added. The cells were imaged on an invertedconfocal microscope (abs. 577 nm, em. 
602 nm) at room temperature. 
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10.5.7 Endothelial Cell Experiments 
Endothelial Cell Polymer Compatibility Study 
One sample of each hydrogel (5 mm swollen diameter) was placed into a well in a 48 
well plate. 0.5 ml of endothelial cell growth medium without supplements was added to 
each well and the polymers were incubated for 72 hours. The medium was removed 
and 0.75 ml of endothelial cell growth medium with supplements was added to each 
well. HDMECs were then seeded at 10,000 cells per well in 0.25 ml of medium. Cells 
were cultured in direct contact with hydrogel samples for four days, with a daily change 
of medium, before the hydrogels were moved to separate wells and an MTT assay was 
carried out. Each polymer was analysed in triplicate in three repeat experiments. 
Endothelial Cell Heparin and VEGF Dosing Experiment 
HDMECs were seeded at a density of 8,000 cells per well in a 96 well plate and allowed 
to attach to the tissue culture plastic for 5 hours in 0.2 ml fully-supplemented medium. 
The cells were then starved overnight in 2% serum endothelial cell growth medium 
(MV2). The starving medium was replaced with 0.2 ml of 2% serum medium 
containing the relevant quantities of VEGF and/or heparin and was incubated for 72 
hours before analysis by MTT assay. Each environment was carried out in triplicate 
within the experiment. 
Endothelial Cell Proliferation with Hydrogel Alone, Heparin-Bound Hydrogel and 
VEGF- and Heparin-Bound Hydrogel (5% Serum Medium) 
Hydrogel discs (5 mm swollen diameter) were equilibrated in sterile PBS before use in 
this experiment. To produce heparin-bound hydrogels, the hydrogel discs were placed in 
1 mg/ml heparin solutions (PBS) and agitated on a shaker plate at room temperature for 
24 hours. The hydrogels were then washed in sterile PBS seven times before storage at 
4°C. VEGF- and heparin-bound hydrogels were produced by placing heparin-hound 
hydro gels in 0.5 ml of a 200 ng/ml VEGF solution (PBS) in a cold room at 4°C. The 
hydro gels were agitated in this solution for 24 hours at 4°C. The hydrogels were then 
washed three times in sterile PBS. The hydrogels were then placed into cold 48 well 
plates and 0.75 ml of 5% serum medium was added to each well. The 48 well plate was 
placed in an incubator for 2 hours. HDMECs were then seeded at a density of 10,000 
cells per well in 0.25 ml of 5% serum medium. The medium was replaced daily and an 
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MTT assay was carried out after 64 hours. Each polymer type was analysed in triplicate 
in three repeat experiments. 
Endothelial Cell with Hydrogel Alone, Heparin-Bound Hydrogel and VEGF- and 
Heparin-Bound Hydrogel (Serum-Starved Medium) 
Hydrogel discs (5 mm swollen diameter) were equilibrated in sterile PBS before use in 
this experiment. To produce heparin-bound hydrogels, the hydrogel discs were placed in 
1 mg/ml heparin solutions (PBS) and agitated on a shaker plate at room temperature for 
24 hours. The hydrogels were then washed in sterile PBS seven times before storage at 
4°C. VEGF - and heparin-bound hydrogels were produced by placing heparin-bound 
hydrogels in 0.5 ml of a 200 ng/ml VEGF solution (PBS) in a cold room at 4°C. The 
hydrogels were agitated in this solution for 24 hours at 4°C and then washed three times 
in sterile PBS. The hydrogels were placed into cold 48 well plates and 0.75 ml of 2% 
serum medium with no further supplements was added to each well. The 48 well plate 
was placed in the incubator for 2 hours. HDMECs had previously been starved 
overnight in 2% serum medium and were then seeded at a density of 10,000 cells per 
well in 0.25 ml of medium. The medium was replaced daily and an MTT assay was 
carried out after 64 hours. Each polymer type was analysed in triplicate in three repeat 
experiments. 
Endothelial CellTracker™ Red Experiment 
50 ~g of CellTracker™ Red was dissolved in 20 ~l DMSO and added to warm PBS (5 
ml). This CellTracker™ Red solution was then added to one confluent T2S flask of 
HDMECs and the cells were then incubated for 40 minutes at 37°C. The CellTracker™ 
Red solution was then removed and the cells were washed three times with PBS before 
5 ml of fully supplemented endothelial cell medium was added. The CellTracker™ Red-
stained HDMECs were then used in experiments as described above. After the 
experiments, the cells were washed three times with warmed PBS before imaging the 
cells in PBS on an inverted confocal microscope (abs. 577 nm, em. 602 nm) at room 
temperature. 
Tubule Formation Assav - Effect of Soluble VEGF and Heparin 
In order to assess the ability of HDMECs to proliferate and differentiate, the tubular 
network formation assay was used. Microtiter 48 well plates were coated with 68 
~l/well of growth factor-reduced Matrigel and placed in an incubator at 37°C to set for 
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1 hour. HDMECs were serum starved overnight (1% FCS) before the experiment, 
trypsinised and washed. 16,000 cells were then seeded per well in starving medium (0.1 
ml, 1 % FCS) and left to attach for 45 min. The medium was then discarded and 
replaced with 1 ml of treatment medium containing starving medium (1 % FCS) either 
alone or with VEGF (10 ng/ml), heparin (50 ng/ml) or a combination of VEGF (10 
ng/ml) and heparin (50 ng/ml). The endothelial cells were incubated at 37°C and 
migrated and formed tubules on this matrix within six hours of plating. Tubule 
formation was monitored at six hours by light microscopy. Each treatment group was 
performed in triplicate and three independent experiments were performed and analysed 
using the image analysis package, Scion Image (Frederick, MA). 
Tubule Formation Assav - Effect of VEGF- and lIeparin-Bound RRR IIvdrogel 
The effect of VEGF- and heparin-bound RRR hydrogels on endothelial cell tube 
formation on growth factor-reduced Matrigel was analysed in vitro. 
VEGF- and heparin-bound hydrogel discs were produced by placing the hydrogels in 
heparin solutions (1 mg/ml) and agitated on a shaker plate at room temperature for 24 
hours. The hydro gels were then washed in sterile PBS 7 times before storage at 4°C. 
VEGF- and heparin-bound hydrogels were produced by placing heparin-bound 
hydrogels in 0.5 ml of a 200 ng/ml VEGF solution (PBS) in a cold room at 4°C. The 
hydrogels were agitated in this solution for 24 hours at 4°C. The hydrogels were washed 
three times in sterile PBS and equilibrated in 1 ml 1 % serum medium for 15 minutes. 
Microtiter 48-well plates were coated with 68 J.1Vwell of growth factor-reduced Matrigel 
and placed in an incubator at 37°C to set for 1 hour. One VEGF- and heparin-bound 
PNDRRR hydrogel disc or PNDRRR hydrogel disc alone was placed into each well and 
was incubated at 37°C for 30 minutes. 16,000 cells (pre-starved in 1% serum medium 
overnight) were then seeded per well in starving medium (0.1 ml, 1 % FCS) and left to 
attach for 45 minutes at 37°C. Further starving medium (0.9 ml, 1% FCS) was added to 
each well before incubation at 37°C. HDMECs on this matrix migrated and formed 
tubules within six hours of plating. Tubule formation was monitored at six hours by 
light microscopy. Each treatment group was performed in triplicate and three 
independent experiments were performed and analysed using the image analysis 
package, Scion Image (Frederick, MA). 
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